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ABSTRACT: Mycobacterium tuberculosis (Mtb), the etiological agent of Tuberculosis 
(TB) is developing new multi drug-resistant (MDR) and extensively drug-resistant (XDR) 
strains to the current drugs used in therapy. Of particular concern  the wide spreading of 
tuberculosis, the high rate of development of resistance, and the high mortality of the patients 
due to the lack of effective therapy against TB infections. In order to face this problem, two 
series of novel compounds were designed, synthesised and evaluated against a panel of 
mycobacterial strains. The first series of compounds includes analogues of the third line drug 
thioridazine (TZ). TZ is a known antipsychotic drug belonging to the phenothiazine drug 
group, which showed good activity against MDR-TB infections but causes severe side 
effects which limit its use in therapy. Among the first series of compounds, five new 
compounds showed anti-tubercular activity similar or higher than TZ. Moreover, two 
derivatives showed potent inhibition towards the whole-cell drug efflux pump activity of 
mycobacteria comparable to that of verapamil, and turning to be promising multi-drug 
resistance reversal agents. A second series of compounds consist of small molecules which 
have originally been designed as hybrids of the anti-tubercular drugs BM212 and SQ109. 
Computational studies revealed a perfect superposition of the structures of SQ109 and 
BM212 and showed that the two drugs share common features. Five of the resulting 
compounds showed micromolar anti-tubercular activity on pathogenic TB. Two of them 
proved to be highly active also against multi-drug resistant clinical isolates and one of these 
also showed minimal eukaryotic cell toxicity, and therefore would be an excellent lead 
candidate for preclinical trials. In parallel to the identification of novel compounds active 
against mycobacteria, new synthetic methodologies for the synthesis of antitubercular 
heterocyclic scaffolds have been developed. In particular two approaches for the synthesis 
of pyrrole compounds were developed. Both procedures involve an olefin or enyne 
metathesis reaction as a key step. The first approach involves the synthesis of 1,2,3-
substituted pyrroles, through a tandem enyne cross metathesis-cyclization reaction of 
propargylamines with ethyl-vinyl ether. The reaction is rapid, procedurally simple and 
represents a facile entry to the synthetically challenging 4,5-unsubstituted pyrroles. The 
second methodology allows the synthesis of substituted pyrroles from diallyl-amines via a 
chemo-enzymatic cascade based on the combination of olefin metathesis together with 
monoamine oxidase (MAO) biocatalysts. These reactions were carried out in aqueous media 
and mild temperature leading to the formation of substituted pyrroles in a single step and in 
high yields.  
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1. Introduction. 
1.1. Statement of the Problem. 
In 1882, Robert Koch discovered and demonstrated that Mycobacterium tuberculosis, (Mtb), 
is the etiological agent of Tuberculosis (TB),1 an airborne, chronic, progressive infection 
which, nowadays, causes almost 1.5 million deaths per year.2  The  WHO (World Health 
Organisation) report 2016 shows that one third of worldwide population has got a latent, 
asymptomatic infection of Mtb and that one patient with latent infection in ten will develop 
the active form at some point during their life.2 Active infections are symptomatic and 
contagious causing death of tissue in the infected organs, possibly resulting in death. Mtb 
most often affects the lungs, causing pulmonary TB, however, in immunocompromised 
individuals, a primary lung infection can spread through blood vessels to any part of the 
body causing an extra-pulmonary infection. Typical locis for extra-pulmonary infection are 
the upper portion of the lungs, followed by kidneys, meninges, corpus vertebrae and 
epiphyses of the long bones. The most common symptoms are intense cough, fever, weight 
loss caused by lack of appetite and general malaise. The diagnosis is difficult for the 
asymptomatic latent infection cases, but easy and day by day more reliable for the active 
infections. Diagnosis usually occurs by the culture and analysis of the sputum and, recently, 
by rapid molecular-based diagnostic assay.2 According to the last WHO report, the new TB 
cases were estimated at 9.6 million worldwide (Figure 1).  
 
 
Figure 1. Estimated incidence TB rates (WHO 2015)2 
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The global incidence is 122 cases per 100,000 population, however it is noteworthy that, the 
disease is not homogenously widespread. In fact, 58% of the population affected by Mtb 
infection is in Asia while the 28% and the 8% are respectively in Africa and the Eastern 
Mediterranean region. The smallest incidence values are pointed out in the American 
continent (3%) and in the European region (3%).2 Despite the grim epidemic scenario, 
nowadays, the majority of TB cases are treatable with a 6-12 months multidrug therapy. 
However the breakdown in health services, the development of multidrug-resistant 
Mycobacterium tuberculosis strains (MDR-TB) and extensively resistant Mycobacterium 
tuberculosis strains (XDR-TB), combined with the wide spreading of HIV-1 infections
3 (the 
most common and widespread human immunodeficiency virus strain) and diabetes4 are 
compromising the chemotherapy used for the treatment of TB. In 1993, WHO declared TB 
a global emergency and stipulated a plan that aimed to end the global TB, MDR and XDR-
TB threat. One of the key points for the success of this plan is to speed up the discovery and 
the development of new anti-TB agents. During the last 20 years, huge progress in the 
treatment of Mtb infections was achieved thanks to the WHO, several investors, and the 
development of an increased awareness of the TB threat by the governments. Relevant 
improvements have been the optimization of the multidrug therapy and the study conducted 
on its potential interaction with the antiretroviral therapy (ARVs) for the treatment of HIV-
1 positive TB patients. However, nowadays, no new class of drugs active against Mtb and 
MDR/XDR-TB have been put in the market yet. Therefore, it is of remarkable relevance to 
speed up the discovery of novel anti-tubercular agents in order to have new therapeutic 
strategies to stem the epidemic TB threat. Moreover, it is noteworthy to point out that the 
traditional way to develop new drugs is a long, slow and expensive process. Thus, it is 
evident both the necessity to discover new drugs as well as new technologies and 
methodologies, which would streamline and expedite the drug-discovery process. Therefore, 
the intention of this work is to design and synthesise molecules endowed with activity 
against TB and MDR-TB and to develop new, more sustainable and faster synthetic 
methodologies for the production of drug-like compounds. 
 
1.2. Mycobacterium tuberculosis. 
Mycobacterium is the single genus within the family of Mycobacteriaceae, in the order  
Actinomycetales.5 They are rod shaped organisms, which are characterised by slow growth 
speed under aerobic conditions as well as by a staining property called acid-fastness (i.e., 
resistant to de-colorization by acid after staining with carbol-fuchsin).6 Furthermore, 
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mycobacteria are classified into two major groups, slow growers and fast growers depending 
on their generation time. Mycobacterium tuberculosis is a typical slow grower with a 
generation time of 15-20 hours. It is possible to observe visible colonies only after days to 
weeks of incubation from the dilute inoculum in a cell culture. Such a slow generation time, 
compared to other bacterial species, is one of its main peculiar physiological features and 
contributes to its virulence. Mtb is an obligate aerobe, rod-shaped, non-spore forming and 
featured by a cell wall. Human lungs are natural hosts for this pathogen, where it causes 
pulmonary tuberculosis, although it can affect every part of the human body causing the so-
called “extra-pulmonary infection”. One of the distinctive feature of Mtb is its mycobacterial 
cell wall (Figure 2).  
 
 
Figure 2. Structure of Mycobacterium cell wall. 
 
It consists of an inner and an outer layer which envelope the plasma membrane. This 
structure is unique among prokaryotes, and it plays a paramount role for the virulence of the 
bacterium. The outer layer is composed mainly of lipids and proteins while the inner one has 
a more complex structure. The inner compartment consists of a frame of peptidoglycan (PG) 
and arabinogalactan (AG). This structure links covalently to an impermeable layer of 
extremely long chain -branched -hydroxylated fatty acids (C60-C90) called mycolic acids 
(MA).7 Across this frame, there are several glycolipids, such as lipoarabinomannan (LP), 
which is a major determinant on the inactivation of macrophages. PG is the major cause of 
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bacteria shape maintaining and protecting the bacteria from osmotic changes of the 
environment. AG links the PG and the important mycolic acids (MA). The mycolic acids are 
critical as well for the growth of the mycobacterium as for its survival in the infected host. 
MA affect the permeability of the cell wall forming an impermeable layer which shields the 
organism from environmental stress.8 
1.3. Pathogenesis. 
TB is an airborne disease, which is transmitted by individuals with Mtb active infection 
through droplet nuclei containing bacilli expelled by sneezing, coughing or even talking. 
Infection requires the inhalation of such small droplets. Then, once inhaled, Mtb have to 
overcome the upper respiratory defences reaching the terminal alveoli in the lungs. Usually, 
long and repeated exposure is necessary to an infected individual in order to start a primary 
infection.  
1.3.1. Primary infection. 
The first step of the infection is the recognition of Mycobacteria as non-self-pathogen by the 
innate immune system. Mtb is recognised by macrophages and dendritic cells through Toll 
like receptors (TLRs), nucleotide binding oligomerization domain-like receptors (NLRs), 
and C-type lectins.9 The alveolar macrophage ingests the Mycobacteria, enveloping it in a 
phagosome.10 Phagosomes are a class of endosome which are small vesicles utilized by the 
cell to internalize external material from the extracellular environment.11 Once formed, the 
endosome is then distributed to other parts of the cell depending on the cellular needs. The 
natural route for a phagosome is the lysosome, where the cargo material is finally degraded 
and digested. However, Mtb, once inside the phagosome, activates a series of defensive 
methods which allows its survival. As mentioned before the mycobacteria existence inside 
the phagosome is mainly dependant on its cell wall. LP interferes with the generation of 
phosphatidylinositol 3-phosphate (PIP3) which is a host membrane component that plays a 
paramount role in the phagosome-lysosome fusion.12 Moreover, LP blocks the macrophage 
activation interfering with MAPK, interferon--mediated gene expression, TLR activation 
and phagosome lysosome fusion.13,14 However, if the phagosome-lysosome fusion occurs, 
forming a structure called phagolysosome, Mtb is able to resist  the digestion process caused 
by reactive oxygen species and acid environment by its thick, mycolic acid cell wall layer. 
Furthermore, Mtb secretes a series of proteins such as coronin 1/tryptophan aspartate coat 
protein (TACO),15 the phosphate SapM16 and the serine/threonine kinase PknG in order to 
enhance its chances of surviving in the host organism. All the proteins secreted from Mtb, 
 5 
 
aim to prevent the formation of the phagolysosome and so the consequent attempt to digest 
the content of the vescicle.17 However, once Mtb has been ingested, the immune system 
isolates the macrophages containing phagosomes surrounding them with other macrophages 
and T cells, forming a granuloma.18 The granuloma is a classic structure cluster of the cell-
mediated immune response, which aims to stop the bacterial proliferation and isolate the 
infection site. In the early weeks of infection, it is possible that infected macrophages could 
travel to regional lymph nodes, where they gain access to the circulatory system and 
therefore, to any part of the body, developing potential extra-pulmonary infections. On the 
other hand, the classic scenario of primary infections ends with the macrophagic digestion 
of the Mycobacteria. When it happens the macrophage combines the antigenic fragments of 
Mtb to the major histocompatibility complex (MHC) class II molecules exposing it on its 
plasma membrane.19 There, antigen-MHC class II complex activates T cells which secrete 
cytokines and chemokines activating the other granuloma macrophages and ensuring the 
recruitment of other immune cells to the site of infection.20 The activation of the granuloma’s 
cells induce consequently the activation of the adaptive immune system which leads, in brief 
time, to the suppression of bacillary replication. Anyway, even in this scenario,  the 
complete eradication of the infection is rare.21 The Mycobacteria could survive inside the 
granulomas for long time, even up to the lifetime of the host. However, in 95% of cases the 
primary infection is arrested and as long as the host immune system is effective Mtb do not 
cause any adverse effect on the host health.22,23 This stage of the infection is completely 
asymptomatic and it is called “latent infection”. 
  
1.3.2. Active infection. 
People with Mtb latent infection have circa 10% lifetime risk of developing the active 
infection.2 In the majority of the cases, TB primary infection reactivates within the first 
couple of years, but it can also occur decades later. The active infection occurs when the 
granuloma is no more capable to keep at bay the replication of the Mycobacteria inside the 
immune system cells. Any deterioration of the host immune system such as 
immunosuppressive medication, co-infection with HIV-1 or other diseases, and even  
malnutrition or ageing, could transform a latent infection to an active infection, which is 
symptomatic and contagious.24 The active infection causes tissue lesions, which often mature 
in granulomatous lesions characterized by mononuclear cells surrounding a core of caseous 
necrosis tissue rich with Mtb bacilli. Such clusters are characteristic of lung tissue Mtb 
infections and they are called tubercles. The erosion of the tubercles into an adjacent airway 
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leads to the formation of a cavity in the lung tissue, the infection of another alveolar space, 
and the release of a huge load of bacilli into the sputum. The course of infection varies 
greatly, depending on the state of host defenses and the virulence of the Mtb strain. Without 
an effective treatment the mortality caused by TB is estimated to be 50%.25 
 
1.4. Tuberculosis and HIV. 
TB infections are the second leading cause of death from an infectious disease worldwide.2 
TB mortality is second only to HIV-1 ones but it is demonstrated that the chances of 
developing an active TB infection is definitely higher among people infected with HIV-1 
than healthy individuals.2 In 2014, among the 9.6 million people with active Mtb infection 
1.2 million were HIV-1 co-infected; and the majority of them (75%) were from the African 
region (Figure 3).2  
 
 
Figure 3. Estimated HIV-1 prevalence in new TB cases 2014.
2 
 
The risk of contracting TB mainly depends by the average degree of immunodeficiency of 
the community, followed by the predominant socioeconomic conditions and the incidence 
of TB infections among the population. In fact, following HIV-1 infection the risk of 
contracting TB increase from 10% in a lifetime to 10% every year.26 HIV-1 causes a 
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depletion of CD4+ T4 helper cell which rules the recognition of the antigens in the adaptive 
immune system response.27 When the CD4+ T4 helper cells counts start to decrease because 
of HIV-1 infection, the immune system is no more capable to fight Mtb latent infections or 
to protect the body from a first contact with the Mycobacterium.28 Furthermore, the treatment 
of HIV-1 and Mtb co-infected patients is extraordinarily challenging and expensive. The 
combination of HIV-1 treatment with the multidrug treatment often lead to severe side effects 
exacerbating the bad compliance of the patience with the therapy. 
 
1.5. Treatment of TB  
Hospitalised individuals affected by Mtb infection are treated with a 6 months ambulatory 
therapy with so-called first line anti-mycobacterial drugs, such as isoniazid, rifampin, 
pyrazinamide and ethambutol (paragraph 1.5.1). The therapy begins with an “intensive” 
treatment phase of two months followed by a four months “continuation” phase. During the 
intensive treatment, the patient takes all the first line drugs, while during the continuation 
phase the treatment is reduced at just isoniazid and rifampin. The therapy is so structured in 
order to prevent the development of drug resistant strains and it is considered concluded 
when there is disappearance of viable tubercle bacilli from sputum, rendering the patient 
non-infectious. If TB condition persists over the first six months, it means that the infection 
has developed resistant strains to the first line drugs.11 In case of resistant infections, the first 
period of treatment is followed by at least other six months with second line drugs (paragraph 
1.5.2.). In the most extreme cases of resistance, the treatment is prolonged by another six 
months with third line drugs and MDR-TB reversal agent drugs. The drugs used for TB 
treatment are classified on the base of their activity, toxicity levels, availability and price in 
first line, second line, third line drugs and MDR-TB reversal agent drugs. 
1.5.1. First line drugs 
The first line drugs are the drugs endowed with higher activity for the treatment of TB and 
they are all available for oral administration (per os).  
 Isoniazid  
Isoniazid (INH) (Figure 4) is a synthetic bactericidal agent with a MIC of ~0.24 μg/mL 
against Mtb characterized by high tissue penetration.  
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Figure 4. Chemical structure of isoniazid. 
It is considered the single cheapest and most useful antitubercular agent among the first line 
drugs. INH is a prodrug which is converted in situ to its bactericidal active forms by 
Mycobacteria catalase peroxidase KatG.29,30 KatG converts INH in reactive species such as 
the isonicotinic hydrazyl radical and the isonicotinic acyl radical (IAR) which form adducts 
with the coenzyme nicotinamide adenine dinucleotide (NAD+). The adduct IAR-NAD 
blocks the biosynthesis of long chain mycolic acids through the inhibition of enol-acyl 
carrier protein reductase (InhA), which is a key component of the fatty acid synthesis 
complex (FAS II).31 It is used for the prevention and the treatment of both latent and active 
TB32. However, decades of wrong use in many developing countries, often as monotherapy, 
have greatly increased the percentage of INH resistant strains.33 Studies on the identification 
of mutations that could lead to INH resistant strains proved to be not exhaustive. In fact, the 
50-60% of INH resistant strains show mutations, insertions or small deletions that are not 
present on INH sensitive control strains. Mutations leading to INH resistance have been 
identified in different genes involved in the bio-synthesis of INH cellular targets such as 
KatgG (36.8%), InhA (31.6%), ahpC (13.2%) and other genes which function remain to be 
established.34  
 Rifampin 
Rifampin (RIF) together with INH is one of the key component of the initial anti-TB 
treatment. It is a bactericidal semi-synthetic agent derived from a metabolite of 
Amycolatopsis rifamycinica and it shows good tissue and cell penetration, acting rapidly. 
Furthermore it affects extra and intra-macrophagical mycobacteria and is dramatically 
effective for the treatment of latent infections. 
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Figure 5. Chemical structure of rifampin. 
 
RIF carries out its action on the DNA-dependent RNA polymerase  subunit.35 However, 
Mtb generates easily rifampin resistant strains. In the 96% of the RIF resistant Mtb strains 
there is a mutations in the 81-bp core region of rpoB gene, which encodes the subunit of 
RNA polymerase. It is noteworthy that 90% of rifampin resistant isolates are also resistant 
to isoniazid, making RIF resistance a useful surrogate marker for the identification of MDR-
TB strains.36 
 Ethambutol 
Ethambutol (EMB) possess the safest profile among the first-line drugs (Figure 6).  
 
 
Figure 6. Chemical structure of ethambutol. 
 
Despite the fact that its mechanism of action has not been completely elucidated, there is 
evidence that EMB exerts its bacteriostatic activity blocking the biosynthesis of the 
mycobacterial cell wall constituent AG, inhibiting the activity of the arabinosyl transferase.35 
The lack of a clear mechanism of action limits also the investigation on the causes of 
development of EMB resistant strains. Mutation in the gene EmbB is the cause of EMB 
resistance in roughly 70% of Mtb clinical isolates. However, EMB resistance has been 
observed in many organisms lacking mutations in EmbB, suggesting that mutation in other 
genes could encode for resistant strains.37 
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 Pyrazinamide 
Pyrazinamide (PZA) is a bactericidal prodrug converted inside the granuloma to the active 
pyrazinoic acid by a nicotinamidase-peroxydase enzyme known as pyrazinamidase mycolic 
acids. It acts synergistically with RIF, it kills the semi-dormant tubercle bacilli, and its 
activation seems to be directly correlated to the acidic environment of the phagolysosome 
(pH 5.5) in the presence of pyrazinamidase. In fact, PZA shows its high sterilizing activity 
in vitro only if in acidic cultures. Its mechanism of action has not yet been elucidated but 
there is evidence that it binds to the ribosomal protein S1 affecting the trans-translation.38 In 
order to understand how Mtb develops PZA resistant strains, mutations on the pncA gene 
encoding pyrazinamidase have been widely studied. A remarkably large array of pncA 
mutations (70%) lead to tertiary structure modification of pyrazinamidase. Such 
modifications are often followed by a detrimentally change to the enzyme function, avoiding 
the conversion of pyrazinamide in the active pyrazinoic acid.39 Furthermore, some PZA-
resistant strains show mutations in the genes panD and RpsA which encode respectively for 
aspartate decarboxylase and the ribosomal protein S1.40 
 
 
Figure 7. Chemical structure of pyrazinamide. 
 
1.5.2. Second and third line drugs. 
The second and third line drugs were not specifically designed as antitubercular drugs but, 
they found a relevant application in the TB treatment since they possess activity against Mtb 
and its resistant strains. They are generally less active, more toxic and more expensive than 
the first line drugs. Their application is limited to treat MDR/XDR-TB cases or when the 
patient, after the first six months treatment, still shows the presence of Mtb spores in the 
sputum. 
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Figure 8. Some examples of second line drugs.  
 
 Streptomycin 
Streptomycin (SM) is an antibiotic of the class of the aminoglycosides, and it was the first 
drug to be used in the treatment of TB in 1948.41 Nowadays, the SM is considered a second 
line drug because its administration is only intramuscular and because it causes severe 
ototoxicity and nephrotoxicity after prolonged treatment. Furthermore, SM bactericidal 
effect is limited to actively growing tubercle bacilli (MICs between 2–4 μg/mL), but it is 
completely ineffective against non-growing or intracellular bacilli. SM mechanism of action 
consists of the inhibition of protein synthesis by its binding with the subunit 16S ribosomal 
RNA.42 Direct mutations on its cellular target associated with genes rrs and rpsL are the 
main cause of SM resistance strains (75% of the cases). However, failure to identify 
resistance-associated mutations in these genes on the 25% of organisms indicates that other 
molecular mechanisms of SM resistance take place.43 
 Fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin and 
moxifloxacin) 
The Fluoroquinolones (FQs) are a class of broad-spectrum antibiotics which are commonly 
used for the treatment of gastrointestinal, respiratory, and urinary tract bacterial infections 
as well as sexually transmitted diseases.44 FQs show good activity against Mtb and their 
cellular targets are the bacterial DNA gyrase and topoisomerase IV.45 They are the safest 
and most active antitubercular drugs after INH and RIF, however they are not considered 
first-line drugs because their high rate of development of FQs resistant Mtb strains.45,46 
 Aminoglycosides (kanamycin, amikacin and capreomycin) 
The aminoglycosides amikacin (AMK), kanamycin (KAN) and the cyclic polypeptide 
capreomycin (CAP) are important injectable drugs for the MDR-TB treatment. All of them 
interfere with protein synthesis at the level of protein translation. AMK/KAN and CAP based 
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therapy easily develop nephrotoxicity and their use is limited by the high rate of development 
of cross resistant Mtb strains.47,48 However, KAN is the most commonly used injectable for 
MDR-TB. 
 Ethionamide/Prothionamide 
Ethionamide (ETH) and prothionamide (PTH) are derivatives of isonicotinic acid and have 
been used as anti-tubercular agents since 1956. They both act as prodrugs, and they share 
the same mechanism of action of INH blocking the mycolic acid synthesis pathway.49,50 
However, ETH and PTH active metabolite forms have not been identified yet. Studies have 
demonstrated that Mtb resistant strains to ETH show cross-resistant to PTH and INH.51 Their 
use is limited to the MDR-TB treatment because they both causes severe gastrointestinal 
side effects. They cannot be associated in the treatment with p-amino salicylic acid because 
the co-administration causes hypothyroidism, further shortening their therapeutic window as 
second line drugs.  
 p-Amino salicylic acid 
p-Amino salicylic acid (PAS) is one of the oldest known antitubercular agents and it has 
been used in co-administration with INH and SM till the discovery of more effective and 
safer alternatives such as RIF.52 Despite the fact PAS is one of the oldest molecules to be 
used as antitubercular agent, its mechanism of action is still not clear. Furthermore, PAS use 
is limited only to the treatment of XDR-TB cases because of its extreme gastrointestinal 
toxicity.2  
 Cycloserine 
Cycloserine (CS) is an antibiotic, for which the exact mechanism of action is still unknown. 
However, there is evidence showing its effect on the biosynthesis of the peptidoglycan which 
is a paramount constituent of the mycobacterial cell wall. CS possesses high gastric 
tolerance, and lacks cross-resistance to other compounds, but it causes severe adverse 
psychiatric effects;53 which relegates it as second line drug. However, CS shows good 
application in the treatment for MDR-TB and XDR-TB.54 
 Phenothiazine (thioridazine, chlorpromazine) 
Phenothiazine derivatives, especially thioridazine (TZ), have been recently used in therapy 
as third line drugs (Figure 9).55  
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Figure 9. Chemical structures of thioridazine and chlorpromazine. 
 
These compounds are normally employed for the management of psychosis56 but, activity 
assessment against mycobacteria demonstrated that phenothiazines inhibit the growth in 
vitro of Mtb, affecting also MDR-TB and XDR-TB.57 The mechanism of action is still 
unclear but there are evidence that they affect Mtb at several biological targets.55 
Furthermore, they interfere with the synthesis of efflux pumps which is correlated to the 
development of resistant strains turning out to be good anti-TB reversal agent. However, 
their use is limited to the treatment of XDR-TB infections because their severe cardiac side 
effects and their potent activity on the CNS.58 
 
1.5.3. MDR-TB reversal agents 
Against some MDR-TB and XDR-TB cases, the application of first line drugs and second 
line drugs alone have no efficacy. The more relevant and the most frequent tool for the 
development of resistance adopted by the bacteria is the expression of efflux pumps. This 
special mechanism of active efflux allows the bacteria to extrude unwanted toxic substances 
through specific protein channels deployed on the cell wall.59,60 Some efflux systems are 
drug-specific, whereas others may accommodate multiple drugs, and thus contribute to 
bacterial multidrug resistance (MDR). MDR-TB reversal agents are compounds, which 
inhibit directly, or reduce the expression of efflux pumps in the mycobacteria. Once the 
efflux pump system is inhibited, drugs, which previously were extruded by such 
mechanisms, are again free to reach their site of action and have effect on the bacteria. The 
cornerstone of the reversal agents is  Verapamil (a Ca2+ antagonist) that has high efficacy in 
blocking the efflux pump proteins such as P-glycoproteins.61 An other example of an MDR-
TB reversal agent is thioridazine, which has been used successfully in co-administration with 
INH for the treatment of XDR-TB cases.58,62  
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1.5.4. Vaccination. 
During the last century, several disease which have afflicted humanity have been annihilated 
with the development of vaccines. The slow decline in TB incidence globally and the 
growing problem of MDR-TB have been the driving force for the development of a vaccine 
for Mtb infections. The older vaccine available is the Bacille Calmette-Guerin (BCG) which 
is obtained by an antivirulent strain of Mycobacterium bovis.63 BCG however is almost a 
century old, and while the vaccine is effective against severe forms of TB in children, its 
efficacy in preventing pulmonary TB in adults is highly variable. BCG is also not 
recommended for patients infected with HIV-1 due to the risk of disseminated BCG 
disease.64 The development of novel genetic manipulation techniques combined with the 
completion of the M. tuberculosis genome sequence in the 1990s, provide in the past two 
decades, the chance to approach the development of novel vaccines with two different 
strategies. The first involves the research of vaccines that would have a higher efficacy than 
BCG. That includes the study of an improved version of BCG or a new attenuated Mtb strain 
vaccine.65 The second strategy instead is based on the development of a second vaccine to 
be used as a “booster” for the BCG dose given to neonates which would aim to increase the 
efficacy and extend the duration of protection.66 TB vaccine candidates in clinical trials in 
August 2015 are shown in Figure 10. 
 
 
Figure 10. TB vaccine candidates in clinical trials in August 20152 
1.6. MDR-TB, XDR-TB and causes of development of resistance. 
Bacteria become resistant to drugs used in therapy through several mechanisms. First of all 
the organism may produce enzymes or metabolites capable to modify, inactivate or degrade 
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the antibacterial agent before it can conduct its effect. Next in order, the bacteria could 
change the permeability of the cell wall, limiting the contact with the antimicrobial agent. In 
fact, one of the most common causes of drug resistance in bacteria is the development and 
expression on the cell wall of efflux pumps capable of expelling unwanted molecules out of 
the cell.67 All these mechanisms involve spontaneous mutations or the acquisition of genetic 
information that encodes resistance from other bacteria.59 The new strains, which evolved in 
such ways, may be no more affected by the class of drugs, which were previously sensitive. 
Paradoxically, studies have demonstrated that the major cause of development of mutated 
strains is erroneous antimicrobial drugs use. Incomplete, erratic, or single-drug therapy for 
the treatment of TB selected over the last five decades, Mtb resistant mutated strains (DR-
TB). Moreover, this phenomenon, combined with 40 years of no active research for novel 
antitubercular agents endowed with novel mechanism of actions against Mtb, has played a 
paramount rule in the formation of DR-TB.25,68 Once DR-TB has developed and proliferated, 
it potentially can gain resistance to additional drugs through the same process, developing 
multidrug-resistant strains. The development of MDR-TB and XDR-TB has complicated 
enormously the treatment of hospitalized patients. MDR-TB infections are hardly treatable, 
because they are Mtb strains resistant to at least two of the four first line drugs. They require 
a longer hospitalization time and the use of alternative treatment course with more toxic, less 
effective, and more expensive drugs.2 As reported in the WHO annual reports the incidence 
of MDR-TB cases is increasing year by year. In 2011 the estimated MDR-TB cases 
worldwide were between 220,000 to 440,000 while in the last report the estimated worldwide 
cases were 480,000.2,69 On the other hand, XDR-TB are MDR-TB strains which have 
developed resistance to fluoroquinolones and at least one injectable drug (e.g., streptomycin, 
amikacin, kanamycin, capreomycin).2 The treatment of XDR-TB infections is complicated 
and in some cases completely ineffective. The drugs used against XDR-TB infections consist 
of the co-administration of the remaining active drugs available, which usually cause severe 
side effects and have high costs. The outcome of resistant strain infections depends strictly 
on the number of effective drugs still available as well as the compliance of the patients for 
the entire length of the enhanced treatment. However, for XDR-TB infection the mortality 
is higher than all the other TB cases.68 In 2013 the “Centers for Diseases Control and 
Preventions” of South Africa reported the first cases of infection caused by total drug 
resistant Mtb strain (TDR-TB) which was unaffected in vitro by all the known antitubercular 
agents.70 Nowadays, in order to stem the development of new DR-TB, several new anti-TB 
drugs are in preclinical or clinical development. The diamine SQ109,71 the fluoroquinolone 
gatifloxacin72 and linezolid73 are just some of a large pipeline of compounds. However, the 
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validation process for a new drug candidate is so long and so severely selective that the 
majority of the molecules presented in the pipeline probably will never be available or they 
will be after several years of intense study and optimization. For example, TBA-354, a 
nitroimidazole derivative such as delamanid and pretomanid, is the first lead candidate 
endowed with antitubercular activity in the last 6 years to enter a Phase I clinical trial.74,75 
Only recently, two new molecules endowed with activity against TB and MDR-TB gained 
partial access to the market: bedaquiline and delamanid (Figure 11). In December 2012, 
bedaquiline was approved by the US Food and Drug Administration (FDA) for treatment of 
adults with pulmonary MDR-TB as part of combination therapy when other available 
therapeutic strategies have failed. However, safety and efficacy parameters of bedaquiline, 
in combination with first or second line drugs for short duration treatment, are currently 
being investigated as part of the Phase III trial.76 In November 2013, the European Medicines 
Agency (EMA) granted a conditional marketing authorization for delamanid which is now 
used as part of a multi-drug therapy for pulmonary MDR-TB in adult patients. However its 
application as antitubercular agent is limited only “when an effective treatment regimen 
cannot otherwise be composed for reasons of resistance or tolerability”.77 Despite these two 
molecules represent a huge step onward for the treatment of MRD-TB and XDR-TB, their 
limited application does not satisfy the need of novel alternatives for tackling the TB threat. 
In fact, nowadays, no new class of molecules active against MDR/XDR-TB have been 
approved worldwide. Finally, until treatment programs are consolidated (eg., by full 
supervision of each dose, and improved access to culture and susceptibility testing), stepwise 
resistance to the new drugs discovered is still likely.78 
 
Figure 11. Chemical structures of bedaquiline and delamanid. 
 
1.7. Correlation between new advances in synthetic methodologies and drug discovery 
and optimization. 
One of the main difficulties that modern medicinal chemists have to face during the drug 
discovery process is to identify, synthesise, and optimize molecules endowed with the 
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desired and specific pharmaceutical activity. The synthesis of a putative drug has to be as 
cheap, fast and simple as possible, in order to reduce costs and research time. At an early 
stage of the drug discovery, traditional synthetic protocols are usually applied, however, the 
use of novel reactions which increase the repertory of the available bond forming strategies 
have often a remarkable impact in reducing the costs of the drug optimization programs.79 
Furthermore, the detection of new reactions often unlock and made highly desirable 
synthetic pathways considered previously impractical to follow in a drug discovery 
program.80 Therefore, the development of novel methodologies is a field of research at high 
impact for the discovery of the bioactive compounds of the future. Every new reaction is 
important and has the potential to increase the chances of success of a drug discovery 
program. However, the transformations which have major appeal on both academia and 
industry, are reactions with application toward the synthesis of heterocycles.81 Heterocycles 
are recurrent structures in several natural products and thus relevant building blocks to be 
used for the production of compounds of pharmaceutical interests.82 Therefore, the discovery 
of new methodology toward the synthesis of such privileged scaffold could be the key 
turning point to solve challenging synthetic problems which affects nowadays the drug 
discovery and optimization process making more efficient and faster the development of 
novel medicines. 
1.8. Statement of research objectives. 
The TB treatment scenario  urgently require acceleration of  the development of novel 
alternatives to the drugs available in the market. Therefore, the research presented hereafter 
is intended to show the rational design, synthesis and effective antimicrobial screening of 
novel molecules endowed with activity against Mtb following two validated strategies of the 
phenotypic drug discovery approach.2 Furthermore, as mentioned in paragraph 1.7, it is well 
documented that every drug discovery program and drug optimization process heavily relies 
on the synthetic methodologies available for the synthesis of heterocycles.80 Therefore, the 
pharmaceutical work presented in this thesis is enriched with the development of new and 
sustainable synthetic methodologies for the production of highly valuable building blocks to 
be used in the synthesis of antitubercular drugs.  
1.8.1. Structure of the thesis. 
This thesis consists of two main sections. Each section has two self-contained chapters, 
including their introduction, results and discussion, experimental part, and conclusion.  
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The  first section focuses on the discovery, synthesis and biological evaluation of novel anti-
tubercular drugs through two distinct strategies. The first strategy adopted is the molecular 
simplification approach applied to the synthesis of derivatives of a drug recently repurposed 
against TB. The drug chosen for this approach is thioridazine (TZ), which is a well-known 
neuroleptic drug, endowed with good anti-tubercular activity. TZ has been recently used for 
the treatment of MDR and XDR-TB cases where alternative treatment resulted ineffective.83 
The second strategy used for the design of novel TB agents, is the virtual molecular 
hybridization approach. The molecular hybridization approach is one of the strategies 
included within the rational design protocol for identification of new biologically relevant 
small molecules. This approach is based on the recognition of structurally comparable or 
similar molecular portions of two or more bioactive compounds. The approach was applied 
to two molecules endowed with anti-tubercular activity (BM212 and SQ109) (Figure 12). 
 
 
Figure 12. Chemical structures of BM212 and SQ109. 
 
The activity against a panel of mycobacteria of all the compounds synthesised have been 
finally reported. The most promising molecules were also assessed against a panel of MDR-
TB clinical isolates. Moreover, the most active compounds were evaluated as whole-cell 
efflux pump inhibitors.  
In the second section, two novel cascade processes for the synthesis of drug-like compounds, 
namely pyrroles, were fully explored and developed. The development of novel synthetic 
methodologies has always been the driving force for the synthesis of more and more complex 
molecules in a faster, easier, cheaper, greener and competitive fashion. The two cascade 
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processes described in these chapters involve metathesis reactions applied for the synthesis 
of heterocycles, especially pyrroles, which are the scaffold of many drugs including the 
antitubercular compounds developed in this work. The first methodology allows the 
synthesis of 1,2,3-substituted pyrroles through a one-pot tandem enyne cross metathesis 
(CM)-cyclization reaction starting from appropriate propargylamines.84 A large variety of 
synthetically challenging pyrroles bearing aryl, hetero-aryl and alkyl substituents were 
obtained in medium-good yields through this process, which involves microwave irradiation 
and a weak Lewis acid as CuSO4 to promote the cyclization step. The reaction is rapid, 
procedurally simple and represents a facile entry to the synthetically challenging 4,5-
unsubstituted pyrroles. In the second part of this section, a novel and sustainable chemo-
enzymatic process for the synthesis of pyrroles is described. Pyrroles were obtained 
exploiting the oxidative and previously undisclosed aromatizing properties of monoamine 
oxidase (MAO) biocatalysts combined efficiently in the same reaction medium with a ring 
closing metathesis (RCM) reaction.85 The main charm of this technique is represented by the 
successful combination of chemo- and enzymatic catalysis in a concurrent fashion. 
Mimicking the compartmentalization of cellular processes by appropriate choice of solvents 
and reaction conditions, it has been possible to overcome the compatibility issues of the 
catalysts and the difference of the reaction conditions in which these generally operate. The 
novel methodology can be exploited for the sustainable production of highly valuable 
putative antitubercular drugs.  
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2. Design and synthesis of potent antitubercular agents effective against multidrug-
resistant mycobacteria. 
2.1. Introduction. 
2.1.1. Approaches for the drug discovery of novel molecules active against Mtb. 
The drug discovery process is a slow, expensive process with high risk of failure but it is in 
continual evolution and optimization. Nowadays, new biologically relevant small molecules 
active against bacteria are identified by the means of a rational design protocol, which may 
involve two distinct approaches, the target based approach and the phenotypic approach.86 
The target-based approach consists of the identification of a key biological target and in the 
design and development of a molecular entity capable to have a selective and potent activity 
on it. The phenotypic approach instead selects a drug candidate on the base of its overall 
effect on intact biological systems (cells, tissues, or animals). The target-based approach is 
often simpler and faster to execute than a phenotypic approach, and provides detailed data 
on the interaction of a molecule with the specific target. However, this approach does not 
take into account several variables, which characterize the “druggability” of a molecule 
(bioavailability, metabolic pathways etc.), and it has never been applied successfully to the 
design of antibacterial compounds.87 Furthermore, the reliability of this approach is directly 
related to the precision of the available information on the selected cellular site of action, 
limiting its application to drug discovery processes where there is available a clearly 
validated target. On the other hand, the phenotypic approach generally takes more effort and 
resources, but usually the in-vitro results are more directly related to the in-vivo activity. In 
contrast with target based approach, the phenotypic systems often do not take into account 
the mechanism of action and the biological target of assessed molecules. Therefore, the 
identification of the structure activity relationship (SAR) and the further optimization is 
slower and perilous. However, this approach finds a huge application in the drug discovery 
process whenever there is a lack of information about a validated cellular target (new or 
neglected diseases) or in the development of new treatments for diseases which develop 
quickly drug resistance.87 One of these diseases is TB, which has been considered for over 
40 years a neglected disease until the MDR-TB and XDR-TB cases, raised all around the 
world, forced the WHO to declare TB treatment a health emergency. In order to identify 
molecules endowed with potent activity against Mtb and MDR-TB two different approaches 
have been adopted: the virtual molecular hybridization approach and the molecular 
simplification approach starting from a recently repurposed drug. The virtual molecular 
hybridization approach is based on the recognition of structurally comparable or similar 
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molecular portions of two or more bioactive compounds. By means of merging of these 
molecular portions, new hybrid chemical entities that maintain structural elements of the 
parent compounds could be designed. On the other hand, the molecular simplification 
approach applied to the structure of a recently repurposed molecule aims to identify 
structurally simpler derivatives of a well-known biologically active structure, allowing a 
pioneering study of a potential novel class of bio-active compounds. The synthesis and the 
activity assessment of the drug derivatives could elucidate unexpected novel biological 
targets, which can lead to the discovery of putative innovative lead compounds. 
 
2.2. Repurposing and molecular simplification of thioridazine as a strategy for the 
development of novel antitubercular agents effective against multidrug-resistant 
mycobacteria. 
In 2012, bedaquiline (Figure 11),88,89 the first MDR-TB drug to be developed in 40 years, 
was launched in the market and as of now there is a blooming pipeline of putative new 
molecules endowed with antitubercular activity in clinical trials. However, the conventional 
overall therapeutic approach, and the slowness of the drug discovery process make probable 
that further new MDR-TB strains will relentlessly evolve also for these novel drugs.90 The 
practical solution, adopted nowadays for avoiding development of resistant strains after 
point mutations, is the administration of several antitubercular drugs simultaneously.91,92 
However, this is not a perfect solution, especially for TB treatment. The nature of Mtb forces 
the application of a multidrug therapy for months decreasing even further the already bad 
compliance of the patients with the actual TB treatment.93,94 Hence, the ideal approach to 
defeat TB, is to discover a drug capable of inhibiting multiple Mtb targets simultaneously 
while also retaining activity against MDR and latent TB. Studies aimed to the elucidation of 
the mechanism of action of the third line antitubercular drug TZ (Figure 12), 55,83  showed 
that the mechanism of action of this drug involves several mycobacterial targets and it affects 
a large variety of bacterial pathways at the same time.. . It induces an increase in the wall-
cell permeability,95 and reduces the expression of genes related to the over-expression of 
efflux pumps in Mtb,60,96 which is one of the most common causes of multidrug 
resistance.33,97 By the inhibition of efflux pump genes such as mmpL7, p55, efpA, mmr, 
Rv1258c and Rv2459 TZ makes MDR-TB strains susceptible again to the attach of first line 
drugs.98,99 Moreover, Dutta et al. demonstrated that TZ is active against many genes which 
code for essential proteins on the mycobacteria.100,101 One of them is the ndh gene that 
encodes the type-2 NADH dehydrogenase (NDH-2) which is a key enzyme on the 
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mycobacterial aerobic respiratory pathway.102 Furthermore, thioridazine kills dormant 
Mtb103,104 by the mean of an effect on the macrophage which could represent a novel way 
for the treatment of pulmonary TB. By targeting both the macrophage and the mycobacteria, 
TZ has the chance to bypass any developed drug resistance of the bacteria. It is noteworthy 
that, thioridazine is accumulated inside the alveolar macrophages reaching concentrations 
ten times higher than its concentration in plasma which justifies its scarce activity in vitro. 
In order to explain this host target mechanism Amaral and coworkers demonstrated that high 
intracellular concentration of TZ in macrophages inhibits the transport of calcium and 
potassium ions, causing a reduction of the pH in the phagolysosomal vacuole.105 The 
acidification of this latter promotes the hydrolysis of the mycobacterium entrapped in the 
phagolysosome.106–108 This mechanism of action enhances the killing activity of the 
macrophages which become then capable to degrade even the most XDR-TB strain within 
the latent stage of the infection.109 Moreover, it has been reported by Amaral and coworkers 
that several drugs of the phenothiazine class have similar mechanism of action against Mtb. 
However, among them just chlorpromazine, trifluoroperazine and thioridazine showed 
enough potency to have a practical application in TB therapy and only this latter is possible 
to be used at the dose required as third line antitubercular agent (Figure 13).101 
 
 
Figure 13. Thioridazine, chlorpromazine and trifluoroperazine. 
 
Despite the huge variety of potential targets that TZ has against Mtb and its resistant strains 
only few derivatives have been synthesised so far and no drug derivatization and 
optimization studies have been carried out on TZ analogues as inhibitors of MDR-TB.110–112 
Thus, a new library of TZ derivatives has been designed, synthesised and evaluated for their 
antitubercular activity against a panel of mycobacteria including MDR-TB clinical isolates. 
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The role of the aliphatic side chain of 1 and its importance for the antitubercular activity was 
firstly explored as shown in Figure 14.113 
 
Figure 14. First set of 1 analogues. Replacement of the methyl group. 
The N-methyl substituent on the piperidine ring of 1 has been removed and then decorated 
with groups other than the methyl one. Furthermore, the impact on the antitubercular activity 
of a basic side chain was investigated through the synthesis and the biological evaluation of 
derivatives with the amine nitrogen protected as carbamate. Then a second series of 
derivatives was synthesised where the piperidine ring of 1 was replaced with different 
aliphatic heterocycles, keeping fixed the distance between the piperidine nitrogen and the 
phenothiazine ring (Figure 15).  
 
 
Figure 15. Second and third series of TZ derivatives. 
 
Finally, the 2-thiomethyl-phenothiazine core, which is responsible for the main side effects 
on the central nervous system, was replaced with different hetero-aromatic rings, with the 
aim to reduce the toxicity of the molecule. 
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2.2.1. Results and discussion. 
2.2.1.1. Synthesis of thioridazine derivatives.  
The N-substituted derivatives 6a-c have been synthesised in order to investigate the role of 
the methyl substituent on the piperidine nitrogen. 1 has been successfully de-methylated 
following the procedure described by Hopfner and coworkers.114 yielding compound 5 in 
85% yield (Scheme 1). Compound 4 has been isolated in order to investigate the impact of 
a basic side chain on the antitubercular activity of 1 derivatives. 
 
Scheme 1. Synthesis of nor-thioridazine. 
 
Then, compound 5 was reacted with the appropriate ketone/aldehyde (namely propanone, 
propionaldehyde, and benzaldehyde) in the presence of the reducing agent sodium 
triacetoxyborohydride (NaBH(AcO)3) affording the corresponding alkyl-piperidine 6a-c 
with good yields (Scheme 2). 
 
 
Scheme 2. Reductive amination reaction conditions for the synthesis of 6a-c. 
 
A second series of derivatives where the piperidine ring was replaced with commercially 
available N-substituted piperazine and thiomorpholine was then synthesised. In this second 
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series, the 2-thiomethyl substituent on the phenothiazine ring was removed or replaced with 
chlorine, to evaluate its importance for the antitubercular activity. (Scheme 3, Table 1). In 
particular, the chlorine substituent was chosen because of structural similarity with 
chlorpromazine 2, a phenothiazine derivative closely related to TZ.  
Firstly, commercially available aromatic compounds 9a-d (namely 9a 10H-phenothiazine, 
9b 2-Cl-10H-phenothiazine, 9c 2-SMe-10H-phenothiazine, 9d indole) were alkylated to 1-
bromo-3-chloropropane obtaining compounds 10a-c and 10e. Furthermore, 9c was also 
reacted with 2-chloroacetyl chloride leading to 10d (Scheme 3). 
 
 
Scheme 3. Synthesis of compounds 10a-e. 
 
Then, 2-Adamantyl-pyperazine 8 was obtained through a two step synthesis as described in 
Scheme 4.  
 
 
Scheme 4. Synthesis of 2-Adamantyl-piperazine 8. 
 
 
 26 
 
Finally, compounds 11a-j and 12 were finally obtained through alkylation of compounds 
10a-e with thiomorpholine and other N-substituted piperazines (Table 1). 
 
Table 1. Synthesis of 11a-j and 12. 
 
 
Cmpd R R1 Yields%a 
11a H 1-methyl-piperazine 99% 
11b H 1-phenyl-piperazine 62% 
11c SMe 1-methyl-piperazine 99% 
11d SMe 1-phenyl-piperazine 77% 
11e SMe thiomorpholine 99% 
11f SMe 1-adamantantyl-piperazine 71% 
11g SMe 2-adamantantyl-piperazine (8) 72% 
11h Cl 1-phenyl-piperazine 57% 
11i Cl thiomorpholine 90% 
11j - 1-methyl-piperazine 96% 
12 - 1-methyl-piperazine 63% 
a Isolated yields. 
Finally, a library of TZ derivatives bearing different aromatic cores was synthesized 
according to classical synthetic procedures. 2-(Piperidin-2-yl)ethanol 13 was Boc-protected 
on the piperidine via Schotten-Baumann reaction. The resulting carbamate then undergoes 
Appel reaction with triphenylphosphine (PPh3) and tetrabromomethane (CBr4) in 
dichloromethane (DCM) giving the bromide 14 in good yield (98%) (Scheme 5). 
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Scheme 5. Synthesis of bromide 14. 
 
Then, several commercially available heteroaromatic compounds were alkylated with 14 
(namely 9a phenothiazine, 9b 2-Cl-phenothiazine, 9d indole, 9e carbazole and 9f 
benzo[d]imidazole) in the presence of NaH in N,N-dimethylformamide (DMF) obtaining 
Boc-protected compounds 15a-e which led to the desired amines 16a-e after HCl-mediated 
Boc-cleavage.  
 
 
Scheme 6. Synthesis of piperidine 16a-e. 
 
Finally, compounds 16a-e and formaldehyde were reacted in the presence of the reducing 
agent NaBH(AcO)3 in THF to yield the corresponding methylated compounds 17a-d with 
medium to good yields (38-70%).  
 
 
Scheme 7. Synthesis of TZ derivatives 17a-d. 
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The methylation of the indole 16e has not been attempted because according to a recent 
paper by Pieroni and coworkers the methylated indole have poor activity against M. 
tuberculosis mc27000.112 
 
2.2.1.2. Evaluation against a panel of mycobacteria.  
All the compounds were initially evaluated for their biological activity by determining the 
minimum inhibitory concentrations (MIC90) against a panel of mycobacteria including the 
fast-growing nonpathogenic strains of Mycobacterium smegmatis115 followed by the vaccine 
strain Mycobacterium bovis BCG and the non pathogenic Mtb mc27000 (Table 2). The first 
activity assessment and all the tests were performed by Dr Alistair Brown at Northumbria 
University. A preliminary SAR analysis from the compounds synthesised showed that 
removal of the methyl group of TZ did not affect the activity as reported for 5. On the other 
hand, from compounds 6a-c it is possible to observe that bulky aromatic substituents on the 
nitrogen of piperidine (6b) are favourable for the activity while aliphatic substituents, bulkier 
than methyl, (6a, and 6c) are not. Noteworthy is that, the replacement of the piperidine-ethyl 
moiety with alkyl chains bearing piperazine or thiomorpholine rings as in 11 lead to a 
dramatic decrease of antimycobacterial activity, with the only exception of the bulky 
derivative 11g which showed a MIC = 4 g/mL on M. smegmatis. Thedata collected from 
the biological evaluation of the Boc protected derivatives 15a-e show that none of them are 
active against the tested panel of mycobacteria. These data suggest that a hydrogen atom 
acceptor (HAA) in the side chain is paramount for the antibacterial activity. However, it is 
noteworthy that the carbamate 4 shows activity values similar to 5. This data is possible to 
be explained by the fast hydrolysis which the labile chloroethyl carbamate 4 could undergo 
in the buffer used for the activity assessment affording directly in vitro the compound 5. 
Furthermore, as shown in Table 2, removal of the methyl-thio substituent of 1 and 5 (as in 
17a and 16a), as well as the replacement of the phenothiazine scaffold with different 
heterocyclic moieties (as in 17c-d and 16c-d) led to a significant loss in activity. On the 
contrary, replacement of the same SMe group with a chloride group (as in 16b and 17b) 
resulted in compounds with an antimycobacterial activity comparable to or better than that 
of 1 and 5. In particular, the chloro-phenothiazine derivative 16b showed a good activity 
against BGC and Mtb mc2700 strains with MIC = 5.3 g/mL and 4 g/mL, respectively. 
Similarly, the methylated analogue 17b retained 8 g/mL MIC value against M. tuberculosis 
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mc27000. Interestingly, the indole derivative 16e proved to be highly active against M. 
smegmatis with MIC = 1.6 g/mL. 
 
Table 2. Antitubercular activity (MIC90) on M. smegmatis strains, M. bovis BCG and Mtb 
mc27000. 
Compound M. smeg WT 
(MIC90)g/mL 
g/mL 
M. smeg mmpL3 
(MIC90) g/mL 
M. bovis BCG 
(MIC90) g/mL 
Mtb mc27000 
(MIC90) g/mL 
TZ 16 12 16 8-5(6.5) 
4 16 8 8 8 
5 16 8 8 8 
6a >64 64 >64 64 
6b 16 8 8 8 
6c >64 >64 64 >64 
11a 64 32 64 26.7 
11b >64 >64 >64 >64 
11c 32 16 8 26.7 
11d >64 >64 >64 >64 
11e >64 >64 >64 >64 
11f 64 64 64 64 
11g 4 8 >64 >64 
11h >64 >64 >64 >64 
11i >64 >64 >64 >64 
11j >64 >64 >64 >64 
12 >64 >64 >64 >64 
15a >64 >64 >64 >64 
15b >64 >64 >64 >64 
15c >64 >64 >64 >64 
15d >64 >64 >64 >64 
15e >64 >64 >64 >64 
16a >64 64 >64 >64 
16b 16 16 5.3 4 
16c >64 >64 >64 >64 
16d >64 >64 >64 >64 
16e 1.6 1.6 64 64 
17a 32 32 64 16 
17b 16 16 8 8 
17c >64 64 >64 64 
17d >64 >64 >64 >64 
INH N.Da 4 0.063 0.125 
aN.D not determined. The experiments were performed in triplicate. 
 
Then, the most promising compounds have been assessed against the pathogenic M. 
tuberculosis H37Rv, susceptible M. tuberculosis strain CF73, and two MDR-TB clinical 
isolates (CF104 and CF81). All the tests and the activity assessmet were performed by Prof. 
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Fernando R. Pavan at Universidade Estadual Paulista "Júlio de Mesquita Filho" (UNESP) 
(Table 3). Compound 5 and 6b which are active against Mtb mc27000 showed weak activity 
against Mycobacterium tuberculosis  H37Rv. The same trend was observed for compounds 
11a and 11c bearing an N-Me-piperazine moiety on the side chain. On the other hand, 
compounds 16b, 16e, and 17b, bearing the piperidine side chain, showed the best results. In 
particular, the chloro-derivatives 16b and 17b showed an activity toward CF73 and the MDR 
strains similar to that of 1 in the same range of concentration (8-16 g/mL). On the other 
hand, the indole derivative 16e proved to be the best compound of the series, with an 
increased activity against both Mtb H37Rv and CF73 strains (2.9 and 1.0 g/mL, 
respectively, in comparison to 10.0 and 8.0 g/mL found for 1). Moreover, 16e also showed 
a similar profile of 1 against MDR-CF104 (10 vs 11 g/mL) and a slightly improved activity 
against MDR-CF81 (4 vs 10g/mL). These data suggested that the presence of a secondary 
amine on the scaffold of the side chain could be beneficial for the antitubercular activity, as 
also observed in the work exposed in paragraph 2.3.1.116 
 
Table 3. Antitubercular activity on a panel of photogenic M. tuberculosis strains. 
Cmpd Mtb     
H37Rv 
MIC90g/mL) 
Susceptible  
(CF73) 
MIC90g/mL) 
MDR-TB 
(CF104) 
MIC90g/mL) 
MDR-TB   (CF81) 
MIC90g/mL) 
TZ 10 8 11 10 
5 100 >100 >100 >100 
6b >100 37 32 44 
11a 100 >100 >100 >100 
11c 69 27 23 33 
11g 43 98 20 48 
16b 26 11 19 11 
16e 2.9 1 10 4 
17a >64 47 >64 58 
17b 19 16 16 12 
INH 0.03 0.03 >25 >25 
RIF 0.3 8 >25 >25 
The experiments were performed in triplicate. 
 
Finally, to prove the effectiveness of the most active compounds, their citotoxicity was 
evaluated by Prof. Fernando R. Pavan at Universidade Estadual Paulista "Júlio de Mesquita 
Filho" (UNESP) on human lung fibroblast MRC-5 cells and murine macrophage J774A.1 
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cells (ATCC TIB-67). Mouse models are routinely used for testing the efficacy of both 
antitubercular drugs and vaccines and are considered a highly appropriate model. Mouse 
models such as J774A.1 cells and the murine macrophage RAW264.7 cells are key players 
in the stimulation of specific immune reactions capable of eliciting a whole host of 
inflammatory responses and have been studied and characterized in great detail over many 
decades.117 The ratio of the MIC90 observed against M. tuberculosis Susc. (CF73) and the 
GIC50 values provided the selectivity index (SI), or the therapeutic window, offered by these 
molecules. As a result, 16e showed a selectivity index 15 fold higher than that of TZ (Table 
4). 
 
Table 4. Cytotoxicity of compounds TZ, 16b, 16e and 17b. 
Cmpds GIC50 (g/mL) SIa 
MRC-5 J774A.1 MRC-5 J774A.1 
TZ  8.2 4.1 1 0.5 
16b 10  10.7 1.1 1 
16e 15  7.3 15 7.3 
17b 13  8.3 1.2 1.9 
aSelectivity index are calculated as the ratio between the M. tuberculosis Susc. (CF73) MIC90 
and the GIC50. The experiments were performed in triplicate. 
 
 
2.2.1.3. Evaluation as efflux pump inhibitors. 
The efflux pump inhibitory (EPI) activity of TZ derivatives on the model M. smegmatis was 
tested in order to investigate their effect as potential MDR-TB reversal agents. Dr. Bhakta 
group at Birbeck College London carried out an efflux pump activity whole-cell-based assay 
and as a consequence, the results account for the total activity of the whole population of 
efflux pumps present in the cells. Verapamil (VP) was chosen as positive control for the test. 
The numbers 1−4 shows low to very high EPI (as a representation of an increased level of 
ethidium bromide accumulation above the cell control). In detail, EPI value of 0 indicates 
no inhibition, 1 indicates low inhibition (efflux substrate accumulation above cell control to 
20000 relative fluorescence units), 2 indicates moderate inhibition (between 20000 and 
30000 units), 3 indicates high inhibition (between 30000 and 40000 units), and 4 indicates 
very high inhibition (between 40000 and 50000 units). The experiments were performed in 
triplicate, and the Table 5 reports the average values obtained. 
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Table 5. Efflux pump inhibitory (EPI) activity. 
Cmpd EPI M. smegmatis Cmpd EPI M. smegmatis 
4 2 16b 2 
5 2 16e 1 
6b 2 17a 2 
11a 3 17b 2 
11c 3 2 3 
11g 1 VP 4 
 
The efflux pump assay showed that some TZ derivatives are endowed with a good EPI 
activity. However, a weak correlation between inhibition of bacterial growth and efflux 
pump mechanism is observed. The compounds 16b and 16e, which showed the most 
promising antimycobacterial activities, proved to be poor efflux pump inhibitors (Table 3 – 
Scheme 6). On the other hand, the piperazine derivatives 11a and 11c which showed a MIC 
of 26.7 g/ml on Mtb mc27000, inhibit efflux pumps similarly to the reference 
chlorpromazine 2, thus looking as promising candidates in a multidrug therapy owing to 
synergistic combinations.  
 
2.2.2. Conclusions. 
Within this chapter the synthesis and the development of novel anti-tubercular drugs was 
described following the drug simplification approach on the structure of the third line drug 
thioridazine.55,83A small library of TZ derivatives bearing structural changes in three key 
different positions of the original scaffold, has been synthesised. Antimycobacterial activity 
of the resulting compounds showed that the piperidine-ethyl side chain of TZ is required to 
inhibit non-pathogenic, pathogenic and MDR mycobacterial strains. Moreover, the SMe-
phenothiazine scaffold of 1 could be only replaced with the Cl-phenothiazine analogue or 
simplified into an indole moiety. The most active compound 16e, bearing a demethylated 
piperidine ring in addition to an indole heterocycle, showed an activity profile better than 
that of 1 and a cytotoxicity about 15-fold lower toward MRC-5 and J774A.1 cells. 
Furthermore, the most promising compounds were evaluated for their ability to inhibit the 
efflux pump activity in mycobacteria. Compounds 11a and 11c showed similar EPI activity 
than the reference 2 proving to be potential MDR-TB reversal agents. 
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2.3. Synthesis of novel antitubercular agents effective against multidrug-resistant 
mycobacteria via molecular hybridization approach. 
The virtual molecular hybridization approach is one of the strategies included in the rational 
design protocol for the identification of new biologically relevant small molecules. It 
consists on the recognition of structurally comparable or similar molecular portions of two 
or more bioactive compounds. Then, through merging these molecular portions, it is possible 
to design new hybrid chemical entities that maintain structural elements of the parent 
compounds. The two bioactive compounds chosen for the virtual molecular hybridization 
are BM212 (I) and SQ109 (II) (Figure 12). About fifteen years ago, the pyrrole compound 
I was discovered to be a potent antimycobacterial agent.118 In an effort to identify new 
pyrrole analogues with improved solubility and ability to kill multidrug-resistant and 
extensively drug-resistant mycobacteria, many I derivatives were designed and 
synthesized.119 I congeners showed a submicromolar activity toward M. tuberculosis 
H37Rv. However, the first series of I analogues (including I itself) suffered from poor 
pharmacokinetic parameters (in terms of clearance and microsomal stability) and significant 
cytotoxicity.118 Although the most recent derivatives showed an improved pharmacokinetic 
and cytotoxic profile, their physicochemical parameters (such as lipophilicity and 
aromaticity) need further optimization. On the other hand, adamantane-diamine compound, 
SQ109 II was described as an antitubercular drug that is active against susceptible and drug 
resistant M. tuberculosis strains.71 SQ109 exhibited promising activity in drug combination 
during animal preclinical studies and it is currently undergoing phase 2 clinical trials for 
further development.120 The cellular target of both these molecules is the trehalose 
monomycolate exporter, MmpL3 protein (Rv0206c), and member of the MmpL 
(mycobacterial membrane protein large) family.116,121 MmpL3 is a validated drug target in 
M. tuberculosis.121 This family has primary structure homology to the resistance-nodulation-
cell division (RND) protein family, mainly involved in drug resistance in Gram-negative 
bacteria.119 Although the M. tuberculosis genome encodes 13 members of the MmpL family, 
their function has not been clearly elucidated. Despite their annotation as multidrug 
transporters, they do not contribute to antimycobacterial drug resistance.122 MmpL3 has also 
been implicated in heme acquisition by M. tuberculosis, although it might not be its primary 
role in an endogenous environment.121 By means of an in silico molecular modelling 
approach conducted by Prof Fabrizio Manetti at the University of Siena (see paragraph 
2.3.1.1) the three-dimensional structure of both compounds I and II was studied (Figure 16).  
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Figure 16. Graphical representation of I and II (left panel), a rough superimposition of the 
topological distribution of their chemical features and superimposition of their three 
dimensional conformers (central upper panel) and superimposition of their three-
dimensional conformers as generated by the common feature hypothesis generation routine 
(central lower panel), general hybrid derivative structure (right upper panel) and its three 
dimension conformation (right lower panel). 
 
Although the apparent structural dissimilarity between the two compounds, a rough 
superposition of specific conformers of I and II showed an unexpected high similarity 
between them (Figure 16). In fact, except from the terminal adamantyl moiety of SQ109 and 
the p-Cl phenyl ring at the C5 position of I, the remaining part of the SQ109 structure was 
superimposable to that of I. Because of this similarity, a molecular hybridization approach 
has been applied to design new putative antimycobacterial compounds. The more rigid 
scaffold of I was chosen as the template for the new hybrid derivatives and adjusted  upon 
comparison with the flexible structure of II. As a result, the N-(substituted-phenyl)pyrrole 
core of I with a piperazinylmethyl side chain at position C3 was maintained, while the second 
phenyl substituent at position C5 of I was deleted from the new hybrid compounds. In 
addition, the adamantyl moiety present in II was inserted as the terminal group bound to N4 
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of the piperazine ring, leading to the design of a general hybrid derivative structure as shown 
in Figure 16. Hence, a set of novel pyrrole derivatives inspired to the general hybrid structure 
obtained by the superimposition of the antitubercular agents I and II, have been designed, 
synthesized, and biologically evaluated. To explore the chemical space around the C3 
piperazino-methyl moiety of the new compounds, the distal piperazine nitrogen was 
substituted with different bulky moieties, such as adamantyl, norbornyl, cyclohexyl, or aryl 
groups. Moreover, the role of the substituent on C5 and its importance for the antitubercular 
activity were explored. According to the superposition hypothesis, the aryl moiety at C5 of 
I was replaced by a methyl substituent, thus leading to design the first series of pyrroles 
derivatives described in Figure 17.  
Figure 17. Synthetic plan for the synthesis of the first and second series of pyrroles 
derivatives. 
 
In addition, a second series of hybrid derivatives was also designed through molecular 
simplification of the general hybrid structure described in Figure 16 in order to evaluate the 
influence of the piperazine ring on the antitubercular activity. Within this series, also 
according to previous works,123 the piperazine ring was removed from the structure and 
replaced with a secondary amine (or hydroxylamine) at C3. In both cases, the methyl 
substituent at C2 and C5, as well as the N1 aryl groups, were left unchanged as shown in 
Figure 17. 
2.3.1. Results and discussion 
2.3.1.1. Computational design and hypothesis on the common chemical features shared 
by BM212 and SQ109.  
In order to confirm the superposition pattern above-described for I and II, and in 
collaboration with Prof. Manetti at the University of Siena, the Phase software (Phase, 
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version 3.3, Schrodinger LLC, New York, 2011.) was used to find the three-dimensional 
arrangements of the common chemical portions shared by I and II (thereafter referred to as 
common feature models or superposition models). As a result, a four-feature representation 
was obtained, comprised of two hydrophobic groups and two protonatable atoms (Figure 
18). 
  
 
Figure 18 Graphical representation of the four-feature superposition model common to I 
(thin lines) and II (thick lines). The two protonatable chemical features (P7 and P8) are in 
blue, while the two hydrophobic regions (H4 and H6) are in green. The conformer of I 
represented in the picture is 0.013 kJ/mol from the lowest energy conformation, while the 
energy difference between the lowest energy conformation of II and the conformer 
reported in the picture is 4.660 kJ/mol. 
 
In detail, the p-Cl group at the phenyl in N1 position of the pyrrole ring of I and one of the 
terminal methyl groups of II matched one of the common hydrophobic regions (H6). The 
central methyl group of II and the 2-methyl group of I corresponded to the second 
hydrophobic portion (H4). On the other hand, the two positively ionizable features (P7 and 
P8) accommodated the two basic nitrogen atoms of both compounds. It is important to point 
out that this representation of the common chemical features of I and II showed two 
protonatable sites that are chemically unrealistic at neutral pH. However, this qualitative 
model only accounts for the presence of the two piperazine nitrogens of I and for the two 
amine nitrogens of II, while it does not take into consideration the mutual influence of the 
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two amines during the protonation steps. Analysis of the superposition pattern of I and II 
suggested to omit the aromatic portion at position 5 of I. In fact, a visual inspection of the 
superimposed structures of I and II showed that this moiety does not match an analogous 
group on II (Figure 18) and consequently, it does not represent a common feature of both 
compounds. Moreover, since the three aromatic rings forced the structure of these 
compounds toward planarity, the removal of one or more of them could be in principle 
profitable for better solubility and bioavailability. In addition, given the well-established 
relationship between late-stage drug development problems (i.e., the high attrition rate of 
compounds entering the clinical phase) and the lipophilicity of compounds,124 modulation 
of lipophilicity should be taken into account when new putative anti-mycobacterial 
compounds are designed. In addition, since the terminal methyl group of I is partially 
superimposed on the adamantyl moiety of II, a hydrophobic group at this position was 
maintained. Following these suggestions and taking into account the similarity between I 
and II, a new class of pyrrole derivatives was designed on the basis of the molecular 
hybridization routine with the aim of obtaining new putative antimycobacterial compounds. 
The more rigid scaffold of I was chosen as the template for the design of novel antitubercular 
compounds while the adamantyl group (already found in II) and other bulky alkyl 
substituents were introduced on the piperazine ring, while the 5-phenyl ring of 1 was 
removed. 
 
2.3.1.2. Synthesis of BM212-SQ109 hybrid derivatives. 
A library of pyrrole derivatives bearing an N-substituted piperazinomethyl chain at C3 was 
first synthesised according to classical synthetic procedures. Pyrroles 22a−f were 
synthesized through a microwave-assisted Paal−Knorr reaction starting from diones 20a and 
20b and different anilines (Table 6).123,125 1-(4-Chlorophenyl)pentane-1,4-dione 20b was 
obtained from p-chloro-benzaldehyde via a Stetter reaction catalysed by thiazolium salt 
(Scheme 8).126  
 
Scheme 8. Synthesis of 20b. 
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Computational studies suggested that the p-Cl-Ph moiety in position N1 of I should be kept 
in the hybrid derivatives, however, a small number of different substituents were also 
introduced in the phenyl ring to evaluate their steric and electronic effects on the anti-
mycobacterial activity confronting their impact on the activity with the BM212 derivatives 
already reported in the literature.118 (Table 6). 
 
Table 6. Synthesis of pyrroles 22a-f. 
 
Aniline R R1 Pyrrole Yield% 
21a Me 4-Cl 22a 93% 
21b Me 4-F 22b 98% 
21a 4-Cl-C6H4 4-Cl 22c 90% 
21c Me 2-F 22d 92% 
21d Me 4-i-Pr 22e 95% 
21e Me 3-Me 22f 97% 
 
 
Moreover, different bulky substituents were introduced on the piperazine ring to explore the 
chemical space around the pyrrole nucleus. 2-Norbornyl-piperazine 23a was synthesised 
through a two step synthesis as shown in Scheme 9 and then reacted with pyrroles 22a and 
22c-f.  
 
 
Scheme 9. Synthesis of piperazine 23a. 
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The Boc-piperazine 7 and 2-norbornanone were reacted in the presence of the reducing agent 
NaBH(OAc)3 to yield the corresponding alkylpiperazine intermediate as a mixture of 
exo/endo isomers, which was immediately converted into the desired piperazines 23a by 
TFA-mediated Boc cleavage. Finally, the piperazines 8, (synthesised following Scheme 4) 
23a−d (N-cyclohexylpiperazine 23b, N-phenylpiperazine 23c, 1-adamantylpiperazine 23d 
are commercially available) were coupled via Mannich reaction with the pyrroles 22a and 
22c-f affording pyrroles 24a−m. The yields of the reactions are reported in Table 7.  
 
Table 7. First series of pyrrole derivatives 24a-m. 
 
Cmpd R R1 X Yield%a 
24a Me 4-Cl 2-Adamantyl 56 
24b Me 2-F 2-Adamantyl 45 
24c Me 4-iPr 2-Adamantyl 51 
24d Me 3-Me 2-Adamantyl 48 
24e Me 4-Cl Phenyl 65 
24g Me 4-Cl 2-Norbornylb 55 
24h Me 4-Cl Cyclohexyl 52 
24i Me 4-Cl 1-Adamantyl 54 
24j 4-Cl-C6H4 4-Cl Phenyl 64 
24k 4-Cl-C6H4 4-Cl 2-Adamantyl 65 
24l 4-Cl-C6H4 4-Cl 1-Adamantyl 60 
24m 4-Cl-C6H4 4-Cl 2- Norbornyl
 b 56 
aIsolated yields are reported. bMixture of exo/endo isomers. Compound 24f was isolated as a 
side product, 35% yield. 
Then, a second series of pyrrole derivatives was synthesised according to the strategy 
described on chapter 2.3. Pyrroles 22a-c were formylated through the Vilsmeir−Haack 
reaction, affording the aldehydes 25a-c with good yields (Scheme 10).  
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Scheme 10. Synthesis of aldehydes 25a-c. 
 
The aldehydes 25a-c were then reacted with different primary amines in the presence of 
NaBH(AcO)3 to yield pyrroles 26a−i. as shown in Table 8. 
 
Table 8. Synthesis of second series of hybrids 26a-i 
 
Cmpd R R1 R2 Yields%a 
26a 4-Cl Me PhCH2CH2 75 
26b 4-Cl Me PhCH2 79 
26c 4-Cl Me Cyclohexyl 77 
26d 4-Cl Me 2-Adamantyl 60 
26e 4-Cl Me 4-Me-Bn 82 
26f 4-Cl Me 4-Cl-Bn 78 
26g 4-Cl Me 4-F-Bn 80 
26h 4-F Me PhCH2 82 
26i 4-Cl 4-Cl-C6H4 PhCH2 78 
aIsolated yields 
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Furthermore, aldehydes 25a and 25b were reacted with benzylhydroxylamine to afford 
oximes 27a and 27b,123 which, after treatment with NaBH3CN, led to the corresponding 
hydroxylamines 28a and 28b in excellent yields. (Table 9). 
 
Table 9. Synthesis of pyrroles 27a, 27b, 28a and 28b. 
 
Cmpd R Yields%a 
27a 4-Cl 75 
27b 4-F 78 
28a 4-Cl 80 
28b 4-F 82 
aIsolated yields 
 
 
2.3.1.3. Evaluation of hybrid derivatives of I and II against a panel of mycobacteria. 
Compounds 24-28 were assessed for their biological activity by determining the minimum 
inhibitory concentrations (MIC90) against a panel of fast-growing and slow-growing 
mycobacterial species and clinical isolates by collaborators at Birkbeck College and UCL 
London.  
A preliminary screening has been conducted by Dr. Bhakta group at Birbeck college London 
on the fast-growing non-pathogenic strains of Mycobacterium smegmatis, the vaccine strain 
M. bovis BCG, and relatively fast-growing intra-cellular surviving Mycobacterium aurum,115 
(Tables 10).  
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Table 10. Antitubercular activity on M. smegmatis, M. bovis BCG, and M. aurum 
mycobacterial strains of compound 24-28. 
Cmpd 
M. smegmatis mc2155 
MIC90 (μg/mL) 
M. bovis BCG 
MIC90 (μg/mL) 
M. aurum 
MIC90 (μg/mL) 
24a 8.0 3.3 7.8 
24b 13 1.3 250 
24c 21 4.0 500 
24d 64 62 500 
24e 32 32 31 
24f >64 >64 250 
24g 27 32 16 
24h 27 21 31 
24i 8.0 16 16 
24j >64 2.0 >125 
24k >64 64 >125 
24l 3.3 2.0 62 
24m 64 64 250 
26a 32 16 16 
26b 4.0 0.5 1.9 
26c 8.0 0.4 7.8 
26d 16 2.0 62 
26e 8.0 4.0 1.9 
26f 4.0 8.0 1.9 
26g 2.0 0.5 1.9 
26h 16 13 7.8 
26i 8.0 8.0 1.0 
27a >64 >64 >125 
27b >125 >125  >125 
28a >64 >64 >125 
28b >64 >64 >125 
I 25 0.78 16 
II 4.0 2.0 7.8 
INH N.D a N.D a N.D a 
a not determined. The experiments were performed in triplicate. 
 
Then all the compounds have been assessed by Dr. Bhakta group at Birbeck college London 
for their activity against the non-pathogenic M. tuberculosis mc27000, the pathogenic M. 
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tuberculosis H37Rv, and finally against a panel of MDR-TB clinical isolates obtained from 
Royal Free Hospital NHS Trust, London, UK. (Table 11). 
Table 11. Biological evaluation of compounds against a panel of M. tuberculosis strains. 
Cmpd 
M. tuberculosis 
mc27000 
MIC90 (μg/mL) 
H37Rv 
MIC90 (μg/mL) 
MDR1MIC90 
(μg/mL) 
MDR2 
MIC90 (μg/mL) 
24a 3.3 7.8 7.8 16 
24b 1.0 3.9 7.8 16 
24c 3.3 16 62 125 
24d 32 16 31 125 
24e 32 7.8 31 >125 
24f >64 31 62 >125 
24g 2.0 1.9 3.9 31 
24h 8.0 3.9 7.8 62 
24i 8.0 16 125 125 
24j 1.0 1.9 3.9 >125 
24k >64 62 125 125 
24l 0.5 7.8 16 62 
24m 64 ND N.D N.D 
26a 4.0 1.0 1.9 7.8 
26b 0.5 0.5 1.0 3.9 
26c 0.5 0.2 0.5 16 
26d 1.0 1.9 3.9 125 
26e 2.0 1.0 3.9 7.8 
26f 2.0 16 31 >125 
26g 0.7 >125 >125 16 
26h 4.0 1.0 7.8 62 
26i 16 N.D N.D N.D 
27a >64 >125 >125 >125 
27b >125 25 N.D N.D 
28a >64 >125 125 >125 
28b >64 >125 62 >125 
I 8.0 1.0 3.9 16 
II 2.0 0.51 N.D N.D 
INH N.D 0.24 10 25 
The experiments were performed in triplicate. N.D not determined. 
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The data arising from the screening of non-pathogenic M. tuberculosis mc27000 (Table 11) 
have been analysed for first. In agreement with initial hypothesis (paragraph 2.3.1.1), the 
insertion of a 1- and a 2- adamantylpiperazine group in place of the N-methylpiperazine of 
I led to compounds 24l and 24k which are endowed with significantly contrasting activity. 
In fact, 24k, bearing the same 2-adamantyl group found in II, was inactive (MIC value >64 
μg/mL). On the contrary, the corresponding 1-adamantyl analogue 24l showed a strong 
activity against Mtb mc27000, with a MIC value of about 0.5 μg/mL. Compound 24l was 
then chosen as the most representative compound to be further studied for deducing SAR 
considerations of the new class of hybrid compounds on Mtb mc27000. In particular, 
according to the suggestions derived from the superposition pattern between I and II, the p-
Cl phenyl moiety at C5 of 24l was simplified to a methyl group, leading to 24i, with a 
significant 16-fold drop in activity (8.0 μg/ mL). The corresponding 2-adamantyl analogue 
24a showed a slight increase in activity (3.3 μg/mL). Moreover, small changes in 
substituents and substitution pattern at its 1-phenyl ring clearly showed that small 
substituents (i-Pr and F) at para and o-positions (such as in 24c and 24b) guaranteed activity 
retention or enhancement (3.3 and 1.0 μg/mL, respectively). On the other hand, a m-methyl 
group as in 24d caused a significant drop in activity (32 μg/mL), in agreement with that 
previously found for derivatives of I.118,127 Decreasing the bulkiness of the hydrophobic 
moiety on the piperazine ring from an adamantyl (such as in 24i or 24a) to a norbornane 
group led to a slight improvement of activity (MIC of 24g was 2.0 μg/mL). On the contrary, 
a further simplification to a cyclohexyl ring (24h) and its aromatization to a phenyl ring 
(24e) further reduced activity to 8.0 and 32 μg/mL, respectively. Introduction of a second p-
Cl phenyl moiety at C5 of 24e restored a 1.0 μg/mL activity in 24j. SAR considerations 
obtained from data collected in Table 11 for  both 24j and 24e (1.0 and 32 μg/mL, 
respectively) suggested that in several cases the presence of the p-Cl phenyl moiety at C5 
could improve antimycobacterial activity. On the other hand, a comparison between the 
activity of 24e and its adamantyl analogues 24a and 24i (3.3 and 8.0 μg/mL, respectively) 
clearly showed that the p-Cl phenyl moiety at C5 was not mandatory for obtaining active 
compounds, as suggested by the common feature model described in paragraph 2.3.2.1. 
Also, the comparison of the biological profiles of 24g and 24m bearing norbornyl groups at 
N4 clearly shows that the p-Cl phenyl moiety at C5 in 24m could be detrimental for the 
antitubercular activity (2.0 and 64 μg/mL, respectively). Moreover, after the observation of 
the comparable antimycobacterial activities of 24j and 24l (1.0 and 0.5 μg/mL, respectively) 
it is possible to hypothesize that the distal nitrogen atom of the piperazine ring (which is 
protonatable in 24l but has anilino character in 24j) could be inconsequential for activity. 
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This result was in agreement with previous pharmacophoric-based calculations and the in 
vitro activity of piperidine analogues of I.119 In order to validate this hypothesis, the second 
series of hybrid derivatives 26, 27, and 28 bearing a linear amino spacer instead of the 
piperazine ring were synthesised. Among them, 26a had an overall size comparable to that 
of 24e and lacked the distal nitrogen atom of the parent piperazine ring. Its activity was 8-
fold better than that of the piperazine analogue 24e (4.0 and 32 μg/mL, respectively). 
Attempts to modify the phenylethylamino side chain of 26a by introduction of an oxygen 
atom (as in 28a and 28b) or by partial rigidification into an aryl oxime (as in 27a) led to 
inactive compounds (>64 μg/mL). Alternatively, shortening the phenylethylamino spacer 
led to very active compounds. As an example, the benzylamino analogue 26b showed a 0.5 
μg/mL MIC value. Decoration of the para position of the terminal phenyl ring with small 
substituents (such as F, Cl, and Me) led to 26g, 26f, and 26e which are endowed with 
comparable or slightly lower activity (0.7, 2.0, and 2.0 μg/mL, respectively). These data 
further confirm that the distal nitrogen atom of the piperazine ring was not necessarily 
required for the antimycobacterial activity of the new hybrid compounds. On the contrary, 
replacement of the p-Cl of 26b with a p-F group as in 26h caused an 8-fold drop in activity 
(from 0.5 to 4.0 μg/mL). A further reduction of the amino side chain length to a 
cyclohexylamino and to the bulky 2-adamantylamino moiety as in 26c and 26d, respectively, 
also maintained a 0.5 and 1.0 μg/mL activity. Interestingly, when the methyl group at C5 of 
compounds 26b was replaced with a p-Cl phenyl moiety leading to derivative 26i, a 
significant drop in activity was observed (16 μg/mL). Compounds 26b and 26c proved to be 
much more active than I against Mtb mc27000. These latter data confirm the initial 
hypothesis that an aryl substituent at C5, such in I, is not mandatory to obtain derivatives 
active against M. tuberculosis. Furthermore, compounds bearing a secondary amine show a 
better activity profile than II, thus pointing out that a diamine backbone could be unessential 
for antitubercular activity. All the compounds were also assayed on additional mycobacterial 
strains. Activity against the pathogenic Mtb H37Rv (Table 11.) followed the same trend 
already shown for the Mtb mc27000 strain. Compounds 26f and 26g were the only 
exceptions. They resulted both inactive or weakly active toward Mtb H37Rv (16 and >125 
μg/mL, respectively), while their congener compounds 26e and 26b showed a 1.0 and 0.5 
μg/mL activity. The hybrid compounds 24a, 24b, 24e, and 24h showed a good profile with 
MIC = 7.8, 3.9, 7.8, and 3.9 μg/mL, respectively. The derivative 24j bearing a p-Cl-phenyl 
substituent at C5 showed an improved biological profile (1.9 μg/mL). As a general trend, the 
simplified compounds 26 showed higher activity against Mtb H37Rv than derivatives 24. In 
particular, compounds 26b and 26c proved to be the most active, with MIC values of 0.5 and 
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0.2 μg/mL, respectively resulting more active than I and II. Furthermore, it is noteworthy 
that the hybrid compounds showed weak activity toward M. smegmatis mc2155 (MIC values 
ranging from 4.0 to >64 μg/mL), with the only exception of compounds 24l and 26g which 
showed MIC values of 3.3 and 2.0 μg/mL, respectively (Table 10). Similarly, M. aurum was 
scarcely sensitive to the test compounds: only four compounds (namely, 26b, 26e, 26f, and 
26g) showed a MIC value of about 2.0 μg/mL (Table 10). As the whole genome sequence 
of M. aurum has been published recently, comparative genomic analyses of these transporter 
proteins should elucidate why the difference in their drug susceptibilities is observed.115 On 
the contrary, a better antimycobacterial activity profile was found toward M. bovis BCG 
(Table 10). Ten hybrid derivatives showed MIC values in the range below 4.0 μg/mL and 
three of them (namely, 26b, 26c, and 26g) with a MIC value of 0.5 μg/mL. The data arising 
from the screening of MDR-TB strains (Table 11) showed that the test compounds were 
poorly active against MDR2 strain with 26a and 26b as the only exceptions, which showed 
a good activity of 7.8 and 3.9 μg/mL. Differently, MDR1 growth was inhibited by seven 
compounds with MIC values lower than 4.0 μg/mL. Exceptional results were observed for 
compounds 26b and 26c, which showed MIC values of about 1.0 and 0.5 μg/mL, 
respectively. 26b and 26c proved to have a better activity profile than those of the parent 
compound I and INH. From an analysis of the data reported on Table 10 and 11, compounds 
26a-c show the best activity profile whilst they are characterized by structural features 
significantly different from those of the parent compound I. In detail, they lacked both the 
distal nitrogen atom of the original piperazine ring and the p-Cl-Ph group at position C5 of 
the pyrrole nucleus. Furthermore, it is noteworthy that the overall activity underwent an 
improvement when the basic linear side chain was shortened from the phenylethylamino of 
26a, to the benzylamino of 26b, to the cyclohexylamino of 26c. The aryl moiety at position 
C5 was not a mandatory substituent for the synthesis of active compounds, and data 
suggested that small modifications on N1-phenyl ring are allowed. A bulky terminal group, 
such as an adamantyl or norbornanyl, improve the activity of piperazine analogues, while 
antimycobacterial activity highly benefits from the replacement of the piperazine moiety 
with shorter, linear aryl and alkylamino side chains. Finally, cytotoxicity analysis of 
compounds 24-28 was carried out by collaborators at Birkbeck College (Table 12.). The 
eukaryotic cell toxicity of each compound was tested against murine macrophage 
RAW264.7 cells and human monocyte-derived THP-1 cell line to ascertain the 50% growth 
inhibitory concentration (GIC50). The ratio of the MIC90 observed against Mtb H37Rv and 
the GIC50 values provided the selectivity index offered by these molecules. It must brought 
to note that there are differences in the assay methods to determine the inhibitory 
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concentrations of the compounds against the bacterial pathogen and the eukaryotic cells. 
However, these methods have been extensively standardized so as to reduce ambiguity in 
inferring the selectivity index from these assays.128 
 
Table 12. Biological evaluation of compounds 24-28 against a panel of Eukaryotic cells. 
Cmpd GIC50 (μg/mL) SI b 
RAW264.7 THP-1 RAW264.7 THP-1 
24a 5.7 32 ± 1 0.7 4.1 
24b 11 26 ± 1 2.8 6.7 
24c 92 72 ± 1 5.7 4.5 
24d 22 37 ± 1 1.4 2.3 
24e 33 25 ± 1 4.2 3.2 
24f 500 113 ± 1 16 3.6 
24g 5.6 16 ± 1 2.9 8.4 
24h 5.5 16 ± 1 1.4 4.1 
24i 0.1 16 ± 1 0.006 1.0 
24j 175 294 ± 5 92 155 
24k 95 500 ± 10 1.5 8.1 
24l 23 35 ± 18 2.9 4.5 
24m N.D 429 N.D 6.7 
26a 9.9 7.3 ± 2.7 10 7.3 
26b 5.5 7.2 ± 3.7 11 14 
26c 10 7.4 ± 1.4 50 37 
26d 19 15 ± 10 10 7.8 
26e 0.1 6.1 ± 2.1 0.1 6.1 
26f 0.1 18 ± 1 0.006 1.1 
26g 26 8.4 ± 1.7 - - 
26h 5.6 28 ± 1 5.6 28 
26i N.D 99 ± 1 N.D 6.1 
27a 128 500 ± 22 ≅1 < 4.0 
27b - a - a N.D N.D 
28a 133 67 ± 1 - - 
28b 123 292 ± 41 ≅1 < 2.3 
I 19 3.23 19 3.23 
II N.D - a N.D N.D 
INH N.D - a N.D - 
a no inhibition was seen b Selectivity index (SI) is calculated as the ratio between M. 
tuberculosis H37Rv and GIC50. The experiments have been performed in triplicate. N.D not 
determined. 
Among the most active compounds 24j, 26b and 26c, showed an excellent cytotoxicity 
profile, with a SI of 92, 11, and 50 against RAW264.7 cells and 155, 14 and 37 against THP-
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1 cells, respectively. Both 24j and 26c have a higher SI than the parent compound I against 
both the murine and human cells. 
2.3.1.4. SAR considerations and development of a new pharmacophoric model. 
The high antimycobacterial activity maintained even after a significant structural 
simplification of 1,5-diarylpyrroles derivatives of I into the corresponding 1-aryl hybrid 
analogues (Table 10 – Table 11) could be accounted for by a comparison of the original 
pharmacophoric model for antimycobacterial compounds belonging to the pyrrole class of 
I127 with the simplified common feature model described in paragraph 2.3.1.1. In fact, the 
original pharmacophoric model127 was able to accommodate I and its derivatives in two 
different orientations, rotated by about 180° around the pyrrole plane. Following this, the 
aryl moieties at positions N1 and C5 of I could reciprocally change their spatial location and, 
consequently, match with the pharmacophore. These results suggested that the 
pharmacophoric portions able to accommodate the substituents at positions N1 and C5 are 
redundant and could be simplified, as also suggested by the superposition between I and II. 
In a further attempt to codify the structural features of the new hybrid pyrroles, a second-
generation common feature model was built at the University of Siena starting from a larger 
set of compounds, comprised of I, II, and the most active pyrroles (with MIC values ≤1.0 
μg/mL) (Figure 19). 
 
Figure 19. Graphical representation of the four-feature improved model matched by the 
most active hybrid pyrrole 26c. 
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The improved model showed that the distal nitrogen of the piperazine ring of I 
(corresponding to P8 in the previous common feature model) was omitted, while an 
additional hydrophobic region (H2), adjacent to the P7 feature (a positively ionizable 
feature), accommodated the terminal hydrophobic groups of the C3 side chain. 
2.3.1.5. Evaluation of the hybrid derivatives of I and II as efflux pump inhibitors. 
Finally, the effect of pyrroles on the efflux pump inhibitory (EPI) activity of the model 
surrogate organism M. aurum was tested by Dr. Bhakta group at Birbeck College Londonin 
order to identify compounds able to reverse multidrug resistance in TB. An efflux pump 
activity whole-cell-based assay has been carried out, and therefore, the results account for 
the total activity of the whole population of efflux pumps present in the cells. Verapamil 
(VP) was chosen as positive control for the test. The numbers 1−4 shows low to very EPI 
activity (as a representation of an increased level of ethidium bromide accumulation above 
the cell control). In detail, EPI value of 0 indicates no inhibition, 1 indicates low inhibition 
(efflux substrate accumulation above cell control to 20000 relative fluorescence units), 2 
indicates moderate inhibition (between 20000 and 30000 units), 3 indicates high inhibition 
(between 30000 and 40000 units), and 4 indicates very high inhibition (between 40000 and 
50000 units). The experiments were performed in triplicate, and the Table 13 reports the 
average values obtained. 
 
Table 13. Efflux pump inhibitory (EPI) activity of 24, 26, 27 and 28. 
Cmpd EPI M. aurum Cmpd EPI M. aurum Cmpd EPI M. aurum 
24a 1 24l 3 27a 1 
24b 1 24m N.D 27b N.D 
24c 3 26a 2 28a 2 
24d 2 26b 2 28b 4 
24e 1 26c 2 I 2 
24f 2 26d 1 II 2 
24g 1 26e 2 INH N.D 
24h 4 26f 2 VP 4 
24i 4 26g 1   
24j 2 26h 1   
24k 0 26i 1   
ND: not determined. 
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The efflux pump assay revealed that most of the pyrrole compounds, except 24k, possess at 
least low or moderate inhibitory property. However, a weak correlation between inhibition 
of bacterial growth and efflux pump mechanism is observed. For example, 26a−c are very 
efficient in killing mycobacterial cells but only display moderate modulatory effect on the 
pumps. Differently, the inactive compound 28b inhibits efflux inhibition on a par with the 
control inhibitor Verapamil. Interestingly, 24c, 24h, 24i, and 24l, bearing a bulky alkyl 
substituent on the piperazine ring, showed good/ excellent inhibitory activity. These findings 
suggest that specific endogenous targets for these compounds are still elusive; however, the 
results indicate that they may have pleiotropic modes of action and thus, potential to reverse 
antimicrobial resistance. As TB treatment involves a combination of complementary drugs, 
this off-target effect of the compounds could enhances the effectiveness of drug treatment 
regimens. Within this context, it is noteworthy that five compounds (namely, 28b, 24c, 24h, 
24i, 24l) show a much higher EPI activity than I and II (Table 13) which are known 
inhibitors exclusively of the pump transporter MmpL3. In fact, the less potent mycobacterial 
growth inhibitors but, endowed with higher whole-cell efflux inhibitory features, may also 
prove to be prospective leads in a multidrug therapy owing to synergistic combinations, 
should that arise. Thus, unlike I and II, which show poor EPI activity, 28b and 24b could be 
used in combination with standard antitubercular drugs such as INH or RIF to reverse 
multidrug resistance in tuberculosis. 
 
2.3.2. Conclusions. 
Within this chapter the synthesis and development of novel anti-tubercular drugs through the 
application of a molecular hybridization approach was described. A library of hybrid pyrrole 
derivatives was designed, synthesised, and then evaluated for its antitubercular activity 
against Mtb and MDR-TB clinical isolates. Five compounds showed antitubercular activity 
on Mtb at ≤1.0 μg/mL, and two of them (26b and 26c) proved to be highly active also against 
MDR-TB strains. SAR studies have been conducted and they revealed the key features 
essential for the antimycobacterial activity for this new class of antitubercular compounds. 
Finally, compound 26c showed a better drug profile than I in terms of activity, cytotoxicity, 
and potency toward MDR-TB clinical isolates turning out to be an excellent lead candidate 
for preclinical trials.  
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3. Development of novel methodologies for the synthesis of heterocyclic drug-like 
compounds. 
 
3.1 Introduction 
Heterocycles are recurring structural moieties in Nature and they have remarkable relevance 
in organic chemistry, particularly finding outstanding applications in  medicinal 
chemistry.129 The development of new drugs in the last century has largely taken into account 
the use of natural products as source of structures endowed with biological activity. Often, 
such molecules are decorated with, or even made of, heterocycles making these structures 
interesting building blocks for the design of medicines. Applications of heterocycles in 
medicinal chemistry range from their ability to modify key characteristics of a drug scaffold 
(such as its lipophilicity, polarity and its solubility), to their application as bioisosteres for a 
large variety of functional groups. Therefore, they are great tools for the drug optimization 
processes in modulating potency and efficacy of a drug.130 It is noteworthy that the 
occurrence of aromatic nitrogen heterocycles in many natural and synthetic biologically 
active compounds is high. This represents an incentive toward the development of new 
synthetic methodologies towards these important chemicals.129 Moreover, it has been 
estimated that more of 50% of the bestselling drugs contain a nitrogen heterocyclic nucleus, 
thus fuelling a demand for broadly applicable synthetic methods that deliver aromatic 
heterocycles in high yield. In chapter 2.3 the discovery of a class of pyrroles endowed with 
potent activity against drug-resistant tuberculosis was described. In the following chapters 
two novel and sustainable approaches for the production of this extremely important class 
of heterocycles are described.116  
 
3.1.1. New approaches for the synthesis of pyrroles: Metathesis reaction. 
Typical approaches for the synthesis of pyrroles include the Paal−Knorr131 and 
Clauson−Kass reactions,132 the aza-Wittig reaction133 or other multicomponent 
approaches.134 More recently, metathesis emerged as a powerful and effective reaction for 
the synthesis of many functionalized pyrroles from acyclic precursors. Metathesis is a Greek 
word (μετάθεσις) which means transposition and it is used in organic chemistry to define a 
class of bimolecular processes involving the exchange of one or more bonds between similar 
interacting chemical species affording products with similar or identical bonding affiliations 
to those in the reactants. The most widely used metathesis reactions are catalysed by metal 
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carbene complexes which allow the formation of a carbon-carbon bond through exchange of 
groups on two alkenes (olefin metathesis) or between an alkene and an alkyne (enyne 
metathesis). From the first discovery of metathesis reactions by Karl Ziegler, over 60 years 
ago, metathesis reactions have become very important tools for organic chemists both in 
research and industry.135 The widely accepted mechanism for olefin metathesis reactions 
was proposed by Yves Chauvin in 1971.136The Chauvin mechanism involves the formation 
of a metallocyclobutane intermediate between a metal carbene complex (also called 
carbenoid) and an alkene double bond. The instable intermediate, thus could lead to either 
the original species or a new alkene and alkylidene (Scheme 11). 
 
 
 
Scheme 11. Chauvin mechanism.  
 
The applications of this molecular process developed as quickly as the development of new, 
more and more stable, selective and powerful carbenoids. In 1988, Schrock and coworkers 
introduced a variety of stable and easy to prepare Mo and W catalysts. These complexes 
provided the first controlled catalysts in metathesis and enabled the reaction to occur under 
milder conditions than ever before. Furthermore, they are powerful enough to allow the 
conversion of sterically demanding substrates in the desired products. However, their 
applications are limited by their poor tolerance towards functional groups.137  
Grubbs and coworkers expanded the studies conducted by Schrock and developed two 
generations of Ru alkylidene catalysts endowed with high specificity for olefinic groups and 
increased stability to oxygen and moisture which make them easier to handle than the more 
powerful but unstable Schrock catalysts.138 During the last decade, many groups dedicated 
their effort to the development of novel ruthenium carbene complexes bearing various 
ligands which enhance the stability of the carbenoid, the functional group tolerance and the 
potency of the catalysts toward structurally complex substrates (Figure 20).139–143 
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Figure 20. Schrock and Grubbs’ catalysts. 
 
Olefin metathesis was the first metathesis reaction to be widely used for the synthesis of a 
large variety of chemicals of interest. This class of reaction found several applications such 
as ring-closing metathesis (RCM), cross metathesis (CM), ring-opening cross metathesis 
(ROCM), ring-opening metathesis polymerization (ROMP) and acyclic diene metathesis 
polymerization (ADMET) as shown in Figure 21.  
 
  
Figure 21. Classification of Olefin Metathesis. 
 
Enyne metathesis (EYM) consists in a bond reorganization between an alkene and an alkyne 
to produce a 1,3-diene. EYM could be intramolecular (enyne RCM) and intermolecular 
(enyne CM, enyne ROMP) depending on the nature of the starting materials.144 The general 
mechanism for EYM is showed in Scheme 12.  
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Scheme 12. Enyne metathesis reaction mechanism. 
 
The EYM mechanism of reaction involves an activation step followed by the proper catalytic 
cycle. In the activation step, the olefin group reacts with the catalyst affording a 
metallocyclobutane intermediate, which then undergoes cycloelimination forming a metallo-
carbene complex and ethylene as a side product. The metallo-carbene complex so formed 
enters  the catalytic cycle reacting with an alkyne, leading to a vinylcarbene intermediate 
via a metallocyclobutene transition state. Finally, the vinyl carbene reacts with another olefin 
group yielding the 1,3-diene and restoring the metallo-carbene complex, which enters again 
into a new catalytic cycle. Both olefin and enyne metathesis reactions generally occur with 
low catalyst loading (1-10%) and afford products in high yields and short reaction times. 
Furthermore, the catalyst high affinity for olefin and olefin moiety combined with its large 
tolerance for other functional groups, makes the reaction highly chemo-specific, and 
therefore, minimal substrate protection is necessary. The large amount of advantages which 
metathesis reactions offer over other metal catalysed carbon-carbon bond formation 
processes has inspired several groups to use this reaction for the synthesis of high requested 
substrates such as functionalised pyrroles. Donohoe145,146 and Rutjies147 first developed a 
two step sequence to pyrroles from diallylamines III via olefin ring-closing metathesis 
followed by aromatization mediated by RuCl3, Pd/C, FeCl3 or t-BuOOH (Figure 22).
148–151 
This latter step is supposed to occur through the oxidation of the amine IV into the 
corresponding iminium intermediate V leading in turn to pyrrole VI by tautomerization. 
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Figure 22. Olefin metathesis approaches to pyrroles. 
 
More recently, Donohoe152 and Grela153 described an olefin cross-metathesis approach for 
the synthesis of pyrroles. Both approaches are based on the CM of appropriately substituted 
allylamines and enones followed by acid catalysed cyclization (Figure 23). 
 
 
Figure 23. Two steps olefin CM-cyclization approach.152,153 
 
Also the alkyne-alkene (enyne) metathesis has been successfully applied toward the 
synthesis of heterocyclic compounds.144,154 Both RCM-enyne and CM-enyne approaches 
have found large application for the synthesis of indoles, pyrrolines, dihydrofurans and 
dihydropyranes.155 However, only Stevens and coworkers156 described a synthesis of 
pyrroles via a RCM-enyne metathesis-aromatization sequence whilst there are no examples 
in the literature describing the synthesis of pyrroles via a CM-enyne approach (Figure 24). 
 
 
Figure 24. Stevens’s RCM enyne approach. 
 
Therefore, the development of a methodology involving enyne CM toward the synthesis of 
this important class of heterocycles could have the double potential to enhance the 
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application field of enyne CM class of reaction and to make accessible versatile building 
blocks such as functionalised pyrroles for application in medicinal chemistry. In paragraph 
3.2 a novel methodology for the synthesis of 1,2,3 substituted pyrroles from inexpensive 
starting materials such as propargylamines via a tandem enyne CM-cyclization reaction is 
described.  
 
3.1.2. Novel insight for the sustainable synthesis of pyrroles. 
It is noteworthy that the majority of the approaches for the synthesis of pyrroles described 
in this chapter relies on the oxidation of a cyclic amine like a pyrroline to an iminium ion, 
which then leads via tautomerization and aromatization to the formation of the desired 
pyrrole. The direct oxidation of amines into imines or iminium ions still represents a 
challenge in organic synthesis and only few approaches have been described so far. These 
methods rely on the use of metal catalysts such Fe, Pd, Ru in the presence of oxygen or 
TEMPO and often require harsh reaction conditions.148 However, in Nature, the oxidation 
of an amine group into the corresponding imine is a common biochemical transformation 
catalysed by a class of oxidoreductases enzymes called amino oxidases.157–159Among this 
class of enzymes, monoamine oxidase (MAO), in particular MAO variants from Aspergillus 
niger (MAO-N) and 6-hydroxy-D-nicotine oxidase (6-HDNO) found a broad application as 
biocatalysts for asymmetric synthesis of pharmaceuticals and natural products. Furthermore 
both MAO-N and 6-HDNO have been widely studied as biocatalysts for the production of 
enantiomerically pure amines through the selective oxidation and deracemization of a range 
of chiral aliphatic substrates such as chiral pyrrolidines (Figure 25).160–162 
 
 
Figure 25. General mechanism for the dynamic deracemization of chiral aliphatic 
substrates. 
 
The structural similarity between the pyrrolidine ring and the pyrroline inspired the 
development of a sustainable approach for the synthesis of pyrroles from 3-pyrrolines 
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exploiting the oxidizing property of MAO-N biocatalysts described in paragraphs 3.3.1.3. 
and 3.3.1.4. Furthermore, oxidizing/aromatizing properties of MAO-N biocatalysts have 
been coupled with the RCM approach generally used for the synthesis of 3-pyrrolines thus 
leading to the development of a chemo-enzymatic cascade for the synthesis of pyrroles as 
described in paragraph 3.3.1.6.  
 
3.2. Synthesis of 1,2,3-substituted pyrroles from propargylamines via a one-pot tandem 
enyne cross metathesis – cyclization reaction. 
Pyrroles are a class of compounds widely present in Nature, (Figure 26) and they are  
interesting heterocyclic scaffolds to be used for the synthesis of compounds of 
pharmaceutical interest.  
 
 
Figure 26. Some example of pyrroles in Nature and in pharmaceutical industry. 
 
Only a few examples for the synthesis of 4,5-unsubstituted pyrroles have been reported so 
far and most of them rely on multistep synthetic sequences.163,164 As described in paragraph 
3.1.1, there are no examples reported in the literature about the synthesis of pyrroles via 
enyne cross-metathesis reaction. The development of the first synthetic approach to pyrroles 
involving such reaction is described. Enyne-CM reaction is an useful version of catalytic 
olefin metathesis, and it involves the formation of a diene from an alkene and an alkyne. The 
synthetic appeal of enyne cross-metathesis is that it offers a catalytic, direct, and 
regiocontrolled access to conjugated dienes, which have broad application in synthesis. 
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Castagnolo et al. recently demonstrated that ethyl vinyl ether (EVE) can be used as the olefin 
synthetic equivalent of the acetaldehyde in enyne CM reactions, leading to the formation of 
crotonaldehydes when reacted with terminal alkynes in the presence of the weak Lewis acid 
CuSO4 as shown in Scheme 13.
165 
 
 
Scheme 13. EVE used as olefin equivalent of acetaldehyde in an enyne CM.  
 
This reaction allows the formation of diene ii that, in presence of CuSO4 in aqueous medium 
is hydrolysed, affording the corresponding enol. The latter finally tautomerizes into 
crotonaldeyde iii. It was hypothesized that an analogous strategy could be a short and elegant 
approach for the synthesis of 4,5-unsubstituted pyrroles when propargylamines are used as 
starting materials as shown in Scheme 14. 
 
Scheme 14. Proposed one-step enyne CM-cyclization approach for the synthesis of 
pyrroles. 
 
In the proposed method the propargylamines iv and EVE undergo enyne CM reaction under 
microwave irradiation conditions affording the corresponding diene v. The weak Lewis acid 
CuSO4 catalyses both the cleavage of the ethoxy group and the electrophilic activation of the 
diene v which undergoes a cyclization reaction affording the five membered ring 
intermediate vi. Such intermediates quickly tautomerize into the desired pyrrole vii. In the 
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next pages is therefore described the exploration, the development and the application of a 
one-pot tandem enyne cross metathesis-cyclization reaction for the production of the 
synthetically challenging 1,2,3-substituted pyrroles from opportunely substituted 
propargylamines.84  
 
3.2.1. Results and discussion. 
3.2.1.1. Optimization of the reaction conditions. 
Bearing in mind the work present in literature, the research of the best reaction conditions 
for the one pot synthesis of pyrrole 41a from the simple N-Boc propargylamine 29a was 
investigated as described in Table 14.  
 
Table 14. Optimization of the reaction conditions. 
 
Entry Solvent GII mol% CuSO4 T °C/ Time Yield %a 
1 H2O/tBuOH 5 2 eq. 80°C/20min 29% 
2 H2O/tBuOH 10 2 eq. 80°C/20min 25% 
3 Toluene 5 2 eq. 80°C/30min 36% 
4 Toluene 5 2 eq. 120°C/30min 56% 
5 Toluene 5 - 120°C/30min 0%b 
6 Toluene 5 1 eq. 120°C/30min 18% 
7 Toluene 10 2 eq. 120°C/30min 55% 
8 Toluene 5 - c 120°C/30min 56% 
a Isolated yields. b 41% diene 30 isolated. c 2 eq. of Cu(OTf)2 were used. 
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The Boc-protected propargyl amine 29a was first reacted with EVE, in the presence of GII 
and CuSO4 at 80 °C under microwave irradiation in 1:1 tert-butanol/water leading to the 
formation of the desired pyrrole 41a with 25-29% yield (entries 1-2). The use of a higher 
GII loading (entry 2) did not lead to any improvement of the yield, while a slightly higher 
amount of pyrrole 41a was isolated when the reaction was run in degassed toluene (36%, 
entry 3). In entry 4, it is shown that increasing the temperature to 120°C and the time at 30 
minutes, was beneficial for the reaction outcome, enhancing the yield to 56%. When the 
reaction was run with the same reaction condition of entry 4 but without CuSO4 the pyrrole 
41a is not formed and the reaction led to the formation of the corresponding diene 30 in 41% 
yield (entry 5). Moreover, the use of a stoichiometric amount of CuSO4 led to 41a in only 
18% yield (entry 6). It is noteworthy that when the reaction was performed with 5 mol% or 
10 mol% catalyst loading there were no significant differences in the yield (entries 4-7). 
Finally, the use of a different copper source, such as the stronger Lewis acid Cu(OTf)2, did 
not lead to any improvement in the yield of the reaction (entry 8). These data suggest that 
CuSO4 plays a relevant role for the outcome of the reaction thus, further experiments were 
carried out in order to understand better the influence of the Lewis acid as additive for the 
cyclization step which led to 41a from 30 (Table 15). 
 
Table 15. Investigation of the role of CuSO4. 
 
Entry GII mol % Additive Time T.°C Conv. %a 
1 - - 24h 110 °C 70% 
2 - 2 eq. CuSO4 6h 110 °C 100% 
3 - 2 eq. CuSO4 20 minutes 120 °C Mw 30% 
4 10 mol % 2 eq. CuSO4 10 minutes 120 °C Mw 100% 
a Converison values were measured by 1H-NMR spectroscopy. 
 
It is noteworthy that without CuSO4 the formation of pyrrole 41a from propargylamine 29a 
and EVE did not occur leading only to the formation of the diene 30 (Table 14, entry 5). 
When, the diene intermediate 30 was reacted in refluxing toluene for 24 h  (entry 1, table 
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15) 41a was obtained only with 70% yield, while in the presence of CuSO4 (2 eq.) the 
reaction reached completion after 6 h (entry 2). These data suggests that Cu2+ could help the 
cyclization step coordinating the ethoxy group and facilitating its cleavage. Surprisingly, 
when 30 was heated at 120 °C under microwave irradiation and in the presence of CuSO4 (2 
eq.) for 20 min, only 30% of conversion was observed (entry 3). Moreover,, if the same 
reaction was run in the presence of 10 mol % of GII, the full conversion of 30 into 41a was 
observed after 10 min. Thus, the data gathered suggest that both the Cu2+ and [Ru] (from the 
GII) contribute to the cyclization of 30 and to the formation of 41a. 
In order to assess the flexibility of the methodology toward different amine group 
substituents a set of N-substituted propargylamines 29b-e was synthesised according to the 
literature.166–169N-Tosyl-propargylamine 29b and N-benzoyl-propargylamine 29c were 
obtained from propargylamine 31 reacted respectively with tosyl chloride and benzoyl 
chloride in DCM and TEA (Scheme 15).  
 
Scheme 15. Synthesis of propargylamines 29b and 29c. 
 
Subsequently, N-phenyl-propargylamine 29d was obtained reacting propargylbromide 32 
with aniline in EtOH, while the treatment of propargylbromide with benzylamine in DCM 
afforded N-benzyl-propargylamine 29e in good yields as shown in Scheme 16.  
 
Scheme 16. Synthesis of propargylamines 29d and 29e. 
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The propargylamines 29b-e were then reacted with EVE, in the presence of GII and 2 
equivalent of CuSO4 at 120 °C under microwave irradiation in degassed toluene as described 
in Table 16  
 
Table 16. Synthesis of pyrroles 41b-e. 
 
Entry Cmpd R GII mol% Additive Pyrrole Yield %a 
1 29b Ts 5 - 41b 25% 
2 29b Ts 10 - 41b 53% 
3 29c Bz 10 - 41c 39% 
4 29d Ph 10 - 41d 54% 
5 29e Bn 10 - 41e N.Ob 
6 29e Bn 10 TsOH*H2O (1.2 eq.) 41e N.O
b 
aIsolated yields were reported. b Product 41e was not observed 
 
 
The treatment of the tosyl derivative 29b with 5 mol% of GII led to desired 41b in 25% 
yield, while a higher amount of 41b (53%) was recovered when 10 mol% of catalyst was 
used (entry 1-2). The pyrrole 41c was obtained in moderate yield from the benzoyl 
compound 29c (entry 3) while propargylaniline 29d afforded the phenyl-pyrrole 41d in good 
yield (entry 4). On the contrary, the benzyl-derivative 29e was recovered unreacted from the 
reaction mixture and no pyrrole 41e was observed (entry 5). It is reported in literature that, 
contrary to the electron poorer anilines and tertiary hindered amines, the aliphatic primary 
and secondary amines poison the Ru-catalysts thus preventing the metathesis reactions.170,171 
In order to overcome such issue, in entry 6, a Brønsted acid was added to the reaction mixture 
in order to coordinate the nitrogen lone pair of the amine 29e making it unable to poison the 
ruthenium.172 Unfortunately, when the amine 29e was treated with a stoichiometric amount 
of p-toluensulfonic acid (PTSA) and then reacted with an excess of EVE under standard 
reaction conditions no pyrrole 41e was formed and a mixture of side products was observed 
from the crude  reaction mixture by 1H-NMR spectroscopy. 
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In order to expand the scope of this tandem metathesis-cyclization protocol to the 
synthetically challenging 1,2,3-substituted pyrroles, propargylamines 37a-h, 36 and 40a-d 
were synthesised. Three different synthetic approaches for the synthesis of highly substituted 
propargylamines were employed. In order to synthesise the propargylamines 37a-h and 36 
a first batch of aryl-propargylalcohols 34a-e was synthesised in high yields from the 
appropriately substituted benzyl aldehydes 33a-e (Scheme 17) 173–175 
 
 
Scheme 17. Synthesis of aryl-propargyl-alcohols 34a-e. 
 
Compounds 33a-e were reacted with ethynyl magnesium bromide in dry tetrahydrofuran 
(THF) affording the aryl-propargyl alcohols 34a-e in excellent yield (96-99%). As shown in 
Scheme 18, propargyl alcohol 34a was acetylated to give the alkyne 35 which was in turn 
converted into the phenyl substrate 36 through a copper mediated amination reaction 
(59%).176 
 
 
Scheme 18. Synthesis of aniline 36. 
 
Moreover, propargyl-alcohols 34a-e were treated with H2SO4 in CH3CN and Na2SO4 
affording aryl-propargylacetamides 37a-e in good yields. Then, the hydrolysis of 37a-b 
followed by Boc-, Bz and Ts-protections led to substrates 37f-h with good yields as shown 
in Table 17. 
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Table 17. Synthesis of compounds 37a-h. 
 
Cmpd R R1 Yield %a 
37a H Ac 78% 
37b 4-Cl Ac 77% 
37c 3-F Ac 73% 
37d 2,4-Cl Ac 76% 
37e 4-C6H5 Ac 75% 
37f H Ts 62% 
37g 4-Cl Boc 60% 
37h 4-Cl Bz 65% 
aIsolated yields. 
 
A second batch of aliphatic and heteroaryl substituted propargylamines 40a-d was obtained 
by a multicomponent strategy.177 The appropriate aldehydes 33f-i were refluxed in toluene 
in the presence of p-toluenesulfonamide and (triisopropylsilyl)acetylene (TIPS) 38 and 
Cu(OTf)2 affording tosyl propargylamines 39a-d, which afforded the terminal alkynes 40a-
d after silyl-deprotection with tetra-N-butylammonium fluoride (TBAF). (Table 18).  
 
Table 18. Synthesis of aliphatic and heteroaryl derivatives 40a-d. 
 
Aldehyde R Product Yield %a 
33f 2-Furyl 40a 82 
33g Cyclohexyl 40b 99 
33h i-Propyl 40c 95 
33i i-Butyl 40d 93 
aIsolated yields. 
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3.2.1.2. Synthesis of pyrroles from propargylamines via one-pot tandem enyne CM-
cyclization reaction. 
The alkynes 34a-h, 36 and 40a-d were then reacted with EVE in the presence of GII and 
CuSO4 under microwave irradiation in toluene at 120 °C for 20 minutes obtaining pyrroles 
41f-r (Table 19.).  
 
Table 19. Synthesis of 1,2,3-substituted pyrroles 41f-r. Scope of the reaction. 
 
Alkyne R R1 Pyrrole Yielda 
34a Ph Ac 41f 70% 
34b 4-Cl-C6H4 Ac 41g 72% 
34c 3-F-C6H4 Ac 41h 76% 
34d 2,4-Cl-C6H3 Ac 41i 38% 
34e 4-Ph-C6H4 Ac 41j 59% 
34f Ph Ts 41k 38% 
34g 4-Cl-C6H4 Boc 41l 50% 
34h 4-Cl-C6H4 Bz 41m 64% 
36 Ph Ph 41n Tracesb 
40a 2-Furyl Ts 41o 76% 
40b Cyclohexyl Ts 41p 43% 
40c i-Pr Ts 41q 71% 
40d i-Bu Ts 41r 69% 
aIsolated yields were reported. bObserved by GC-MS 
 
 
Acetamides 34a-e were first reacted with EVE and GII leading to desired pyrroles 41f-j in 
high yields (59-76%). Only pyrrole 41i bearing a 2,4-Cl-phenyl group was obtained in lower 
yield (38%) probably due to a combination of steric and electronic factors. The pyrroles 41l 
and 41m, bearing the bulky groups Boc and Bz respectively, were obtained in lower yields 
than the acetyl analogue 41g. Similarly, the tosyl-pyrrole 41k was isolated in lower yield 
than 41f. On the other hand, the aliphatic and the furyl N-tosyl-propargylamides 40a-d were 
converted into pyrroles 41o-r in excellent yields with the only exception of the bulky 
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cyclohexyl derivative 41p. Finally, the treatment of the substrate 36 with EVE and GII did 
not lead to the desired pyrrole 41n in significant amount. Traces of 41n were detected only 
by GC-MS analysis of the crude reaction mixture.  
In order to expand the flexibility of the cascade reaction to the synthesis of 1,2,4-substituted 
pyrroles, propargylamine 29a was reacted with 2-methoxypropene, a substituted of EVE, in 
order to obtain 41s. However all the attempts to obtain the desired pyrrole proved to be 
unsuccessful (Table 20). 
 
Table 20. Attempts for the synthesis of 1,2,4 substituted pyrrole 41s 
 
 
 
Methoxypropene proved to be unreactive toward enyne-CM due to its steric hindrance and 
propargylamine 29a was recovered unreacted from the reaction mixtures in all the reaction 
conditions tested.  
 
3.2.1.3. Functionalization of pyrroles on C5 and derivatization on the methyl on C3. 
The enyne cross metathesis-cyclization reaction described in paragraph 3.2.1.2. allows the 
synthesis in one synthetic step of pyrroles unsubstituted on C4-C5 from appropriately 
substituted propargylamines, EVE and a weak Lewis acid. In order to expand the library of 
compounds synthesised, the possibility to further functionalise the 1,2,3-substituted pyrroles 
Entry GII mol%   Time Temp. °C Yield % 
1 5% 10 min. 120 °C Mw - 
2 10% 10 min. 120 °C Mw - 
3 5% 20 min. 120 °C Mw - 
4 10% 20 min. 120 °C Mw - 
5 5% 6h 110 °C - 
6 10% 6h 110 °C - 
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in the methyl at C3 and  C5 was explored. All the pyrroles 41 have a methyl group at C3 
deriving from the diene intermediate 30 of the enyne metathesis reaction. Attempts to 
decorate the methyl group through N-bromosuccinimide-mediated (NBS) bromination178 or 
KMnO4 oxidation
179 of 41b,r were unsuccessful due to the presence of the reactive CH at 
positions C4 and C5, leading to a complex mixture of polymeric derivatives (Scheme 19). 
 
 
Scheme 19. Attempts of derivatization on the methyl at C3 of 41b and 41r. 
 
Derivatization of the methyl at position C3 was accomplished after reduction with 
NaCNBH3 in TFA of the pyrroles 41b and 41r to the corresponding pyrrolines 45a,b.
180 The 
pyrrolines so obtained were in turn oxidized at the methyl group on C3 with SeO2 affording 
the aldehydes 46a,b in 65-56% yield (over two-steps) respectively (Scheme 20).  
 
 
Scheme 20. Functionalization of methyl group in C3. 
 
The aldehyde 46a proved to be an interesting building block for the production of the 
racemic form of the alkaloid from the poison gland of ants Leptothoracini 48.181 46a was 
converted into the corresponding pyrrolidine 47 through reduction with NaBH4-CoCl2 
following the procedure described by Aramini et al. 182,183 The alkaloid 48 could be obtained 
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in its racemic form, in two steps from precursor 47 as described by Aramini’s work (Scheme 
21). 
 
Scheme 21. Synthesis of alkaloid 48. 
 
Finally, modification in C5 was easily obtained in two steps. De-protection of compound 
41f with 2.5 M NaOH affords pyrrole 49 with good yields which was then formylated at C5 
via the Vilsmeier-Haack reaction obtaining the aldehyde 50 with 86% yield. 
 
 
Scheme 22. Derivatization at C5 of pyrrole 50. 
 
3.2.2. Conclusions 
In conclusion, the first approach for the synthesis of pyrrole scaffolds from propargylamines 
and EVE has been planned, fully developed and described within this chapter. This 
methodology is the first example of one-pot synthesis of pyrroles via enyne CM reaction and 
it constitutes a facile approach to the synthetically challenging 1,2,3-substituted pyrroles. It 
is noteworthy that the substituent at C3 of the pyrroles obtained with this methodology is 
always a methyl group deriving from the diene intermediate of the enyne metathesis reaction. 
However, the value of the methodology is corroborated by the conversion of pyrroles into 
3-pyrrolines and consequent derivatization of the methyl substituent in C3. Furthermore, the 
pyrroles obtained with this methodology could be further decorated by formylation in 
position C5 obtaining reactive functionalised scaffolds to be used for the synthesis of 
compounds of pharmaceutical interest. Finally, the methodology has been applied toward 
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the production of compound 47, which proved to be an important building block for the 
synthesis of the alkaloid 48.  
 
3.3. Novel applications of mono-amino oxidase (MAO-N & 6-HDNO) biocatalysts 
toward the synthesis of pyrroles.  
Nature has always fascinated and inspired scientists all around the world in developing new 
molecular transformations, which allow the conversion of one molecule into one other. 
However, only recently the interest of the organic chemists began to strive for matching the 
ability of Nature to synthesise molecules of interest under the greenest possible conditions. 
The classic synthetic procedures developed during the past two centuries allow the 
conversion of one compound into one other exploiting the large array of reagents, solvents 
and catalysts available in the market. With a series of transformations, in which the starting 
material of one is the product of the previous reaction, organic chemists could plan the 
synthesis of molecules of interest with controlled, multi-step protocols. This systematic, 
precise and laborious approach often needs drastic reaction conditions such as high 
temperature or special atmosphere. Furthermore, almost all the synthetic steps require the 
isolation and the purification of a product producing large amounts of waste and high 
manufacturing costs. However, the large number of reactions available, the possibility to 
combine them, and the versatility of their applications make them the easiest way available 
to synthesise molecules. On the other hand, Nature, in billions of years of evolution, evolved 
a vast array of tools (enzymes) which allow the synthesis of small molecules at ambient 
temperature, in one vessel (the cell), and in an aqueous environment. Every enzyme catalyses 
a few or even a single reaction, usually, with high substrate specificity which leads to 
products with an unmatched chemo-control, regio-control, and stereo-control of the reaction. 
The application of enzymes to the production of molecules of interests have always attired 
investors due to the unique catalytic characteristics of biocatalysts combined to the lower 
costs and waste production. Nowadays, some enzymes and even entire living cells are used 
for the production of small molecules of interests.184 Moreover, advances in DNA 
sequencing and gene synthesis have allowed a huge progress in tailoring enzymes with 
protein engineering. Metabolic engineers use the most modern molecular biology techniques 
for the modification of biocatalysts leading to enzymes with enhanced ability to process non-
natural substrates or to work in non-physiological conditions.185–187 However, despite these 
advances in the field of biocatalysis, organic chemistry has a wider repertoire of reactions 
compared to the ones offered by enzymatic catalysts. Moreover, despite the fact that in a 
near future advances in enzymatic engineering will broaden even more the application of 
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modified enzymes, it seems unlikely that biocatalysis will be able to equal the versatility of 
classic organic chemistry techniques. Therefore, probably, the future of the organic 
chemistry is to absorb biocatalysis.188 Organic chemists will eventually collaborate with the 
molecular engineers for the discovery of novel synthetic procedures, which incorporate the 
unparalleled selectivity of the enzymes with the versatility of  organic chemistry reactions. 
The discovery of novel reactions catalysed by enzymes and the development of chemo-
enzymatic cascade protocols is the future of the organic chemistry as well the topic of this 
chapter. Within this chapter novel applications of mono-amino-oxidase (MAO) enzymes 
toward the synthesis of pyrroles are described. In Nature, the flavoproteins MAO catalyse 
the oxygen-dependent oxidation of primary, secondary and tertiary amines, respectively, 
into imines or iminium ions by means of the flavin adenine dinucleotide (FAD/FADH2) 
redox cofactor. As described in Scheme 23, the Schiff’s base so formed is then hydrolysed 
under the physiological environment forming aldehydes and ammonium from primary 
amines, or the cleavage of the secondary or tertiary amine.157–159  
 
Scheme 23. Oxidation of amines catalyzed by flavoproteines MAO. 
 
The exact mechanism of reaction of MAO has not been fully elucidated, and several models 
have been suggested based on the observation of the interaction of the substrates with the 
enzymes. The models suggested are: 1) single electron transfer (SET) mechanism, 2) 
hydrogen atom transfer mechanism, 3) nucleophilic mechanism, 4) hydride transfer 
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mechanism.189 The most accredited model among them is the nucleophilic mechanism which 
is showed in Scheme 24.  
 
Scheme 24. Plausible mode of action of MAO-N. Nucleophilic mechanism. 
 
Following the nucleophilic mechanism the amine attacks the redox cofactor flavin adenine 
dinucleotide (FAD) leading to the adduct A. Consequent transfer of proton from amine to 
FAD leads to the formation of the reduced form of the flavin (FADH2) and the 
corresponding iminium ion as shown in Scheme 24. The catalytic cycle is then closed by the 
oxidation of FADH2 to FAD by O2 with the formation of H2O2. During the last decade, 
Turner and coworkers designed and developed the directed evolution of a set of different 
MAO variants from Aspergillus niger (MAO-N).190–193 
 
 
Figure 27. Directed evolution of MAO variants from Aspergillus niger.193  
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The original MAO-WT (wild type) oxidises only simple primary amines to imines while the 
new variants D3-D11 found broad application as biocatalysts for asymmetric synthesis of 
pharmaceuticals and natural products. Furthermore, MAO-N have been widely studied as 
biocatalysts for the production of enantiomerically pure amines through the selective 
oxidation and deracemization of tertiary, secondary and primary racemic amines with broad 
structural variability.157,160–162 For instance, the variant MAO-D5 catalyses the dynamic 
deracemization of racemic pyrrolidines in the presence of a chemical reducing agent such as 
NH3BH3 as shown in Scheme 25. 
 
 
Scheme 25. Dynamic deracemization of racemic 1,2 substituted pyrrolidine. 
 
The oxygen dependant oxidation to iminium ion catalysed by MAO-N enzyme is faster for 
the (S) enantiomer of the racemic mixture. The reaction affords the iminium ion which is 
reduced in situ by a chemical reducing agent obtaining again the pyrrolidine as a racemic 
mixture. After every catalytic oxidation/reduction cycle the racemic mixture became more 
and more enriched with the (R) enantiomer. Recently, a similar but (R) selective 
biotransformation was obtained with the monoamine oxidase 6-HDNO as well.  
 
 
Scheme 26. Dynamic deracemization of racemic 6-hydroxy nicotine catalyzed by 6-HDNO. 
 
Furthermore, Turner and coworkers developed a variant of 6-HDNO (E350L/E352D) with 
a wider substrate scope compared to the wild- type enzyme, which is active only with (S)-6-
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hydroxy nicotine.162 A large variety of enantiomerically pure cyclic amines, including 
functionalized pyrrolidines, have been synthesised by combining the oxidizing properties of 
6-HDNO variants with an in situ reduction as shown in Scheme 26. Due to the structural 
similarity between the pyrrolidine ring and the pyrroline structure, it is possible to 
hypothesise that the oxidation of the carbon-nitrogen bond on a pyrroline ring, is feasible 
with MAO-N and 6-HDNO biocatalysts leading to the formation of pyrroles (Scheme 27).  
 
 
Scheme 27. Hypothetical approach for the MAO-N & 6-HDNO catalysed aromatization of 
3-pyrrolines into pyrroles. 
 
The remaining part of this doctoral thesis is dedicated to the description of MAO catalysed 
highly sustainable approach for the synthesis of pyrroles from opportunely substituted 3-
pyrrolines. Furthermore, as shown extensively on paragraph 3.1.1, 3-pyrrolines are easily 
prepared from the corresponding appropriately substituted diallylamines via RCM 
reaction.145–148,156 It is thus reasonable to think that the development of a one pot chemo-
enzymatic reaction, which streamlines the conversion of diallylamines or anilines directly in 
pyrroles, would be an high requested protocol for the synthesis of this important class of 
heterocycles. Accordingly to the potential high impact which such procedure would have in 
all the branches of chemistry, the last part of this chapter is dedicated to the discovery, 
development and full exploration of a novel methodology which involves the in-situ 
combination of RCM reaction with MAO-N catalysed oxidation for the production of 
pyrroles from appropriately substituted diallylamines and anilines (Scheme 28).85  
 
 
 
Scheme 28. Hypothesised RCM-MAO-N approach for the synthesis of pyrroles from 
diallylamines and anilines. 
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3.3.1. Results and discussion. 
3.3.1.1. Preliminary investigation of the MAO-N & 6-HDNO biocatalyst aromatization 
property. 
A preliminary investigation was carried out in order to test the hypothesis that 3-pyrrolines 
are good substrates for MAO-N and 6-HDNO biocatalysts. A library of N-substituted 
pyrroline derivatives was first synthesised according to classical synthetic procedures as 
reported in Scheme 29.  
 
 
Scheme 29. Synthesis of 1-substituted pyrrolines 64a and 65a-c. 
 
Aniline 21f was N-alkylated with allyl-bromide affording diallylaniline 63a which was 
treated with GII in toluene obtaining N-phenyl-pyrroline 64a with 79% yield. Alkyl 
pyrrolines 65a-c were synthesised through reductive amination reaction of 3-pyrroline 51a 
and appropriately substituted aldehydes 52a-c (namely, 52a benzaldehyde, 52b, 
isovalerylaldehyde, 52c cyclohexylaldehyde) in presence of the reductive agent 
NaBH(OAc)3. Then, the MAO aromatization properties on the 3-pyrroline substrates 64a 
and 65a-c, were investigated (Table 21). MAO-N freeze-dried whole cell variants D5 and 
D9 were selected on the basis of their known activity and selectivity towards structurally 
related pyrrolidines.160,193,194 In addition, the oxidising/aromatizing properties of the recently 
developed nicotine oxidase biocatalyst 6-HDNO E350L/E352D13 were also explored. All 
the enzymatic biotransformations were initially carried out at 37 oC in a phosphate buffer 
solution (1 M pH = 7.8) using DMF as co-solvent where appropriate, according to the 
protocols.193 
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Table 21. Conversion of N-substituted 3-pyrroline in pyrroles 66a, 67a-c. 
 
Entry Cmpd R Biocatalysta Pyrrole Conversion %b 
1   MAO-D5  61% 
2 64a Phenyl MAO-D9 
 
66a 32% 
3   6-HDNO  60% 
4   MAO-D5  99% 
5 65a Benzyl MAO-D9 
 
67a 61% 
6   6-HDNO  95% 
7   MAO-D5  99% 
8 65b Isovaleryl MAO-D9 
 
67b 54% 
9   6-HDNO  96% 
10  
 
MAO-D5  99% 
11 65c MAO-D9 
 
67c 57% 
12  6-HDNO  94% 
aFreeze-dried E.coli whole cells were used. bConversion values were measured by GC-MS. 
 
The phenyl-pyrroline 64a was converted into pyrrole 66a by MAO-D5 and 6-HDNO (entry 
1 and entry 3) in good amount (61%), whilst the variant D9 led to 66a in only 32% 
conversion (entry 2). Full conversion of N-benzylpyrroline 65a, N-isovaleryl pyrroline 65b 
and N-methylcycloexyl-pyrroline 65c in the corresponding pyrroles 67a-c were observed 
with MAO D5 (99%) (entry 4-7-10), while 6-HDNO converted the substrates for the 94-
96% in the corresponding pyrroles (entry 6-9-12). On the other hand, MAO-D9 proved to 
be the less active enzyme toward the substrates affording pyrroles in medium conversions 
(32%-61%).  
 
3.3.1.2. Synthesis of additional substrates for biocatalysis. 
In order to assess the versatility of the MAO-N catalysed aromatization reaction of 3-
pyrrolines in pyrroles a small set of substrates was synthesised. First, a small library of aryl 
3-pyrrolines bearing various substituents in the phenyl ring was obtained starting from 
appropriately substituted anilines, following the retrosynthetic approach shown in Scheme 
30.  
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Scheme 30. Retrosynthetic approach for the synthesis of pyrrolines A. 
 
The retrosynthetic plan shows how 3-pyrrolines A can be obtained from a RCM reaction on 
appropriately substituted diallylanilines B. Aryl and alkyl substituents were inserted as R1 
and R2 in the scaffold of B by alkylation of N-allyl-anilines C with appropriately substituted 
allyl halides. Finally, allylanilines C were obtained from appropriately decorated anilines D 
by alkylation with allyl-bromide. Accordingly to the retrosynthetic approach proposed in 
Scheme 30, a set of N-diallylanilines 63b-h bearing various substituents on the phenyl ring, 
was synthesised from allyl-bromide and commercially available anilines 21b, 21d and 21g-
k (namely, 4-F-aniline 21b, 4-i-Br-aniline 21d, 4-Pr-aniline 21g, 4-OMe-aniline 21h, 2-5-
Me-aniline 21i, 4-NO2-aniline 21j, 4-CN-aniline 21k). N-diallylanilines 63b-h were isolated 
with excellent to good yields as reported in Table 22.  
Table 22. Synthesis of N-allylanilines 63b-h. 
 
Aniline R Diallylaniline Yield%a 
21b 4-F 63b 93% 
21d 4-Br 63c 86% 
21g 4-iPr 63d 94% 
21h 4-OMe 63e 79% 
21i 2-5-Me 63f 92% 
21j 4-NO2 63g 92% 
21k 4-CN 63h 92% 
aIsolated yields were reported. 
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A second set of N-diallylanilines 63i-k was synthesised in order to obtain, according to the 
retrosynthetic approach proposed previously, a set of di-substituted pyrrolines. This set aim 
is to explore the affinity of MAO biocatalysts toward 3-pyrrolines bearing groups on various 
position of the five-member ring. Compound 63i was obtained according to Scheme 31.  
 
 
Scheme 31. Synthesis of compound 63i. 
 
In detail, aniline was mono alkylated affording N-allylaniline 53 which was then reacted 
with 3-chloro-2-methylprop-1-ene and NaH obtaining compound 63i with 94% yield. 
Moreover, the synthesis of N-diallylanilines 63j and 63k was accomplished as described in 
Scheme 32. 
 
Scheme 32. Synthesis of compounds 63j and 63k.  
 
1-Phenylprop-2-yn-1-yl acetate 35 (obtained as previously described in Scheme 18) was 
converted into the propargyl aniline 54 through a copper mediated amination reaction with 
N-allylaniline 53 (90%).176 Then, compound 54 was reduced to the desired compound 63j 
through hydrogenation reaction catalysed with Lindlar’s catalyst and quinoline in order to 
prevent over reduction of the allyl groups to alkane. On the other hand, compound 63k was 
synthesised by alkylation of N-allylaniline 53 with the bromide 56. Compound 56 was 
obtained, according to the procedure reported in literature, by NBS promoted bromination 
reaction on -methylstyrene 55.195 Finally the diallylanilines 63b-k were converted into the 
corresponding 3-pyrrolines 64b-k via RCM reaction catalysed by GII in DCM. (Table 23). 
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Table 23. Synthesis of aryl 3-pyrroline 64b-k. 
 
Cmpd R R1 R2 Pyrroline Yield% 
63b 4-F H H 64b 75% 
63c 4-Br H H 64c 75% 
63d 4-iPr H H 64d 79% 
63e 4-OMe H H 64e 79% 
63f 2-5-Me H H 64f 79% 
63g 4-NO2 H H 64g 80% 
63h 4-CN H H 64h 79% 
63i H Me H 64i 79% 
63j H H Ph 64j 65% 
63k H Ph H 64k 70% 
 
Then, a set of N-alkyl 3-pyrrolines 65d-m were synthesised in order to study how different 
substituents on the pyrroline nitrogen and steric factors could influence the reactivity toward 
the MAO biocatalysts. A first set of N-alkyl 3-pyrrolines 65d-f was obtained from 
commercially available 3-pyrroline 51a or 2,5-methyl-3-pyrroline 51b via reductive 
amination reaction as described in Table 24.  
 
Table 24. Synthesis of pyrrolines 65d-f. 
 
Cmpd R R1 Pyrroline Yield%a 
51a H 4-Cl-C6H4 65d 76% 
51b Me Cyclohexyl 65eb 52% 
51b Me 4-Cl-C6H4 65f
b 46% b 
aIsolated yields , bmixture of cis and trans. 
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Moreover, pyrroline 65g was obtained from 3-pyrroline 51a and cyclohexanone under 
reductive amination conditions affording the desired compound with 82% yield (Scheme 
33). 
 
Scheme 33. Synthesis of pyrroline 65g. 
 
Furthermore, N-alkyl 3-pyrroline 65h,i were synthesised, as reported in Scheme 33, in order 
to understand if the MAO-N biocatalyst aromatization reaction could occur in pyrrolines 
bearing branched or bulky alkyl substituents. In detail, N-diallylamine 57 was converted into 
63l through reductive amination reaction with acetophenone and the weak reducing agent 
NaBH(AcO)3. Then, compound 63l afforded pyrroline 65h with 75% yield via RCM 
reaction. In addition, racemic mixture of leucine methyl ester 58 was reacted with 
allylbromide and NaH in DMF affording N-diallylamine 63m in excellent yield. Then 65i 
was obtained from compound 63m via RCM reaction. 
  
 
Scheme 34. Synthesis of pyrrolines 65h and 65i. 
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Finally, a retrosynthetic approach for the synthesis of 3-phenyl-1-alkyl-3 pyrrolines 65j-k 
was planned (Scheme 35).  
 
  
Scheme 35. Retrosynthetic approach for 3-pyrroline 65j-k. 
Target pyrrolines 65 (E) could be obtained from the N-unsubstituted pyrroline F via 
reductive amination reaction with appropriate carbonyl compounds. F is the result of 
protective group de-protection of the pyrroline G which can be achieved by RCM reaction 
on the N-protected diallylamine H. This latter is obtained after protection of the aminic 
nitrogen of I which is the result of alkylation reaction between J (compound 56) and N-
allylamine. 
Following the retrosynthetic approach proposed, compound 56 was reacted with an excess 
of N-allylamine and NaH in order to obtain N-diallylamine 59 (Scheme 36). 
 
 
Scheme 36. Synthesis of N-diallylamine 59. 
 
Compound 59, was then N-protected with 1-chloroethyl chloroformate and N,N-
diisopropylethylamine (DIPEA) in DCM affording the carbamate 60 in excellent yield 
(92%). Then the carbamate 60 underwent RCM reaction yielding 61 with 72% yield. 
(Scheme 37). 
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Scheme 37. Synthesis of compound 61. 
 
The amine 59 is protected as a chloroethyl carbamate for a dual reason. Firstly, protection 
of the nitrogen is necessary to overcome the well-known poor reactivity of secondary 
unprotected amines toward RCM reactions.196 This is due to the inactivation of GII which 
forms stable complexes with the amine and thus prevents the RCM reaction to occur.171 The 
second reason is that chloroethyl carbamate 61 quickly hydrolyses when dissolved in a protic 
solvent, such as MeOH, affording 3-pyrroline 62 in quantitative yield and short reaction 
times. Finally, N-substituted pyrrolines 65j and 65k were obtained by reductive amination 
reaction of 62 with formaldehyde and acetone, respectively, as described in Scheme 38. 
 
 
Scheme 38. Synthesis of pyrrolines 62, 65j and 65k. 
3.3.1.3. MAO-N and 6-HDNO catalysed aromatization of 1-aryl-3-pyrrolines into 1-
aryl-pyrroles. 
The 1-aryl-3-pyrrolines 64b-k were converted into pyrroles 41d, 66b-h and 66j-k with very 
poor to excellent yields depending on the substituents on the pyrroline ring and on the 
substituents on the N-aryl group (Table 25). 
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Table 25. MAO-N and 6-HDNO aromatization of pyrrolines 64b-k. 
 
3-pyrroline R R1 R2 Biocat.a pyrrole Conv (%)b 
64b 4-F-C6H4 H H MAO-D5 66b 60 
64c 4-Br-C6H4 H H MAO-D5 66c 40 
  H H MAO-D5  >99 
64d 4-iPr-C6H4 H H MAO-D9 66d 50 
  H H 6-HDNO  27 
    MAO-D5  82 
64e 4-MeO-C6H4 H H MAO-D9 66e 54 
    6-HDNO  21 
    MAO-D5  45 
64f 2,5-Me-C6H3 H H MAO-D9 66f 34 
    6-HDNO  30 
    MAO-D5  2 
64g 4-NO2-C6H4 H H MAO-D9 66g 2 
    6-HDNO  1 
    MAO-D5  2 
64h 4-CN-C6H4 H H MAO-D9 66h 2 
    6-HDNO  1 
    MAO-D5  >99 
64i Ph H Me MAO-D9 41d 51 
    6-HDNO  55 
    MAO-D5  0 
64j Ph Ph H MAO-D9 66j 0 
    6-HDNO  0 
    MAO-D5  0 
64k Ph H Ph MAO-D9 66k 0 
    6-HDNO  0 
aFreeze-dried E.coli whole cells were used. bConversion values were measure by 1H-NMR 
spectroscopy. 
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As described previously in Table 21, pyrroline 64a was partially converted into the pyrrole 
66a by MAO-D5 (61%). In Table 25 is shown that pyrrolines 64b and 64c, bearing an 
halogen atom in para position of the phenyl ring, when reacted with MAO-D5, afforded 
respectively pyrrole 66b and 66c with medium conversion values (60%, 40%). On the other 
hand, full conversion (>99%) of pyrrolines 64d and the 3-methyl-substituted 64i was 
observed with MAO-D5, while D9 and 6-HDNO converted only moderately the substrates 
in the corresponding pyrroles. A similar trend was observed also for pyrrolines 64e and 64f, 
which were converted respectively in pyrrole 66e and 66f in 82% and 45%, while the variant 
D9 and 6-HDNO led to the corresponding pyrroles in less amount. On the countrary, 
substrates 64g and 64h bearing an electron withdrawing group on the aromatic ring (-NO2 
and –CN, respectively) were not converted into corresponding pyrroles. Despite the exact 
mechanism of action of MAO has not fully elucidated, as mentioned in paragraph 3.3, one 
of the proposed models suggests that the oxidation of amines proceeds through a 
nucleophilic mechanism where the amine attacks the FAD by nucleophilic addition and it is 
in turn oxidised to imine leading to the formation of the reduced FADH2.197,198Thus, it is 
likely that the electron withdrawing substituents on the phenyl ring of 64g and 64h reduce 
the electronic density and consequently the nucleophilicity of the pyrroline nitrogen, thus 
preventing the attack of 64g,h to FAD and their following oxidation into pyrroles. 
Furthermore, no conversion of the pyrrolines 64j-k into the corresponding pyrroles 66j-k 
bearing a phenyl substituent at C2 and C3 respectively was observed for all the set of 
enzymes. As shown by docking simulations carried out by collaborators at King’s College 
London, steric factors prevented 64j-k to enter into the catalytic site of MAO-D5 (Figure 
28). The docking simulations purpose was to show the interaction of 1-phenyl-3-pyrrolines 
64a and 64k within the catalytic site of MAO-D5 and explain the experimental data 
observed. The substrates 64a and 64k were docked into MAO-N-D5 (PDB: 2VVM)199 with 
the PLANTS 1.2 software200 using the ChemPLP201 scoring function. In the docking pose 
both 64a and 64k orient their pyrroline group over the tricyclic system of FAD, while the  
N-phenyl ring interacts with the highly lipophilic region below. The pocket is formed by the 
residues W94, F210, C214, W230, L231, L245, M246, F382, W430, S465 and F466. The 
approximate shape is that of an inverted cone with a base of about 6Å in diameter departing 
from the polycyclic portion of FAD and terminating with F210 with a height of about 10Å. 
Docking simulations predict a close contact between the pyrroline ring and FAD for 
molecules such as 64a that bear on the heterocycle an hydrophobic substituent of the size of 
a phenyl ring and have no or only small additional substituents. However, docking 
simulations were able to suggest that the size of the active site strongly influences the 
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reactivity of certain, bigger, molecules such as 64k. Whilst 64a fits within the catalytic site 
of MAO-D5, the phenyl substituent (in yellow, Figure 28) of the bulkier 64k lays in a region 
of the catalytic site where an aminoacidic residue is located, thus preventing 64k from 
entering the enzyme's active site and being aromatized. Thus, it is plausible to hypothesise 
that the nonconversion of 64k and 64j is due to steric factors that prevent entering of the 
compound into the active site 
.  
Figure 28. Docking of pyrroline 64a into the MAO-D5 catalytic site and superposition of 
64k on the predicted conformation of 64a.  
  
3.3.1.4. MAO-N and 6-HDNO catalysed aromatization of 1-alkyl-3-pyrrolines in 1-
alkyl-pyrroles. 
1-Alkyl-3-pyrrolines 65d-k, and 3-pyrroline 62 were treated with MAO-N and 6-HDNO 
biocatalyst as shown in Table 26. After a practical analysis of the conversion values obtained 
by the biotransformations shown in paragraph 3.3.1.1., MAO-D5 biocatalyst was chosen as 
the key enzyme for the next set of biotransformations.  
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Table 26. MAO-N and 6-HDNO catalyse aromatization of pyrrolines 65d-k and 62 into 
pyrroles 67d-l. 
 
3-Pyr. R R1 R2 Biocat.a Pyrrole Conv (%)b 
65d 4-Cl-Bn H H MAO-D5 67d 88 
65e 
 
Me H 
MAO-D5 
MAO-D9 
67e 
48 
32 
65f 4-Cl-Bn Me H 
MAO-D5 
MAO-D9 
67f 
51 
33 
65g 
 
H H 
MAO-D5 
MAO-D9 
6-HDNO 
67g 
>99 
51 
65 
65h 
 
H H MAO-D5 67h >99 
65i 
 
H H MAO-D5 67i 56 
    MAO-D5  92 
65j Me H Ph MAO-D9 67j 78 
    6-HDNO  87 
65k iPr H Ph 
MAO-D5 
67k 
31 
MAO-D9 0 
    MAO-D5  33 
62 H H Ph MAO-D9 67l 57 
    6-HDNO  10 
aFreeze-dried E.coli whole cells were used. c Conversion values were measured by 1H-NMR 
spectroscopy. 
 As further confirmation that the oxidation of amines with MAO-D5 proceeds through a 
nucleophilic mechanism, the more nucleophilic alkyl pyrrolines 65d, 65g, 65h were fully 
converted (88%, >99% and >99%, respectively) by MAO-D5. 65g undergoes partial 
oxidation when treated with MAO-D9 and 6-HDNO (51% and 65%, respectively) 
Furthermore, the nicotine oxidase 6-HDNO was able to oxidise pyrroline 65j (87%) while 
lower conversion (10%) was observed for the secondary amine 62. Pyrroline 65i bearing a 
bulky substituent on the nitrogen was oxidised in low yields as well as the pyrrolines 65e-f 
bearing two methyl substituents on the heterocyclic nucleus (48-51%). Finally, when the 
biotransformation was carried out with MAO-D5 and MAO-D9 both the amine 65k and the 
secondary pyrroline 62 were poorly converted respectively into the pyrroles 67k and 67l. On 
the countrary, excellent conversion values were observed for the tertiary pyrroline 65j 
(Figure 29). 
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3.3.1.5. Development and Optimization of chemo-enzymatic cascade. 
The combination of RCM reactions with MAO biocatalysts in the same reaction medium 
was then investigated with the aim to develop a chemo-enzymatic cascade synthesis of 
pyrroles from allyl-amines/anilines as shown in Table 27. MAO-D5 was selected for the 
detection of the best reaction conditions because it was the enzyme that showed the best 
ability to oxidize aryl and alkyl 3-pyrrolines (paragraph 3.3.1.3., paragraph 3.3.1.4). 
Furthermore, the diallylamine 63a was chosen as reference for the development of the 
chemo-enzymatic cascade because it undergoes easily RCM under standard conditions, and 
showed good conversion with MAO-D5 as shown in Table 21.Table 27. Study of the best 
reaction conditions. 
 
 
Entry Co-Solvent Buffer/Cosolvent Ratio 63a/64a/66a (%)a 
1 DMF 60:1 90/10/0 
2 Acetone 60:1 10/90/0 
3 - 100:0 5/95/0 
4 DMF 4:1 77/23/0 
5 DMSO 4:1 73/27/0 
6 THF 4:1 92/8/0 
7 DCM 4:1 75/25/0 
8 Toluene 4:1 53/47/0 
9 Hexane 4:1 100/0/0 
10 EtOAc 4:1 100/0/0 
11 Et2O 4:1 100/0/0 
12 Iso-octane 4:1 0/12/88 
aConversion values were measured by 1H-NMR. 
 
The diallylaniline 63a was first dissolved in a 1:60 DMF/ phosphate buffer pH=7.8 1 M 
solution and treated simultaneously with 5 mol% GII and MAO-D5 at 37 °C. Unfortunately 
aniline 63a was recovered from the reaction mixture after 24h and only 10% of 3-pyrroline 
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64a was obtained, whilst no traces of the pyrrole 66a were detected by 1H-NMR analysis of 
the crude of reaction (entry 1). A set of experiments were carried out in order to evaluate the 
influence of the co-solvent toward the reaction outcome with the aim to make the RCM 
reaction possible in the same medium of the MAO catalysed oxidation reaction. Acetone 
was selected in entry 2, because it is reported that it is a more suitable solvent for RCM 
reactions than DMF.202In fact, when the same biotransformation was performed in 1:60 
acetone/buffer mixture, 90% of 64a was recovered. However, no traces of 66a were 
observed in the reaction mixture. It is noteworthy that, when the reaction was carried out 
(entry 3), in absence of co-solvent pyrroline 64a was obtained in 95% but no oxidation to 
66a occurred. Increasing the co-solvent/buffer ratio to 1:4 (entry 4) and using different 
water-miscible co-solvents (THF and DMSO) (entries 5 and 6) did not affect the outcome 
of the biotransformation. In all cases, variable amounts of the RCM product 64a were 
detected but no traces of the desired pyrrole 66a were obtained. Previous work of Turner 
and coworkers showed that MAO biocatalysts generally suffer the co-presence of chemo-
catalysts in the same reaction medium.160 In order to avoid the interaction between the Ru 
catalyst and the enzyme, the possibility to perform the reaction in a biphasic system was 
investigated. When the reaction was carried out with not-water-miscible-solvents (entry 7-
11) no RCM reaction occurred, except when toluene or DCM or iso-octane were used as co-
solvent. However, even in these cases (entry 7-8), only variable amount of 64a and no traces 
of pyrrole 66a were detected from the reaction mixture. Recently Zhao et al., showed that 
iso-octane can work as an excellent co-solvent in chemo-enzymatic biotransformations, due 
to its ability to form a biphasic system with low mass transfer together with the buffer 
solution.203–205 When the chemo-enzymatic reaction was carried out in an iso-octane/buffer 
1:4 mixture (entry 12), the pyrrole 64a was highly converted (88%) in the corresponding 
pyrrole 66a (Figure 30). The use of the non-water miscible co-solvent iso-octane proved to 
be crucial to prevent the interaction between the Ru-catalyst and the MAO-D5 and avoid the 
deactivation of the enzyme due to the Ru binding. In fact, in an immiscible iso-octane-buffer 
mixture, the homogeneous Ru-catalyst is portioned in the organic phase, while the 
biocatalyst is suspended in water. The diene 63a  undergoes RCM reaction affording the 3-
pyrroline 64a in the iso-octane phase, and then, 64a is oxidised by MAO-D5 leading to the 
desired pyrrole 66a. The biphasic reaction medium acts mimicking the 
compartmentalization of cellular processes allowing thus the cascade reactions to take place 
in an efficient manner.  
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Figure 30. Analysis of the chemo-enzymatic reaction of 63a with MAO-D5 affording 66a. 
1H-NMR analysis of diallylaniline 63a, 3-pyrroline 64a, crude of reaction with MAO-D5 
and N-phenyl pyrrole 66a.  
 
 
 
 90 
 
3.3.1.6. Expanding the scope of the RCM-MAO cascade reaction. 
In order to enhance the structural diversity of the small library of substrates obtained so far, 
a second set of N-diallylanilines/amines 63n-r were synthesised as shown in Table 28.  
 
Table 28. Synthesis of N-diallylanilines/amines 63n-r 
 
diallylaniline/amine R Yield %a 
63n 4-Cl-C6H4 74% 
63o 4-Me-C6H4 88% 
63p 2-MeO-C6H4 88% 
63q 3,4-(OCH2O)-C6H3 92% 
63r - 97% 
aIsolated yield. 
 
 
In detail, allylbromide was reacted with opportunely substituted anilines (namely 21a 4-Cl-
aniline, 21l 4-Me-aniline, 21m, 2-MeO-aniline and 21n benzo[d][1,3]dioxol-5-amine,) 
affording N-diallylanilines 63n-q with good to excellent yields (74%-92%). Differently, 
compound 63r was obtained through the reductive amination reaction from N,N-
diallylamine 57 and benzaldehyde with the presence of the mild reducing agent 
NaBH(AcO)3. 
Then the scope of the chemo-enzymatic reaction has been explored as shown in Table 29. 
N,N-diallylamines/anilines 63a-f, 63i, and 63l-o and 63r were reacted in a 1:4 iso-
octane/Buffer pH=7.8 mixture and treated simultaneously with 5 mol% GII and MAO-D5 
at 37 °C (method A). Furthermore, a two steps method was also set up, (method B) with the 
aim to improve the conversion in pyrroles of the substrates. In method B, the substrates were 
reacted with GII and MAO-D5 and stirred at 37 oC for 6 h, after which time an additional 
amount of MAO-D5 was added. 
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Table 29. Chemo-enzymatic cascade of N-diallylanilines- substrate scope. 
 
Entry R R1 Pyrrole Conv. (%)a Yield (%)b Method 
1 Ph H 66a 88 78 A 
2 Ph H 66a 95 65 B 
3 4-F-C6H4 H 66b 86 63 A 
4 4-F-C6H4 H 66b 99 59 B 
5 4-Br-C6H4 H 66c 13 10 A 
6 4-Br-C6H4 H 66c 15 10 B 
7 4-iPr-C6H4 H 66d 35 22 A 
8 4-iPr-C6H4 H 66d 75 70 B 
9 4-MeO-C6H4 H 66e 45 35 A 
10 4-MeO-C6H4 H 66e 50 42 B 
11 2,5-Me-C6H4 H 66f 24 19 A 
12 2,5-Me-C6H4 H 66f 25 20 B 
13 Ph Me 41d 82 45 A 
14 Ph Me 41d 87 64 B 
15 4-Cl-C6H4 H 66l 73 65 A 
16 4-Cl-C6H4 H 66l 90 56 B 
17 4-Me-C6H4 H 66m 99 50 A 
18 4-Me-C6H4 H 66m 90 45 B 
19 2-MeO-C6H4 H 66n 94 84 A 
20 2-MeO-C6H4 H 66n 81 72 B 
21 3,4-(OCH2O)-
C6H3 
H 66o 75 51 A 
22 3,4-(OCH2O)-
C6H3Ph 
H 66o 84 57 B 
23 Bn H 67a 9 5 A & B 
aConversion values were measured by 1H-NMR spectroscopy. bIsolated yields 
 
 
Pyrrole 66a was obtained in 88% conversion and 78% isolated yield following method A 
while, higher conversion (95%), but poorer yield (65%) was observed with the one-pot two 
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steps protocol (entry 1 and 2). It is noteworthy that the treatment of 64a with MAO-D5 led 
to 66a with 61% conversion, while the chemo-enzymatic cascade led to 66a from 
diallylaniline 63a in 95% conversion. It is plausible that in the chemo-enzymatic cascade the 
aniline 63a is converted into the pyrroline 64a slowly. As soon as 64a is formed, it is 
immediately oxidised by MAO-D5 affording 66a. In this way only a low amount of 64a is 
oxidised by MAO-D5 time by time allowing a more rapid enzyme turnover. Similarly, 
pyrroles 66b and 66l (entries 3-4, 15-16) were isolated in high yields when the one-pot one-
step method A was used, whilst higher conversion values were observed with the two steps 
one-pot protocol B. As general trend, excellent conversion and high yields were observed 
for pyrroles bearing chloro- (66l), methyl-(66m) and alkoxy-substituents (66n, 66o) (entries 
15-22). Medium to good conversions (50-75%) were observed for N-aryl-pyrroles 66d-e 
(entries 8-10). One possible explanation of this trend could be found in the lower reactivity 
of electron-rich N,N-diallylanilines toward the RCM reaction. Furthermore, several other 
factors must be taken into account in the chemo-enzymatic cascade, such as the reactivity of 
anilines in the metathesis reaction, where electron donating substituents on the phenyl ring 
disfavour the ring closure, as well as the biocatalytic oxidation, where electron withdrawing 
substituents prevent the pyrroline oxidation. Not surprisingly, the benzylpyrrole 67a was 
obtained in low yield (entry 23) due to the poor reactivity of alkyl-diallylamines toward 
RCM reactions.206  
An elegant way to overcome Ru inactivation with tertiary amines is to convert them into the 
corresponding salts in order to make impossible the attachment of the nucleophilic nitrogen 
to the Ru catalyst. However, this strategy cannot be chosen with the purpose of this 
biotransformation because the ammonium salt would be added to the aqueous mixture 
needed for the biotrasformation. The presence of the buffer in the reaction mixture dissolves 
the ammonium salt affording the corresponding tertiary amine which will be partitioned 
between the organic phase and the aqueous phase. Thus the dissolution of the ammonium 
salt in the buffer restores the ability of the lone pair of the amine to poison the metal catalyst. 
Therefore, a series of experiments were carried out in order to obtain the ring-closing 
metathesis of N-benzyl-diallylamine 63r in an aqueous environment. A variety of co-
solvents and different catalyst loadings were employed in these experiments in order to find 
an alternative route toward the synthesis of benzylpyrroline 65a. Furthermore, Hoveyda 
Grubbs’ catalyst (HGII) which has been used successfully for metathesis reaction conducted 
in water was tested as an alternative catalyst of the versatile GII (Table 30).207,208  
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Table 30. Studies on RCM of N-benzyl-diene 63r in aqueous medium. 
 
Entry Solvent Catalyst Catalyst mol% Buffer/solvent Conversion % 
1 DME GII 30% 62:1 32% 
2 DME GII 30% 1:1 4% 
3 DME GII 20% 62:1 28% 
4 DME GII 10% 62:1 25% 
5 DME GII 5% 62:1 27%  
6 Acetone GII 30% 62:1 55% 
7 Acetone GII 30% 1:1 56% 
8 Acetone GII 20% 62:1 42% 
9 Acetone GII 10% 62:1 27% 
10 Acetone GII 5% 62:1 22% 
11 Acetone GII 5% 10:1 0% 
12 t-BuOH GII 5% 10:1 1% 
13 Toluene GII 5% 10:1 8% 
14 Toluene GII 30% 62:1 14% 
15 Toluene GII 30% 1:1 11% 
16 - GII 5% 62:1 0% 
17 Acetone HGII 20% 62:1 0% 
18 Acetone HGII 10% 62:1 0 % 
19 Acetone HGII 5% 62:1 0%  
20 DME HGII 20% 62:1 3%  
21 DME HGII 10% 62:1 1%  
22 DME HGII 5% 62:1 1%  
23 DME HGII 5% 4:1 0% 
24 Toluene HGII 5% 4:1 0% 
aConversion values were measured both by GC-MS as well as 1H-NMR spectroscopy. 
When acetone was used as co-solvent the pyrroline 65a was obtained with 52% yield, 
however, as described before with N-phenyl-N-diallylaniline.63a, acetone does not prevent 
the inactivation of the enzyme from the Ru catalyst. On the other hand, the use of Hoveyda-
Grubbs catalyst did not lead to any improvement of the reaction and the pyrroline 65a was 
obtained only in poor yields. Also the use of different co-solvents like DME (1,2-
dimethoxyethane) or toluene in combination with different catalyst loading did not lead to 
the desired pyrrole 65a. These results confirmed that tertiary benzyl-amines cannot be used 
as substrates for the chemo-enzymatic reaction proposed. However, in order to expand the 
scope of the chemo-enzymatic reaction, conversion of the hindered substrates 63l-m and the 
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secondary amine 59 was attempted following the one pot-two step procedure (method B) as 
described in Table 31. 
Table 31. Synthesis of pyrroles 67h, 67i and 67l. 
 
 
 
 
 
 
Entry R R1 Pyrrole Conv.%a Yield%b 
1 
 
H 67h 63 41 
2  H 67i 37 21 
3 H Ph 67l 0 0 
aConversion values were measured by 1H-NMR spectroscopy. bIsolated yields 
Diallylamines 63l, 63m and the secondary amine 59 were reacted with GII and MAO-D5 
and stirred at 37 oC for 6 h, after which time an additional amount of MAO-D5 was added. 
Branched pyrroles 67h and 67i were obtained from the corresponding allylamines 63l and 
63m respectively with 63% and 37% conversion values (entries 1-2). These data suggest 
that branched 1-alkyldiallylamines could be included in the scope of the chemo-enzymatic 
reaction because the steric hindrance of the N-substitution prevent the nitrogen of the amine 
to poison the catalyst. On the other hand, as expected from previous results obtained with 
compound 63r, the attempt to obtain the pyrrole 67l via chemo-enzymatic cascade from the 
corresponding secondary amine 59 was unsuccessful (entry 3). An alternative route was thus 
developed as described in Scheme 39 leading to 67l in one-pot from the carbamate 60. 
 
Scheme 39. Chemo-enzymatic synthesis of pyrrole 67l. 
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The carbamate protecting group allows the RCM reaction of 60 to take place almost 
instantaneously (around 20 minutes) affording the intermediate 61. The chloroethyl 
carbamate protecting group is labile under the reaction conditions and it is slowly cleaved 
leading to pyrroline 62 which is in turn oxidised by MAO-D5 affording the desired pyrrole 
67l in 42% overall yield. 
 
3.3.1.7. Application of MAO oxidation/aromatization reaction toward the synthesis of 
a putative antitubercular pyrrole derivative. 
Finally the present methodology has been applied to the synthesis of a pyrrole derivative of 
the novel class of antitubercular agents described in chapter 2 (Scheme 40).116 
 
Scheme 40. MAO-Mannich cascade for the synthesis of the putative antitubercular agent 
68. 
Pyrroline 64b was converted in a single step into pyrrole 68 by treatment with MAO-D5 
followed by in situ Mannich reaction with N-phenylpiperazine and formaldehyde. It is 
noteworthy that compound 68 has not been assessed yet for its antitubercular activity and it 
shows only moderate structural similarity with the antitubercular agents described in chapter 
2. The pyrrole ring is not substituted at C2 and C5 with a methyl group, however the N-aryl 
substitution of the pyrrole and the presence of a substituted piperazine at C3 are common 
features to all the antitubercular compounds 24. Therefore, if the antitubercular activity of 
this compound is confirmed this MAO-Mannich cascade approach would be a faster and 
greener procedure for the production of pyrroles endowed with antitubercular activity than 
the methodology used in chapter 2 for the production of BM212/SQ109 hybrid derivatives 
24a-m.  
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3.3.2. Conclusions 
In conclusion, the aromatizing properties of MAO-N and 6-HDNO biocatalysts have been 
described and explored  for the first time. MAO biocatalysts, and in particular the variant 
MAO-D5, catalyse the aromatization of a wide range of N-aryl- and N-alkyl-3-pyrrolines 
into the corresponding pyrroles. The ability of MAO-N biocatalysts to work in a concurrent 
way together with Grubbs’ catalyst was also investigated leading to the development of a 
chemo-enzymatic cascade reaction for the one pot synthesis of pyrroles from N,N-
diallylanilines and N,N-diallylamines. This work represents the first example of a chemo-
enzymatic cascade combining in the same reaction medium MAO-N with a metal-catalyst, 
other than boron reducing agents. Finally, the aromatizing properties of MAO-D5 have been 
exploited for the synthesis of pyrrole 68, which has structural similarity to the novel class of 
antitubercular compounds described within chapter 2, via a MAO-N-Mannich cascade 
reaction. 
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4. Thesis conclusions. 
The aim of this doctoral thesis was to discover and synthesise molecules endowed with 
activity against TB and MDR-TB and to develop novel sustainable and faster synthetic 
methodologies for the synthesis of heterocycles for the production of drug-like compounds. 
To address these objectives, in the first section of this work was described the discovery of 
two novel classes of antitubercular agents, while in the second section, the development of 
two procedurally simple and fast methodologies for the synthesis of pyrroles were described. 
Within the first part of this work, two distinct strategies have been applied respectively to 
the research of two novel classes of antitubercular agents. The first strategy adopted was the 
molecular simplification approach on the structure of the third line drug thioridazine. 
Following the modification on the TZ scaffold described in paragraph 2.2, two series of 
derivatives were synthesised and assessed against a panel of Mycobacteria including clinical 
isolates. The analysis of the activity data of the set of thioridazine derivatives synthesised 
allowed the identification of the SAR summarized in Figure 31.  
 
 
Figure 31. Diagrammatic summary of structure activity relationship of 1 derivatives. 
The screening of TZ derivatives led to the identification of compound 16e: a thioridazine 
derivative obtained by the demethylation of the piperidine ring in addition to the replacement 
of the phenothiazine core with an indole heterocycle (Figure 32). 16e showed an activity 
profile better than that of TZ and a cytotoxicity about 15-fold lower toward both the cells 
lines MRC-5 and J774A.1. Despite the molecular target of this new class of molecules being 
still elusive, and the construction of a pharmacophoric model is still challenging to be 
formulated, the identification of 16e opened a new field of research indeed. The future 
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synthesis of putative 16e derivatives have the potential to lead to the identification of a novel 
class of potent antitubercular compounds and to increase the understanding on the 
mechanism of action of this new class of molecules. 
 
Figure 32. Thioridazine derivative 16e and its activity profile. 
 
In the second part of the first section of this work, a novel class of molecules, active against 
Mtb and MDR-TB, has been designed by the application of a molecular hybridization 
approach on the structures of the antitubercular agents BM212 (I) and SQ109 (II). The 
molecules synthesised have been evaluated for their activity against Mtb and MDR-TB 
clinical isolates leading to the identification of exhaustive SAR, which suggested the key 
features paramount for the antitubercular activity of this new class of pyrroles (Figure 33).  
 
Figure 33. Diagrammatic summary of structure activity relationship of the hybrid 
derivatives of BM212 (I) and SQ109 (II). 
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Five compounds showed MIC values on Mtb H37Rv at ≤1.0 μg/mL, and two of them (26b 
and 26c) proved to be highly active also against MDR-TB strains (Figure 34). 
 
 
Figure 34. Superimposition of BM212 and SQ109 led to the discovery of hybrid 
derivatives 26b and 26c. 
 
Among the compounds which had the better antitubercular profile, 26c showed the best drug 
profile proving to be superior to BM212 in terms of activity, cytotoxicity, and potency toward 
MDR-TB clinical isolates, thus turning out to be an excellent lead candidate for preclinical 
trials. Moreover, compounds 24c, 24h, 24i, and 24l, bearing a bulky alkyl substituent on the 
piperazine ring, showed potent EPI activity, comparable to that of verapamil, turning out to 
be promising multi-drug resistance reversal agents. 
Furthermore, the second section of this work was dedicated to the research of novel 
methodologies toward the synthesis of relevant building blocks for the production of drug-
like compounds, in detail pyrroles . Therefore, two novel cascade processes involving the 
metathesis reaction for the production of functionalised pyrroles have been described. The 
first methodology allowed the synthesis of 1,2,3-substituted pyrroles through a one-pot 
tandem enyne cross metathesis (CM)-cyclization reaction starting from appropriate 
propargylamines and the inexpensive ethyl vinyl ether. The scope of the reaction was 
demonstrated by the synthesis with medium-good yields of a large variety of pyrroles 
bearing aryl, hetero-aryl and alkyl substituents (Table 32). 
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Table 32. Synthesis of 1,2,3-substituted pyrroles from propargylamines vis one pot enyne 
CM-cyclization reaction. 
 
 
 
 
The reaction is rapid, procedurally simple and represents a facile entry to the synthetically 
challenging 4,5-unsubstituted pyrroles. All the pyrroles obtained with this methodology have 
a methyl group at C3 deriving from the diene intermediate of the enyne metathesis reaction. 
Attempts to decorate directly the methyl group were unsuccessful due to the presence of the 
reactive CH at positions C4 and C5. However, the value of the methodology is corroborated 
by the conversion of pyrroles into 3-pyrrolines and the consequent derivatization of the 
methyl substituent in C3 (Scheme 20). Moreover, the reaction was used for the synthesis of 
compound 47 that is an important building block for the synthesis of an alkaloid from the 
poison gland of ants Leptothoracini 48 (Scheme 21). This application highlights the 
versatility and usefulness of this reaction toward the production of important 
pharmaceuticals of interest.  
The second part of chapter 3 was dedicated to the discovery and exploration of a novel 
chemo-enzymatic process for the synthesis of pyrroles. Firstly, the precedent undisclosed 
aromatization property of monoamine oxidase (MAO-N & 6-HDNO) biocatalysts has been 
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unveiled for the first time within this work, converting a library of 3-pyrrolines in the 
corresponding pyrroles through whole cell MAO catalysed oxidation-aromatization 
reaction. This biotransformation represents the first application of MAO biocatalysts as 
aromatizing agents and a series of pyrroles bearing alkyl and aryl substituents were 
synthesised with high conversion factors and good yield.  
 
Table 33. MAO-D5 aromatization of 3-pyrroline in pyrroles. 
 
 
 
From an analysis of the biotransformation conversion factors is highlighted that the success 
of the oxidation of 3-pyrrolines in pyrroles by MAO biocatalyst heavily depends on steric 
factors and on electronic effects that the pyrroline ring substituents could have on the 
nitrogen. As a general trend, N-alkyl-substituted pyrrolines afford the corresponding 
pyrroles with higher conversion factors than the N-aryl pyrrolines. Furthermore, N-aryl 
pyrrolines bearing electron withdrawing groups on the aromatic ring are not processed by 
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MAO biocatalyst. This is mainly due to the reduced nucleophilicity of the pyrroline nitrogen 
of these substrates, as described in paragraph 3.3.1.3. Moreover, in the same paragraph it is 
described that steric factors prevent N-aryl pyrrolines decorated with a phenyl group on C2 
or C3 to be converted in the corresponding pyrroles. Despite these limitations, the discovery 
of the aromatizing property of MAO biocatalysts make them a valid and sustainable 
alternative to the chemical or metal agents used for the oxidation of C-N bonds for the 
synthesis of pyrroles. Moreover, further directed evolution of this class of enzyme could lead 
to the discovery of a monoamine oxidase with a larger substrate scope expanding even more 
the application field for such biocatalysts. Additionally, in the last part of this work is 
described the first attempt to combine efficiently MAO oxidation reaction in the same 
reaction medium with RCM reaction in order to produce pyrroles by convenient starting 
materials such as opportunely substituted N,N-diallylamines and anilines (Table 34).  
 
Table 34. Novel one-pot chemoenzymatic methodology toward the synthesis of pyrroles. 
 
 
 
 
The main charm of this technique is the successful combination of chemo- and enzymatic 
catalysis in a concurrent fashion. Mimicking the compartmentalization of cellular processes 
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by appropriate choice of solvents and reaction conditions, it is possible to overcome the 
compatibility issues of the catalysts and the difference on the reaction conditions in which 
these generally operate. This work is the first example of a chemo-enzymatic cascade which 
combines in the same reaction medium MAO-N with a metal-catalyst, other than boron 
reducing agents. Finally, the aromatizing properties of MAO-D5 has been exploited for the 
synthesis of pyrrole 68 which has structural similarity to the novel class of antitubercular 
compounds described within chapter 2. Further investigation on the aromatizing property of 
MAOs biocatalysts toward other unsaturated heterocyclic rings (e.g. 3-pyrazoline, 1,4-
dihydropyridine, 1,2-dihydropyridine) is highly recommended. Success in these 
biotransformations could be an important turning point for the development of more 
sustainable and competitive synthesis of building blocks for compounds of pharmaceutical 
interest.  
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5. Materials and Methods. 
5.1. Materials. 
All solvents and reagents were purchased from Sigma-Aldrich, and Alfa-Aesar and used 
without further purification unless otherwise specified. Reactions were followed by 
commercially available precoated TLC plates using silica gel with UV light at 254 nm 
fluorescent indicator; KMnO4 or ninhydrin solutions were used to reveal the products. Flash 
column chromatography was carried out using Fluorochem Davisil 40−63 μm, 60 Å. THF 
was distilled under nitrogen atmosphere from sodium using a benzophenone indicator. 
Dichloromethane was purchased from Aldrich. Petroleum ether refers to the fraction of light 
petroleum ether boiling between 40 and 65 °C. All reactions were conducted under a nitrogen 
atmosphere in oven-dried glassware unless stated otherwise. 
5.1.1. Physical measurements. 
1H NMR and 13C NMR spectra were recorded on an AVANCE 400 spectrometer Bruker, 
Germany or JEOL ECS-400 spectrometers operating at r.t. at the frequencies indicated. 
Chemical shifts (δ) are in ppm, referenced to tetramethylsilane. Coupling constants (J) are 
reported in hertz and rounded to 0.5 Hz. Splitting patterns are abbreviated as follows: singlet 
(s), doublet (d), triplet (t), quartet (q), quintet (quint), multiplet (m), broad (br) or some 
combination of them. Mass spectra (HRMS) were recorded at the EPSRC National Mass 
Spectrometry Service Centre on a Thermo Scientific LTQ Orbitrap XL mass spectrometer 
using low-resolution ESI or high-resolution nanoESI techniques. The purity of the 
compounds which have been evaluated for their antitubercular activity was assessed by 
reverse-phase liquid chromatography coupled with a mass spectrometer (Agilent series 1100 
LC/MSD) with a UV detector at k = 254 nm and an electrospray ionization source (ESI). 
HPLC analyses were performed at 0.4 mL/min flow rate and using a binary solvent system 
of 95:5 methanol/water. All the solvents were of HPLC grade. Mass spectra were acquired 
in positive mode scanning over the mass range of 50−1500. The following ion source 
parameters were used: drying gas flow, 9 mL/min; nebulize pressure, 40 psig; and drying 
gas temperature, 350 °C. All target compounds possessed a purity of ≥95%, as verified by 
HPLC analyses. GC-MS analyses were performed on a Thermo Electron Co. Focus GC 
coupled to a Thermo DSQ1 mass spectrometer and an AI3000 Auto Injector. Aliquots of the 
compound were dissolved in DCM (5 μL) and injected onto a DB-5MS (30 mm × 0.25 mm 
i.d. × 0.15 μm film thickness) column at 250 °C. The oven temperature was set at 40 °C for 
4 min and raised at 15 °C/min to 135 °C, then at 5 °C/min to 250 °C and held at 250 °C for 
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5 min. The carrier gas flow was 1.0 mL/min. The mass spectrometer was operated in the full 
scan mode. The transfer line and ion source temperatures were 250 and 200 °C, respectively. 
5.1.2. Microwave Irradiation Experiments. 
Microwave irradiations were conducted using a CEM Discover Synthesis Unit. The machine 
consists of a continuous focused microwave power delivery system with operator, selectable 
power output from 0 to 300 W. The temperature of the contents of the vessels was monitored 
using a calibrated infrared temperature control mounted under the reaction vessel. All the 
experiments were performed using a stirring option whereby the contents of the vessel are 
stirred by means of rotating magnetic plate located below the floor of the microwave cavity 
and a Teflon coated magnetic stirring bar in the vessel. 
5.2. Methods. 
5.2.1. Repurposing and molecular simplification of thioridazine for the synthesis of 
novel antitubercular agents effective against multidrug-resistant mycobacteria 
5.2.1.1. Biology. 
Bacterial strains and growth conditions: The bacterial species used in this study were 
Mycobacterium smegmatis mc2155 (ATCC 700084), Mycobacterium bovis BCG Pasteur 
(ATCC 35734), Mycobacterium tuberculosis mc27000, Mycobacterium tuberculosis 
H37Rv (ATTC27294), Mycobacterium tuberculosis CF73 and two MDR-TB clinical 
isolates (CF104 and CF81) obtained from Clemente Ferreira Hospital, Saõ Paulo, 
Brazil.209 Mycobacterial species were cultured in either Middlebrook 7H9 broth or 
Middlebrook 7H10 agar media supplemented with albumin-dextrose-catalase (ADC) or 
oleic acid-albumin-dextrose-catalase (OADC) enrichments, respectively, purchased from 
BD Biosciences. All reagents were purchased from Sigma-Aldrich unless stated 
otherwise.Mycobacterium smegmatis mc2155 (ATCC 700084), Mycobacterium bovis 
BCG Pasteur (ATCC 35734), Mycobacterium tuberculosis mc27000, growth was carried 
out by by Dr. Alistair Brown at Northumbria University. Prof. Fernando R. Pavan at 
Universidade Estadual Paulista "Júlio de Mesquita Filho" (UNESP) performed the growth 
of Mycobacterium tuberculosis H37Rv (ATTC27294), Mycobacterium tuberculosis CF73 
and of the two MDR-TB clinical isolates (CF104 and CF81), 
 
Bacterial growth inhibition assays: This assay was carried out by Dr. Alistair Brown at 
Northumbria University. The MIC90 of the compounds against Mycobacterium smegmatis 
mc2155, Mycobacterium bovis BCG, and Mycobacterium tuberculosis mc27000 were 
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calculated by standard MABA (Microplate Alamar Blue assay) as previously described.116 
Briefly, 200 µL of sterile deionized water was added to all outer-perimeter wells of a 
sterile 96-well plate (Corning Incorporated, Corning, NY) to minimize evaporation of the 
medium in the test wells during incubation. The wells in rows B to G in columns 3 to 11 
received 100 µL of 7H9 medium containing 0.2% casamino acids, 24 µg/mL pantothenate 
and 10% OADC (Beckton Dickinson, Sparks, MD). Compounds were added to rows B–
G followed by 1:2 serial dilutions across the plate to column 10, and 100 µL of excess  
medium was discarded from the wells in column 10. The bacterial culture at 0.5 
McFarland standard diluted 1:50 (100 µL) was added to the wells in rows B to G in 
columns 2 to 11, where the wells in column 11 served as drug-free controls. The plates 
were sealed with parafilm TM and were incubated at 37 °C. A freshly prepared 1:1 
mixture of Alamar Blue (Celltiter-Blue™, Promega Corp, Madison, WI) reagent and 10% 
Tween® 80 (50 µL) and re-incubated at 37 °C for 24 h. 
 
Determination of Minimal Inhibitory Concentration (MIC90): This assay was performed 
by Prof. Fernando R. Pavan at Universidade Estadual Paulista "Júlio de Mesquita Filho" 
(UNESP). The anti-M. tuberculosis activity of the compounds against Mycobacterium 
tuberculosis H37Rv (ATTC27294), Mycobacterium tuberculosis CF73 and two MDR-TB 
clinical isolates (CF104 and CF81) was determined using the Resazurin Microtiter Assay 
(REMA) method according to Palomino et al..210 Stock solutions of the tested compounds 
were prepared in dimethyl sulfoxide (DMSO), then diluted in Middlebrook 7H9 broth 
(Difco, Detroit, MI, USA) supplemented with oleic acid, albumin, dextrose and catalase 
(OADC enrichment) to obtain a final drug concentration range of 0.09–100 µg/mL. A 
suspension of the Mycobacterium tuberculosis H37Rv ATCC 27294 and clinical isolates 
were cultured in Middlebrook 7H9 broth supplemented with OADC and 0.05% Tween 80 
for one week at 37 °C in an atmosphere of 5% CO2. The concentration was adjusted at 
McFarland 1 and diluted to 2.4 × 105 CFU/mL. 100 µL of the inoculum was added to each 
well of a 96-well microplate together with 100 µL of the compounds. The plate was 
incubated for 7 days at 37 °C in an atmosphere of 5% CO2. After 24 h, 30 µL 0.01% 
resazurin (solubilized in water) was added. The fluorescence of the wells was read after 
24 h using a Cytation 3 (BioTek®, Winooski, VT, USA). The MIC90 was defined as the 
lowest concentration resulting in 90% inhibition of growth of Mycobacterium 
tuberculosis. Samples were set up in three independent assays. 
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Cytotoxic Analysis (GIC50) of MRC-5 cell line: This analysis was performed by Prof. 
Fernando R. Pavan at Universidade Estadual Paulista "Júlio de Mesquita Filho" (UNESP).  
In these experiment, cells were collected in a solution of trypsin/ethylenediamine 
tetracetic acid (EDTA) (Vitrocell®) and centrifuged (252× g for 5 min). The number of 
cells was counted using a Neubauer chamber (Celeromics, Valencia, Spain) after staining 
non-viable cells with 0.4% trypan blue solution (Sigma-Aldrich®) via the cell exclusion 
assay. Then, the cell concentration was adjusted to 7.5 × 104 cells/mL in Dulbecco's 
Modified Eagle's Medium (DMEM) and MRC-5 cells (ATCC CCL-171). Next, a 200 μL 
suspension was deposited into each well of a 96-well microplate to a cell density of 1.5 × 
104 cells/well. The cells were incubated at 37 °C in an atmosphere of 5% CO2 for 24 h to 
allow the cells to attach to the plate.211 The compounds were solubilized in DMSO to an 
initial concentration of 10,000 µg/mL. Test solutions of the compounds were prepared to 
obtain concentrations from 500 to 1.95 μg/mL. The diluted solutions were added to the 
cells after changing the medium to remove any non-adherent cells, and the cultures were 
incubated for an additional 24 h. The cytotoxicity of the compounds was determined after 
incubating the cells in 30 μL of resazurin for approximately 2 h. The measurement was 
performed using a Synergy H1 microplate reader (BioTek®, Winooski, VT, USA) with 
excitation and emission filters at wavelengths of 530 and 590 nm, respectively. The assays 
were performed in three independent experiments. 
 
Cytotoxicity assay (GIC50) of J774 cell line: This experiment was carried out by Prof. 
Fernando R. Pavan at Universidade Estadual Paulista "Júlio de Mesquita Filho" (UNESP). 
In vitro cytotoxicity assays (GIC50) were performed on the J774 cell line, as previously 
reported.212The cells were routinely maintained in Complete Medium (RPMI-1640 
supplemented with 10% heat-inactivated fetal bovine serum (FBS); 100 U/mL penicillin 
and 100 μg/mL streptomycin), at 37 °C, in a humidified 5% CO2 atmosphere. After 
reaching confluence, the cells were detached and counted. For the cytotoxicity assay, 1 × 
105 cells/mL were seeded in 200 μL of Complete Medium in 96-well plates (NUNC). The 
plates were incubated at 37 °C under a 5% CO2 atmosphere for 24 h, to allow cell adhesion 
prior to drug testing. The compounds were dissolved in DMSO and subjected to two-fold 
serial dilution from 1250 to 3.9 μg/mL. Cells were exposed to the compounds at various  
concentrations for a 24 h-period. Resazurin solution was then added to the cell cultures 
and incubated for 6 hours. Cell respiration, as an indicator of cell viability, was detected 
by reduction of resazurin to resorufin, whose pink colour and fluorescence indicates cell 
viability. A persistent blue colour of resazurin is a sign of cell death. The fluorescence 
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measurements (530 nm excitation filter and 590 nm emission filter) were performed in a 
SPECTRAfluor Plus (Tecan) microfluorimeter. The IC50 value was defined as the highest 
drug concentration at which 50% of the cells are viable relative to the control.  
 
Efflux pump inhibition assays: This assay was performed by Dr. Bhakta group at Birbeck 
College London. The assay was performed based on previously published protocols.112 In 
brief, early log phase cells of Mycobacterium smegmatis were taken and the OD600 was 
adjusted to 0.4 in 1× PBS. The test samples contained (4−6) × 107 bacteria/mL in PBS, 0.4% 
glucose (as a source of energy for efflux pumps activity), 0.5 mg/L ethidium bromide (as a 
substrate for efflux pumps), and the compounds being tested at 1/4× MIC concentrations. 
Blank samples contained all of the components mentioned above, except the bacterial 
suspension, which was replaced with 1× PBS. Verapamil and chlorpromazine, known efflux 
pump inhibitors, were used as positive controls at concentrations of 125 μg/mL and 10 
μg/mL respectively. The experiment was performed in a 96-well plates that was read in a 
fluorimeter (FLUOstar OPTIMA, BMG Labtech) with the following parameters: 
wavelengths of 544 and 590 nm for excitation and detection of fluorescence, gain 2200, a 
temperature of 37 °C, and a cycle of measurement every minute for a total period of 60 min. 
The accumulation or efflux of ethidium bromide was monitored in real-time for the 
mentioned period. 
 
5.2.1.2. Chemistry. 
Synthesis of 1-chloroethyl 2-(2-(2-(methylthio)-10H-phenothiazin-10 
yl)ethyl)piperidine-1-carboxylate (4). 
 
 
Thioridazine hydrochloride 1 (1575 mg, 3.87 mmol, 1 eq.) was dissolved in a round bottom 
flask containing dry DCE (20 mL) and TEA (1.07 mL, 7.74 mmol, 2 eq.). The mixture was 
stirred at r.t for 20 minutes, then, 1-chloroethyl chloroformate (1099.1 mg, 7.74 mmol, 2 eq.) 
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was added to the solution. The mixture was left under N2 atmosphere at 110 °C for 12 h. 
Then, the reaction mixture was quenched with 10 mL of water and extracted twice with 20 
mL of EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow-brown crude oil. The crudeproduct was 
purified by chromatography on silica gel, using hexane/EtOAc (4:1) as eluent, affording the 
pure product as a yellow solidYield: 84% (1505 mg,). 1H NMR (400 MHz CDCl3) δ 7.13-
7.01 (m, 2H), 7.01-6.90 (m, 1H), 6.89-6.60 (m, 4H), 6.59-6.29 (m, 1H), 4.20-3.90 (m, 1H), 
3.90-3.60 (m, 2H), 2.90-2.74 (m, 1H), 2.74-2.57 (m, 1H), 2.36 (s, 3H), 2.25-2.04 (m, 1H), 
1.77-1.60 (m, 3H), 1.58-1.16 (m, 7H) ppm. 13C NMR (100 MHz CDCl3) δ 152.9, 145.1, 
145.0, 137.9, 127.8, 127.7, 127.4, 122.8, 122.6, 121.2, 121.0, 115.2, 114.5, 83.4, 49.9, 44.5, 
39.8, 29.1, 27.8, 25.4, 19.1, 16.5, 14.3 ppm. LRMS (ESI+): m/z = 463 [M + H]+. 
 
Synthesis of 2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (5). 
 
 
1-chloroethyl2-(2-(2-(methylthio)-10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate 
4 (1505 mg, 3.25 mmol, 1 eq.) was dissolved in MeOH (20 mL). The reaction was allowed 
to stir at 78°C for 12 h then the reaction mixture was concentrated by reduced pressure 
evaporation. Then, the reaction mixture was quenched with 20 mL of water and extracted 
twice with 20 mL of EtOAc. The combined organic layers were washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. The 
obtained product 5 was purified by chromatography on silica gel, using EtOAc/MeOH/TEA 
(3.9:1:0.1) as eluent. The pure product 5 was obtained as a yellow-brown oil. Yield: 85% 
(1021.7 mg). 1H NMR (400 MHz CDCl3) δ 9.25 (br s., 1H), 7.20-7.08 (m, 2H), 7.03 (d, J = 
7.0 Hz, 1H), 6.90 (d, J = 7.0 Hz, 2H), 6.82 (m, 2H), 4.13-3.93 (m, 2H), 3.29 (d, J = 13.0 Hz, 
1H), 3.02 (m, 1H), 2.68 (t, J = 12.0 Hz, 1H), 2.46 (s, 3H), 2.18-2.05 (m, 1H), 1.90-1.75 (m, 
3H), 1.75-1.53 (m, 3H), 1.44-1.28 (m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 145.9, 144.4, 
138.3, 127.8, 127.7, 127.7, 125.9, 123.2, 122.5, 121.2, 116.3, 114.5, 55.7, 44.7, 43.7, 30.7, 
28.8, 22.5, 22.2, 16.4 ppm. LRMS (ESI+): m/z = 357 [M + H]+. 
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General procedure for the synthesis of thioridazine derivatives (6a-c). 
 
2-(methylthio)-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine 5 (49.8 mg, 0.14 mmol, 1 
eq.) was added to a round bottom flask containing a solution of the appropriate 
aldehyde/ketone (0.21 mmol, 1.5 eq.) and AcOH (0.024 mL, 0.28 mmol, 1 eq.) in THF (5 
mL). The solution was then allowed to stir at room temperature for 30 minutes. Then, 
NaBH(AcO)3 (59.3 mg, 0.28 mmol, 2.0 eq.) was added and the reaction was allowed to react 
for 12 h at r.t. Then the reaction was quenched with (20mL) NaOH 1N solution and the 
mixture was allowed to stir for 20 minutes. Then the organic solvent was removed through 
reduced pressure evaporation. The residue was diluted with EtOAc, extracted with EtOAc 
(3 X 10 mL) and dried over anhydrous MgSO4. The obtained product 6a-c was purified by 
chromatography on silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent. Pure products 
6a-c were obtained as yellow-brown oils. 
 
Synthesis of 2-(methylthio)-10-(2-(1-propylpiperidin-2-yl)ethyl)-10H-phenothiazine 
(6a). 
Yield: 62% (34.5 mg). 1H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 
2H), 7.03 (d, J = 4.0 Hz, 1H), 6.92-6.88 (m, 2H), 6.80 (d, J = 4.0 Hz, 
2H), 3.94-3.99 (m, 1H), 3.83-3.79 (m, 1H), 2.82-2.77 (m, 1H), 2.51-
2.48 (m, 2H), 2.45 (s, 3H), 2.33-2.22 (m, 2H), 2.16-2.06 (m, 1H), 
1.85-1.56 (m, 4H), 1.43-1.29 (m, 5H), 0.75 (t, J = 8.0 Hz, 3H) ppm. 
13C NMR (100 MHz CDCl3) δ 145.8, 145.0, 137.6, 127.6, 127.5, 
127.3, 125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 57.9, 55.7, 51.4, 44.4, 30.2, 27.9, 25.2, 23.3, 
18.9, 16.6, 12.0 ppm. LRMS (ESI+): m/z = 399 [M + H]+. HRMS (ESI) m/z calcd. for 
C23H31N2S2 [M +H] 399.1923, found 399.1916. 
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Synthesis of 10-(2-(1-benzylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine 
(6b). 
Yield: 67% (42.0 mg). 1H NMR (400 MHz CDCl3) δ 7.28-7.17 (m, 
5H) 7.14-7.10 (m, 2H), 7.03 (d, J = 4.0 Hz, 1H), 6.92-6.84 (m, 2H), 
6.81 (d, J = 4.0 Hz, 2H), 3.97-3.83 (m, 3H), 3.32 (d, J = 8.0 Hz, 1H), 
2.75-2.70 (m, 1H), 2.60-2.55 (m, 1H), 2.43 (s, 3H), 2.14 (s, 2H), 
2.00-1.94 (m, 1H), 1.77-1.41 (m, 6H) ppm. 13C NMR (100 MHz 
CDCl3) δ 146.0, 145.1, 139.7, 137.6, 129.1, 128.8, 128.6, 128.3, 127.6, 127.6, 127.3, 126.8 
125.4, 122.6, 122.3, 120.9, 115.8, 114.7, 58.4, 57.7, 55.7, 50.6, 44.2, 29.6, 24.4, 23.1, 16.6 
ppm. LRMS (ESI+): m/z = 447 [M + H]+. HRMS (ESI) m/z calcd. For C27H31N2S2 [M +H] 
447.1923, found 447.1913. 
 
Synthesis of 10-(2-(1-isopropylpiperidin-2-yl)ethyl)-2-(methylthio)-10H-phenothiazine 
(6c). 
Yield: 68% (38.0 mg). 1H NMR (400 MHz CDCl3) δ 7.15-7.11 (m, 
2H), 7.03 (d, J = 4.0 Hz, 1H), 6.92-6.88 (m, 2H), 6.80 (d, J = 4.0 Hz, 
2H), 3.96-3.98 (m, 1H), 3.83-3.79 (m, 1H), 3.15 (t, J = 8.0 Hz, 1H), 
2.81-2.75 (m, 1H), 2.62-2.59 (m, 1H), 2.44 (s, 3H), 2.20-2.03 (m, 
2H), 1.85-1.24 (m, 7H), 1.05 (d, J = 8.0 Hz, 3H), 0.77 (d, J = 8.0 Hz, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 145.8, 127.6, 127.5, 127.3, 
122.6, 122.3, 120.9, 115.7, 114.7, 56.1, 44.1, 43.9, 31.0, 28.5, 26.0, 24.0, 21.8, 16.6, 13.9 
ppm. LRMS (ESI+): m/z = 399 [M + H]+. HRMS (ESI) m/z calcd. for C23H31N2S2 [M +H] 
399.1923, found 399.1916. 
Synthesis of 1-(Adamantan-2-yl)piperazine (8) 
 
The Boc-piperazine 7 (372.2 mg, 2.0 mmol, 1 eq.) and adamantan-2-one (300.0 mg, 2.0 
mmol, 1 eq.) were dissolved in THF (8 mL), and the resulting mixture was stirred for 5 min. 
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The reaction was cooled at 0 °C, and then NaBH(AcO)3 (508.6 mg, 2.4 mmol, 1.2 eq.) and 
AcOH (0.115 mL, 2 mmol, 1 eq.) were carefully added. The resulting mixture was stirred at 
r.t. for 16 h. The reaction was quenched with NaOH (1 N, 20 mL) and the product was 
extracted with EtOAc (3 × 25 mL). The EtOAc extract was dried (MgSO4), and the solvent 
was evaporated to give the crude piperazine derivatives, which were filtered through a pad 
of silica gel (eluent EtOAc/petroleum ether 1:1). The filtered compounds were then 
dissolved in DCM (4 mL) and treated with 1 mL of TFA. The resulting mixture was stirred 
at r.t for 12 h. The solvents were removed, and the crude compound was dissolved in EtOAc 
(10 mL) and washed several times with 1 N NaOH (20 mL). The organic phase was dried 
(MgSO4), and the solvent was evaporated to yield the crude piperazines 8 which was purified 
by column chromatography using petroleum ether/EtOAc 1:1 as eluent. The pure product 8 
was obtained as a yellow-brown oil. Yield: 78% (343.1 mg). 1H NMR (400 MHz CDCl3) δ 
3.31 (m, 4H), 2.81 (m, 2H), 2.31 (br s, 2H), 2.01−1.94 (m, 4H), 1.76−1.68 (m, 5H), 
1.60−1.53 (m, 4H), 1.42−1.39 (m, 1H), 1.30−1.27 (m, 1H) ppm; LRMS (ESI+): m/z = 221 
[M + H]+. 
 
General procedure for the synthesis of compound (10a-c). 
 
The appropriate 2-substituted phenothiazine 9a-c (0.42 mmol, 1 eq.) was added to 5 mL of 
DMF in a double neck round bottom flask under N2 atmosphere. NaH (6.34 mg, 0.46 mmol, 
1.1 eq.) was added to the stirred solution at 0°C, which then was allowed to reach r.t stirring 
for 20 minutes. Then, 1-bromo-3-chloropropane (72.5 mg, 0.46 mmol, 1.1 eq.) was added to 
the stirring solution. The reaction mixture was allowed to stir under N2 atmosphere for 3 h 
at 155 °C. Then, the reaction mixture was quenched with 10 mL of water and extracted twice 
with EtOAc (20 mL). The combined organic layers were washed with brine (10 mL), dried 
over Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. Pure 
product 10a-c was obtained as yellow-brown oil after purification of the crude mixture by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent.  
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Synthesis of 10-(3-chloropropyl)-10H-phenothiazine (10a). 
Yield: 82% (100.8 mg). 1H NMR (400 MHz CDCl3) δ 7.19-7.15 (m, 4H), 
6.96-6.89 (m, 4H), 4.07 (t, J = 8.0 Hz, 2H), 3.66 (t, J = 8.0 Hz, 2H), 2.23 
(quint, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.2, 127.8, 
127.4, 125.8, 122.9, 115.7, 44.0, 42.6, 29.7 ppm. LRMS (ESI+): m/z = 
276 [M + H]+. 
 
Synthesis of 2-chloro-10-(3-chloropropyl)-10H-phenothiazine (10b). 
Yield: 84% (106.4 mg). 1H NMR (400 MHz CDCl3) δ 7.19-7.14 (m, 
2H) 7.04 (d, J = 8.0 Hz, 1H), 6.95 (t, J = 8.0 Hz, 1H), 6.91-6.88 (m, 
2H), 6.86 (s, 1H), 4.04 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 
2.25-2.18 (quint, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) 
δ 146.5, 144.4, 133.4, 128.2, 127.8, 127.6, 125.5, 124.2, 123.3, 122.7, 116.0, 115.9, 44.1, 
42.3, 29.5 ppm. LRMS (ESI+): m/z = 332 [M+Na]+ 
 
Synthesis of 10-(3-chloropropyl)-2-(methylthio)-10H-phenothiazine (10c). 
Yield: 93% (125.4 mg). 1H NMR (400 MHz CDCl3) δ 7.18-7.14 
(m, 2H), 7.06 (d, J = 8.0 Hz, 1H), 6.95-6.88 (m, 2H), 6.81 (s, 2H), 
4.06 (t, J = 8.0 Hz, 2H), 3.65 (t, J = 8.0 Hz, 2H), 2.46 (s, 3H), 2.22 
(quint, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.6, 
145.9, 137.8, 127.8, 127.7, 127.5, 125.8, 123.0, 122.7, 121.1, 115.9, 
114.6, 44.1, 42.5, 29.7, 16.5 ppm. LRMS (ESI+): m/z = 322 [M + H]+. 
 
Synthesis of 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (10d).  
 
2-SMe-phenothiazine 9c (298.4 mg, 1.22 mmol, 1 eq.) was added to 15 mL of DMF in a 
double neck round bottom flask under N2 atmosphere. NaH (25.2 mg, 1.83 mmol, 1.5 eq.) 
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was added to the stirring solution at 0°C which then was allowed to reach r.t stirring for 20 
minutes. Then, 2-chloroacetyl chloride (0.288 mL, 3.66 mmol 3 eq.) was added to the stirring 
solution. The reaction mixture was allowed to stir under N2 atmosphere for 3h at 155 °C. 
Then, the reaction mixture was quenched with water (10 mL) and extracted twice with 
EtOAc (20 mL). The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure giving a yellow-brown crude oil. The obtained 
product was purified by chromatography on silica gel, using hexane/EtOAc (3:2) as eluent. 
Yield: 58% (227.2 mg). 1H NMR (400 MHz CDCl3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.47-7.43 
(m, 2H), 7.36-7.31 (m, 2H), 7.27-7.23 (m, 1H), 7.14-7.11 (m, 1H), 4.16 (s, 2H), 2.49 (s, 3H) 
ppm. 13C NMR (100 MHz CDCl3) δ 166.3, 138.8, 138.3, 137.5, 128.3, 128.2, 127.7, 127.5, 
126.5, 125.7, 124.1, 40.7, 15.9 ppm. LRMS (ESI+): m/z = 322 [M + H]+. 
 
Synthesis of 1-(3-chloropropyl)-1H-indole (10e). 
 
Indole 9d (60.8 mg, 0.52 mmol, 1 eq.) was added to 10 mL of DMF in a double neck round 
bottom flask under N2 atmosphere. NaH (7.8 mg, 0.57 mmol, 1.1 eq.) was added to the 
stirring solution at 0 °C which then was allowed to reach r.t stirring for 20 minutes. Then, 1-
bromo-3-chloropropane (88.8 mg, 0.57 mmol 1.1 eq) was added to the stirring solution. The 
reaction mixture was allowed to stir under N2 atmosphere for 3h at 155 °C. Then, the reaction 
mixture was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow-brown crude oil. The  product 9e was 
purified by chromatography on silica gel, using hexane/EtOAc (4:1) as eluent, affording 9e 
as a light-yellow oil. Yield: 82% (82.3 mg). 1H NMR (400 MHz CDCl3) δ 7.69 (d, J = 8.0 
Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.27 (t, J = 8.0 Hz, 1H), 7.19-7.15 (m, 2H), 6.56 (d, J = 
4.0 Hz, 1H), 4.37-4.33 (m, 2H), 3.46 (t, J = 8.0 Hz, 1H), 3.32 (t, J = 8.0 Hz, 1H), 2.37-2.26 
(quint, J = 8.0 Hz, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 135.9, 128.8, 128.1, 121.8, 
121.2, 119.6, 109.4, 101.6, 42.9, 42.0, 32.7 ppm. LRMS (ESI+): m/z = 194 [M + H]+. 
 
 
 115 
 
General procedure for the synthesis of thioridazine derivatives (11a-i). 
 
Cmpd R R1 Yields 
11a H 1-methyl-piperazine 99% 
11b H 1-phenyl-piperazine 62% 
11c SMe 1-methyl-piperazine 99% 
11d SMe 1-phenyl-piperazine 77% 
11e SMe thiomorpholine 99% 
11f SMe 1-adamantantyl-piperazine 71% 
11g SMe 2-adamantantyl-piperazine 72% 
11h Cl 1-phenyl-piperazine 57% 
11i Cl thiomorpholine 90% 
 
The appropriate N substituted piperazine or thiomorpholine (0.72 mmol, 4 eq.) was dissolved 
in a round bottom flask containing dry DMF (10 mL) and DIPEA (0.033 mL, 0,19 mmol, 
1.1 eq.) under N2 atmosphere. The mixture was stirred at r.t for 20 minutes, then, the 
appropriate compound 10a-c, (0.18 mmol, 1 eq.) was added to the solution followed by NaI 
(5.7 mg, 0.04 mmol, 0.2 eq.). Then, the mixture was left under N2 atmosphere at 155 °C for 
3 h. Then, the reaction mixture was quenched with water (10 mL) and extracted twice with 
EtOAc (10 mL). The combined organic layers were washed with brine, dried over Na2SO4 
and concentrated under reduced pressure. The pure product was obtained as a yellow oil 
after purificationof the crude mixture by chromatography on silica gel, using 
EtOAc/MeOH/TEA (3.9:1:0.1) as eluent. 
 
Synthesis of 10-(3-(4-methylpiperazin-1-yl)propyl)-10H-phenothiazine (11a).213 
Yield: 99% (61.1 mg). 1H NMR (400 MHz CDCl3) δ 7.12 (t, J = 8.0 
Hz, 4H), 6.90 (t, J = 8.0 Hz, 4H), 3.90 (t, J = 8.0 Hz, 2H), 2.46 (t, J 
= 8.0 Hz, 2H), 2.42-2.34 (m, 8H), 2.26 (s, 3H), 1.94 (t, J = 8.0 Hz, 
2H) ppm. 13C NMR (100 MHz CDCl3) δ 145.2, 127.5, 127.3, 125.1, 
122.5, 115.6, 55.7, 55.1, 53.2, 46.0, 45.4, 24.5 ppm. LRMS (ESI+): 
m/z = 340 [M + H]+. 
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Synthesis of 10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (11b). 
Yield: 62% (44.7 mg). 1H NMR (400 MHz CDCl3) δ 7.25 (t, J = 
8.0 Hz, 2H), 7.13 (d, J = 8.0 Hz, 4H), 6.92-6.88 (m, 6H), 6.84 (t, J 
= 8.0 Hz, 1H), 3.95 (t, J = 8.0 Hz, 2H), 3.14 (t, J = 8.0 Hz, 4H), 
2.57 (t, J = 8.0 Hz, 4H), 2.53 (t, J = 8.0 Hz, 2H), 2.02-1.95 (m, 2H) 
ppm. 13C NMR (100 MHz CDCl3) δ 151.4, 145.3, 129.2, 127.5, 
127.3, 125.2, 122.5, 119.7, 116.1, 115.6, 55.7, 53.4, 49.2, 45.3, 
24.4 ppm. LRMS (ESI+): m/z = 402 [M + H]+. HRMS (ESI) m/z calcd. for C25H28N3S [M 
+H] 402.1998, found 402.1995. 
 
Synthesis of 10-(3-(4-methylpiperazin-1-yl)propyl)-2-(methylthio)-10H-phenothiazine 
(11c). 
Yield: 99% (69.7 mg). 1H NMR (400 MHz CDCl3) δ 7.11-7.09 (m, 
2H), 7.01 (d, J = 8.0 Hz, 1H), 6.90-6.85 (m, 2H), 6.80-6.77 (m, 2H), 
3.89 (t, J = 8.0 Hz, 2H), 2.50-2.33 (m, 8H), 2.46 (t, J = 8.0 Hz, 2H), 
2.44 (s, 3H), 2.26 (s, 3H), 1.94-1.92 (m, 2H) ppm. 13C NMR (100 
MHz CDCl3) δ 145.2, 144.9, 137.5, 127.6, 127.5, 127.3, 125.2, 
122.6, 122.2, 120.8, 115.8, 114.7, 55.6, 55.1, 53.2, 46.0, 45.3, 24.4, 
16.6 ppm. LRMS (ESI+): m/z = 386 [M + H]+. HRMS (ESI) m/z calcd. for C21H28N3S2 [M 
+H] 386.1719, found 386.1739. 
 
Synthesis of 2-(methylthio)-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine 
(11d). 
Yield: 77% (61.9 mg). 1H NMR (400 MHz CDCl3) δ 7.24 (t, J = 8.0 
Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 7.03 (d, J = 8.0 Hz, 1H), 6.92-6.88 
(m, 4H), 6.85-6.80 (m, 3H), 3.94 (t, J = 8.0 Hz, 2H), 3.14 (t, J = 8.0 
Hz, 4H), 2.56 (t, J = 8.0 Hz, 4H), 2.51 (t, J = 8.0 Hz, 2H), 2.45 (s, 
3H), 1.99-1.96 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 151.4, 
145.7, 145.02, 137.6, 129.2, 127.6, 127.5, 127.3, 125.3, 122.7, 122.3, 
120.9, 119.7, 116.1, 115.8, 114.8, 55.7, 53.4, 49.2, 45.3, 24.4, 16.6 ppm. LRMS (ESI+): m/z 
= 448 [M + H]+. HRMS (ESI) m/z calcd. for C26H30N3S2 [M +H] 448.1876, found 448.1866. 
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Synthesis of 2-(methylthio)-10-(3-thiomorpholinopropyl)-10H-phenothiazine (11e). 
Yield: 99% (69.3 mg). 1H NMR (400 MHz CDCl3) δ 7.14-7.03 (m, 
2H), 7.01 (d, J = 8.0 Hz, 1H), 6.91-6.86 (m, 2H), 6.80-6.77 (m, 2H), 
3.90 (t, J = 8.0 Hz, 2H), 2.63-2.57 (m, 8H), 2.45 (s, 3H), 1.89 (t, J = 
8.0 Hz, 2H) 1.34-1.22 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 
145.7, 144.9, 137.6, 127.6, 127.5, 127.3, 122.6, 122.2, 120.8, 115.9, 
114.8, 56.1, 55.2, 45.1, 28.1, 24.1, 16.6 ppm. LRMS (ESI+): m/z = 
389 [M + H]+. HRMS (ESI) m/z calcd. for C20H25N2S3 [M +H] 389.1174, found 389.1172.  
 
Synthesis of 10-(3-(4-adamantan-1-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-
phenothiazine (11f).  
Yield: 71% (64.5 mg). 1H NMR (400 MHz CDCl3) δ 7.17-
7.07 (m, 2H), 7.02 (d, J = 7.5 Hz, 1H), 6.92-6.85 (m, 2H), 
6.84-6.76 (m, 2H), 3.89 (t, J = 7.0 Hz, 2H), 2.56-2.26 (m, 
10H), 2.44 (s, 3H), 2.07-1.88 (m, 8H), 1.88-1.74 (m, 4H), 
1.71-1.53 (m, 4H), 1.36 (d, J = 12.0 Hz, 2H) ppm. 13C NMR 
(100 MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 127.5, 127.3, 
125.3, 122.7, 122.3, 120.8, 115.9, 114.7, 55.4, 54.3, 53.2, 46.7, 45.4, 45.2, 44.0, 43.9, 41.0, 
38.7, 38.0, 36.8, 36.7, 29.7, 24.3, 16.6 ppm. LRMS (ESI+): m/z = 506 [M + H]+. HRMS 
(ESI) m/z calcd. for C30H40N3S2 [M +H] 506.2658, found 506.2644. 
 
Synthesis of 10-(3-(4-(-adamantan-2-yl)piperazin-1-yl)propyl)-2-(methylthio)-10H-
phenothiazine (11g). 
Yield: 72% (65.4 mg). 1H NMR (400 MHz CDCl3) δ 7.15-
7.04 (m, 2H), 7.01 (d, J = 7.5 Hz, 1H), 6.92-6.81 (m, 2H), 
6.81 - 6.73 (m, 2H), 3.87 (t, J = 6.5 Hz, 2H), 3.50-3.49 (m, 
1H), 3.33-3.32 (m, 1H), 2.81-2.65 (m, 3H), 2.64-2.59 (m, 
4H), 2.59-2.44(m, 5H), 2.43 (s, 3H), 2.07 (m, 5H), 1.97-1.87 
(m, 2H), 1.73 (m, 5H), 1.64 (d, J = 2.0 Hz, 3H) ppm. 13C 
NMR (100 MHz CDCl3) δ 145.8, 144.9, 137.6, 127.6, 
127.5, 127.3, 125.2, 122.6, 122.2, 120.8, 115.8, 114.7, 67.8, 56.0, 54.0, 49.6, 45.6, 40.6, 
37.9, 37.3, 31.4, 29.1, 28.9, 27.6, 27.4, 24.4, 16.6 ppm. LRMS (ESI+): m/z = 506 [M + H]+. 
HRMS (ESI) m/z calcd. for C30H40N3S2 [M +H] 506.2658, found 506.2644.
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Synthesis of 2-chloro-10-(3-(4-phenylpiperazin-1-yl)propyl)-10H-phenothiazine (11h). 
Yield: 57% (44.6 mg). 1H NMR (400 MHz CDCl3) δ 7.24 (t, 
J = 8.0 Hz, 2H), 7.17-7.11 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 
6.94-6.63 (m, 7H), 3.92 (t, J = 8.0 Hz, 2H), 3.15 (t, J = 8.0 Hz, 
4H), 2.57 (t, J = 8.0 Hz, 4H), 2.51 (t, J = 8.0 Hz, 2H), 2.00-1.96 
(m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 151.4, 146.6, 
144.6, 133.3, 129.2, 128.0, 127.6, 127.5, 124.8, 123.6, 123.0, 122.3, 119.8, 116.1, 115.9, 
55.6, 53.5, 49.2, 45.4, 24.3 ppm. LRMS (ESI+): m/z = 436 [M + H]+. HRMS (ESI) m/z 
calcd. for C25H27ClN3S [M +H] 436.1609, found 436.1618. 
 
Synthesis of 2-chloro-10-(3-thiomorpholinopropyl)-10H-phenothiazine (11i). 
Yield: 90% (60.9 mg). 1H NMR  (400 MHz CDCl3) δ 7.15-7.08 
(m, 2H), 6.99 (d, J = 8.0 Hz, 1H), 6.93-6.81 (m, 4H), 3.88 (t, J = 
8.0 Hz, 2H), 2.66-2.57 (m, 8H), 2.45 (t, J = 8.0 Hz, 2H), 1.91-1.85 
(m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 146.5, 144.6, 133.2, 
127.9, 127.6, 127.5, 124.8, 123.5, 122.9, 122.3, 115.9, 56.0, 55.8, 
45.1, 28.1, 24.0 ppm. LRMS (ESI+): m/z = 377 [M + H]+. HRMS (ESI) m/z calcd. for 
C19H21ClN2S2 [M +H] 377.0834, found 377.0849. 
 
Synthesis of 2-(4-methylpiperazin-1-yl)-1-(2-(methylthio)-10H-phenothiazin-10-
yl)ethanone (11j). 
 
N-methylpiperazine (63.0 mg, 0.63 mmol, 4 eq.) was dissolved in a round bottom flask 
containing dry DMF (5 mL) and DIPEA (0.031 mL, 0.17 mmol, 1.1 eq.) under N2 
atmosphere.Then, 2-chloro-1-(2-(methylthio)-10H-phenothiazin-10-yl)ethanone (10d) 
(48.1 mg 0.15 mmol, 1 eq.) was added to the solution followed by NaI (4.5 mg, 0.03 mmol, 
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0.2 eq.). The mixture was left under N2 atmosphere at 155 °C for 3 h. Then, the reaction 
mixture was quenched with water (10 mL) and extracted twice with EtOAc (20 mL). The 
combined organic layers were washed with brine (10 mL), dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow-brown crude oil. The  pure product 
11j was obtained as a brown solid after purificationof the crude mixture by chromatography 
on silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent. Yield: 96% (55.4 mg). 1H 
NMR (400 MHz CDCl3) δ 7.51-7.47 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.32-7.26 (m, 2H), 
7.22-7.18 (m, 1H), 7.10-7.08 (m, 1H), 3.30-3.31 (m, 2H), 2.47 (s, 3H), 2.44-2.27 (8H), 2.22 
(s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 168.6, 139.3, 138.6, 137.9, 128.0, 127.9, 127.0, 
126.9, 125.1, 124.9, 60.4, 54.9, 52.9, 45.9, 16.2 ppm. LRMS (ESI+): m/z = 386 [M + H]+. 
HRMS (ESI) m/z calcd.  for C20H24N3S2O [M +H], 386.1355 found 386.1351. 
 
Synthesis of 1-(3-(4-methylpiperazin-1-yl)propyl)-1H-indole (12). 
 
N-methylpiperazine (104.2 mg, 1.04 mmol, 4 eq.) was dissolved in a round bottom flask 
containing dry DMF (5 mL) and DIPEA (0.051 mL, 0.28 mmol, 1.1 eq.) under N2 
atmosphere. Then, 1-(3-chloropropyl)-1H-indole (50.2 mg, 0.26 mmol, 1 eq.) 10e was added 
to the solution followed by NaI (10.5 mg, 0.07 mmol, 0.2 eq.). The mixture was left under 
N2 atmosphere at 155 °C for 3 h. Then, the reaction mixture was quenched with water (10 
mL) and extracted twice with EtOAc (20 mL). The combined organic layers were washed 
with brine (10 mL), dried over Na2SO4 and concentrated under reduced pressure giving a 
yellow-brown crude oil. The pure product 12 was obtained as a yellow oil after purificationof 
the crude mixture by chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. 
Yield: 63% (42.1 mg). 1H NMR (400 MHz CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.36 (d, J = 
8.0 Hz, 1H), 7.18 (t, J = 8.0 Hz, 1H), 7.12 - 7.03 (m, 2 H), 6.46 (d, J = 3.0 Hz, 1H), 4.19 (t, 
J = 6.0 Hz, 2H), 2.45 (m., 8H), 2.29 (s, 3H), 2.28-2.23 (m, 2H), 1.98 (m, 2H) ppm. 13C NMR 
(100 MHz CDCl3) δ 136.1, 128.6, 128.0, 121.4, 121.0, 119.3, 109.5, 101.0, 55.3, 54.9, 53.1, 
46.1, 43.9, 27.4 ppm. LRMS (ESI+): m/z = 258 [M + H]+ HRMS (ESI) m/z calcd. for 
C16H24N3 [M +H] 258.1965, found 258.1966.
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tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate (S1). 
 
2-(piperidin-2-yl)ethanol 13 (200.2 mg, 1.55 mmol 1 eq.) was added to 10 mL mixture (1:1) 
of CH2Cl2 and Na2CO3 satured solution in water (10 mL) in a round bottom flask. Di-tert-
butyl dicarbonate (371.4 mg, 1.70 mmol, 1.1 eq.) was added to the stirring solution. The 
reaction mixture was allowed to stir under N2 atmosphere for 12h at room temperature. Then, 
the reaction mixture was diluited with 10 mL of water and extracted twice with 20 mL of 
EtOAc. The combined organic layers were washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow crude oil. The pure product S1 was 
obtained as a yellow oil after purification of the crude mixture by chromatography on silica 
gel, using hexane/EtOAc (3:2) as eluent. Yield: 98% (314.4 mg). 1H NMR (400 MHz 
CDCl3) δ 4.35-4.19 (m, 1H) 3.85-3.80 (m, 2H), 3.48-3.42 (m, 1H), 3.27 (br s, 1H), 2.59-2.52 
(m, 1H), 1.81 (t, J = 12.0 Hz, 1H), 1.64-1.54 (m, 1H), 1.51-1.37 (m, 5H), 1.37 (s, 9H), 1.29-
1.25 (m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 155.0, 80.2, 58.7, 46.1, 39.4, 32.5, 28.5, 
28.4, 25.6, 19.0 ppm. LRMS (ESI+): m/z = 230 [M+Na]+  
 
Synthesis of tert-butyl 2-(2-bromoethyl)piperidine-1-carboxylate (14). 
 
  
 
To a solution of tert-butyl 2-(2-hydroxyethyl)piperidine-1-carboxylate (S1) (89.1 mg, 0.43 
mmol, 1 eq.) in CH2Cl2 (10 mL) was added PPh3 (123.3 mg, 0.47 mmol, 1.1 eq.) followed 
by a solution of CBr4 (155.8 mg, 0.47mmol, 1.1 eq.) in 20 mL of CH2Cl2 at r.t, and the 
mixture was allowed to stir for 45 min. Then, the reaction mixture was concentrated under 
reduced pressure giving a yellow crude oil. The obtained product was then immediately 
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purified by chromatography on silica gel, using hexane/EtOAc (9:1) as eluent. The pure 
product 14 was obtained as a yellow oil. Yield: 79% (99.5 mg). 1H NMR (400 MHz CDCl3) 
δ 4.35-4.31 (m, 1H) 4.02-3.84 (m, 1H), 3.33-3.19 (m, 2H), 2.70-2.64 (t, J = 12.0 Hz, 1H), 
2.33-2.23 (m, 1H), 1.90-1.64 (m, 1H), 1.63-1.43 (m, 5H), 1.40 (s, 9H), 1.38-1.31 (m, 1H) 
ppm. 13C NMR (100 MHz CDCl3) δ 155.2, 79.6, 49.5, 38.7, 33.6, 30.3, 28.7, 28.5, 25.5, 
19.2 ppm. LRMS (ESI+): m/z = 292 [M + H]+ 294 [M + H]+ 
General procedure for the synthesis of Boc-protected thioridazine derivatives (15a-b). 
 
The appropriate 2-substituted phenothiazine (9a-b) (0.42 mmol, 1 eq.) was added to 10 mL 
of DMF in a double neck round bottom flask. NaH (19.3 mg, 0.52 mmol, 1.2 eq.) was added 
to the stirred solution at 0°C that then was allowed to reach r.t stirring for 20 minutes. Then, 
t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate (14) (113.2 mg, 0.52 mmol 1.2 eq.) and 
NaI (2.98 mg, 0.02 mmol, 0.1 eq.) were added to the stirring solution. The reaction mixture 
was allowed to stir under N2 atmosphere for 12h at r.t. Then, the reaction mixture was 
quenched with 20 mL of water and extracted twice with 20 mL of EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure giving a yellow-brown crude oil. The obtained product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. The pure products 15a-
b were isolated as yellow-brown oil.  
Synthesis of tert-butyl 2-(2-(10H-phenothiazin-10-yl)ethyl)piperidine-1-carboxylate 
(15a).  
Yield: 45% (77.4 mg). 1H NMR (400 MHz CDCl3) δ 7.16-7.12 (m, 
4H), 6.93-6.89 (m, 2H), 6.84 (d, J = 8.0 Hz, 2H), 4.45-4.35 (m, 1H), 
4.08-3.96 (m, 1H), 3.92-3.74 (m, 2H), 3.38-3.28 (m, 1H), 2.83-2.69 (m, 
1H), 2.37-2.18 (m, 1H), 1.91-1.85 (m, 1H), 1.67-1.49 (m, 5H), 1.40 (s, 
9H) ppm. 13C NMR (100 MHz CDCl3) δ 155.1, 145.3, 127.6, 127.3, 
125.1, 122.5, 115.3, 79.4, 49.5, 38.7, 33.6, 30.3, 28.7, 28.5, 25.5, 19.2 
ppm. LRMS (ESI+): m/z = 411 [M + H]+. 
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Synthesis of t-butyl 2-(2-(2-chloro-10H-phenothiazin-10-yl)ethyl)piperidine-1-
carboxylate (15b). 
Yield: 61% (114.1 mg). 1H NMR (400 MHz CDCl3) δ 7.17-7.11 (m, 
2H) 7.02 (d, J = 8.0 Hz, 1H), 6.95-6.83 (m, 3H), 6.78 (d, J = 4.0 Hz, 
1H), 4.44-4.39 (m, 1H), 4.38-4.35 (m, 1H), 4.05-4.00 (m, 1H), 3.88-
3.79 (m, 2H), 2.78 (t, J = 12.0 Hz, 1H), 2.22-2.16 (m, 1H), 1.90-1.81 
(m, 1H), 1.68-1.45 (m, 5H), 1.42 (s, 9H) ppm. 13C NMR (100 MHz 
CDCl3) δ 155.2, 146.7, 144.6, 133.4, 128.1, 127.5, 124.9, 123.0, 122.4, 115.7, 79.6, 48.8, 
44.8, 39.1, 29.3, 28.5, 27.7, 25.6, 19.3 ppm. LRMS (ESI+): m/z = 468 [M+Na]+. 
 
Synthesis of t-butyl 2-(2-(9H-carbazol-9-yl)ethyl)piperidine-1-carboxylate (15c). 
 
Carbazole (93.5 mg, 0.56 mmol, 1 eq.) 9e was added to 5 mL of DMF in a double neck round 
bottom flask under N2 atmosphere. NaH (26.2 mg, 0.68 mmol, 1.2 eq.) was added to the 
stirring solution at 0 °C which then was allowed to reach r.t stirring for 20 minutes. Then, t-
butyl 2-(2-bromoethyl)piperidine-1-carboxylate 14 (199.1 mg, 0.68 mmol, 1 eq.) was added 
to the stirring solution. The reaction mixture was allowed to stir under N2 atmosphere for 12 
h at r.t. Then, the reaction mixture was quenched with 10 mL of water and extracted twice 
with 20 mL of EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure giving a yellow-brown crude oil. The 
obtained product was purified by chromatography on silica gel, using hexane/EtOAc (4:1) 
as eluent. The pure product 15c was obtained as a yellow oil. Yield: 61% (127.1 mg). 1H 
NMR (400 MHz CD3OD) δ 8.37 (d, J = 7.5 Hz, 2H),7.87-7.64 (m, 4H), 7.60-7.35 (m, 2H), 
4.74 (m, 1H), 4.69-4.59 (m, 1H), 4.36-4.18 (m, 1H), 3.69-3.60 (m, 2H), 3.10-3.07 (m, 1H), 
2.73-2.53 (m, 1H), 2.22 (m, 1H), 2.00-1.86 (m, 5H), 1.85- 1.76 (m, 9H) ppm. 13C NMR (100 
MHz CD3OD) δ 155.8, 140.6, 140.5, 125.9, 125.6, 123.4, 123.3, 120.4, 120.0, 119.1, 118.7, 
110.8, 108.7, 80.1, 78.6, 40.2, 33.2, 28.5, 27.9, 27.8, 25.7, 19.1, 19.0 ppm. LRMS (ESI+): 
m/z = 401 [M+Na]+. 
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Synthesis of t-butyl 2-(2-(1H-benzo[d]imidazol-1-yl)ethyl)piperidine-1-carboxylate 
(15d). 
 
benzo[d]imidazole 9f (79.1 mg, 0.67 mmol, 1 eq.) was added to 5 mL of DMF in a double 
neck round bottom flask. NaH (11.5 mg, 0.80 mmol, 1.2 eq.) was added to the stirring 
solution at 0°C under N2 atmosphere that then was allowed to reach r.t. stirring for 20 
minutes. Then, t-butyl 2-(2-bromoethyl)piperidine-1-carboxylate 14 (233.2 mg, 0.80 mmol 
1.2 eq.) and NaI (14.9 mg, 0.1 mmol, 0.1eq.) were added to the stirring solution. The reaction 
mixture was allowed to stir under N2 atmosphere for 12 h at r.t. Then, the reaction mixture 
was quenched with 10 mL of water and extracted twice with 20 mL of EtOAc. The combined 
organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure giving a yellow-brown crude oil. The obtained product was purified by 
chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. The pure product 15d 
was obtained as a yellow oil. Yield: 63% (138.9 mg). 1H NMR (400 MHz CDCl3) δ 7.91 (s, 
1H), 7.84-7.67 (m, 1H), 7.39-7.31 (m, 1H), 7.31-7.09 (m, 2H), 4.49-4.19 (m, 1H), 4.10-3.90 
(m, 2H), 2.81-2.65 (m, 1H), 2.38-2.18 (m, 1H), 1.96-1.77 (m, 1H), 1.72-1.44 (m, 7H), 1.44-
1.29 (m, 9H) ppm. 13C NMR (100 MHz CDCl3) δ 155.2, 144.0, 143.2, 133.7, 122.9, 122.1, 
120.6, 109.5, 79.9, 60.4, 42.4, 30.1, 28.9, 28.5, 25.5, 19.2, 14.2 ppm. LRMS (ESI+): m/z = 
330 [M + H]+. 
Synthesis of tert-butyl 2-(2-(1H-indol-1-yl)ethyl)piperidine-1-carboxylate (15e). 
 
 
1H-indole 9d (49.2 mg, 0.42 mmol, 1 eq.) was added to 5 mL of DMF in a double neck 
round bottom flask. NaH (20.0 mg, 0.50 mmol, 1.2 eq.) was added to the stirring solution at 
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0°C under N2 atmosphere that then was allowed to reach r.t stirring for 20 minutes. Then, t-
butyl 2-(2-bromoethyl)piperidine-1-carboxylate 14 (145.0 mg, 0.50 mmol 1.2 eq.) and NaI 
(2.98 mg, 0.02 mmol, 0.1 eq.) were added to the stirring solution. The reaction mixture was 
allowed to stir under N2 atmosphere for 12 h at r.t. Then, the reaction mixture was quenched 
with 10 mL of water and extracted twice with 20 mL of EtOAc. The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure giving 
a yellow-brown crude oil. The obtained product was purified by chromatography on silica 
gel, using hexane/EtOAc (4:1) as eluent. The pure product 15e was obtained as a yellow-
brown oil. Yield: 42% (59.6 mg). 1H NMR (400 MHz CDCl3) δ 7.62 (d, J = 8.0 Hz, 1H) 
7.31 (d, J = 8.0 Hz, 1H), 7.22-7.18 (m, 1H), 7.12-7.07 (m, 2H), 6.48 (d, J = 4.0 Hz, 1H), 
4.38-4.33 (m, 1H), 4.15-4.03 (m, 3H), 2.81 (t, J = 8.0 Hz, 1H), 2.31-2.21 (m, 1H), 1.93-1.86 
(m, 1H), 1.68-1.58 (m, 6H), 1.45 (s, 9H) ppm 13C NMR (100 MHz CDCl3) δ 155.2, 135.8, 
128.8, 127.9, 121.5, 121.1, 119.4, 109.2, 101.2, 79.7, 43.8, 30.7, 29.0, 28.6, 25.6, 19.2 ppm. 
LRMS (ESI+): m/z = 351 [M+Na]+. 
 
General procedure for the synthesis of Thioridazine derivatives (16a-e). 
 
The appropriate Boc-protected compound 16a-e (0.243 mmol 1 eq.) was added to a round 
bottom flask containing 10 mL saturated solution of HCl in EtOAc. Then, the reaction 
mixture was allowed to stir at room temperature for 12 h. The solvent was concentrated 
under reduced pressure giving a white solid as product of the reaction. 
Synthesis of 10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (16a). 
Yield: 99% (74.5 mg). 1H NMR (400 MHz CDCl3) δ 9.41 (br s., 1H), 
9.24 (br s., 1H), 7.15-7.12 (m, 4H), 6.92-6.86 (m, 4H), 3.97-3.92 (m, 2H), 
3.49-3.45 (m, 1H), 3.08-3.05 (m, 1H), 2.73-2.57 (m, 1H), 2.45-2.43 (m, 
1H), 2.18-2.06 (m, 1H), 1.93-1.74 (m, 3H), 1.69-1.60 (m, 2H), 1.44-1.34 
(m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 145.3, 127.7, 127.4, 125.4, 
122.7, 115.6, 55.6, 46.8, 44.3, 33.7, 32.4, 25.9, 24.5 ppm. LRMS (ESI+): m/z = 312 [M + 
H]+. HRMS (ESI) m/z calcd. for C19H22N2S [M +H] 311.1503, found 311.1579. 
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Synthesis of 2-chloro-10-(2-(piperidin-2-yl)ethyl)-10H-phenothiazine (16b). 
Yield: 94% (79.2 mg). 1H NMR (400 MHz CDCl3) δ 9.54 (br s, 1H), 
9.34 (br s, 1H), 7.19 (t, J = 8.0Hz 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.04 
(d, J = 8.0 Hz, 1H), 6.95-6.89 (m, 4H), 4.07-3.96 (m, 2H), 3.31 (d, J 
= 8.0 Hz, 1H), 3.12-3.04 (m, 1H), 2.77-2.68 (m, 1H), 2.50-2.42 (m, 
1H), 2.13-2.09 (m, 1H), 1.85-1.69 (m, 6H) ppm. 13C NMR (100 MHz 
CDCl3) δ 146.6, 144.5, 133.3, 128.0, 127.6, 127.5, 125.1, 123.9, 123.1, 122.5, 115.9, 55.4, 
46.7, 44.4, 33.5, 29.7, 25.8, 24.4 ppm. LRMS (ESI+): m/z = 367 [M+Na]+. HRMS (ESI) 
m/z calcd. for C19H21ClN2S [M +H] 345.1113, found 345.1194. 
 
 
Synthesis of 9-(2-(piperidin-2-yl)ethyl)-9H-carbazole (16c). 
Yield: 95% (64.17 mg). 1H NMR (400 MHz CDCl3) δ 9.66 (br s, 1H), 
9.41 (br s, 1H), 8.02 (d, J = 8.0, 2H), 7.46-7.37 (m, 4H), 7.17 (t, J = 8.0, 
2H), 4.51-4.43 (m, 1H), 4.31-4.25 (m, 1H), 3.38-3.36 (m, 1H), 3.02-2.90 
(m, 1H), 2.70-2.67 (m, 1H), 2.49-2.48 (m, 1H), 2.18-2.12 (m, 1H), 1.88-
1.61 (m, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 140.0, 126.1, 122.9, 
120.4, 119.3, 108.8, 55.5, 44.9, 39.5, 32.7, 30.0, 22.3, 22.0 ppm. LRMS (ESI+): m/z = 279 
[M + H]+. HRMS (ESI) m/z calcd. for C19H22N2 [M +H] 279.1782, found 279.1855. 
 
 
Synthesis of 1-(2-(piperidin-2-yl)ethyl)-1H-benzo[d]imidazole (16d). 
Yield: 90% (50.4 mg). 1H NMR (400 MHz CDCl3) δ 10.17 (s 1H), 9.68 
(br s, 2H), 7.82 (t, J = 8.0 Hz, 2H), 7.44-7.36 (m, 2H), 5.01-4.79 (m, 
2H), 3.46-3.43 (m, 1H), 3.36-3.25 (m, 1H), 2.98-2.94 (m, 1H), 2.85-
2.71 (m, 1H), 2.50-2.36 (m, 1H) 1.90-1.75 (m, 6H) ppm. 13C NMR (100 
MHz CDCl3) δ 140.9, 130.7, 126.9, 126.7, 115.6, 112.7, 54.1, 45.0, 
43.7, 33.4, 28.7, 22.3, 20.9 ppm. LRMS (ESI+): m/z = 230 [M + H]+. HRMS (ESI) m/z 
calcd. for C14H19N3 [M +H] 230.1578, found 230.1652. 
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Synthesis of 1-(2-(piperidin-2-yl)ethyl)-1H-indole (16e). 
Yield: 94% (52.2 mg). 1H NMR (400 MHz CD3OD) δ 7.42-7.34 (m, 1H), 
7.24-7.19 (m, 1H), 7.10-7.01 (m, 2H), 6.90-6.80 (m, 2H), 4.12-4.01 (m, 
2H), 3.39-3.24 (m, 1H), 2.95-2.89 (m, 2H), 2.82-2.73 (m, 1H), 2.75-2.59 
(m, 1H), 2.49-2.40 (m, 1H), 2.38-2.29 (m, 2H), 1.84-1.67 (m, 3H) ppm. 
13C NMR (100 MHz (CD3)2SO) δ 135.8, 127.9, 121.8, 121.1, 119.6, 
119.1, 109.7, 54.2, 45.2, 43.6, 33.3, 28.8, 22.1, 20.8 ppm. LRMS (ESI+): m/z = 229 [M + 
H]+. HRMS (ESI) m/z calcd. for C15H20N2 [M +H] 229.1626, found 229.1701. 
 
General procedure for the synthesis of thioridazine derivatives (17a-d). 
 
The appropriate compounds 16a-d (0.14 mmol, 1 eq.) was added to a round bottom flask 
containing THF (5 mL) and formaldehyde aqueous solution 37% w/v (0.75mL, 0.28 mmol, 
2 eq.). The solution was then allowed to stir at room temperature for 30 minutes. Then, 
NaBH(AcO)3 (59.2 mg, 0.28 mmol, 2.0 eq.) was added. The reaction was allowed to stir for 
12h at r.t. Then the solution was quenched with (20 mL) NaOH 1N solution. The mixture 
was allowed to stir for 20 minutes then the organic solvent was removed through reduced 
pressure evaporation. The residue was diluted with EtOAc, extracted with EtOAc (3 x 10 
mL) and dried over anhydrous MgSO4. The product was purified by chromatography on 
silica gel, using EtOAc/MeOH/TEA (3.9:1:0.1) as eluent affording the product as a yellow-
brown oil. 
Synthesis of 10-(2-(1-methylpiperidin-2-yl)ethyl)-10H-phenothiazine (17a). 
Yield: 47% (21.3 mg). 1H NMR (400 MHz CDCl3) δ 7.19-7.07 (m, 4H), 
6.95-6.85 (m, 4H), 3.95 (ddd, J = 13.9, 8.6, 5.5 Hz, 1H), 3.89-3.77 (m, 
1H), 2.89-2.72 (m, 1H), 2.22-2.16 (m, 3H), 2.16-1.99 (m, 3H), 1.93-1.80 
(m, 1H), 1.71 (d, J = 10.0 Hz, 1H), 1.64-1.50 (m, 2H), 1.34-1.18 (m, 3H) 
ppm. 13C NMR (100 MHz CDCl3) δ 145.4, 127.6, 127.3, 125.4, 122.5, 
115.6, 62.2, 57.0, 43.9, 43.1, 30.8, 30.0, 25.7, 24.2 ppm. LRMS (ESI+): 
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m/z = 325 [M + H]+. HRMS (ESI) m/z calcd. for C20H25N2S [M +H] 325.1733, found 
325.1735. 
 
Synthesis of 2-chloro-10-(2-(1-methylpiperidin-2-yl)ethyl)-10H-phenothiazine (17b). 
Yield: 38% (19.1 mg). 1H NMR (400 MHz CDCl3) δ 7.11-7.02 (m, 
2H), 6.94 (d, J = 8.0 Hz, 1H), 6.85 (t, J = 7.0 Hz, 1H), 6.82-6.73 (m, 
3H), 3.91-3.78 (m, 1H), 3.78-3.63 (m, 1H), 2.85-2.68 (m, 1H), 2.14 (s, 
3H), 2.07-1.95 (m, 3H), 1.85-1.72 (m, 1H), 1.69-1.58 (m, 2H), 1.56-
1.46 (m, 2H), 1.28-1.11 (m, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 
147.5, 145.2, 133.8, 128.4, 128.1, 127.8, 126.0, 125.1, 123.6, 122.8, 
116.8, 116.5, 62.5, 57.1, 44.4, 42.3, 30.9, 29.7, 25.6, 24.1 ppm. LRMS (ESI+): m/z = 359 
[M + H]+. HRMS (ESI) m/z calcd. for C20H24ClN2S [M +H] 359.1343, found 359.1347.
 
 
Synthesis of 9-(2-(1-methylpiperidin-2-yl)ethyl)-9H-carbazole (17c). 
Yield: 67% (27.4 mg). 1H NMR (400 MHz CDCl3) δ 8.10 (d, J = 7.0 Hz, 
2H), 7.52-7.32 (m, 4H), 7.29-7.06 (m, 2H), 4.52-4.38 (m, 1H), 4.38-4.22 
(m, 1H), 2.97-2.82 (m, 1H), 2.33 (s, 3H), 2.17-2.06 (m, 2H), 2.06-1.94 (m, 
2H), 1.79 (d, J = 12.0 Hz, 2H), 1.67-1.60 (m, 2H), 1.40-1.27 (m, 2H) ppm. 
13C NMR (100 MHz CDCl3) δ 140.2, 125.7, 123.0, 120.5, 118.8, 108.6, 
61.7, 57.0, 43.0, 39.2, 31.5, 30.7, 25.6, 24.4 ppm. LRMS (ESI+): m/z = 
293 [M + H]+ HRMS (ESI) m/z calcd. for C20H24N2 [M +H], 293.19 found 293.2014.
 
 
Synthesis of 1-(2-(1-methylpiperidin-2-yl)ethyl)-1H-benzo[d]imidazole (17d). 
Yield: 70% (23.8 mg). 1H NMR (400 MHz CD3OD) δ 8.86 (s, 1H), 8.33-
8.22 (m, 2H), 7.99-7.90 (m, 2H), 5.03-4.95 (m, 2H), 3.55-3.50 (m, 1H), 2.90 
(s, 3H), 2.70-2.42 (m, 4H), 2.28-2.24 (m, 2H), 2.00-1.80 (m, 4H) ppm. 13C 
NMR (100 MHz CD3OD) δ 144.0, 143.3, 134.0, 123.7, 122.9, 119.6, 110.7, 
62.2, 57.1, 42.1, 32.8, 30.6, 30.1, 25.4, 24.1 ppm. LRMS (ESI+): m/z = 244 
[M + H]+. HRMS (ESI) m/z calcd. for C15H22N3 [M +H] 244.1808, found 
244.1811. 
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5.2.2. Virtual molecular hybridization approach for the synthesis of novel 
antitubercular agents effective against Multidrug-Resistant Mycobacteria. 
5.2.2.1. Biology. 
Bacterial Strains and Growth Conditions: The bacterial species used in this study were 
Mycobacterium smegmatis mc2155 (ATCC 700084), Mycobacterium aurum (ATCC23366), 
Mycobacterium bovis BCG Pasteur (ATCC 35734), Mycobacterium tuberculosis 
mc27000,214–216 Mycobacterium tuberculosis H37Rv (ATTC27294), and two MDR-TB 
clinical isolates (MDR1 and MDR2) obtained from Royal Free Hospital NHS Trust, London, 
UK. The bacterial growth was carried out by Dr. Bhakta group at Birbeck College London. 
The cell lines utilized for cytotoxicity studies were the murine macrophage cell line 
RAW264.7 (ATCC TIB-71) and the human peripheral blood nomocyte-derived cell line 
THP-1. Mycobacterial species were cultured in either Middlebrook 7H9 broth or 
Middlebrook 7H10 agar media supplemented with albumin−dextrose−catalase (ADC) or 
oleic acid−albumin−dextrose−catalase (OADC) enrichments, respectively, purchased from 
BD Biosciences. All reagents were purchased from Sigma-Aldrich unless stated otherwise. 
 
Bacterial Growth Inhibition Assays. Antimycobacterial Activity: This assay was conducted 
by Dr. Bhakta group at Birbeck College London. HT-SPOTi was performed based on 
previously published protocols217,218 to assess the minimum inhibitory concentrations of the 
compounds on M. aurum,219 M. tuberculosis H37Rv, and the MDR strains of the pathogen. 
Briefly, the assay was conducted in a semiautomated 96-well plate format. The compounds 
were dissolved in a suitable solvent to a concentration of 50 mg/mL and serially diluted (2-
fold dilutions). Two microliters of each dilution was dispensed into a well of a 96-well plate 
to which 200 μL of Middlebrook 7H10 agar medium kept at 55 °C supplemented with 0.05% 
(v/v) glycerol and 10% (v/v) OADC was added. The concentration range of the compounds 
used was 500 − 0.5 μg/mL. Wells with no compounds (DMSO only) and with isoniazid were 
used as experimental controls. To all the plates, a drop (2 μL) of early-to mid-log bacterial 
culture containing 2× 103 colony forming units (CFUs) was spotted in the middle of each 
well, and the plates were incubated at 35 or 37°C, depending on the bacterial species, until 
distinct spots were observed in the control wells (this took 4 days in the case of 
Mycobacterium aurum, 7 days in the case of Mycobacterium tuberculosis H37Rv, and 9 days 
for the drug-resistant clinical isolates). The MICs were determined as the lowest 
concentration of the compound where mycobacterial growth was completely inhibited. The 
MIC of the compounds against Mycobacterium smegmatis mc2155, Mycobacterium bovis 
BCG, and Mycobacterium tuberculosis mc27000 were calculated by standard MABA as 
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previously described.214 Briefly, 200 μL of sterile deionized water was added to all outer-
perimeter wells of a sterile 96-well plate (Corning Inc., Corning, NY) to minimize 
evaporation of the medium in the test wells during incubation. The wells in rows B−G in 
columns 3−11 received 100 μL of 7H9 medium containing 0.2% casamino acids, 24 μg/mL 
pantothenate, and 10% OADC (Beckton Dickinson, Sparks, MD). Compounds were added 
to rows B−G followed by 1:2 serial dilutions across the plate to column 10, and 100 μL of 
excess medium was discarded from the wells in column 10. The bacterial culture at 0.5 
McFarland standard diluted 1:25 (100 μL) was added to the wells in rows B−G in columns 
2−11, where the wells in column 11 served as drug-free controls. The plates were sealed 
with parafilm and were incubated at 37°C. A freshly prepared 1:1 mixture of Alamar Blue 
(Celltiter-Blue, Promega Corp, Madison, WI) reagent and 10% Tween 80 (50μL) was added, 
and theplates reincubated at 37°C for 24 h.  
 
Eukaryotic Cell Toxicity and Selectivity Indices: The eukaryotic cell toxicity test was carried 
out by Dr. Bhakta group at Birbeck College London. The cell lines were grown and 
maintained in RPMI-1640 supplemented with 10% FBS incubated at 37°C with 5% CO2 in 
a humidified incubator. For the experiment, 2 μL of the 50 mg/mL stock solution of each 
compound was diluted in 200 μL of RPMI-1640 medium in the first row of a 96-well 
microplate and 2-fold dilutions were performed along the rows, leaving the last one (row H) 
as a solvent control. Then 100 μL containing 105 cells/mL of confluent murine macrophage 
cells (RAW 264.7) or THP-1 cells in logarithmic growth phase were added to each well. The 
plates were incubated at 37°C in a humidified CO2 incubator (5% CO2) for 48 h. Each well 
was washed twice with 1× PBS, and 170 μL of fresh RPMI-1640 was added to each well, 
followed by 30 μL of 0.01% Trypan Blue. As THP-1 cells are suspension cultures, the plates 
were centrifuged between the washing steps. After overnight incubation, the change in 
colour was observed and the fluorescence intensity was measured at 560/590 nm (λex/ λem).  
 
Assaying Whole-Cell Drug Efflux Pump Inhibition: The assay was modified from a 
previously published protocol.220 The experiments were carried out by Dr. Bhakta group at 
Birbeck College London. Early log phase cells of M. aurum (OD600 ∼ 0.8) were taken and 
the OD600 was adjusted to 0.4 by diluting the cells with culture medium. The cells were 
collected by centrifugation and resuspended in an equivalent volume of 1× PBS. The test 
samples contained (4−6)× 107 bacteria/mL in PBS, 0.4% glucose (as a source of energy for 
efflux pumps activity), 0.5 mg/L ethidium bromide (as a substrate for efflux pumps), and the 
compounds being tested at 1/4× MIC concentrations. Blank samples contained all of the 
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components mentioned above, except the bacterial suspension, which was replaced with 1× 
PBS. Verapamil, a known efflux pump inhibitor, was used as the positive control at a 
concentration of 125 μg/mL. Compounds I and II were also included in the experiment to 
obtain a comparison between them and the newly synthesized compounds with regard to 
their efflux inhibitory properties. The experiment was performed in a 96-well plate that was 
placed in a fluorimeter (FLUOstar OPTIMA, BMG Labtech), and the instrument was 
programmed with the following parameters: wavelengths of 544 and 590 nm for excitation 
and detection of fluorescence, gain 2200, a temperature of 37 °C, and a cycle of measurement 
every minute for a total period of 60 min. The accumulation or efflux of ethidium bromide 
was monitored for the mentioned period on a real-time basis. 
 
5.2.2.2. Computational details. 
All the computational analysis have been performed by by Prof. Fabrizio Manetti at the 
University of Siena. The structures of all the molecules were sketched using Maestro 
(Maestro, version 9.2; Schrodinger LLC, New York, 2011) and then subjected to the 
program LigPrep to generate high-quality, all-atom 3D structures to be used as the input for 
the next calculations. The OPLS_2005 force field was applied, and possible ionization states 
were generated for the structures at pH 7 ± 2 using Epik. Conformers were generated by 
MacroModel (MacroModel, version 9.9; Schrodinger LLC, New York, 2011) with the 
Systematic Pseudo Monte Carlo (a systematic torsional sampling protocol) search algorithm 
and OPLS-2005 force field with implicit GB/SA distance-dependent dielectric solvent 
model (water as the solvent) at a cut-off root-mean-square deviation of 0.5 with 1000 steps. 
All the conformers were subsequently minimized using Polak−Ribiere conjugate gradient 
minimization with 5000 iteractions. For each molecule, a conformer set with a maximum 
energy difference of 25 kcal/mol relative to the global energy minimum conformer was 
stored.  
Both I and II were used to build three-dimensional common feature models comprised of 
chemical features common to the two compounds. Considering the reduced number of 
compounds and the fact that their antimycobacterial activity was assayed by different 
research groups with different tests, we chose to apply a common feature hypothesis 
generation routine, instead of building a quantitative model. Phase software (Phase, version 
3.3, Schrodinger LLC, New York, 2011.) has been applied to generate the models. Minimum 
and maximum number of sites for all the features were set to 4 and 5, respectively. Only the 
positively ionisable group (P) and the hydrophobic region (H) features were used to build a 
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series of hypotheses, while the aromatic ring (R) feature was not further considered by the 
software because it was not present in the structure of II. The resulting four-feature 
hypotheses were constituted by two H and two P features. 
 
5.2.2.3. Chemistry. 
Synthesis of 1-(4-chlorophenyl)pentane-1,4-dione (20b). 
 
4-chlorobenzaldehyde (799.4 mg, 5.69 mmol, 1.2 eq.) 18 was dissolved in a dry round 
bottom flask containing a solution of but-3-en-2-one (0.395 mL, 4.74 mmol, 1 eq.) 19 and 
3-ethyl-5-(2-hydroxyethyl)-4-methylthiazol-3-ium bromide (597.2 mg, 2.37 mmol, 0.2 eq) 
in TEA (2.113 mL14.22 mmol, 3 eq.). The reaction mixture was allowed to stir at 80 °C for 
5 h under N2 atmosphere. Then, the reaction mixture was quenched with HCl 2N (20 mL) 
and the product was extracted twice with DCM (20 mL). The organic layer were collected 
and washed with NaHCO3 (20 mL) and brine (20 mL), dried over Na2SO4 and concentrated 
under reduced pressure giving a yellow-brown crude oil. The obtained product 20b was 
purified by chromatography on silica gel, using hexane/EtOAc (7:3) as eluent. The pure 
product 20b was obtained as a pale yellow oil. Yield: 74% (884.2 mg). 1H NMR (400 MHz 
CDCl3) δ 7.91-7.78 (d, J = 8.0 Hz, 2H), 7.45-7.31 (d, J = 8.0 Hz, 2H), 3.16 (t, J = 8.0, Hz, 
2H), 2.82 (t, J = 8.0 Hz, 2H), 2.19 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 207.1, 197.3, 
139.6, 135.0, 129.5, 128.9, 37.0, 32.3, 30.1 ppm. LRMS (ESI+): m/z = 211 [M + H]+. 
 
General procedure for the synthesis of pyrroles 22a-f. 
 
The appropriate aniline 21 (1 mmol 1 eq.) was dissolved in a round bottom flask containing 
a solution of EtOH (15 mL), and the appropriate methyl keton 20a,b (1 mmol 1 eq.) PTSA 
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(172.2 mg, 1 mmol 1 eq.). The reaction was allowed to stir at 160°C under microwave 
irradiation for 15 min. Then the reaction was quenched with NaHCO3 saturated aqueous 
solution (20 mL) and the solvent was concentrated through reduced pressure evaporation. 
The crude product was dilutedin EtOAc (20 mL).The combined organic layers were washed 
with brine (20 mL), dried over Na2SO4 and concentrated under reduced pressure giving a 
yellow-brown crude oil. The obtained product (22a-f) was purified by chromatography on 
silica gel, using hexane/EtOAc (4:1) as eluent affording a yellow-brown oil. 
 
Synthesis of 1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrole (22a).221 
Yield: 93% (190.6 mg) 1H NMR (400 MHz CDCl3) δ 7.36 (d, J = 8.5 Hz, 
2H), 7.08 (d, J = 8.5 Hz, 2H), 5.81 (s, 2H), 1.93 (s, 6H) ppm. 13C NMR (100 
MHz CDCl3) δ 137.9, 133.9, 129.9, 129.7, 129.1, 106.4, 13.3 ppm. GC-MS 
m/z (ES+) m/z: 205 [M]+ 
 
Synthesis of 1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrole (22b).221 
Yield: 98% (186.2 mg). 1H NMR (400 MHz CDCl3) δ 7.25-7.10 (d, J = 8.0 
Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 6.04-5.80 (s, 2H), 2.22-1.92 (s, 6H) ppm. 13C 
NMR (100 MHz CDCl3) 135.2, 130.1, 130.0, 128.9, 116.2, 116.0, 106.1, 13.0 
ppm. GC-MS m/z (ES+) m/z 190 [M]+. 
 
 
Synthesis of 1,2-bis(4-chlorophenyl)-5-methyl-1H-pyrrole (22c). 
Yield: 90% (270.2 mg). 1H NMR (400 MHz CDCl3) δ 7.33 (d, J = 
8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 7.06 (d, J = 8.0 Hz, 2H), 6.94 
(d, J = 8.0 Hz, 2H), 6.41-6.17 (d, J = 4.0 Hz, 1H), 6.07 (d, J = 4.0 
Hz, 1H), 2.11 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 163.2, 
160.8, 137.7, 135.1, 129.7, 129.3, 129.0, 128.8, 128.3, 117.3, 117.0, 
105.8, 13.3 ppm. GC-MS m/z (ES+) m/z 301 [M]+. 
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Synthesis of 1-(2-fluorophenyl)-2,5-dimethyl-1H-pyrrole (22d).221 
Yield: 92% (173.9 mg). 1H NMR (400 MHz CDCl3) δ 7.58-7.41 (m, 1H), 
7.40-7.25 (m, 3H), 6.08 (s, 2H), 2.16 (s, 6H) ppm. 13C NMR (100 MHz 
CDCl3) δ 130.9, 130.1, 130.0, 129.3, 124.8, 124.7, 116.9, 116.7, 106.4, 12.7, 
12.7 ppm. GC-MS m/z (ES+) m/z: 189 [M]+. 
 
Synthesis of 1-(4-isopropylphenyl)-2,5-dimethyl-1H-pyrrole (22e).221 
Yield: 95% (202.3 mg). 1H NMR (400 MHz CDCl3) δ 7.28 (d, J = 8.0 Hz, 2H), 
7.10 (d, J = 8.0 Hz, 2H), 5.89 (s, 2H), 2.97 (m, 1H), 2.03 (s, 6H), 1.30 (d,J = 
8.0 Hz, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 148.2, 136.5, 128.9, 128.0, 
127.0, 105.3, 36.9, 33.8, 24.0, 13.1 ppm. GC-MS m/z (ES+) m/z: 213 [M]+. 
 
 
Synthesis of 2,5-dimethyl-1-(m-tolyl)-1H-pyrrole (22f).221 
Yield: 97% (179.5 mg). 1H NMR (400 MHz CDCl3) δ 7.42 (t, J = 7.5 Hz, 1H), 
7.29 (d, J = 7.0 Hz, 1H), 7.18-7.07 (m, 2H), 6.00 (s, 2H), 2.49 (s, 3H), 2.14 (s, 
6H) ppm. 13C NMR (100 MHz CDCl3) δ 137.1, 136.3, 130.6, 128.9, 128.2, 
128.1, 127.1, 105.6, 22.0, 13.2 ppm. GC-MS m/z (ES+) m/z 185 [M]+. 
 
Synthesis of 1-(Bicyclo[2.2.1]heptan-2-yl)piperazine 23a. 
 
 
The Boc-piperazine 7 (372.5 mg, 2 mmol, 1eq.) and bicyclo[2.2.1]heptan-2-one (220.3 mg, 
2 mmol, 1 eq.) were dissolved in THF (8 mL), and the resulting mixture was stirred for 5 
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min. The reaction was cooled at 0 °C, and then NaBH(AcO)3 (507.3 mg, 2.4 mmol, 1.2 eq.) 
and AcOH (0.116 mL, 2 mmol, 1 eq.) were carefully added. The resulting mixture was stirred 
at r.t. for 16 h. The reaction was quenched with NaOH (1 N, 20 mL) and the product was 
extracted with EtOAc (3 × 25 mL). The organic layers were gathered, dried over MgSO4, 
and the solvent was evaporated to give the crude piperazine derivative, which were filtered 
through a pad of silica gel (eluent EtOAc/petroleum ether 1:1). The filtered compounds were 
then dissolved in DCM (4 mL) and treated with 1 mL of TFA. The resulting mixture was 
stirred at r.t. for 12 h. The solvents were removed, and the crude compound was dissolved 
in EtOAc (10 mL) and washed several times with 1 N NaOH (20 mL). The organic phase 
was dried over MgSO4 and the solvent was evaporated to yield the crude piperazine 23a 
which was purified by column chromatography using petroleum ether/EtOAc 1:1 as eluent. 
The pure piperazine 23a was obtained as a pale yellow solid. Yield: 95% (343.4 mg).1H 
NMR (400 MHz CDCl3) δ 2.88−2.82 (m, 5H), 2.28 (br s, 3H), 2.20−2.09 (m, 3H), 1.67−1.60 
(m, 2H), 1.41−1.39 (m, 1H), 1.28−1.19 (m, 4H), 0.82−0.79 (m, 1H) ppm. LRMS (ESI+): 
m/z = 181 [M + H]+. 
 
General procedure for the synthesis of pyrrole derivatives 24a−m.  
 
 
  
Following the Mannich reaction, to a stirred solution of an appropriate pyrrole 22a, 22c-f 
(1.5 mmol, 1eq.) in acetonitrile (5 mL) were added a mixture of the appropriate piperazine 
8, 23a-d (1.5 mmol, 1 eq.), formaldehyde (40% in water) (1.5 mmol 1 eq.), and acetic acid 
(0.087 mL, 1.5 mmol, 1 eq.) which was added dropwise. After the addition was complete, 
the mixture was stirred at r.t. for 3 h. The mixture was then treated with a solution of sodium 
hydroxide (20%, w/v) (20 mL) and extracted with EtOAc (10 mL). The organic extracts 
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were combined, washed with water, and then dried over MgSO4. After removal of solvent, 
the residue was purified by column chromatography, using silica gel and petroleum 
ether/ethyl acetate (4:1 v/v) as eluent affording the desired product as a yellow-brown oil. 
 
 
Synthesis of 1-(Adamantan-2-yl)-4-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (24a). 
Yield: 56% (367.1 mg). 1H NMR (400 MHz CDCl3) δ 7.41 (d, J = 
8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 2H), 5.92 (s, 1H), 3.36 (s, 2H), 2.50 
(br s, 4H), 2.05−2.02 (m, 6H), 1.98 (s, 3H), 1.95 (s, 3H), 1.85−1.72 
(m, 5H), 1.68−1.62 (m, 5H), 1.37−1.34 (m, 3H) ppm. 13C NMR 
(100 MHz CDCl3) δ 137.7, 133.4, 129.7, 129.3, 127.6, 126.8, 115.2, 
108.7, 67.9, 54.4, 53.5, 49.6, 37.9, 37.3, 31.6, 31.4, 29.0, 27.6, 27.4, 
22.7, 14.2, 12.9, 11.0 ppm. LRMS (ESI+): m/z = 438 [M + H]+. 
HRMS (ESI) calcd for C27H37ClN3 (M + H
+) 438.2671, found 
438.2664. 
 
 
Synthesis of 1-(Adamantan-2-yl)-4-((1-(2-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (24b).  
Yield: 45% (284.8 mg). 1H NMR (400 MHz CDCl3) δ 
7.37−7.36 (m, 1H), 7.22−7.17 (m, 3H), 5.95 (s, 1H), 3.36 (s, 2H), 
2.59−2.29 (br s, 4H), 2.08−2.03 (m, 6H), 1.97 (s, 3H), 1.93 (s, 
3H), 1.83−1.75  (m, 5H), 1.67−1.62 (m, 5H), 1.36−1.24 (m, 3H) 
ppm. 13C NMR (100 MHz CDCl3) δ 159.81, 157.31, 130.84, 
129.6, 128.06, 127.2, 126.9, 124.5, 124.4, 116.7, 116.5, 115.3, 
108.6, 67.9, 54.6, 53.6, 49.6, 39.3, 37.3, 31.9, 31.4, 29.0, 27.6, 27.5, 22.7, 14.2, 12.4, 10.5 
ppm. LRMS (ESI+): m/z = 422 [M + H]+. HRMS (ESI) calcd for C27H37FN3 (M + H
+) 
422.2966, found 422.2889. 
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Synthesis of 1-(Adamantan-2-yl)-4-((1-(4-isopropylphenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (24c).  
Yield: 51% (340.4 mg). 1H NMR (400 MHz CDCl3) δ 
7.27−7.24 (m, 2H), 7.10−7.04 (m, 2H), 5.91 (s, 1H), 3.46 (s, 
2H), 2.97−2.92 (m, 1H), 2.52 (br s, 4H), 2.06−2.03 (m, 6H), 1.95 
(s, 3H), 1.93 (s, 3H), 1.83−1.75 (m, 5H), 1.68−1.62 (m, 5H), 
1.29 (s, 3H), 1.27  (s, 3H), 1.25 (m, 3H) ppm. 13C NMR (100 
MHz CDCl3) δ 148.2, 136.6, 128.2, 128.1, 127.9, 127.1, 126.9, 
108.0, 67.9, 54.5, 53.4, 50.8, 49.5, 37.9, 37.3, 33.8, 31.6, 31.4, 
29.0, 27.6, 27.4, 24.0, 22.7, 14.2, 12.9, 11.2, 11.0 ppm. LRMS (ESI+): m/z = 446 [M + H]+. 
HRMS (ESI) calcd for C30H44N3 (M + H
+) 446.3530, found 446.3523. 
 
Synthesis of 1-(Adamantan-2-yl)-4-((1-(3-methylphenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (24d). 
Yield: 48% (300.2 mg). 1H NMR (400 MHz CDCl3) δ 7.32−7.29 
(m, 1H), 7.18−7.16 (m, 1H), 6.99−6.95 (m, 2H), 5.91 (s, 1H), 3.39 
(s, 2H), 2.53 (br s, 4H), 2.38 (s, 3H), 2.03 (m, 6H), 1.99 (s, 3H), 1.95 
(s, 3H), 1.83−1.75 (m, 5H), 1.68−1.62 (m, 5H), 1.37−1.34 (m, 3H) 
ppm. 13C NMR (100 MHz CDCl3) δ 139.1, 138.9, 129.0, 128.7, 
128.3, 127.7, 125.4, 108.2, 67.9, 54.5, 53.4, 49.5, 41.0, 37.9, 37.3, 
31.4, 29.03, 28.5, 27.6, 27.4, 21.3, 12.9, 11.0 ppm. LRMS (ESI+): 
m/z = 418 [M + H]+. HRMS (ESI) calcd for C28H40N3 (M + H+) 418.3217, found 418.3234. 
Synthesis of 1-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-4-
phenylpiperazine (24e). 
Yield: 65% (369.4 mg). 1H NMR (400 MHz CDCl3) δ 7.44 (d, J = 8.0 
Hz, 2H), 7.26 (dd, J = 8.0, 7.0 Hz, 2H), 7.15 (d, J = 7.0 Hz, 2H), 6.94 
(d, J = 7.0 Hz, 2H), 6.85 (m, 1H), 5.96 (s, 1H), 3.45 (s, 2H), 3.23 (m, 
4H), 2.66 (m, 4H), 2.02 (s, 3H), 2.00 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 151.5, 137.6, 133.5, 129.7, 129.3, 129.1, 127.8, 126.8, 119.5, 
115.0, 108.6, 54.5, 52.9, 49.2, 12.9, 11.0 ppm; LRMS (ESI+): m/z = 380 
[M + H]+. HRMS (ESI) calcd for C23H27ClN3 (M + H
+) 380.1888, found 380.1884. 
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Synthesis of 4,4'-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrole-3,4-
diyl)bis(methylene))bis(1-phenylpiperazine) (24f). 
Yield: 35% (290.3 mg). 1H NMR (400 MHz CDCl3) δ 7.29 (d, J = 
8.0 Hz, 2H), 7.08 (dd, J = 8.0, 7.0 Hz, 4H), 7.01 (d, J = 8.0 Hz, 2H), 
6.77 (d, J = 8.0 Hz, 4H), 6.66 (m, 2H), 3.34 (s, 4H), 3.03 (m, 8H), 
2.47 (m, 8H), 1.85 (s, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 
151.5, 137.7, 133.4, 129.8, 129.3, 129.1, 126.5, 119.5, 116.0, 53.0, 
52.8, 11.0 ppm. LRMS (ESI+): m/z = 555 [M + H]+. HRMS (ESI) 
calcd for C34H41ClN5 (M + H
+) 554.3045, found 554.3032. 
Synthesis of 1-((1S,4R)-Bicyclo[2.2.1]heptan-2-yl)-4-((1-(4-chlorophenyl)-2,5-
dimethyl-1H-pyrrol-3-yl)methyl)piperazine (24g). 
Yield: 55% (327.0 mg). 1H NMR (400 MHz CDCl3) δ 7.40 (d, J = 
8.0 Hz, 2H), 7.11 (d, J = 8.0 Hz, 2H), 5.90 (s, 1H), 3.37 (s, 2H), 2.48 
(br m, 5H), 2.24−2.12 (m, 4H), 1.97 (s, 3H), 1.94 (s, 3H), 1.72−1.65 
(m, 2H), 1.46 (m, 1H), 1.33−1.22 (m, 5H), 0.88−0.81 (m, 2H) ppm. 
13C NMR (100 MHz CDCl3) δ 137.7, 133.4, 129.7, 129.3, 127.6, 
126.8, 115.2, 108.7, 67.9, 54.4, 52.8, 52.7, 39.0, 38.1, 36.8, 35.8, 
30.6, 21.1, 12.8, 11.0 ppm. LRMS (ESI+): m/z = 398 [M + H]+. 
HRMS (ESI) calcd for C24H33ClN3 (M + H
+) 398.2358, found 
398.2352. 
Synthesis of 1-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-4-
cyclohexylpiperazine (24h). 
Yield: 52% (300.3 mg). 1H NMR (400 MHz CDCl3) δ 7.40 (d, J = 
8.0 Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 5.89 (s, 1H), 3.37 (s, 2H), 2.60 
(br s, 8H), 2.20 (m, 1H), 1.96 (s, 3H), 1.93 (s, 3H), 1.88−1.86 (m, 
2H), 1.77−1.75 (m, 2H), 1.61−1.58 (m, 1H), 1.26−1.11 (m, 5H) 
ppm. 13C NMR (100 MHz CDCl3) δ 137.6, 133.5, 129.7, 129.6, 
129.3, 127.7, 118.7, 108.7, 63.5, 56.2, 54.3, 53.0, 48.8, 29.0, 26.3, 
25.9, 12.8, 11.0, 10.5 ppm. LRMS (ESI+): m/z = 386 [M + H]+. 
HRMS (ESI) calcd for C23H33ClN3 (M + H
+) 386.2358, found 386.2356. 
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Synthesis of 1-(Adamantan-1-yl)-4-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-
yl)methyl)piperazine (24i). 
Yield: 54% (353.1 mg). 1H NMR (400 MHz CDCl3) δ 7.41 (d, J = 
8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 5.89 (s, 1H), 3.38 (s, 2H), 2.67 
(br s, 4H), 2.50 (br s, 4H), 2.05 (m, 4H), 1.96 (s, 3H), 1.93 (s, 3H), 
1.69−1.59 (m, 11H) ppm. 13C NMR (100 MHz CDCl3) δ 137.7, 
133.4, 129.7, 129.8, 129.3, 127.6, 126.8, 115.0, 108.8, 60.4, 56.1, 
54.2, 53.5, 44.0, 38.5, 37.0, 31.6, 29.7, 25.3, 22.7, 20.7, 18.8, 14.1, 
11.0 ppm. LRMS (ESI+): m/z = 439 [M + H]+. HRMS (ESI) calcd 
for C27H37ClN3 (M + H
+) 438.2671, found 438.2680. 
 
Synthesis of 1-((1,5-Bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)methyl)-4-
phenylpiperazine (24j). 
Yield: 64% (456 mg). 1H NMR (400 MHz CDCl3) δ 7.33 (d, J 
= 8.0 Hz, 2H), 7.23 (m, 2H), 7.04 (d, J = 8.0 Hz, 2H), 6.97 (d, J 
= 8.0 Hz, 2H), 6.92 (m, 4H), 6.82 (m, 1H), 6.36 (s, 1H), 3.49 (s, 
2H), 3.21 (m, 4H), 2.67 (m, 4H), 2.07 (s, 3H) ppm. 13C NMR 
(100 MHz CDCl3) δ 151.4, 137.8, 133.5, 132.0, 131.7, 131.5, 
130.3, 129.8, 129.4, 129.1, 128.8, 128.4, 119.7, 116.9, 116.1, 
111.7, 54.5, 52.9, 49.2, 11.3 ppm. LRMS (ESI+): m/z = 477 [M 
+ H]+. HRMS (ESI) calcd for C28H28Cl2N3 (M + H
+) 476.1655, found 476.1648. 
 
Synthesis of 1-(Adamantan-2-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)piperazine (24k). 
Yield: 65% (519.2 mg). 1H NMR (400 MHz CDCl3) δ 7.33 
(d, J = 8.0 Hz, 2H), 7.10−7.04 (m, 4H), 6.93 (d, J = 8.0 Hz, 
2H), 6.36 (s, 1H), 3.44 (s, 2H), 2.54 (br s, 4H), 2.05 (s, 3H), 
2.03 (m, 4H), 1.84−1.75 (m, 4H), 1.68−1.63 (m, 4H), 
1.38−1.25 (m, 5H), 0.88−0.82 (m, 2H) ppm. 13C NMR (100 
MHz CDCl3) δ 137.8, 133.4, 131.9, 131.5, 130.2, 129.8, 
129.4, 128.8, 128.3, 117.1, 111.5, 67.9, 54.4, 53.5, 49.6, 
37.9, 37.3, 31.6, 31.4, 29.0, 27.6, 27.4, 22.7, 14.2, 11.2 ppm. 
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LRMS (ESI+): m/z = 534 [M + H]+. HRMS (ESI) calcd for C32H38Cl2N3 (M + H
+) 534.2437, 
found 534.2425. 
 
 
Synthesis of 1-(Adamantan-1-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-
yl)methyl)piperazine (24l). 
Yield: 60% (479.2 mg). 1H NMR (400 MHz CDCl3) δ 
7.34−7.32 (m, 2H), 7.10−7.03 (m, 4H), 6.91 (m, 2H), 6.33 
(s, 1H), 5.92 (s, 1H), 3.48 (s, 2H), 2.72−2.70 (br s, 8H), 
2.07−2.02 (m, 4H), 2.04 (s, 3H), 1.71−1.56 (m, 11H) ppm. 
13C NMR (100 MHz CDCl3) δ 137.8, 133.4, 131.6, 131.5, 
130.3, 129.7, 129.4, 128.8, 128.3, 125.1, 116.5, 111.9, 66.6, 
54.1, 53.2, 44.0, 38.3, 36.9, 32.2, 29.7, 26.4, 23.5, 18.7, 
13.2, 11.3 ppm. LRMS (ESI+): m/z = 534 [M + H]+. HRMS (ESI) calcd for C32H38Cl2N3 
(M + H+) 534.2437, found 534.2424. 
 
 
Synthesis of 1-(bicyclo[2.2.1]heptan-2-yl)-4-((1,5-bis(4-chlorophenyl)-2-methyl-1H-
pyrrol-3-yl)methyl)piperazine (24m). 
Yield: 56% (414.6 mg).  1H NMR (400 MHz CDCl3) δ 7.26 
(d, J = 8.0 Hz, 2H), 7.04 (d, J = 8.0 Hz, 2H), 6.99 (d, J = 8.0 
Hz, 2H), 6.85 (d, J = 8.0 Hz, 2H), 6.30 (s, 1H), 3.44 (s, 2H), 
2.51 (br s, 6H), 2.19−2.17 (m, 2H), 2.12−2.07 (m, 1H), 2.00 
(s, 3H), 1.66−1.62 (m, 2H), 1.43−1.40 (m, 1H), 1.29−1.17 
(m, 7H) ppm. 13C NMR (100 MHz CDCl3) δ 137.8, 133.4, 
131.9, 131.5, 129.7, 128.7, 128.3, 111.8, 67.9, 65.9, 54.2, 
52.6, 38.9, 38.0, 36.8, 36.8, 31.6, 30.6, 22.7, 21.0, 14.2, 11.2 
ppm. LRMS (ESI+): m/z = 494 [M + H]+. HRMS (ESI) calcd for C29H34Cl2N3 (M + H
+) 
494.2124, found 494.2113. 
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General Procedure for the synthesis of Compounds 25a−c.  
 
Phosphorus oxychloride (POCl3) (0.571 mL, 6 mmol, 6 eq.) was added dropwise to a round-
bottom flask containing ice cooled DMF (5 mL) under N2 atmosphere. After 15 min, a 
solution of the appropriate pyrrole 22a-c (1 mmol, 1eq.) was added to the stirring solution. 
Then the reaction mixture was allowed to stir at 155 °C for 3 h. The reaction was monitored 
through TLC. After completion, the reaction was quenched with 10% w/v NaOH solution 
(20 mL). The reaction mixture was then diluted with EtOAc (10 mL), extracted two times 
with EtOAc (10 mL) and then the organic extract was washed with brine (20 mL). The 
organic extracts were collected and dried over MgSO4, filtered, and concentrated under 
reduced pressure. The residue was then purified by flash chromatography (hexanes/EtOAc, 
4:1 v/v), affording the desired compounds 25a−c as a yellow-brown solid. 
 
Synthesis of 1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde (25a).123 
Yield: 93% (217.6 mg). 1H NMR (400 MHz CDCl3) δ 9.71 (s, 1H), 7.40 (d, 
J = 7.5 Hz, 2H), 7.09 (d, J = 7.5 Hz, 2H), 6.25 (s, 1H), 2.17 (s, 3H), 1.88 (s, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 187.3, 129.8, 120.4, 117.2, 116.8, 
116.6, 105.9, 12.7, 11.2 ppm. LRMS (ESI+): m/z = 234 [M + H]+. 
 
 
Synthesis of 1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde (25b).123  
Yield: 97% (210.6 mg). 1H NMR (400 MHz CDCl3) δ 9.86 (s, 1H), 7.20−7.17 
(m, 4H), 6.36 (s, 1H), 2.26 (s, 3H), 1.96 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 185.3, 162.6, 138.7, 135.5, 130.9, 129.6, 129.3, 122.1, 106.1, 12.7, 
11.2 ppm. LRMS (ESI+): m/z = 218 [M + H]+. 
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Synthesis of 1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrole-3-carbaldehyde (25c). 
Yield: 96% (317.3 mg). 1H NMR (400 MHz CDCl3) δ 9.89 (s, 1H), 
7.33 (d, J = 12.0 Hz, 2H), 7.09 (d, J = 12.0 Hz, 2H), 7.01 (d, J = 12.0 
Hz, 2H), 6.87 (d, J = 12.0 Hz, 2H), 6.70 (s, 1H), 2.32 (s, 3H) ppm. 
13C NMR (100 MHz CDCl3) δ 185.6, 140.1, 135.6, 134.5, 133.2, 
132.0, 130.0, 129.8, 129.5, 129.4, 128.6, 122.9, 108.9, 11.5 ppm. 
LRMS (ESI+): m/z = 331 [M + H]+. 
 
 
General procedure for the synthesis of pyrrole derivatives 26a−i.  
 
 
 
The appropriate aldehyde 25a−c (1 mmol, 1 eq.) was dissolved in 5 mL of THF in a round-
bottom flask. Then AcOH (0.058 mL, 1 mmol, 1 eq.) and the appropriate amine (1 mmol, 1 
eq.) were added to the stirring solution at room temperature. The mixture was allowed to stir 
at room temperature for 20 min before NaBH(AcO)3 (635.7 mg, 3 mmol, 3 eq.) was added. 
The mixture was allowed to stir at room temperature for 18 h. Then, after completion, the 
reaction was quenched with 1 M NaOH solution (25 mL). The mixture was then allowed to 
stir for 30 min. The reaction mixture was then diluted with EtOAc (10 mL), extracted two 
times with EtOAc (10 mL) and then the organic extracts were washed with brine (20 mL). 
The organic extracts were collected and then dried over MgSO4, filtered, and concentrated 
under reduced pressure. The residue was then purified by flash chromatography 
(hexane/EtOAc, 6:4 v/v, affording the desired compounds 26a−i as a yellow-brown solid. 
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Synthesis of N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-2-
phenylethan-1-amine (26a).  
Yield: 75% (254.2 mg). 1H NMR (400 MHz CDCl3) δ 7.41 (d, J = 
8.0 Hz, 2H), 7.29−7.27 (m, 2H), 7.24−7.22 (m, 3H), 7.11 (d, J = 8.0 
Hz, 2H), 5.90 (s, 1H), 3.63 (s, 2H), 2.95 (m, 2H), 2.86 (m, 2H), 1.99 
(s, 3H), 1.94 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 140.3, 
137.6, 133.5, 129.6, 129.3, 128.8, 128.5, 128.0, 126.1, 125.5, 118.1, 
107.1, 51.0, 45.7, 36.4, 12.8, 10.7 ppm. LRMS (ESI+): m/z = 339 
[M + H]+. HRMS (ESI) calcd for C21H24ClN2 (M + H
+) 339.1623, found 339.1603. 
 
Synthesis of N-benzyl-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-
methanamine (26b).  
Yield: 79% (256 mg). 1H NMR (400 MHz CDCl3) δ 7.39 (d, J = 8.5 Hz, 
2H), 7.34−7.27 (m, 4H), 7.22−7.20 (m, 1H), 7.10 (d, J = 8.5 Hz, 2H), 
5.92 (s, 1H), 3.83 (s, 2H), 3.60 (s, 2H), 1.97 (s, 3H), 1.91 (s, 3H) ppm. 
13C NMR (100 MHz CDCl3) δ 140.7, 137.6, 133.5, 129.6, 129.3, 128.3, 
128.1, 127.9, 126.8, 125.6, 118.1, 107.1, 53.5, 45.0, 12.8, 10.7 ppm. 
LRMS (ESI+): m/z = 325 [M + H]+. HRMS (ESI) calcd for C20H22ClN2 
(M + H+) 325.1466, found 325.1466. 
 
Synthesis of N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)-
cyclohexanamine (26c).  
Yield: 77% (243.9 mg). 1H NMR (400 MHz CDCl3) δ 7.40 (d, J = 8.0 
Hz, 2H), 7.10 (d, J = 8.0 Hz, 2H), 5.91 (s, 1H), 3.59 (s, 2H), 2.53−2.48 
(m, 1H), 1.98 (s, 3H), 1.95 (s, 3H), 1.94−1.90 (m, 2H), 1.74−1.70 (m, 
2H), 1.16−1.06 (m, 3H), 0.85−0.81 (m, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 137.6, 133.4, 129.6, 129.3, 128.0, 125.3, 118.6, 107.0, 56.7, 
42.8, 33.6, 26.3, 25.1, 12.8, 10.7 ppm. LRMS (ESI+): m/z = 317 [M + 
H]+. HRMS (ESI) calcd for C19H26ClN2 (M + H
+) 317.1779, found 317.1779.  
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Synthesis of N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methyl)- adamantan-
2-amine (26d).  
Yield: 60% (221.4 mg). 1H NMR (400 MHz CDCl3) δ 7.41 (d, J = 8.0 
Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 5.94 (s, 1H), 3.57 (s, 2H), 2.81 (m, 
1H), 2.04−2.00 (m, 2H), 1.99 (s, 3H), 1.97 (s, 3H), 1.93 (m, 2H), 
1.86−1.83 (m, 3H), 1.76−1.70 (m, 5H), 1.50−1.47 (m, 2H) ppm. 13C 
NMR (100 MHz CDCl3) δ 137.6, 133.4, 129.6, 129.3, 127.9, 125.4, 
118.8, 107.2, 61.7, 42.9, 38.1, 37.7, 32.1, 31.5, 28.0, 27.8, 12.9, 10.7 
ppm. LRMS (ESI+): m/z = 369 [M + H]+. HRMS (ESI) calcd for C23H30ClN2 (M + H
+) 
369.2092, found 369.2089.  
 
Synthesis of 1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-N-(4-
methylbenzyl)methanamine (26e).  
Yield: 82% (277.1 mg). 1H NMR (400 MHz CDCl3) δ 7.41 (d, J = 
8.5 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 7.13−7.10 (m, 4H), 5.94 (s, 
1H), 3.61 (s, 2H), 3.18 (s, 2H), 2.32 (s, 3H), 1.99 (s, 3H), 1.93 (s, 
3H), ppm. 13C NMR (100 MHz CDCl3) δ 137.6, 137.4, 136.4, 
133.5, 129.6, 129.4, 129.1, 128.2, 128.0, 125.8, 117.9, 107.2, 53.1, 
44.9, 21.2, 12.9, 10.8 ppm. LRMS (ESI+): m/z = 339 [M + H]+. 
HRMS (ESI) calcd for C21H24ClN2 (M + H
+) 339.1623, found 
339.1624. 
 
Synthesis of N-(4-chlorobenzyl)-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol- 3-
yl)methanamine (26f).  
Yield: 78% (278.3 mg).. 1H NMR (400 MHz CDCl3) δ 7.41 (d, J 
= 8.5 Hz, 2H), 7.30−7.24 (m, 4H), 7.11 (d, J = 8.0 Hz, 2H), 5.91 
(s, 1H), 3.81 (s, 2H), 3.59 (s, 2H), 1.99 (s, 3H), 1.92 (s, 3H) ppm. 
13C NMR (100 MHz CDCl3) δ 139.3, 133.7, 129.6, 129.5, 129.4, 
128.4, 128.1, 125.7, 117.9, 107.1, 52.7, 45.1, 12.8, 10.8 ppm. 
LRMS (ESI+): m/z = 359 [M + H]+. HRMS (ESI) calcd for 
C20H21Cl2N2 (M + H
+) 359.1076, found 359.1076.  
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Synthesis of N-(4-fluorobenzyl)-1-(1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol- 3-
yl)methanamine (26g).   
Yield: 80%(274.4 mg).. 1H NMR (400 MHz CDCl3) δ 7.41 
(d, J = 8.5 Hz, 2H), 7.31 (dd, J = 8.5 Hz 2H), 7.11 (d, J = 8.0 
Hz, 2H), 6.99 (t, J = 8.0 Hz, 2H), 5.91 (s, 1H), 3.81 (s, 2H), 
3.59 (s, 2H), 1.99 (s, 3H), 1.92 (s, 3H) ppm. 13C NMR (100 
MHz CDCl3) δ 163.1, 160.7, 137.6, 133.6, 129.7, 129.6, 
129.4, 128.1, 125.7, 118.0, 115.2, 107.1, 52.8, 45.1, 12.8, 10.8 
ppm. LRMS (ESI+): m/z = 343 [M + H]+. HRMS (ESI) calcd 
for C20H21ClFN2 (M + H
+) 343.1372, found 343.1374. 
 
Synthesis of N-benzyl-1-(1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-
methanamine (26h).  
Yield: 82%(252.5 mg).. 1H NMR (400 MHz CDCl3) δ 7.36−7.29 (m, 
4H), 7.23 (t, J = 8.0 Hz, 1H), 7.15−7.09 (m, 4H), 5.92 (s, 1H), 3.85 (s, 
2H), 3.61 (s, 2H), 1.98 (s, 3H), 1.91 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 130.1, 129.9, 128.4, 128.2, 117.9, 116.2, 115.9, 106.8, 53.6, 
45.2, 12.9, 10.8 ppm. LRMS (ESI+): m/z = 309 [M + H]+. HRMS 
(ESI) calcd for C20H22FN2 (M + H
+) 309.1762, found 309.1764. 
 
 
Synthesis of N-benzyl-1-(1,5-bis(4-chlorophenyl)-2-methyl-1H-pyrrol-3-yl)- 
methanamine (26i).  
Yield: 78% (327.6 mg).. 1H NMR (400 MHz CDCl3) δ 7.31−7.25 (m, 
7H), 7.04 (d, J = 12.0 Hz, 2H), 6.97 (d, J = 12.0 Hz, 2H), 6.86 (d, J = 
12.0 Hz, 2H), 6.31 (s, 1H), 3.82 (s, 2H), 3.62 (s, 2H), 1.96 (s, 3H), 
1.80 (br s, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 137.3, 133.9, 
132.7, 132.0, 130.0, 129.6, 129.5, 128.9, 128.3, 111.4, 110.5, 29.1, 
24.6, 11.4 ppm. LRMS (ESI+): m/z = 421 [M + H]+. HRMS (ESI) 
calcd for C25H23Cl2N2 (M + H
+) 421.1233, found 421.1228. 
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General procedure for the synthesis of oximes 27a and 27b.123 
 
 
 
The appropriate aldehyde 25a-b (1 mmol, 1eq.) was dissolved in 5 mL of THF in a round 
bottom flask. Then AcOH (0.058 mL, 1 mmol, 1eq.) and O-benzylhydroxylamine (123.1 
mg, 1 mmol, 1eq.) were added to the stirring solution at room temperature. The mixture was 
allowed to stir at room temperature for 18 h. After completion, the reaction was quenched 
with 1 M NaOH solution (25 mL). The reaction mixture was then diluted with EtOAc (10 
mL) and extracted two times with EtOAc (10 mL) and then the organic phases were washed  
with brine (20 mL). The organic extracts were collected and then dried over MgSO4, filtered, 
and concentrated under reduced pressure. The residue was then purified by flash 
chromatography (hexanes-EtOAc, 6:4 v/v), affording the desired compounds 27a and 27b 
as yellow-brown solids. 
 
Synthesis of 1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde O-
BenzylOxime (27a). 
Yield: 75% (253.5 mg). 1H NMR (400 MHz CDCl3) δ 8.15 (s, 1H), 
7.45−7.41 (m, 4H), 7.37−7.33 (m, 2H), 7.30−7.29 (m, 1H), 7.11 (d, J = 8.5 
Hz, 2H), 6.24 (s, 1H), 5.14 (s, 2H), 2.03 (s, 3H), 1.97 (s, 3H) ppm. 13C 
NMR (100 MHz CDCl3) δ 144.6, 138.0, 136.6, 134.3, 130.8, 130.1, 129.7, 
129.6, 128.5, 128.4, 127.8, 112.9, 104.6, 75.9, 12.8, 11.5 ppm. LRMS 
(ESI+): m/z = 339 [M + H]+; HRMS (ESI) calcd for C20H19ClN2O (M + 
H+) 339.1259, found 339.1260. 
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Synthesis of 1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrole-3-carbaldehyde O-
BenzylOxime (27b).  
Yield: 78% (258.9 mg). 1H NMR (400 MHz CDCl3) δ 8.15 (s, 1H), 7.42 
(d, J = 8.0 Hz, 2H), 7.34 (t, J = 8.0 Hz, 2H), 7.28 (d, J = 8.0 Hz, 1H), 7.15 
(d, J = 8.0 Hz, 2H), 6.23 (s, 1H), 5.13 (s, 2H), 2.01 (s, 3H), 1.96 (s, 3H) 
ppm. 13C NMR (100 MHz CDCl3) δ 144.6, 138.1, 134.1, 131.1, 130.3, 
130.0, 129.9, 128.5, 128.4, 127.8, 127.7, 116.5, 116.3, 104.3, 12.8, 11.1 
ppm. LRMS (ESI+): m/z = 333 [M + H]+ 
 
General procedure for the synthesis of compounds 28a and 28b. 
 
 
 
The appropriate oxime 27a,b (1 mmol, 1eq.) was dissolved in 5 mL of THF in a round-
bottom flask. Then, NaBH3(CN) (635.7 mg, 3 mmol, 1eq.) was added to the solution and the 
mixture was allowed to stir at room temperature for 18 h. Then, the reaction was quenched 
with 1 M NaOH solution (25 mL). The reaction mixture was then diluted with EtOAc (10 
mL) and extracted  two times with EtOAc (10 mL) and then washed  with brine (20 mL). 
The organic extracts were collected and then dried over MgSO4, filtered, and concentrated 
under reduced pressure. The residue was then purified by flash chromatography 
(hexanes/EtOAc, 6:4 v/v), affording the desired compounds 28a and 28b as yellow-brown 
solids. 
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Synthesis of O-benzyl-N-((1-(4-chlorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)- 
methyl)hydroxylamine (28a).  
Yield: 80% (270.4 mg). 1H NMR (400 MHz CDCl3) δ 7.42−7.25 (m, 7H), 
7.10 (d, J = 8.5 Hz, 2H), 5.90 (s, 1H), 5.48 (br s, 1H), 4.74 (s, 2H), 3.91 (s, 
2H), 1.97 (s, 3H), 1.93 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 138.2, 
137.5, 133.6, 129.6, 129.4, 128.6, 128.4, 128.2, 127.3, 126.9, 114.3, 107.6, 
76.1, 48.5, 12.8, 10.7 ppm. LRMS (ESI-): m/z = 339 [M−H+]. HRMS (ESI) 
calcd for C20H20ClN2O (M − H+) 339.1264, found 339.1259.  
 
Synthesis of O-benzyl-N-((1-(4-fluorophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)-
methyl)hydroxylamine (28b).  
Yield: 82% (264.1 mg). 1H NMR (400 MHz CDCl3) δ 7.39−7.28 (m, 5H), 
7.12 (m, 4H), 5.90 (s, 1H), 4.75 (s, 2H), 3.92 (s, 2H), 1.96 (s, 3H), 1.92 (s, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 138.2, 134.9, 130.0, 129.9, 128.6, 
128.4, 128.3, 127.8, 127.1, 116.2, 115.9, 114.0, 107.3, 76.1, 48.5, 12.8, 10.7 
ppm. LRMS (ESI-): m/z = 323 [M−H+]. HRMS (ESI) calcd for 
C20H20FN2O (M−H+) 323.1560, found 323.1554. 
 
5.2.3. Synthesis of 1,2,3-substituted pyrroles from propargylamines via a one-pot 
tandem enyne cross metathesis – cyclization reaction. 
5.2.3.1. Chemistry. 
Synthesis of t-butyl-prop- 2-ynylcarbamate (29a).222 
 
 
 
Propargylamine 31 (0.086 mL, 1.81 mmol, 1 eq.) was added to 20 mL mixture (1:1) of 
CH2Cl2 and Na2CO3 satured solution (ss) in water in a round bottom flask. Di-tert-butyl 
dicarbonate (436.5 mg, 2.00 mmol, 1.1 eq.) was added to the stirring solution. The reaction 
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mixture was allowed to stir under N2 atmosphere for 24 h at room temperature. Then, the 
reaction mixture was diluted with 10 mL of water and the product was extracted twice with 
20 mL of EtOAc. The combined organic layers were collected, washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure giving a yellow crude oil. The 
obtained product 29a was purified by chromatography on silica gel, using hexane/EtOAc 
(9:1) as eluent. The pure product was obtained as a pale yellow solid. Yield: 98% (274.9 
mg). 1H NMR (400 MHz CDCl3) δ 4.78 (br s, 1H), 3.88 (s, 2H), 2.18 (t, J = 2.5 Hz, 1H), 
1.42 (s, 9H) ppm. 13C NMR (100 MHz CDCl3) δ 155.2, 80.1, 80.0, 71.2, 30.4, 28.3 ppm. 
LRMS (ESI+): m/z = 156 [M + H]+.  
 
Synthesis of 4-methyl-N-2-propyn-1-yl-benzenesulfonamide (29b).223 
 
Propargylamine 31 (0.127 mL, 2.69 mmol, 1 eq.), and triethylamine (0.237 mL, 3.23 mmol, 
1.2 eq.) were added to a solution of p-toluenesulfonyl chloride (564 mg, 2.96 mmol, 1.1 eq.) 
in anhydrous DCM at 0 °C, under N2 atmosphere. The reaction mixture was allowed to stir 
at room temperature for 6 h, and then a saturated solution of NH4Cl in water (20mL) was 
added to the reaction mixture. The aqueous layer was extracted with DCM. The combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure, giving the 
crude product which was then purified by chromatography on silica gel, using hexane/EtOAc 
(9:1) as eluent. The pure product 29b was obtained as a yellow oil. Yield: 96% (200.6 mg). 
1H NMR (400 MHz CDCl3) δ 7.69 (d, J = 8.0 Hz, 2H), 7.19 (d, J = 8.0 Hz, 2H), 3.69 (d, J 
= 2.5 Hz, 2H), 2.31 (s, 3H), 2.03 (t, J = 2.0 Hz, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 
143.9, 136.3, 129.6, 127.3, 77.9, 72.8, 32.7, 21.5 ppm. LRMS (ESI+): m/z = 210 [M + H]+. 
Synthesis of N-prop-2-ynylbenzamide (29c).224 
 
 
Benzoyl chloride (0.210 mL1.83 mmol, 1.01 eq.) and TEA (2.21 mmol, 1.2 eq.) were added 
to a solution of propargylamine 31 (1.82 mmol, 1 eq.) in DCM (20 mL) at 0 °C. The reaction 
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mixture was allowed to stir at room temperature for 1 h, then it was quenched with 1M HCl 
solution (20 mL), and extracted with DCM (20 mL). The combined organic layers were 
washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The crude mixture was purified by chromatography on silica gel, using hexane/EtOAc (4:1) 
as eluent, affording 29c as a yellow oil. Yield: 88% (254.6 mg). 1H NMR (400 MHz CDCl3) 
δ 7.77 (d, J = 7.5 Hz, 2H), 7.48-7.39 (m, 3H), 6.64 (br s, 1H), 4.22 (dd, J = 5.5, 3.0 Hz, 2H), 
2.25 (t, J = 2.5 Hz, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 167.2, 133.6, 131.9, 128.6, 
127.0, 79.4, 71.9, 29.7 ppm. LRMS (ESI+): m/z = 160 [M + H]+. 
 
Synthesis of N-2-propyn-1-yl-benzenamine (29d).167  
 
Aniline (0.46 mL, 5 mmol, 5 eq.) was added to a solution of propargyl bromide 32 (0.148 
mL, 1 mmol, 1 eq.) in ethanol. The reaction mixture was stirred at room temperature for 2 
days, and then concentrated under reduced pressure. The crude product was purified by 
chromatography on silica gel, using hexane/EtOAc (9:1) as eluent. The pure product 29d 
was obtained as a yellow oil. Yield: 64% (83.8 mg). 1H NMR (400 MHz CDCl3) δ 7.21 (t, 
J = 7.5 Hz, 2H), 6.78 (t, J = 7.0 Hz, 1H), 6.68 (d, J = 7.5 Hz, 2H), 3.93 (s, 2H), 3.96 (br s, 
1H), 2.20 (t, J = 2.0 Hz, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 146.9, 130.0, 118.7, 113.6, 
81.1, 71.4, 33.4 ppm. LRMS (ESI+): m/z = 132 [M + H]+. 
 
Synthesis of N-benzyl(prop-2-ynyl)amine (29e). 
 
Benzylamine (1.101 mL, 10.08 mmol, 6 eq.) was added to a solution of propargyl bromide 
32 (0.187 mL, 1.68 mmol, 1 eq.) in 1 mL of DCM. The reaction mixture was stirred at room 
temperature for 2 days, and then concentrated under reduced pressure. The crude product 
was purified by chromatography on silica gel, using hexane/EtOAc (9:1) as eluent. 
Compound 29e was obtained as a tan oil. Yield: 56% (136.4 mg). 1H NMR (400 MHz 
CDCl3) δ 7.35−7.25 (m, 5H), 3.85 (s, 2H), 3.40 (s, 2H), 2.25 (s, 1H) ppm. 13C NMR (100 
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MHz CDCl3) δ 141.4, 128.9, 128.4, 126.6, 81.2, 79.3, 52.4, 41.7 ppm. LRMS (ESI+): m/z = 
146 [M + H]+. 
General procedure for the synthesis of propargylalchools 34a-e. 
 
A solution of ethynyl magnesium bromide in THF (2.5 mL, 5 mmol, 2 eq.) was added 
dropwise at 0°C to a solution in anhydrous THF (10 mL) of the appropriate aldehyde 33a-e 
(1 mmol, 1 eq.). The reaction was allowed to stir at r.t. for 1 h under N2 atmosphere. Then 
the reaction mixture was quenched with a saturated NH4Cl solution (20 mL). The aqueous 
layer was extracted with DCM (20 mL). The combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure, giving the crude product which was then 
used in the next reaction without further purifications. 
 
Synthesis of 1-phenylprop-2-yn-1-ol (34a).225  
 Yield: 98% (129.3 mg). 1H NMR (400 MHz CDCl3) δ 7.55 (m, 2H), 7.42–
7.31 (m, 3H), 5.49 (dd, J = 4.0 Hz, 1H), 2.65 (d, J = 2.0 Hz, 1H) 2.44 (br s, 
1H) ppm. 13C NMR (100 MHz CDCl3) δ 140.2, 128.9, 128.8, 126.6, 83.5, 
75.1, 64.6 ppm. LRMS (ESI+): m/z = 133 [M + H]+. 
 
Synthesis of 1-(4-chlorophenyl)prop-2-yn-1-ol (34b). 
Yield: 94% (156.0 mg). 1H NMR (400 MHz CDCl3) δ 7.50 (d, J = 8.0 
Hz, 2H), 7.37 (d, J = 8.0 Hz, 2H), 5.43 (s, 1H), 2.69 (d, J = 4.0 Hz, 1H), 
2.34 (br s, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 138.5, 134.7, 129.1, 
128.2, 83.3, 75.5, 63.9 ppm. LRMS (ESI+): m/z = 167 [M + H]+. 
 
Synthesis of 1-(3-fluorophenyl)prop-2-yn-1-ol (34c). 
Yield: 96% (144.9 mg). 1H NMR (400 MHz CDCl3) δ 7.39-7.27 (m, 3H), 
7.05-7.02 (m, 1H), 5.47 (d, J = 4.0 Hz, 1H), 2.69 (d, J = 4.0 Hz, 1H), 2.33 (br 
s, 1H) ppm. LRMS (ESI+): m/z = 151 [M + H]+.  
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Synthesis of 1-(2,4-dichlorophenyl)prop-2-yn-1-ol (34d).226 
Yield: 97% (193.0 mg). 1H NMR (400 MHz CDCl3) δ 7.68 (d, J = 8.0 
Hz, 1H), 7.40 (br s, 1H), 7.29-7.30 (d, J = 8.0 Hz, 1H), 5.75 (s, 1H), 2.76 
(d, J = 4.0 Hz 1H), 2.66 (br s, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 
135.8, 135.1, 133.2, 129.4, 129.2, 127.4, 81.7, 75.2, 61.1 ppm. LRMS (ESI+): m/z = 200 [M 
+ H]+. 
 
Synthesis of 1-([1,1'-biphenyl]-4-yl)prop-2-yn-1-ol (34e).  
Yield: 98% (204.8 mg). 1H NMR (400 MHz CDCl3) δ 7.55-7.59 (m, 
6H), 7.34-7.45 (m, 3H), 5.48 (d, J = 4.0 Hz, 1H), 2.67 (d, J = 4.0 Hz, 
1H), 2.54 (br s, 1H), 13C NMR (100 MHz CDCl3) δ 141.3 140.4, 138.8, 
128.7, 127.3, 127.5, 127.2, 127.1, 83.5, 74.8, 64.2 ppm. LRMS (ESI+): m/z = 209 [M + H]+. 
 
Synthesis of 1-phenylprop-2-yn-1-yl acetate (35).32 
 
 
 
Acetic anhydride (0.19 mL, 1.96 mmol, 1.3 eq.), triethylamine (0.419 mL, 3.02 mmol, 2 
eq.), and a catalytic amount of 4-dimethylaminopyridine (DMAP) were added to a solution 
of 1-phenyl- 2-propynol 34a (199.3 mg, 1.51 mmol, 1 eq.) in DCM. The reaction mixture 
was stirred at room temperature for 12 h, and then the solvent was concentrated under 
reduced pressure. The crude product was purified by chromatography on silica gel, using 
hexane/EtOAc (9:1) as eluent. Compound 35 was obtained as a yellow-brown solid. Yield: 
77% (201.1 mg). 1H NMR (400 MHz CDCl3) δ 7.53 (d, J = 6.5 Hz, 2H), 7.39 (m, 3H), 6.45 
(d, J = 2.0 Hz, 1H), 2.66 (d, J = 2.0 Hz, 1H), 2.10 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) 
δ 169.8, 136.5, 129.2, 128.8, 127.8, 80.3, 75.5, 65.4, 21.1 ppm. LRMS (ESI+): m/z = 197 
[M+ Na]+. 
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Synthesis of N-(1-phenylprop-2-yn-1-yl)aniline (36).227  
 
Copper iodide (24.7 mg, 0.13 mmol, 0.5 eq.) was added to a solution of propargylic acetate 
35 (44.9 mg, 0.26 mmol, 1 eq.) in MeOH at 0 °C, under N2 atmosphere. The reaction mixture 
was allowed to stir for 10 min before the addition of aniline (0.047 mL, 0.52 mmol, 2 eq.) 
and triethylamine (0.144 mL, 1.04 mmol, 4 eq.). The mixture was then stirred at 0 °C, for 
10 minutes and then allowed to reach room temperature for 12 h. The reaction mixture was 
diluted with EtOAc (20 mL), and NH4Cl (20 mL). The aqueous layer was extracted with 
EtOAc twice. The combined organic layers were dried over MgSO4 and concentrated under 
reduced pressure. The crude product was purified by chromatography on silica gel, using 
hexane as eluent. Compound 36 was obtained as a yellow-brown solid. Yield: 59% (31.7 
mg). 1H NMR (400 MHz CDCl3) δ 7.61 (d, J = 8.0 Hz, 2H), 7.38 (m, 3H), 7.28 (m, 2H), 
6.88-6.84 (m, 3H), 5.29 (s, 1H), 4.06 (br s, 1H), 2.50 (d, J = 2.0 Hz, 1H) ppm. 13C NMR 
(100 MHz CDCl3) δ 146.1, 138.8, 129.1, 128.7, 128.2, 127.2, 118.7, 113.8, 82.9, 73.1, 49.7 
ppm. LRMS (ESI+): m/z = 230 [M + Na]+. 
 
General procedure for the synthesis of propargylamides 37a−e.  
 
 
 
A solution of 96% H2SO4 (5 mmol, 5 eq.) in acetonitrile (2 mL) was added to a stirred 
mixture of the appropriate propargylalcohol 34a-e (1 mmol 1 eq.) and anhydrous Na2SO4 (1 
mmol 1eq.) in dry acetonitrile (3.1 mL) at r.t. The mixture was allowed to reach room 
temperature, and stirring was continued for the required time. The mixture was concentrated, 
poured on ice, and extracted with ether, (20 mL) and dichloromethane (20 mL). The 
combined organic layers were dried over Na2SO4, filtered, and concentrated. Flash 
chromatography, using ethyl acetate/petroleum ether (1:1) as eluent, afforded pure 
propargylamides 37a-e as yellow-brown solids. 
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Synthesis of N-(1-phenylprop-2-yn-1-yl)acetamide (37a).228  
Yield: 78% (135.7 mg). 1H NMR (400 MHz CDCl3) δ 7.58 (d, J = 8.0 Hz, 2H), 
7.37–7.26 (m, 3H), 6.77 (d, J = 8.0 Hz, 1H), 5.98 (d, J = 8.0 Hz, 1H), 2.45 (s, 
1H), 1.96 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 169.2, 138.3, 128.5, 
128.0, 126.9, 81.7, 72.9, 44.1, 22.7 ppm. LRMS (ESI+): m/z = 174 [M + H]+. 
 
Synthesis of N-(1-(4-chlorophenyl)prop-2-yn-1-yl)acetamide (37b).228  
 Yield: 77% (159.4 mg). 1H NMR (400 MHz CDCl3) δ 7.43 (d, J = 8.5 
Hz, 2H), 7.31 (d, J = 8.5 Hz, 2H), 6.00 (br s, 1H), 6.07 (s, 1H), 2.51 (s, 
1H), 2.03 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 168.8, 136.7, 
134.1, 128.8, 128.3, 81.3, 73.4, 43.9, 23.3 ppm. LRMS (ESI+): m/z = 208 [M + H]+. 
 
Synthesis of N-(1-(3-fluorophenyl)prop-2-yn-1-yl)acetamide (37c).228  
Yield: 73% (139.4 mg). 1H NMR (400 MHz CDCl3) δ 7.29-7.15 (m, 3H), 
6.99-6.95 (m, 1H), 6.15 (br d., J = 8.0 Hz, 1H), 5.96 (dd, J = 8.0, 2.0 Hz, 
1H), 2.47 (d, J = 2.0 Hz, 1H) 2.00 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) 
δ 169.0, 164.2, 140.8, 130.4, 122.8, 115.4, 114.3, 81.1, 73.5, 44.1, 23.2 ppm. 
LRMS (ESI+): m/z = 192 [M + H]+. 
 
Synthesis of N-(1-(2,4-dichlorophenyl)prop-2-yn-1-yl)acetamide (37d).  
Yield: 76% (183.1 mg). 1H NMR (400 MHz CDCl3) δ 7.56 (d, J = 8.0 
Hz, 1H), 7.40 (s, 1H), 7.22−7.24 (m, 1H), 6.09 (br s, 1H), 6.08 (s, 1H), 
2.46 (d, J = 1.5 Hz, 1H), 1.99 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) 
δ 168.7, 135.0, 134.2, 134.1, 130.1, 127.5, 80.5, 73.3, 42.8, 23.0 ppm. 
LRMS (ESI+): m/z = 242 [M + H]+, 264 [M + Na]+. HRMS (ESI): calcd for C11H10Cl2NO 
(M + H+) 242.0139, found 242.0137. 
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Synthesis of N-(1-([1,1-biphenyl]-4-yl)prop-2-yn-1-yl)acetamide (37e). 
Yield: 75% (186.7 mg). 1H NMR (400 MHz CDCl3) δ 7.57−7.55 (m, 
6H), 7.45−7.41 (m, 2H), 7.36−7.33 (m, 1H), 6.05 (d, J = 8.0 Hz, 1H), 
6.00 (br d, J = 8.0 Hz, 1H), 2.51 (s, 1H), 2.03 (s, 3H) ppm. 13C NMR 
(100 MHz CDCl3) δ 168.8, 141.4, 140.5, 137.3, 128.9, 127.6, 127.2, 
81.7, 73.2, 44.3, 23.3 ppm. LRMS (ESI+): m/z = 250 [M + H]+, 272 [M + Na]+. HRMS 
(ESI): calcd for C17H16NO (M + H
+) 250.1232, found 250.1227. 
 
General procedure for the synthesis of propynylamines S2a and S2b.173 
 
A suspension of 37a or 37b (0,76 mmol, 1 equiv) and an aqueous 1.2 M HCl solution (5 
mL) was heated to 90°C for 18 h. The reaction mixture was then cooled at room temperature, 
quenched with saturated NaHCO3 solution in water (20 mL), and diluted with Et2O (10 mL). 
The aqueous layer was extracted twice with Et2O (20 mL). The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash column chromatography (SiO2) using 1:1 
EtOAc/hexanes. Compound S2a and compound S2b were obtained as pale yellow oils. 
 
Synthesis of 1-phenylprop-2-yn-1-amine (S2a).225 
 Yield: 72% (71.7 mg). 1H NMR (400 MHz CDCl3) δ 7.57-7.50 (m, 2H), 
7.39-7.29 (m, 3H), 5.06 (d, J = 2.5 Hz, 1H), 2.41 (d, J = 2.5 Hz, 1H), 1.91 
(br s, 2H) ppm. 13C NMR (100 MHz CDCl3) δ 136.3, 129.4, 128.9, 127.7, 
80.2, 75.4, 47.9 ppm. LRMS (ESI+): m/z = 132 [M + H]+. 
 
Synthesis of 1-(4-chlorophenyl)prop-2-yn-1-amine (S2b).228 
 Yield: 74% (92.8 mg). 1H NMR (400 MHz CDCl3) δ 7.49-7.30 (m, 
4H), 4.71 (d, J = 4.2Hz, 1H), 2.49 (d, J = 4.2Hz, 1H), 1.75 (br s, 2H) 
ppm. 13C NMR (100 MHz CDCl3) δ 154.7, 137.4, 134.0, 128.8,, 80.1, 
75.5, 47.8 ppm. LRMS (ESI+): m/z = 166 [M + H]+. 
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Synthesis of 4-methyl-N-(1-phenylprop-2-yn-1-yl)benzenesulfonamide (37f).229 
 
1-Phenyl-2-propynylamine S2a (45.8 mg, 0.35 mmol, 1 eq.) was added to a round-bottom 
flask containing pyridine (5 mL). Then p-toluenesulfonyl chloride (118.2 mg, 0.62 mmol, 
1.77 eq.) was added at 0 °C to the solution previously obtained. The solution was allowed to 
stir at 100 °C for 18 h. The reaction mixture was then quenched with 1 M HCl solution (10 
mL) and washed with (10 mL) DCM. Then, (20 mL) saturated NaHCO3 solution were added 
to the aqueous layer and this was extracted twice with DCM (20 mL). The combined organic 
layers were washed with brine (20 mL), dried over Na2SO4, and concentrated under reduced 
pressure. The crude compound was purified by flash column chromatography (SiO2) using 
1:4 EtOAc/hexanes as the eluent. Compound 37f was obtained as a yellow-brown solid. 
Yield: 62% (61.9 mg). 1H NMR (400 MHz CDCl3) δ 7.75 (d, J = 8.0 Hz, 2H), 7.50-7.35 
(m, 2H), 7.35-7.06 (m, 5H), 5.30 (dd, J = 8.0, 1.5 Hz, 1H), 5.06 (d, J = 8.0 Hz, 1H), 2.41 (s, 
3H), 2.30 (d, J = 1.5 Hz, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 143.7, 137.3, 137.0, 129.6, 
128.8, 128.6, 127.5, 127.2, 80.5, 74.8, 49.0, 21.6 ppm. LRMS (ESI+): m/z = 308 [M + Na]+. 
 
Synthesis of tert-butyl (1-(4-chlorophenyl)prop-2-yn-1-yl)carbamate (37g). 
 
A solution of (Boc)2O (183.1 mg, 0.84 mmol, 1 eq.) in DCM (5 mL) was added dropwise to 
a solution of propargylamine S2b (138.6 mg, 0.84 mmol, 1 eq.) in DCM (5 mL) and Na2CO3 
saturated solution in water (5 mL), at 0 °C. The reaction mixture was then allowed to stir at 
room temperature for 24 h. The solution was diluted with DCM (10 mL). The aqueous layer 
was extracted with DCM (10 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The obtained product was purified by silica gel 
chromatography, using hexane/EtOAc (4:1) as eluent. Compound 37g was obtained as a tan 
oil. Yield: 60% (159 mg). 1H NMR (400 MHz CDCl3) δ 7.45 (d, J = 8.5 Hz, 2H), 7.33 (d, J 
= 8.5 Hz, 2H), 5.64 (d, J = 7.0 Hz, 1H), 5.06 (br s, 1H), 2.51 (d, J = 2.0 Hz, 1H), 1.46 (s, 
9H) ppm. 13C NMR (100 MHz CDCl3) δ 154.7, 137.4, 134.0, 128.8, 128.3, 81.6, 80.6, 73.4, 
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45.6, 28.3 ppm. LRMS (ESI+): m/z = 288 [M + Na]+. HRMS (ESI): calcd for 
C14H16ClNNaO2 (M + Na
+) 288.0767, found 288.0765. 
 
Synthesis of N-[1-(4-chlorophenyl)-2-propyn-1-yl]-benzamide (37h). 
 
Benzoyl chloride (0.062 mL, 0.57 mmol, 1.01 eq.) and triethylamine (0.087 mL, 0.67 mmol, 
1.2 eq.) were added to a solution of propargylic amine S2b (92.4 mg, 0.56 mmol, 1 eq.) in 
DCM (20 mL) at 0 °C. The reaction mixture was allowed to stir at room temperature for 1 
h, and then quenched with 1 M HCl solution (20 mL), and extracted with DCM (20 mL). 
The combined organic layers were washed with brine (20 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The obtained product was purified by chromatography 
on silica gel, using hexane/EtOAc (4:1) as eluent. Compound 37h was obtained as a yellow-
brown oil. Yield: 65% (97.2 mg). 1H NMR (400 MHz CDCl3) δ 7.79 (d, J = 7.0 Hz, 2H), 
7.51 (d, J = 6.0 Hz, 3H), 7.43 (t, J = 7.5 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 6.72 (d, J = 8.0 
Hz, 1H), 6.21 (dd, J = 8.0, 2.0 Hz, 1H), 2.55 (d, J = 2.0 Hz, 1H) ppm. 13C NMR (100 MHz 
CDCl3) δ 166.4, 136.9, 134.2, 133.4, 132.1, 128.9, 128.7, 128.6, 127.2, 81.2, 73.8, 44.4 ppm. 
LRMS (ESI+): m/z = 270 [M + H]+. HRMS (ESI): calcd for C16H13ClNO (M + H
+) 
270.0686, found 270.0683. 
 
General procedure for the synthesis of silylpropargylamines 39a−d. 
 
 
The appropriate aldehyde 33f-i (1.17 mmol, 1.1 eq.) and triisopropylsilyl acetylene 38 (319.2 
mg, 1.75 mmol, 1.5 eq.) were added to a solution of p-toluenesulfonamide (200.3 mg, 1.17 
mmol, 1 eq.), sodium sulfate (166.2 mg, 1.17 mmol, 1 eq.), cesium carbonate (381.2 mg, 
1.17 mmol, 0.1 eq.), and copper triflate (42.3 mg, 0.117 mmol, 0.1 eq.) in anhydrous toluene 
under N2 atmosphere. The reaction mixture was allowed to stir at 120 °C for 48 h. The 
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reaction mixture was then quenched with EtOAc (20 mL), and washed with a saturated 
NaHCO3 solution (20 mL). The combined organic layers were dried over MgSO4 and 
concentrated under reduced pressure. The crude product was purified by chromatography on 
silica gel, using hexane/EtOAc (4:1) as eluent affording the pure products as yellow-brown 
oils. 
 
Synthesis of N-[1-(2-furanyl)-3-[tris(1-methylethyl)silyl]-2-propyn-1-yl]-4-methyl-
benzenesulfonamide (39a).  
Yield: 48% (251.6 mg). 1H NMR (400 MHz CDCl3) δ 7.75 (d, J = 8.0 
Hz, 2H), 7.31 (s, 1H), 7.25 (d, J = 8.0 Hz, 2H), 6.35 (d, J = 3.0 Hz, 1H), 
6.27 (t, J = 3.0 Hz, 1H), 5.41 (d, J = 8.0 Hz, 1H), 4.89 (d, J = 8.0 Hz, 
1H), 2.39 (s, 3H), 0.96 (m, 18H), 0.93−0.82 (m, 3H) ppm. 13C NMR 
(100 MHz CDCl3) δ 150.1, 143.5, 143.2, 137.5, 129.7, 127.2, 110.4, 108.4, 101.4, 87.0, 44.1, 
21.6, 18.5, 11.0 ppm. LRMS (ESI+): m/z = 432 [M + H]+. HRMS (ESI): calcd for 
C23H37SSiN2O3 (M + NH4
+) 449.2294, found 449.2284. 
 
Synthesis of N-[1-cyclohexyl-3-[tris(1-methylethyl)silyl]-2-propyn-1-yl]-4-methyl-
benzenesulfonamide (39b).230 
Yield: 45% (235.3 mg). 1H NMR (400 MHz CDCl3) δ 7.74 (d, J = 
8.0 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 4.55 (d, J = 9.5 Hz, 1H), 3.92 
(dd, J = 9.5, 6.0 Hz, 1H), 2.38 (s, 3H), 1.84−1.68 (m, 5H), 1.68−1.50 
(m, 4H), 1.30−0.97 (m, 2H), 0.91 (d, J = 5.0 Hz, 18H), 0.88−0.81 (m, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 143.4, 138.4, 129.8, 127.1, 104.9, 85.1, 51.3, 43.8, 
29.2, 28.2, 26.2, 25.8, 25.7, 20.7, 18.1, 11.1 ppm. LRMS (ESI+): m/z = 448 [M + H]+. 
 
Synthesis of N-[1-methylethyl-3-[tris(1-methylethyl)silyl]-2-propyn-1-yl]-4-methyl-
benzenesulfonamide (39c).  
Yield: 22% (104.7 mg). 1H NMR (400 MHz CDCl3) δ 7.77 (d, J = 8.5 
Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 4.63 (d, J = 9.0 Hz, 1H), 3.95 (dd, J = 
9.5, 6.0 Hz, 1H), 2.40 (s, 3H), 1.94−1.88 (m, 1H), 1.00 (d, J = 6.5 Hz, 
6H), 0.92 (d, J = 5.0 Hz, 18H), 0.95−0.84 (m, 3H) ppm. 13C NMR (100 
MHz CDCl3) δ 143.4, 137.5, 129.7, 127.2, 104.0, 86.0, 52.3, 34.3, 21.5, 18.7, 18.5, 17.4, 
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11.0 ppm. LRMS (ESI+): m/z = 408 [M + H]+. HRMS (ESI): calcd for C22H41SSiN2O2 (M 
+ NH4
+) 425.2658, found 425.2645.  
 
Synthesis of N-[1-(2-methylbutyl)-3-[tris(1-methylethyl)silyl]-2-propyn-1-yl]-4-
methyl-benzenesulfonamide (39d). 
 Yield: 56% (275.8 mg). 1H NMR (400 MHz CDCl3) δ 7.77 (d, J = 
8.0 Hz, 2H), 7.27 (d, J = 8.0 Hz, 2H), 4.49 (d, J = 9.5 Hz, 1H), 4.13 
(q, J = 7.5 Hz, 1H), 2.40 (s, 3H), 1.96−1.83 (m, 1H), 1.60−1.44 (m, 
2H), 0.92 (d, J = 5.0 Hz, 6H), 0.88 (d, J = 5.0 Hz, 18H), 0.87-0.86 (m, 
3H) ppm. 13C NMR (100 MHz CDCl3) δ 143.4, 137.6, 129.7, 127.2, 85.0, 46.6, 45.0, 24.8, 
22.3, 22.0, 21.5, 18.5, 11.0 ppm. LRMS (ESI+): m/z = 422 [M + H]+. HRMS (ESI): calcd 
for C23H43SSiN2O2 (M + NH4
+) 439.2815, found 439.2804. 
 
General Procedure for the synthesis of propargylamides 40a−d. 
 
A 1 M TBAF solution in THF (0.54 mmol, 1.1 eq.) was added to a solution of compound 39 
(0.27 mmol, 1 eq.) in THF (5 mL) at 0 °C. The reaction mixture was stirred at room 
temperature for 1h, then quenched with a saturated NaHCO3 solution (20 mL), and extracted 
with EtOAc (20 mL). The combined organic layers were washed with brine, dried over 
MgSO4, and concentrated under reduced pressure. The crude product was purified by 
chromatography on silica gel, using hexane/ EtOAc (4:1) as eluent affording the pure 
products as yellow-brown oils. 
 
Synthesis of N-[1-(2-furanyl)-2-propyn-1-yl]-4-methyl-benzenesulfonamide (40a).231 
 Yield: 82% (60.8 mg).1H NMR (400 MHz CDCl3) δ 7.75 (d, J = 8.0 Hz, 
2H), 7.30 (d, J = 1.0 Hz, 1H), 7.28 (d, J = 8.0 Hz, 2H), 6.33 (d, J = 3.0 Hz, 
1H), 6.27 (t, J = 2.0 Hz, 1H), 5.37 (d, J = 2.0 Hz, 1H), 2.42 (s, 3H), 2.30 (d, 
J = 2.0 Hz, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 149.0, 143.6, 143.1, 137.1, 129.4, 
127.3, 110.4, 108.4, 78.3, 73.6, 43.1, 21.5 ppm. LRMS (ESI+): m/z = 298 [M + Na]+. 
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Synthesis of N-(1-cyclohexyl-2-propyn-1-yl)-4-methyl-benzenesulfonamide (40b).231 
Yield: 99% (77.8 mg). 1H NMR (400 MHz CDCl3) δ 7.75 (d, J = 6.5 Hz, 
2H), 7.27 (d, J = 7.0 Hz, 2H), 4.69 (d, J = 7.0 Hz, 1H), 3.86 (m, 1H), 2.40 (s, 
3H), 2.01 (s, 1H), 1.84−1.67 (m, 5H), 1.66−146 (m, 4H), 1.33−0.99 (m, 2H). 
13C NMR (100 MHz CDCl3) δ 143.4,132.2, 129.4, 127.3, 80.7, 73.1, 50.6, 42.8, 28.8, 25.7, 
25.6, 21.5, 14.1 ppm. LRMS (ESI+): m/z = 314 [M + Na]+. 
 
Synthesis of N-(1-isopropyl-2-propyn-1-yl)-4-methyl-benzenesulfonamide (40c).  
Yield: 95% (64.4 mg). 1H NMR (400 MHz CDCl3) δ 7.78 (d, J = 8.0 Hz, 2H), 
7.30 (d, J = 7.5 Hz, 2H), 4.71 (d, J = 9.5 Hz, 1H), 3.90 (ddd, J = 10.0, 5.5, 2.0 
Hz, 1H), 2.43 (s, 3H), 2.04 (d, J = 2.5 Hz, 1H), 1.91 (m, 1H), 0.98 (d, J = 6.5 
Hz, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 143.5, 137.2, 129.5, 127.3, 80.4, 73.1, 51.3, 
33.5, 21.5, 18.5, 17.3 ppm. LRMS (ESI+): m/z = 274 [M + Na]+. 
 
Synthesis of N-(1-methylbutyl-2-propyn-1-yl)-4-methyl-benzenesulfonamide (40d). 
 Yield: 93% (66.5 mg). 1H NMR (400 MHz CDCl3) δ 7.79 (d, J = 8.0 Hz, 
2H), 7.30 (d, J = 8.5 Hz, 2H), 4.71 (d, J = 9.0 Hz, 1H), 4.15−4.04 (m, 1H), 
2.43 (s, 3H), 2.03 (d, J = 2.0 Hz, 1H), 1.89−1.77 (m, 1H), 1.53 (td, J = 7.6, 
3.0 Hz, 2H), 0.89 (dd, J = 6.0, 3.0 Hz, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 143.6, 137.3, 
129.5, 127.5, 82.2, 72.4, 45.6, 44.0, 24.6, 22.2, 22.0, 21.6 ppm. LRMS (ESI+): m/z = 288 
[M + Na]+. HRMS (ESI): calcd for C14H19NNaO2S (M + H
+) 288.1034, found 288.1008. 
 
General Procedure for the synthesis of 3-methyl-pyrroles 41a-r.  
 
Ethyl vinyl ether (0.43 mL, 4.5 mmol, 9 eq.), CuSO4 (159 mg, 1 mmol, 2 eq.) and Grubbs 
catalyst second generation (5−10 mol %) were added to a microwave vial containing a 
solution of the appropriate propargylamine derivative (0.5 mmol, 1 eq.) in 3 mL of degassed 
toluene. The reaction mixture was heated at 120 °C under microwave irradiation (300 W) 
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for 2 × 10 min. The maximum internal pressure observed during the reaction was 44 psi. The 
reaction mixture was then quenched with saturated aqueous NH4Cl solution (10 mL), 
NH4OH solution (0.5 mL), and Et2O (10 mL). The aqueous layer was extracted twice with 
Et2O (10 mL). The combined organic layers were washed with brine (10 mL), dried over 
Na2SO4, and concentrated under reduced pressure. All the crude products were purified by 
flash column chromatography (SiO2) using 1:4 Et2O/hexanes as the eluent to yield the 
desired pyrroles 41 as tan oils. 
 
Synthesis of t-butyl 3-Methyl-1H-pyrrole-1-carboxylate (41a).  
Yield: 56% (50.4 mg). 1H NMR (400 MHz CDCl3) δ 7.12 (d, J = 3.0 Hz, 1H), 
6.95 (s, 1H), 6.04 (d, J = 3.0 Hz, 1H), 2.04 (s, 3H), 1.56 (s, 9H) ppm. 13C NMR 
(100 MHz CDCl3) δ 149.0, 122.6, 120.0, 117.2, 114.1, 83.2, 28.1, 12.0 ppm. GC-MS m/z 
(ES+) m/z: 181 [M]+. HRMS (ESI): calcd for C10H16NO2 (M + H
+) 182.1181, found 
182.1173. 
 
Synthesis of (E/Z)-tert-butyl-(4-ethoxy-2-methylenebut-3-en-1-yl)carbamate (30). 
Yield: 41% (46.3 mg). obtained as a 2:1 mixture of E/Z isomers as 
revealed by GC-MS. This compound was isolated following the 
general procedure for the synthesis of 3-methyl-pyrroles 41a-r without 
the presence of CuSO4. 1H NMR (400 MHz CDCl3) major isomer E. δ 6.63 (d, J = 12.0 Hz, 
1H), 5.53 (d, J = 12.0 Hz, 1H), 4.85 (s, 1H), 4.80 (s, 1H), 4.59 (br s, 1H), 3.84−3.76 (m, 4H), 
1.43 (s, 9H), 1.27 (t, J = 4.0 Hz, 3H) ppm; peaks from minor isomer Z δ 5.96 (d, J = 7.0 Hz, 
1H), 5.09 (s, 1H), 4.96 (s, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 155.8, 148.2, 140.9, 
111.0, 106.2, 79.4, 65.8, 42.8, 28.4, 14.9 ppm; peaks from minor isomer δ 146.0, 113.6, 
105.2, 69.0, 45.5, 27.4, 15.3 ppm. GC-MS m/z (ES+) m/z: 227 [M]+, 171 [M - t-Bu]+, 154 
[M - t-BuOH]+. HRMS (ESI): calcd for C12H21NO3 [M]
+ 227.1516, found 227.1553. 
 
Synthesis of 3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole (41b).  
Yield: 53% (62.0 mg). 1H NMR (400 MHz CDCl3) δ 7.70 (d, J = 7.5 Hz, 2H), 
7.25 (d, J = 7.5 Hz, 2H), 7.03 (d, J = 3.0 Hz, 1H), 6.86 (s, 1H), 6.10 (d, J = 3.0 
Hz, 1H), 2.38 (s, 3H), 2.00 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 144.6, 136.2, 129.8, 
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126.7, 124.5, 120.8, 117.7, 115.7, 21.6, 11.8 ppm. GC-MS m/z (ES+) m/z: 235 [M]+. HRMS 
(ESI): calcd for C12H14NO2S (M + H
+) 236.0745, found 236.0738. 
 
Synthesis of 3-methyl-1-benzoyl-1H-pyrrole (41c). 
Yield: 39% (36.4 mg). 1H NMR (400 MHz CDCl3) δ 7.71 (d, J = 7.0 Hz, 2H), 
7.57−7.55 (m, 1H), 7.50−7.46 (m, 2H), 7.16 (d, J = 2.0 Hz, 1H), 7.03 (d, J = 2.0 
Hz, 1H), 6.18 (s, 1H), 2.08 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 165.5, 
132.0, 129.4, 128.4, 124.1, 121.4, 118.5, 115.6, 12.1 ppm. GC-MS m/z (ES+) m/z: 185 
[M]+. HRMS (ESI): calcd for C12H12NO (M + H
+) 186.0919, found 186.0906. 
 
Synthesis of 3-methyl-1-phenyl-1H-pyrrole (41d).232  
Yield: 54% (42.4 mg). 1H NMR (400 MHz CDCl3) δ 7.40−7.35 (m, 4H), 
7.19−7.18 (m, 1H), 6.98 (d, J = 2.5 Hz, 1H), 6.86 (d, J = 2.5 Hz, 1H), 6.16 (s, 
1H), 2.16 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 140.8, 129.5, 125.1, 121.2, 
120.0, 119.0, 117.2, 112.0, 12.0 ppm. GC-MS m/z (ES+) m/z: 157 [M]+. HRMS (ESI): 
calcd for C11H12N (M + H
+) 158.0970, found 158.0960. 
 
Synthesis of 3-methyl-2-phenyl-1-acetyl-1H-pyrrole (41f).233  
Yield: 70% (69.3 mg). 1H NMR (400 MHz CDCl3) δ 7.42−7.30 (m, 3H), 
7.28 (d, J = 3.5 Hz, 1H), 7.27−7.23 (m, 2H), 6.16 (d, J = 3.5 Hz, 1H), 1.90 
(s, 3H), 1.55 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 169.1, 133.7, 
130.5, 130.2, 128.1, 126.8, 124.5, 120.2, 113.9, 25.0, 11.4 ppm. GC-MS m/z (ES+) m/z: 
199 [M + H]+. 
 
Synthesis of 3-methyl-2-(4-chlorophenyl)-1-acetyl-1H-pyrrole (41g). 
 Yield: 72% (83.5 mg). 1H NMR (400 MHz CDCl3) δ 7.35 (d, J = 8.0 
Hz, 2H), 7.21 (d, J = 3.0 Hz, 1H), 7.17 (d, J = 8.0 Hz, 2H), 6.16 (d, J 
= 3.0 Hz, 1H), 2.29 (s, 3H), 1.89 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 168.4, 133.5, 132.1, 131.5, 129.4, 128.3, 123.9, 120.7, 114.3, 
24.6, 11.4 ppm. GC-MS m/z (ES+) m/z: 233 [M]+. HRMS (ESI): calcd for C13H13ClNO (M 
+ H+) 234.0686, found 234.0677.  
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Synthesis of 3-methyl-2-(3-fluorophenyl)-1-acetyl-1H-pyrrole (41h). 
 Yield: 76% (82.2 mg). 1H NMR (400 MHz CDCl3) δ 7.36−7.29 (m, 
1H), 7.21 (d, J = 3.0 Hz, 1H), 7.06−6.91 (m, 3H), 6.15 (d, J = 3.0 Hz, 
1H), 2.27 (s, 3H), 1.90 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 
168.4, 163.7, 135.8, 129.5, 126.0, 124.1, 120.7, 117.3, 114.6, 114.4, 
114.2, 22.7, 14.2 ppm. GC-MS m/z (ES+) m/z: 217 [M]+. HRMS (ESI): calcd for 
C13H13FNO (M + H
+) 218.0981, found 218.0975. 
 
Synthesis of 3-methyl-2-(2,4-dichlorophenyl)-1-acetyl-1H-pyrrole (41i).  
Yield: 38% (50.5 mg). 1H NMR (400 MHz CDCl3) δ 7.47−7.40 (m, 
1H), 7.30−7.25 (m, 1H), 7.20 (s, 1H), 7.19 (d, J = 3.5 Hz, 1H), 6.20 (d, 
J = 3.5 Hz, 1H), 2.35 (s, 3H) 1.85 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 168.6, 136.0, 134.4, 132.6, 131.9, 129.3, 127.0, 126.4, 124.3, 
102.6, 114.3, 23.6, 11.1 ppm. GC-MS m/z (ES+) m/z: 267 [M]+. HRMS (ESI): calcd for 
C13H12Cl2NO (M + H
+) 268.0296, found 268.0285.  
 
Synthesis of 3-methyl-2-(4-phenyl-phenyl)-1-acetyl-1H-pyrrole (41j).  
Yield: 59% (80.8 mg). 1H NMR (400 MHz CDCl3) δ 7.67−7.59 (m, 
4H), 7.48−7.40 (m, 2H), 7.37−7.30 (m, 3H), 7.28 (d, J = 3.0 Hz, 1H), 
6.18 (d, J = 3.0 Hz, 1H), 2.26 (s, 3H), 1.96 (s, 3H) ppm. 13C NMR (100 
MHz CDCl3) δ 168.9, 140.7, 140.2, 132.6, 130.6, 130.2, 128.8, 127.4, 
127.1, 126.8, 123.8, 120.5, 114.2, 25.0, 11.6 ppm. GC-MS m/z (ES+) m/z: 275 [M]+. HRMS 
(ESI): calcd for C19H18NO (M + H
+) 276.1388, found 276.1380. 
 
Synthesis of 3-methyl-2-phenyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole (41k). 
Yield: 38% (58.9 mg). 1H NMR (400 MHz CDCl3) δ 7.38−7.18 (m, 7H), 
7.08−7.05 (m, 3H), 6.18 (d, J = 3.0 Hz, 1H), 2.34 (s, 3H), 1.80 (s, 3H) ppm. 
13C NMR (100 MHz CDCl3) δ 144.4, 135.9, 131.9, 131.2, 130.7, 129.3, 
128.1, 127.4, 127.2, 123.8, 122.4, 114.2, 21.6, 11.6 ppm. GC-MS m/z (ES+) m/z: 311 [M]+, 
HRMS (ESI): calcd for C18H18NO2S (M +H
+) 312.1058, found 312.1047.  
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Synthesis of tert-butyl 2-(4-chlorophenyl)-3-methyl-1H-pyrrole-1-carboxylate (41l). 
Yield: 50% (72.5 mg). 1H NMR (400 MHz CDCl3) δ 7.39-7.29 (t, J = 
8.2 Hz, 2H), 7.27 (d, J = 3.2 Hz, 1H), 7.19-7.12 (m, J = 8.2 Hz, 2H), 
6.10 (d, J = 3.2 Hz, 1H), 1.89 (s, 3H), 1.30 (s, 9H) ppm. 13C NMR (100 
MHz CDCl3CDCl3) δ 149.2, 133.0, 132.5, 131.6, 129.1, 127.2, 122.6, 
121.3, 113.0, 83.3, 27.6, 11.6 ppm. GC-MS m/z (ES+) m/z: 291 [M]+. HRMS (ESI): calcd 
for C16H19ClNO2 (M + H
+) 292.1104, found 292.1098. 
 
Synthesis of 3-methyl-2-(4-chlorophenyl)-1-benzoyl-1H-pyrrole (41m). 
 Yield: 64% (94.1 mg). 1H NMR (400 MHz CDCl3) δ 7.74 (d, J = 
7.0 Hz, 2H), 7.56 (t, J = 7.0 Hz, 1H), 7.43 (t, J = 7.0 Hz, 2H), 7.29 (d, 
J = 8.0 Hz, 2H), 7.18 (d, J = 8.0 Hz, 2H), 6.96 (d, J = 3.0 Hz, 1H), 
6.18 (d, J = 3.0 Hz, 1H), 2.08 (s, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 168.2, 133.6, 132.7, 131.4, 130.7, 130.2, 128.8, 128.4, 128.2, 128.0, 123.9, 123.7, 
113.9, 11.6 ppm. GC-MS m/z (ES+) m/z: 295 [M]+, HRMS (ESI): calcd for C18H15ClNO 
(M + H+) 296.0842, found 296.0836. 
Synthesis of 2-(furan-2-yl)-3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole (41o).  
Yield: 76% (114.3 mg). 1H NMR (400 MHz CDCl3) δ 7.49 (d, J = 8.0 Hz, 
2H), 7.46 (dd, J = 2.0, 1.0 Hz, 1H), 7.39 (d, J = 3.0 Hz, 1H), 7.22 (d, J = 8.0 
Hz, 2H), 6.47 (dd, J = 3.0, 1.5 Hz, 1H), 6.38 (d, J = 3.0 Hz, 1H), 6.19 (d, J = 
3.0 Hz, 1H), 2.39 (s, 3H), 1.93 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 144.6, 143.1, 
142.9, 136.0, 129.5, 127.7, 127.3, 123.5, 120.9, 113.9, 113.1, 110.7, 21.7, 11.8 ppm. GC-
MS m/z (ES+) m/z: 301 [M]+. HRMS (ESI): calcd for C16H16NO3S (M +H
+) 302.0851, 
found 302.0846. 
 
Synthesis of 2-cyclohexyl-3-methyl-1-[(4-methylphenyl)sulfonyl]-1H-pyrrole (41p). 
Yield: 43% (67.9 mg). 1H NMR (400 MHz CDCl3) δ 7.64 (d, J = 8.0 Hz, 
2H), 7.29 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 3.0 Hz, 1H), 6.03 (d, J = 3.0 Hz, 
1H), 3.10 (dt, J = 12.0, 3.0 Hz, 1H), 2.42 (s, 3H), 2.06 (s, 3H), 1.69−1.58 (m, 
4H), 1.51−1.44 (m,4H), 1.34−1.27 (m, 2H) ppm. 13C NMR (100 MHz 
CDCl3) δ 144.5, 137.1, 134.4, 129.8, 126.8, 120.6, 120.3, 114.7, 36.0, 31.1, 29.7, 27.0, 26.0, 
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21.7, 13.2 ppm. GC-MS m/z (ES+) m/z: 317 [M]+. HRMS (ESI): calcd for C18H24NO2S (M 
+ H+) 318.1528, found 318.1516. 
 
Synthesis of 3-methyl-1-[(4-methylphenyl)sulfonyl]-2-(propan-2-yl)-1H-pyrrole (41q). 
Yield: 71% (97.9 mg). 1H NMR (400 MHz CDCl3) δ 7.60 (d, J = 8.0 Hz, 2H), 
7.28 (d, J = 8.0 Hz, 2H), 7.21 (d, J = 3.0 Hz, 1H), 6.03 (d, J = 3.0 Hz, 1H), 
3.51-3.44 (m, 1H), 2.41 (s, 3H), 2.04 (s, 3H), 1.04 (d, J = 6.5 Hz, 6H) ppm. 
13C NMR (100 MHz CDCl3) δ 144.5, 137.1, 135.3, 129.9, 126.7, 120.6, 120.5, 114.9, 29.7, 
25.4, 21.6, 21.2, 12.9 ppm. GC-MS m/z (ES+) m/z: 277 [M]+. HRMS (ESI): calcd for 
C15H20NO2S (M + H
+) 278.1215, found 278.1207. 
 
Synthesis of 3-methyl-1-[(4-methylphenyl)sulfonyl]-2-(2-methylpropyl)-1H-pyrrole 
(41r). 
Yield: 69% (100.3 mg). 1H NMR (400 MHz CDCl3) δ 7.58 (d, J = 8.0 Hz, 
2H), 7.26 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 3.0 Hz, 1H), 6.09 (d, J = 3.0 Hz, 
1H), 2.46 (d, J = 7.0 Hz, 2H), 2.40 (s, 3H), 2.03−1.93 (m, 1H), 1.92 (s, 3H), 
0.86 (d, J = 6.0 Hz, 6H) ppm. 13C NMR (100 MHz CDCl3) δ 144.4, 137.0, 130.9, 129.8, 
126.4, 122.5, 121.8, 114.5, 34.1, 29.9, 22.7, 22.3, 21.6, 12.0 ppm. GC-MS m/z (ES+) m/z: 
291 [M]+. HRMS (ESI): calcd for C16H22NO2S (M + H
+) 292.1371, found 292.1364. 
 
General procedure for the synthesis of pyrrolines (45a,b). 
 
 
 
Sodium cyanoborohydride (23.8 mg, 0.38 mmol, 3 eq.) was added to a round-bottom flask 
containing trifluoroacetic acid (2 mL). The solution was allowed to stir for 20 min at room 
temperature. Then the appropriate pyrrole 41b or 41r (0.127 mmol, 1 eq.) was added to the 
solution previously obtained. The solution was allowed to stir at room temperature for 1 h. 
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The reaction mixture was then quenched with water (10 mL) and DCM (10 mL). The 
aqueous layer was extracted twice with DCM (20 mL). The combined organic layers were 
washed with a NaHCO3 saturated solution (10 mL), brine (10 mL), dried over Na2SO4, and 
concentrated under reduced pressure. The crude pyrrolines 45a,b proved to be pure enough 
to be used in the next synthetic step without any further purification. 
 
Synthesis of 3-methyl-1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole (45a).  
Yield: 65% (19.6 mg). 1H NMR (400 MHz CDCl3) δ 7.69 (d, J = 8.0 Hz, 2H), 
7.30 (d, J = 8.0 Hz, 2H), 5.22 (t, J = 4.0 Hz, 1H), 4.04 (d, J = 4.0 Hz, 2H), 3.94 
(s, 2H), 2.40 (s, 3H), 1.63 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 143.4, 
135.1, 134.2, 129.8, 127.5, 119.1, 57.7, 55.2, 21.5, 14.1 ppm. LRMS (ESI+): m/z = 238. 
 
Synthesis of 2-isobutyl-3-methyl-1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole 
(45b).  
Yield: 56% (20.9 mg). 1H NMR (400 MHz CDCl3) δ 7.65 (d, J = 8.0 Hz, 
2H), 7.25 (d, J = 8.0 Hz, 2H), 5.02 (t, J = 1.5 Hz, 1H), 4.25 (s, 1H), 4.01 (d, 
J = 1.5 Hz, 2H), 2.38 (s, 3H), 1.92−1.85 (m, 1H), 1.56 (s, 3H), 1.48 (t, J = 
1.5 Hz, 2H), 1.01 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (100 MHz 
CDCl3) δ 149.4, 138.6, 137.5, 129.6, 127.5, 118.9, 68.4, 42.4, 33.9, 24.3, 23.8, 23.2, 14.1 
ppm. LRMS (ESI+): m/z = 294. 
 
General procedure for the synthesis of aldehydes 46a,b.  
 
The appropriate pyrroline 45a,b (0.076 mmol, 1 equiv) was added to a round-bottom flask 
containing anhydrous 1,4-dioxane (2 mL). Then SeO2 (8.4 mg, 0.076 mmol, 1 eq.) was added 
to the solution previously obtained. The solution was allowed to stir at reflux for 1 h under 
N2 atmosphere. The reaction mixture was then cooled at room temperature, quenched with 
10 mL of water, and DCM (10 mL) was added. The aqueous layer was extracted twice with 
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DCM (20 mL). The combined organic layers were washed with a NaHCO3 saturated solution 
(10 mL) and brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The crude aldehydes were purified by flash column chromatography (SiO2) using 2:3 
EtOAc/hexanes as the eluent.  
 
Synthesis of 1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole-3-carbaldehyde 
(46a). 
 Yield: 56% (10.6 mg). 1H NMR (400 MHz CDCl3) δ 9.53 (s, 1H), 7.73 (d, J 
= 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 6.02 (t, J = 2.0 Hz, 1H), 4.38 (s, 2H), 
4.26 (d, J = 2.0 Hz, 2H), 2.41 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 186.6, 
144.1, 142.5, 141.7, 130.1, 127.6, 55.6, 51.9, 21.6 ppm. LRMS (ESI+): m/z = 
252 [M + H]+, HRMS (ESI): calcd for C12H14NO3S (M + H
+) 252.0694, found 252.0686. 
 
Synthesis of 2-isobutyl-1-[(4-methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole-3-
carbaldehyde (46b). 
 Yield: 65% (15.1 mg). 1H NMR (400 MHz CDCl3) δ 9.53 (s, 1H), 7.65 (d, 
J = 8.0 Hz, 2H), 7.25 (d, J = 8.0 Hz, 2H), 6.53 (s, 1H), 4.78 (d, J = 1.0 Hz, 
1H), 4.34−4.32 (m, 2H), 2.41 (s, 3H), 1.92−1.85 (m, 1H), 1.48 (d, J = 2.0 Hz, 
2H), 1.01 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.5 Hz, 3H) ppm. 13C NMR (100 
MHz CDCl3) δ 186.5, 146.1, 143.9, 143.4, 134.3, 129.5, 127.5, 63.7, 54.9, 43.1, 28.3, 28.1, 
24.4, 23.8, 22.4, 21.6 ppm. LRMS (ESI+): m/z = 308 [M + H]+, HRMS (ESI): calcd for 
C16H22NO3S (M + H
+) 308.1320, found 308.1308.  
 
Synthesis of (1-tosylpyrrolidin-3-yl)methanol (47).183 
 
The aldehyde 46a (10 mg, 0.04 mmol 1 eq.) was dissolved in MeOH (2 mL). The solution 
was treated with a mixture of NaBH4 (4.53 mg, 0.12 mmol, 3 eq.) and CoCl2*6H2O (9.5 mg, 
0.04 mmol, 1eq.) at room temperature. The reaction was stirred for 15 min and then further 
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NaBH4 was added until the reaction went to completion (24 h). The crude
 reaction was 
quenched with water (10 mL) and extracted twice with EtOAc (5 mL). The combined organic 
layers were washed with brine (10 mL), dried over Na2SO4 and concentrated under
 reduced 
pressure affording [1-(toluene-4-sulfonyl)-pyrrolidin-3-yl]-methanol 47. Yield: 56% (5.7 
mg). 1H NMR (400 MHz CDCl3) δ 7.68 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 8.0 Hz, 2H), 3.41 
(m, 2H), 3.30 (m, 2H), 3.13 (m, 1H), 3.04 (dd, J = 10.0, 6.0 Hz, 1H), 2.66 (br s, 1H), 2.41 
(s, 3H), 2.27 (m, 1H), 1.85 (m, 1H), 1.54 (m, 1H) ppm. 13C NMR (100 MHz CDCl3) δ 143.5, 
133.1, 129.6, 127.7, 63.5, 50.3, 47.4, 40.6, 27.4, 21.4 ppm. LRMS (ESI+): m/z = 256 [M + 
H]+. 
 
Synthesis of 3-methyl-2-phenyl-1H-pyrrole (49).  
 
The pyrrole 41f (89.4 mg, 0.452 mmol 1 eq.) was added to a round-bottom flask containing 
2.5 M NaOH solution (2 mL). The reaction mixture was allowed to stir at r.t. for 3 h. The 
reaction mixture was then diluted with water (10 mL), and DCM (10 mL) was added. The 
aqueous layer was extracted twice with DCM (10 mL). The combined organic layers were 
washed with brine (10 mL), dried over Na2SO4, and concentrated under reduced pressure. 
The crude pyrrole 49 was purified by flash column chromatography (SiO2) using 2:3 
EtOAc/hexanes as the eluent. Yield: 90% (63.4 mg). 1H NMR (400 MHz CDCl3) δ 8.13 (br 
s, 1H), 7.45−7.37 (m, 4H), 7.25−7.21 (m, 1H), 6.76 (d, J = 2.5 Hz, 1H), 6.14 (d, J = 2.5 Hz, 
1H), 2.27 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 133.7, 128.7, 128.3, 128.0,  126.0, 
117.3, 116.1, 112.2, 14.2 ppm. GC-MS m/z (ES+) m/z: 157 [M]+. 
Synthesis of 4-methyl-5-phenyl-1H-pyrrole-2-carbaldehyde 50. 
 
 
A solution of  DMF (0.11 mmol, 1.1 eq.) and phosphorus oxychloride (0,01 mL, 0.10 mmol, 
1 eq.) were added to a round-bottom flask containing DCM (2 mL). The solution was 
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allowed to stir for 15 min at room temperature. Then the solution was cooled down at 0 °C 
and 3-methyl-2-phenyl-1H-pyrrole 49 (15.6 mg, 0.10 mmol, 1 eq.) in 1 mL of DCM was 
added to the solution previously obtained. The solution was allowed to stir at room 
temperature for 1 h. The reaction mixture was then quenched with 1 M Na2CO3 aqueous 
saturated solution (10 mL). The aqueous layer was extracted twice with DCM (20 mL). The 
combined organic layers were washed with a NaHCO3 saturated solution (10 mL), brine (10 
mL), and dried over Na2SO4 and concentrated under reduced pressure. The crude pyrrole 
was purified by flash column chromatography (SiO2) using 1:4 EtOAc/hexanes as the eluent. 
Yield: 86% (15.9 mg). 1H NMR (400 MHz CDCl3) δ 9.44 (s, 1H), 9.22 (br s, 1H), 7.51−7.43 
(m, 4H), 7.38−7.34 (m, 1H), 6.84 (s, 1H), 2.27 (s, 3H) ppm. 13C NMR (100 MHz CDCl3) δ 
178.6, 136.9, 131.6, 131.4, 129.0, 128.3, 127.2, 123.7, 119.5, 12.5 ppm. GC-MS m/z (ES+) 
m/z: 185 [M]+. HRMS (ESI): calcd for C12H12NO (M + H
+) 186.0919, found 186.0912. 
 
5.2.4. Applications of MAO catalysed oxidation/aromatization reaction toward the 
synthesis of antitubercular pyrrole derivatives. 
5.2.4.1. Preparation of biocatalysts.The preparation of the biocatalysts was performed by 
Prof. Gary Black at Northumbria University. MAO-N (monoamine oxidase from Aspergillus 
niger) was transformed into E. coli according to previously reported procedures.234,235 MAO-
D5 was produced in E. coli BL21(DE3). MAO-D9 was produced in E. coli BL21(DE3). 6-
HDNO E350L/E352D was produced in E. coli BL21(DE3). In all cases an overnight 10 mL 
starter culture of each clone was grown in LB (Luria-Bertani) broth + Ap (Ampicillin) (100 
µg/mL) at 37°C, 200 rpm. The starter culture was then inoculated into 1 L of Auto Induction 
Media Super Broth Base including trace elements (Formedium Ltd, UK) + Ap (100 µg/mL), 
in a 2 L baffled flask, and grown at 30°C, 180 rpm for 2 days. Cells were then harvested by 
centrifugation at 4000 x g for 10 min at 4°C. The supernatant was discarded and the cell 
pellet was resuspended in 10 mL of 18.2 MΩ/cm H2O. The resuspended cells were then 
frozen and freeze-dried. Typically 4 g of lyophilized E. coli cells were obtained from a 600 
mL culture. 
 
5.2.4.2. Computational details. 
The computational analysis was carried out by by collaborators at King’s College 
London.The substrates were docked into MAO-D5 (PDB: 2VVM)236 with the PLANTS 1.2 
software237 using the ChemPLP scoring function. Chain A was chosen for the simulation. 
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The structures were prepared with the protein preparation tool which has been implemented 
in MOE 2014: Hydrogens were added, the missing loops (2VVM: E32-D37, 3ZDN: E32-
P39) were modelled, the C-termini were capped and the protonation states were corrected to 
pH 7.8 with the Protonate3D tool. Search spaces were set as spheres with a radius of 15Å. 
The centre of the search space was positioned, in MAO-D5, on the centre of mass of the 
proline molecule co-crystallised in the active site.  
 
5.2.4.3. Chemistry. 
Synthesis of N-allylaniline (53).238 
 
 
 
Aniline 21f (0.466 mL, 5.15 mmol, 1 eq.) was dissolved in a round bottom flask containing 
dry DMF (10 mL) under nitrogen atmosphere, and NaH (123.6 mg, 5.15 mmol, 1 eq.) was 
added at 0°C. The reaction mixture was allowed to stir for 30 minutes at room temperature. 
Then allylbromide (0.445 mL, 5.15 mmol, 1 eq.) was added to the stirring solution. The 
reaction was allowed to stir at room temperature for 12 h. The reaction mixture was then 
quenched with saturated NaHCO3 aqueous solution (20 mL) and extracted twice with 20 mL 
of Et2O. The combined organic layers were collected, washed with brine, dried over Na2SO4 
and concentrated under reduced pressure giving a yellow crude oil. The crude product was 
purified by chromatography on silica gel, using hexane/EtOAc (30:1) as eluent. The pure 
product 53 was obtained as a pale yellow oil. Yield: 80% (552.1 mg). 1H NMR (400 MHz, 
CDCl3): δ 7.19-7.13 (m, 2H), 6.72-6.67 (m, 1H), 6.64-6.60 (m, 2H), 6.01-5.89 (tdd, J = 18.0, 
10.0, 1.5 Hz, 1H), 5.27 (dd, J = 18.0, 1.5 Hz, 1H), 5.15 (dd, J = 10.0, 1.5 Hz, 1H), 3.78-3.75 
(m, 2H) ppm. LRMS (ESI+): m/z = 134 [M + H]+. 
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Synthesis of N-allyl-N-(1-phenylprop-2-yn-1-yl)aniline (54). 
 
1-phenylpropargyl-acetate 36 (48.7 mg, 0.28 mmol, 1 eq.) was dissolved in a round bottom 
flask containing MeOH (10 mL) and DIPEA (0.059 mL, 0.34 mmol 1.2 eq.). N-allylaniline 
53 (45.2 mg, 0.34 mmol 1.2 eq.) and CuI (5.3 mg, 0.028 mmol 0.1 eq.) were added at 0ºC 
and the resulting solution was left stirring for 12 h at room temperature. After completion of 
the reaction, the solvent was evaporated and the resulting crude product was purified by 
column chromatography (hexane/ethyl acetate 4:1) to give aniline 54 as a colourless oil. 
Yield: 85% (209.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.58 (d, J = 7.0 Hz, 2H), 7.38-7.21 
(m, 5H), 6.94 (d, J = 7.0 Hz, 2H), 6.83 (t, J = 7.0 Hz, 1H), 5.75-5.69 (m, 1H), 5.67 (d, J = 
2.0 Hz, 1H), 5.18 (d, J = 16.0 Hz, 1H), 5.06 (d, J = 16.0 Hz, 1H), 3.90 (dd, J = 16.0, 5.0 Hz, 
1H), 3.82 (dd, J = 16.0, 5.0 Hz, 1H), 2.53 (d, J = 2.0 Hz, 1H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 148.4, 137.9, 135.6, 128.7, 128.4, 128.4, 127.8, 127.6, 118.9, 116.4, 116.1, 80.8, 
74.6, 55.8, 51.3 ppm. LRMS (ESI+): m/z = 248 [M + H]+. 
 
Synthesis of (3-bromoprop-1-en-2-yl)benzene (56).  
 
 
Prop-1-en-2-ylbenzene 55 (3 mmol, 1 eq.) was dissolved in a round bottom flask containing 
DCM (10 mL). NBS (6 mmol, 2 eq.) was added to the solution which was then allowed to 
stir at 45ºC for 18 h. After completion of reaction, the resulting solution was quenched with 
aqueous NaHCO3 solution (30 mL) .The reaction mixture was extracted with Et2O (30 mL 
× 3) and dried over anhydrous MgSO4. After the solvent was evaporated, the crude product 
was purified by column chromatography (hexane 100%) to give (3-bromoprop-1-en-2-
yl)benzene 56 as a colourless oil. Yield: 90% (198 mg). 1H NMR (400 MHz, CDCl3): δ 
7.55–7.23 (m, 5H), 5.58 (d, J = 0.8 Hz, 1H), 5.51 (d, J = 0.8 Hz, 1H), 4.41 (d, J = 0.8 Hz, 
2H) ppm. 13C NMR (100 MHz, CDCl3): δ 144.4, 137.5, 128.6, 128.3, 126.2, 117.3, 
34.4.ppm. LRMS (ESI+): m/z = 197 [M + H]+,199 [M + H]+. 
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Synthesis of N-allyl-2-phenylprop-2-en-1-amine (59).  
 
 
Commercial N-allylamine (0.148 mL, 2.4 mmol, 3 eq.) was dissolved in a round bottom 
flask containing DMF (10 mL). NaH (55.2 mg, 2.4 mmol, 3 eq.) was added at 0 ºC under N2 
atmosphere. The mixture was allowed to stir for 20 minutes at 0ºC. Then compound 56 
(158.4 mg, 0.8 mmol, 1 eq.) was added. The reaction mixture was allowed to stir for 4h at 
room temperature. After completion of reaction, the resulting solution was quenched with 
aqueous NaHCO3 solution (30 mL) .The reaction mixture was extracted with Et2O (30 mL 
×3) and dried over anhydrous MgSO4. After the solvent was evaporated, the crude product 
was purified by column chromatography (hexane/Et2O 9:1) to give 59 as a colourless oil. 
Yield: 55% (76.5 mg). 1H NMR (400 MHz, CDCl3): δ 7.54-7.42 (m, 2H), 7.41-7.22 (m, 
3H), 6.09-5.83 (m, 1H), 5.44 (s, 1H), 5.28 (d, J = 1.3 Hz, 1H), 5.25-5.06 (m, 2H), 3.75-3.63 
(m, 2H), 3.30 (td, J = 1.4, 6.0 Hz, 2H) ppm.13C NMR (100 MHz, CDCl3): δ 145.5, 140.4, 
135.7, 128.0, 127.3, 126.3, 117.3, 115.0, 57.5, 56.4 ppm. LRMS (ESI+): m/z = 174 [M + 
H]+ 
 
Synthesis of 1-chloroethyl-allyl-(2-phenylallyl)-carbamate (60). 
 
Amine 59 (69.2 mg, 0.4 mmol, 1 eq.) was dissolved in a round bottom flask containing DCM 
(10 mL) and DIPEA (0.209 mL, 1.2 mmol, 3 eq.). 1-Chloroethyl chloroformate (0.064 mL, 
0.6 mmol, 1.5 eq.) was added to the stirring solution which was left stirring for 30 minutes. 
After completion of reaction, the solvent was evaporated and the crude product was directly 
used for the next synthetic step without further purification. Yield: 92% (103.1 mg). 1H 
NMR (400 MHz, CDCl3): δ 7.36 (d, J = 8.0 Hz, 2H), 7.32-7.19 (m, 3H), 6.56 (q,  J = 8.0, 
4.0 Hz, 1H), 5.75-5.59 (m, 1H), 5.39 (d, J = 14.0 Hz, 1H), 5.11-5.02 (m, 3H), 4.35-4.33 (m, 
2H), 3.83-3.70 (m, 2H), 1.74 (d, J = 4.0 Hz, 3H) ppm. LRMS (ESI+): m/z = 280 [M + H]+ 
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Synthesis of 1-chloroethyl-3-phenyl-2,5-dihydro-1H-pyrrole-1-carboxylate (61). 
Mixture of rotamers. 
 
 
Compound 60 (139.5 mg, 0.5 mmol, 1 eq.) was dissolved in a round bottom flask containing 
DCM (10 mL) and GII (21.2 mg, 0.025 mmol, 0.05 eq.). The solution was left stirring at 
room temperature for 3h. After completion of the reaction, the solvent was evaporated and 
the crude product was purified by column chromatography (hexane/ethyl acetate 9:1) to give 
61 as a pale yellow oil. Yield: 72% (90.4 mg). 1H NMR (400 MHz, CDCl3): δ 7.33-7.23 
(m, 5H), 6.62-6.56 (q, J = 8.0, 4.0 Hz, 1H), 6.08 (d, J = 12.0 Hz, 1H), 4.58-4.43 (d, J = 12.0 
Hz, 2H), 4.39-4.25 (m, 2H), 1.78 (d, J = , 4.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ 151.8, 137.4, 132.8, 128.7, 125.4, 119.1, 118.8, 83.0, 54.4, 53.9, 53.6, 53.2, 25.6 ppm. 
LRMS (ESI+): m/z = 252 [M + H]+ 
 
Synthesis of 3-phenyl-2,5-dihydro-1H-pyrrole (62).239  
 
 
 
Compound 61 (378 mg, 1.5 mmol, 1 eq.) was dissolved in a round bottom flask containing 
MeOH (10 mL). The solution was left stirring at 80 ºC for 3h. After completion of the 
reaction, the solvent was evaporated and the crude product was purified by column 
chromatography (ethyl acetate/ methanol 4:1) to give 62 as a white solid. Yield: 99% (216.8 
mg). 1H NMR (400 MHz, CDCl3): δ 10.39 (br s, 1H), 7.33-7.26 (m, 5H), 6.04 (s, 1H), 4.48-
4.42 (m, 2H) 4.33-4.27 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ 137.2, 131.1, 129.2, 
128.9, 125.9, 117.5, 52.9, 52.0 ppm.  LRMS (ESI+): m/z = 146 [M + H]+. 
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General procedure for the synthesis of diallylanilines 63a-h and 63n-q. 
 
The opportunely substituted aniline 21 (5.00 mmol, 1 eq.) was dissolved in a round bottom 
flask containing dry DMF (10 mL) and NaH (230 mg, 10.0 mmol, 2 eq.) at 0 °C under 
nitrogen atmosphere. The reaction mixture was stirred for 30 minutes at room temperature. 
Then, allylbromide (0.864 mL, 10.0 mmol, 2 eq.) was added to the stirring solution. The 
reaction was allowed to stir at room temperature for 12h. The reaction mixture was quenched 
with saturated NaHCO3 aqueous solution (20 mL) and extracted twice with 20 mL of Et2O. 
The combined organic layers were collected, washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow crude oil. The crude product was 
purified by chromatography on silica gel, using hexane/EtOAc (9:1) as eluent.   
Synthesis of N,N-diallylaniline (63a).238  
Yield: 73% (631.4 mg). 1H NMR (400 MHz CDCl3): δ 7.38 (t, J = 8.0 
Hz, 2H), 6.90-6.95 (m, 3H) 6.08-5.98 (m, 2H), 5.38-5.32 (m, 4H), 4.08 (d, 
J = 4.0 Hz, 4H) ppm. 13C NMR (100 MHz CDCl3): δ 147.6, 132.9, 128.0, 
115.2, 114.9, 111.2, 51.6 ppm. LRMS (ESI+): m/z = 174 [M + H]+. 
 
Synthesis of N,N-diallyl-4-fluoroaniline (63b).240  
 Yield: 93% (888.1 mg). 1H NMR (400 MHz, CDCl3): δ 6.88 (t, J = 8.0, 
8.0 Hz, 2H) 6.62-6.58 (m, 2H), 5.87-5.78 (m, 2H), 5.18-5.13 (m, 4H), 
3.87-3.86 (m, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 134.0, 116.2, 
115.5, 115.3, 113.6, 113.5, 53.4 ppm. LRMS (ESI+): m/z = 192 [M + H]+.  
 
Synthesis of N,N-diallyl-4-bromoaniline (63c).241  
Yield: 86%(1079 mg). 1H NMR (400 MHz, CDCl3): δ 7.20 (d, J = 9.0 
Hz, 2H), 6.51 (d, J = 7.5 Hz, 2H), 5.77 (m, 2H), 5.11 (m, 4H), 3.85 (m, 
4H) ppm. 13C NMR (100 MHz, CDCl3): δ 147.6, 133.5, 131.7, 116.2, 
114.0, 108.1, 52.9 ppm. LRMS (ESI+): m/z = 252 [M + H]+ 254 [M + H]+.  
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Synthesis of N,N-diallyl-4-isopropylaniline (63d).232  
 Yield: 94% (1010.5 mg). 1H NMR (400 MHz, CDCl3): δ 7.10 (d, J = 
8.5 Hz, 2H), 6.69 (d, J = 8.5 Hz, 2H), 5.94-5.85 (m, 2H), 5.24-5.16 (m, 
4H), 3.92 (d, J = 4.5 Hz, 4H), 2.89-2.79 (m, 1H), 1.24 (d, J = 7.0 Hz, 6H) 
ppm. 13C NMR (100 MHz, CDCl3): δ 147.0, 136.8, 134.5, 127.0, 116.0, 
112.5, 53.0, 33.1, 24.4 ppm. LRMS (ESI+): m/z = 216 [M + H]+.  
 
Synthesis of N,N-diallyl-4-methoxyaniline (63e).242  
Yield: 79% (801.8 mg). 1H NMR (400 MHz, CDCl3): δ 6.78 (d, J = 9.0 
Hz, 2H), 6.66 (d, J = 9.2, 2H), 5.82 (ddt, J = 17.0, 10.0, 5.0 Hz, 2H), 5.16 
(ddd, J = 17.0, 1.5, 1.0 Hz, 2H), 5.12 (ddd, J = 10.0, 1.6, 1.0 Hz, 2H), 
3.82 (dt, J = 5.0, 1.5 Hz, 4H) 3.68 (s, 3H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 151.7, 143.4, 134.6, 115.9, 114.8, 114.7, 55.5, 53.6 ppm. LRMS (ESI+): m/z = 
204 [M + H]+.  
 
Synthesis of N,N-diallyl-2,5-dimethylaniline (63f).243  
 Yield: 79% (793.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.01 (dd, J = 
7.0, 3.5 Hz, 1H), 6.88-6.65 (m, 2H), 5.88-5.67 (m, 2H), 5.12-5.00 (m, 4H), 
3.71-3.42 (m, 4H), 2.21 (s, 3H), 2.20 (s, 3H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 135.5, 130.8, 123.8, 122.6, 116.9, 55.6, 21.2, 18.0 ppm. LRMS (ESI+): m/z = 202 
[M + H]+.  
 
Synthesis of N,N-diallyl-4-nitroaniline (63g).244  
 Yield: 92% (1002.5 mg). 1H NMR (400 MHz, CDCl3): δ 8.11-8.08 (m, 
2H), 6.64-6.61 (m, 2H), 5.89-5.80 (m, 2H), 5.25-5.14 (m, 4H), 4.02 (d, J 
= 2.0 Hz, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 153.3, 137.3, 131.8, 
126.2, 117.0, 111.4, 45.8 ppm. LRMS (ESI+): m/z = 219 [M + H]+. 
 
Synthesis of 4-(diallylamino)benzonitrile (63h).245  
Yield: 92% (910.8 mg). 1H NMR (400 MHz, CDCl3): δ 7.37-7.23 (m, 
2H), 6.60-6.46 (m, 2H), 5.78-5.58 (m, 2H), 5.16-4.90 (m, 4H), 3.92-3.76 
(m, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 149.3, 133.7, 133.6, 133.5, 
126.0, 121.0, 111.2, 97.6, 54.3 ppm. LRMS (ESI+): m/z = 199 [M + H]+.  
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Synthesis of N,N-diallyl-4-chloroaniline (63n).242  
Yield: 74%. 1H NMR (400 MHz, CDCl3): δ 7.11 (dd, J = 9.0, 0.5 Hz, 
2H), 6.59 (d, J = 8.5 Hz, 2H), 5.89–5.74 (m, 2H), 5.19–5.15 (m, 2H), 
5.15–5.09 (m, 2H), 3.91–3.85 (m, 4H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 147.3, 133.6, 128.8, 121.2, 116.2, 113.6, 53.0 ppm. LRMS 
(ESI+): m/z = 208 [M + H]+. 
 
Synthesis of N,N-diallyl-4-methylaniline (63o). 
Yield: 88%. 1H NMR (400 MHz, CDCl3): δ 7.13 (d, J = 12.0 Hz, 2H), 
6.75 (d, J= 12.0 Hz, 2H), 6.00-5.92 (m, 2H), 5.32-5.25 (m, 4H), 4.01 (s, 
2H), 4.00 (s, 2H), 2.37 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 
146.8, 134.5, 129.8, 125.8, 116.1, 112.8, 53.1, 20.4 ppm. LRMS (ESI+): 
m/z = 188 [M + H]+.  
 
Synthesis of N,N-diallyl-2-methoxyaniline (63p). 
 Yield: 88%. 1H NMR (400 MHz, CDCl3): δ 6.98-6.85 (m, 4H), 587-5.77 
(m, 2H), 5.18-5.10 (m, 4H), 3.86 (s, 3H), 3.76 (s, 2H), 3.74 (s, 2H) ppm. 
13C NMR (100 MHz, CDCl3): δ 152.9, 139.5, 135.3, 122.6, 121.2, 120.5, 
117.9, 111.5, 55.5, 54.6 ppm. LRMS (ESI+): m/z = 204 [M + H]+. 
 
Synthesis of N,N-diallylbenzo[d][1,3]dioxol-5-amine (63q). 
Yield: 92%. 1H NMR (400 M0Hz, CDCl3): δ 6.60 (d, J = 8.5 Hz, 1H), 
6.29 (d, J = 2.5 Hz, 1H), 6.06 (dd, J = 8.5, 2.0 Hz, 1H), 5.84 5.67 (m, 2H), 
5.78 (s, 2H), 5.17-5.01 (m, 4H), 3.77 (dt, J = 4.0, 1.5 Hz, 4H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 148.3, 145.1, 138.9, 134.2, 116.2, 108.4, 
104.9, 100.6, 96.2, 53.8 ppm. LRMS (ESI+): m/z = 218 [M + H]+. 
 
Synthesis of N-allyl-N-(2-methylallyl)aniline (63i).232 
 
N-Allylaniline 53 (665 mg, 5.0 mmol, 1 eq.) was dissolved in a round bottom flask 
containing dry DMF (10 mL) under nitrogen atmosphere and NaH (115 mg, 5.0 mmol, 1 
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eq.) was then added at 0°C. The reaction mixture was allowed to stir for 30 minutes at room 
temperature. Then 3-chloro-2-methylprop-1-ene (0.418 mL, 5.0 mmol, 1 eq.) was added to 
the stirring solution. The reaction was allowed to stir at room temperature for 12 h. The 
reaction mixture was quenched with saturated NaHCO3 aqueous solution (20 mL) and 
extracted twice with 20 mL of Et2O. The combined organic layers were collected, washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure giving a yellow 
crude oil. The crude product was purified by chromatography on silica gel, using 
hexane/EtOAc (9:1) as eluent. Compound 63i was obtained as a pale yellow oil. Yield: 94% 
(878.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.11 (t, J = 8.0 Hz, 2H), 6.59 (d, J = 8.5 Hz, 
3H), 5.84-5.74 (m, 1H), 5.11-5.06 (m, 2H), 4.78-4.74 (d, J = 10.5 Hz, 2H), 3.86 (d, J= 4.0 
Hz, 2H), 3.71 (s, 2H), 1.66 (s, 3H) ppm. LRMS (ESI+): m/z = 188 [M + H]+. 
 
Synthesis of N-allyl-N-(1-phenylallyl)aniline (63j). 
 
 
The aniline 54 (0.135 mL, 1.5 mmol, 1 eq.) was dissolved in a two neck round bottom flask 
containing EtOH (20 mL). Lindlar’s catalyst (31.5 mg, 0.15 mmol 0.1 eq.) and quinoline 
(0.177 mL, 1.5 mmol 1 eq.) were added to the reaction mixture. The reaction mixture was 
allowed to stir under H2 atmosphere for 30 minutes. After completion of reaction, the 
mixture was filtered through celite pad and washed three times with EtOAc (30 mL). The 
EtOH was removed under reduced pressure. The reaction mixture was then washed twice 
with aqueous NaHCO3 solution (30 mL) and dried over anhydrous MgSO4. After the solvent 
was evaporated, the crude product was purified by column chromatography (hexane/ethyl 
acetate 4:1) to give aniline 63j as a colourless oil. Yield: 87% (162.7 mg). 1H NMR (400 
MHz, CDCl3): δ 7.26-7.16 (m, 5H), 7.09 (t, J = 8.0 Hz, 2H), 6.71 (d, J = 8.0 Hz, 2H), 6.63 
(t, J = 8.0 Hz, 1H), 6.13-6.04 (m, 1H), 5.72-5.63 (m, 1H), 5.40 (d, J= 8.0 Hz, 1H), 5.23 (t, 
J= 12.0 Hz, 1H), 5.10 (d, J = 8.0 Hz, 1H), 5.05 (d, J = 8.0 Hz, 1H), 4.99 (d, J = 8.0 Hz, 
1H), 3.86-3.84 (m, 2H). 13C NMR (100 MHz, CDCl3): δ 149.0, 140.3, 136.5, 136.4, 136.0, 
129.0, 128.5, 128.1, 127.3, 118.2, 117.2, 116.0, 114.2, 65.3, 50.6. LRMS (ESI+): m/z = 250 
[M + H]+. 
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Synthesis of N-allyl-N-(2-phenylallyl)aniline (63k).  
 
 
 
Allylaniline 53 (0.135 mL, 1 mmol 1 eq.) was dissolved in a round bottom flask containing 
DMF (10 mL). NaH (23 mg, 1 mmol 1 eq.) was added at 0 ºC under N2 atmosphere. The 
mixture was allowed to stir for 20 minutes and then compound 56 (292.2 mg, 1.5 mmol 1.5 
eq.), dissolved in 1 mL of DCM, was added. The reaction mixture was allowed to stir for 12 
h at room temperature. After completion of the reaction, the resulting solution was quenched 
with aqueous NaHCO3 solution (30 mL) .The reaction mixture was extracted with Et2O (30 
mL × 3) and dried over anhydrous MgSO4. After the solvent was evaporated, the crude 
product was purified by column chromatography (hexane/Et2O 9:1) to give N-allyl-N-(2-
phenylallyl)aniline 63k as a colourless oil. Yield: 87% (216.6 mg). 1H NMR (400 MHz, 
CDCl3): δ 7.40-7.33 (m, 2H), 7.32-7.17 (m, 3H), 7.17-7.02 (m, 2H), 6.68-6.52 (m, 3H), 5.86-
5.73 (m, 1H), 5.40-5.30 (m, 1H), 5.15-5.07 (m, 2H), 5.07-5.04 (m, 1H), 4.20 (m, 2H), 3.97-
3.87 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ 148.7, 142.3, 139.7, 133.7, 129.1, 128.5, 
127.8, 126.1, 116.4, 116.2, 112.2, 112.1, 54.0, 52.8 ppm. LRMS (ESI+): m/z = 250 [M + 
H]+. 
 
Synthesis of N-allyl-N-(1-phenylethyl)prop-2-en-1-amine (63l). 246 
 
N-N-Diallylamine 57 (247 mg, 2.0 mmol, 1 eq.) was dissolved in a round bottom flask 
containing dry THF (10 mL) under nitrogen atmosphere. AcOH (0.117 mL, 2.0 mmol, 1 eq.) 
and acetophenone (0.467 mL, 4.0 mmol, 2 eq.) were then added at room temperature. The 
reaction mixture was allowed to stir for 20 minutes after which time NaBH(AcO)3 (1695 
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mg, 8.0 mmol, 4 eq.) was added. The reaction mixture was stirred at room temperature for 
24 h, then quenched with 1M NaOH aqueous solution (20 mL) and extracted twice with 20 
mL of Et2O. The combined organic layers were collected, washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure giving a yellow crude oil. The crude 
compound was purified by chromatography on silica gel, using hexane/EtOAc 1:1 as eluent 
to give N-allyl-N-(1-phenylethyl)prop-2-en-1-amine 63l as a colourless oil. Yield: 93% 
(373.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.41-7.32 (m, 4H), 7.26-7.21 (m, 1H), 5.89 (m, 
2H), 5.29-5.08 (m, 4H), 3.94 (q, J = 6.5 Hz, 1H), 3.18 (dd, J = 14.0, 6.0 Hz, 2H), 3.07 (dd, 
J = 14.0, 6.0 Hz, 2H), 1.44-1.33 (d, 6.5 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 144.1, 
136.7, 128.2, 127.8, 126.8, 116.9, 58.4, 52.6, 17.2 ppm. LRMS (ESI+): m/z = 202 [M + H]+. 
 
Synthesis of methyl-2-(diallylamino)-4-methylpentanoate (63m). 
 
 
 
Leucine (655.8 mg, 5.00 mmol, 1 eq.) was dissolved in a round bottom flask containing dry 
DMF (10 mL) and NaH (230 mg, 10.0 mmol, 2 eq.) at 0 °C under nitrogen atmosphere. The 
reaction mixture was stirred for 30 minutes at room temperature. Then, allylbromide (0.766 
mL, 10.0 mmol, 2 eq.) was added to the stirredsolution. The reaction was allowed to stir at 
room temperature for 12 h. The reaction mixture was quenched with saturated NaHCO3 
aqueous solution (20 mL) and extracted twice with 20 mL of Et2O. The combined organic 
layers were collected, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure giving a yellow crude oil. The crude was purified by chromatography on silica gel, 
using hexane/EtOAc (9:1) as eluent to give methyl-2-(diallylamino)-4-methylpentanoate 
63m as a colourless oil. Yield: 95% (1068.9 mg). 1H NMR (400 MHz, CDCl3): δ 5.70 (m, 
2H), 5.24-4.97 (m, 4H), 3.61 (s, 3H), 3.44 (t, J = 7.0 Hz, 1H), 3.28 (d, J = 7.0 Hz, 2H), 2.96 
(d, J = 7.0 Hz, 2H), 1.70-1.55 (m, 1H), 1.51-1.36 (m, 2H), 0.82 (d, J = 7.0 Hz, 6H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 174.2, 136.7, 116.9, 59.9, 53.4, 51.0, 38.6, 24.6, 23.0, 22.0 ppm. 
LRMS (ESI+): m/z = 226 [M + H]+ 
Synthesis of N-Allyl-N-benzylprop-2-en-1-amine (63r).247  
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N-N-Diallylamine 57 (0.246 mL, 2.0 mmol, 1 eq.) was dissolved in a round bottom flask 
containing dry THF (10 mL) under nitrogen atmosphere. AcOH (0.114 mL, 2.0 mmol, 1 eq.) 
and benzaldehyde (0.408 mL, 4.0 mmol, 2 eq.) were then added at room temperature. The 
reaction mixture was allowed to stir for 20 minutes after which time NaBH(AcO)3 (1695 
mg, 8.0 mmol, 4 eq.) was added. The reaction mixture was stirred at room temperature for 
24 h, then quenched with 1M NaOH aqueous solution (20 mL) and extracted twice with 20 
mL of Et2O. The combined organic layers were collected, washed with brine, dried over 
Na2SO4 and concentrated under reduced pressure giving a yellow crude oil. The crude 
compound was purified by chromatography on silica gel, using hexane/EtOAc 1:1 as eluent 
to give 63r as a colourless oil. Yield: 97% (364.7 mg). 1H NMR (400 MHz, CDCl3): δ 7.35-
7.32 (m, 3H), 7.30-7.21 (m, 2H), 5.88 (ddt, J = 17.0, 10.3, 6.0 Hz, 2H), 5.19 (ddt, J = 17.0, 
2.0, 1.5 Hz, 2H), 5.14 (ddt, J = 10.0, 2.0, 1.0 Hz, 2H), 3.57 (s, 2H), 3.08 (ddd, J = 6.5, 1.5, 
1.0 Hz, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 139.6, 136.0, 129.0, 128.3, 126.9, 117.4, 
57.7, 56.6 ppm. LRMS (ESI+): m/z = 188 [M + H]+. 
 
General procedure for the synthesis of N-aryl-3-pyrroline (64a-k). 
 
Cmpd R R1 R2 Pyrroline 
63a H H H 64a 
63b 4-F H H 64b 
63c 4-Br H H 64c 
63d 4-iPr H H 64d 
63e 4-OMe H H 64e 
63f 2-5-Me H H 64f 
63g 4-NO2 H H 64g 
63h 4-CN H H 64h 
63i H Me H 64i 
63j H H Ph 64j 
63k H Ph H 64k 
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The appropriate diallylaniline 63a-k (1.5 mmol, 1 eq.) was dissolved in a round bottom flask 
containing degassed DCM (10 mL) and GII (63.67 mg, 0.075 mmol 0.05 eq.). The solution 
was left stirring at room temperature. After completion of reaction (monitored by TLC), the 
resulting solution was quenched with a saturated aqueous NaHCO3 solution (30 mL). The 
reaction mixture was extracted with Et2O (30 mL × 3) and dried over anhydrous MgSO4. 
After the solvent was evaporated, the crude product was purified by column chromatography 
(hexane/ethyl acetate 9:1) to give 64 as a yellow-white solid. 
 
Synthesis of 1-phenyl-2,5-dihydro-1H-pyrrole (64a).248 
Yield: 79% (171.2 mg). 1H NMR (400 MHz, CDCl3): δ 7.24 (m, 2H), 6.67 (m, 
1H), 6.54 (m, 2H), 5.95 (s, 2H), 4.11 (s, 4H) ppm. 13C NMR (100 MHz, CDCl3): 
δ 147.1, 129.4, 126.5, 115.6, 111.2, 54.5 ppm. LRMS (ESI+): m/z = 146 [M + 
H]+. 
 
 
Synthesis of 1-(4-fluorophenyl)-2,5-dihydro-1H-pyrrole (64b).249 
Yield: 75% (183.4 mg). 1H NMR (400 MHz, CDCl3): δ 6.95 (t, J = 8.0 Hz, 2H), 
6.42 (d, J = 8.0 Hz, 2H), 5.93 (s, 2H), 4.06 (s, 4H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 142.8, 126.1, 115.9, 115.8, 111.5, 54.2 ppm. LRMS (ESI+): m/z = 164 
[M + H]+. 
 
 
Synthesis of 1-(4-bromophenyl)-2,5-dihydro-1H-pyrrole (64c).250 
Yield: 75% (253.2 mg). 1H NMR (400 MHz, CDCl3): δ 7.23 (d, J = 8.0 Hz, 
2H), 6.32 (d, J = 8.5 Hz, 2H), 5.87 (s, 2H), 3.99 (s, 4H) ppm. 13C NMR (100 
MHz, CDCl3): δ 145.9, 131.9, 126.3, 112.7, 107.4, 54.5 ppm. LRMS (ESI+): 
m/z = 224 [M + H]+ 226 [M + H]+. 
 
Synthesis of 1-(4-isopropylphenyl)-2,5-dihydro-1H-pyrrole (64d). 
Yield: 79% (221.5 mg). 1H NMR (400 MHz, CDCl3): δ 7.07-7.01 (m, J = 8.5 
Hz, 2H), 6.45-6.33 (m, J = 8.5 Hz, 2H), 5.86 (s, 2H), 4.02 (s, 4H), 2.78-2.70 (m, 
1H), 1.15-1.12 (d, J = 3.0 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ 145.4, 
135.9, 127.2, 126.5, 111.1, 54.6, 24.3, 14.1 ppm. LRMS (ESI+): m/z = 188 [M 
+ H]+. 
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Synthesis of 1-(4-methoxyphenyl)-2,5-dihydro-1H-pyrrole (64e).242 
Yield: 79% (207.4 mg). 1H NMR (400 MHz, CDCl3): δ 6.80 (d, J = 8.5 Hz, 
2H), 6.42 (d, J = 8.5 Hz, 2H), 5.87 (s, 2H), 4.00 (s, 4H), 3.69 (s, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 152.2, 141.1, 127.8, 126.9, 114.6, 59.2, 55.6 ppm. 
LRMS (ESI+): m/z = 176 [M + H]+. 
 
 
Synthesis of 1-(2,5-dimethylphenyl)-2,5-dihydro-1H-pyrrole (64f). 
Yield: 79% (205.1 mg). 1H NMR (400 MHz, CDCl3): δ 6.92 (d, J = 7.5 Hz, 
1H), 6.61 (s, 1H), 6.55 (d, J = 7.5 Hz, 1H), 5.83 (s, 2H), 4.11 (s, 4H), 2.28 (s, 
3H), 2.22 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 148.2, 136.2, 132.2, 
126.7, 124.3, 120.4, 116.7, 57.3, 21.3, 21.2 ppm. LRMS (ESI+): m/z = 174 [M 
+ H]+. 
 
Synthesis of 1-(4-nitrophenyl)-2,5-dihydro-1H-pyrrole (64g). 
Yield: 80% (228.0 mg). 1H NMR (400 MHz, CDCl3): δ 8.14 (d, J = 12.0 Hz, 
2H), 6.45 (d, J = 12.0 Hz, 2H), 5.89 (s, 2H), 4.21 (s, 4H) ppm. 13C NMR (100 
MHz, CDCl3): δ = 150.6, 137.3, 126.5, 125.9, 110.2, 54.7 ppm. LRMS (ESI+): 
m/z = 191 [M + H]+. 
 
 
Synthesis of 4-(2,5-dihydro-1H-pyrrol-1-yl)benzonitrile (64h). 
 Yield: 79% (201.4 mg). 1H NMR (400 MHz, CDCl3): δ 7.50-7.36 (d, J = 8.5 
Hz, 2H), 6.51-6.37 (m, J = 8.5 Hz, 2H), 5.90 (s, 2H), 4.08 (s, 4H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 149.4, 133.7, 126.0, 120.9, 111.2, 97.2, 54.3 ppm. LRMS 
(ESI+): m/z = 171 [M + H]+. 
 
 
Synthesis of 3-Methyl-1-phenyl-2,5-dihydro-1H-pyrrole (64i).249  
Yield: 79% (188.4 mg). 1H NMR (400 MHz, CDCl3): δ 7.20-7.07 (m, 2H), 6.60 
(t, J = 7.0 Hz, 1H), 6.44 (d, J = 7.0 Hz, 2H), 5.47 (s, 1H), 3.99 (m, 2H), 3.91 (m, 
2H), 1.77 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 147.2, 135.9, 129.5, 129.3, 
120.0, 111.0, 57.8, 54.8, 14.5 ppm. LRMS (ESI+): m/z = 160 [M + H]+. 
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Synthesis of 1,2-diphenyl-2,5-dihydro-1H-pyrrole (64j). 
Yield: 65% (215.5 mg). 1H NMR (400 MHz, CDCl3): δ 7.37–7.09 (m, 7H), 
6.57 (t, J = 8.0 Hz, 1H), 6.44 (d, J = 4.0 Hz, 2H), 5.89 (m, 1H), 5.80 (m, 1H), 
5.35 (m, 1H), 4.44 (m, 1H), 4.22 (m, 1H) ppm. 13C NMR (100 MHz, CDCl3): 
δ 146.4, 142.6, 132.5, 129.1, 128.8, 127.2, 126.2, 124.3, 116.1, 112.2, 69.8, 
55.2 ppm. LRMS (ESI+): m/z = 222 [M + H]+. 
 
Synthesis of 1,3-diphenyl-2,5-dihydro-1H-pyrrole (64k).251 
Yield: 70% (103.1 mg). 1H NMR (400 MHz, CDCl3): δ 7.59 (d, J = 7.0 Hz, 
2H), 7.50−7.19 (m, 5H), 6.74 (t, J= 7.0 Hz, 1H), 6.68−6.63 (m, 2H), 6.25 (m, 
1H), 4.52−4.40 (m, 2H), 4.32−4.30 (m, 2H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 146.9, 138.1, 135.3, 133.6, 129.6, 129.4, 128.6, 128.1, 125.8, 125.5, 
125.2, 120.4, 115.8, 108.7, 55.7, 54.8 ppm. LRMS (ESI+): m/z = 222 [M + H]+. 
 
General procedure for the synthesis of N-alkyl-3-pyrroline 65a-f.  
 
Cmpd R R1 Pyrroline 
51a H Ph 65a 
51a H iso-Butyl 65b 
51a H Cyclohexyl 65c 
51a H 4-Cl-Ph 65d 
51b Me Cyclohexyl 65e 
51b Me 4-Cl-Ph 65f 
 
The appropriate 3-pyrroline 51a-b (2.0 mmol, 1 eq.) was dissolved under nitrogen 
atmosphere in a round bottom flask containing dry THF (10 mL). Then, AcOH (114.4 mL, 
2.0 mmol, 1 eq.) and the appropriate aldehyde (4.0 mmol, 2 eq.) were added at r.t. and the 
reaction mixture was allowed to stir for 20 minutes. NaBH(AcO)3 (887.8 mg, 8.0 mmol, 4 
eq.) was then added and the reaction mixture was allowed to stir at room temperature for 24 
h. The mixture was quenched with 1M NaOH aqueous solution (20 mL) and extracted twice 
with 20 mL of Et2O. The combined organic layers were collected, washed with brine, dried 
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over Na2SO4 and concentrated under reduced pressure giving a yellow crude oil. The 
obtained product was purified by chromatography on silica gel, using hexane/EtOAc (1:1) 
as eluent to give 51 as yellow-brown oils. 
 
Synthesis of 1-benzyl-2,5-dihydro-1H-pyrrole (65a).252 
Yield: 81% (128.8 mg). 1H NMR (400 MHz, CDCl3): δ 7.34-7.09 (m, 5H), 
5.69 (s, 2H), 3.72 (s, 2H), 3.40 (s, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 
139.6, 128.7, 128.4, 127.8, 127.0, 60.4, 59.7 ppm. LRMS (ESI+): m/z = 160 
[M + H]+. 
 
Synthesis of 1-isopentyl-2,5-dihydro-1H-pyrrole (65b). 
Yield: 84% (116.8 mg). 1H NMR (400 MHz, CDCl3): δ 5.70 (s, 2H), 3.39 (s, 
4H), 2.65-2.46 (m, 2H), 1.56 (dt, J = 13.0, 6.5 Hz, 1H), 1.39-1.27 (m, 2H), 0.90-
0.75 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ = 127.6, 59.7, 54.5, 38.3, 
31.6, 26.3, 22.8 ppm. LRMS (ESI+): m/z = 140 [M + H]+. 
 
Synthesis of 1-(cyclohexylmethyl)-2,5-dihydro-1H-pyrrole (65c). 
Yield: 75% (124.5 mg). 1H NMR (400 MHz, CDCl3): δ 5.70 (s, 2H), 3.37 (s, 
4H), 2.37 (d, J = 7.0 Hz, 2H), 1.74 (d, J = 12.5 Hz, 2H), 1.70-1.53 (m, 3H), 
1.35 (ddd, J = 10.0, 7.0, 4.0 Hz, 1H), 1.27-0.99 (m, 3H), 0.93-0.72 (m, 2H) 
ppm. 13C NMR (100 MHz, CDCl3): δ 127.7, 63.7, 60.2, 37.5, 31.7, 26.8, 26.2 
ppm. LRMS (ESI+): m/z = 166 [M + H]+. 
 
Synthesis of 1-(4-chlorobenzyl)-2,5-dihydro-1H-pyrrole (65d). 
Yield: 76% (146.7 mg). 1H NMR (400 MHz, CDCl3): δ 7.22 (s, 4H), 5.72 
(s, 2H), 3.71 (s, 2H), 3.40 (s, 4H) ppm. 13C NMR (100 MHz, CDCl3): δ 
138.1, 132.6, 130.0, 128.5, 127.7, 59.6, 59.6 ppm. LRMS (ESI+): m/z = 
194 [M + H]+. 
 
Synthesis of 1-(cyclohexylmethyl)-2,5-dimethyl-2,5-dihydro-1H-pyrrole (65e). Mixture 
of cis-trans. 
Yield: 52% (98.4 mg). 1H NMR (400 MHz, CDCl3): δ 1H NMR (400 MHz, 
CDCl3): δ 5.63 (s, 2H), 3.72-3.61 (m, 2H), 2.49 (dd, J = 13.0, 4.0 Hz, 1H), 
2.26-2.08 (m, 1H), 1.92 (d, J = 13.0 Hz, 1H), 1.67-1.56 (m, 4H), 0.97-0.88 
(m, 6H), 0.85-0.76 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ 132.9, 
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104.9, 61.8, 53.2, 36.8, 32.1, 32.0, 27.0, 26.4, 26.1, 26.0, 17.3 ppm. LRMS (ESI+): m/z = 
194 [M + H]+. 
 
Synthesis of 1-(4-chlorobenzyl)-2,5-dimethyl-2,5-dihydro-1H-pyrrole (65f). Mixture of 
cis-trans. 
Yield: 46% (101.7 mg). 1H NMR (400 MHz, CDCl3): δ 7.44-7.17 (m, 
4H), 5.74 (s, 1H), 5.57 (s, 1H), 3.99-3.72 (m, 4H), 3.69 (d, J = 4.0 Hz, 
1H), 1.11-0.96 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ 139.4, 
132.8, 132.3, 132.1, 131.9, 130.3, 129.5, 128.3, 128.1, 67.2, 61.7, 57.2, 
50.1, 22.4, 17.5 ppm. LRMS (ESI+): m/z = 222 [M + H]+. 
 
Synthesis of 1-cyclohexyl-2,5-dihydro-1H-pyrrole (65g). 
 
 
 
 
The appropriate 3-pyrroline 51a (0.152 mL, 2.0 mmol, 1 eq.) was dissolved in a round 
bottom flask containing dry THF (10 mL). Then, AcOH (0.126 mL, 2.0 mmol, 1 eq.) and 
cyclohexanone (0.414 mL, 4.0 mmol, 2 eq.) were added at r.t. and the reaction mixture was 
allowed to stir for 20 minutes. NaBH(AcO)3 (1775 mg, 8.0 mmol, 4 eq.) was then added and 
the reaction mixture was allowed to stir at room temperature for 24 h. The mixture was 
quenched with 1M NaOH aqueous solution (20 mL) and extracted twice with 20 mL of Et2O. 
The combined organic layers were collected, washed with brine, dried over Na2SO4 and 
concentrated under reduced pressure giving a yellow crude oil. The obtained product was 
purified by chromatography on silica gel, using hexane/EtOAc (1:1) as eluent to give 65g as 
a colourless oil. Yield: 82% (247.6 mg). 1H NMR (400 MHz, CDCl3): δ 5.72 (s, 2H), 3.58 
(s, 4H), 2.29-2.09 (m, 1H), 1.91-1.73 (m, 2H), 1.73-1.59 (m, 2H), 1.59-1.46 (m, 1H), 1.28-
0.99 (m, 5H) ppm. 13C NMR (100 MHz, CDCl3): δ 127.5, 62.4, 57.0, 32.0, 26.0, 24.8 ppm. 
LRMS (ESI+): m/z = 152 [M + H]+. 
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General procedure for the synthesis of N-alkyl-3-pyrroline 65h and 65i. 
 
The appropriate diallylamine 63l,m (1.5 mmol, 1 eq.) was dissolved in a round bottom flask 
containing toluene (10 mL) and Grubbs catalyst II generation GII (63.67 mg, 0.075 mmol, 
0.05 eq.). The solution was left stirring at room temperature. After completion of reaction 
(6h, monitored by TLC), the resulting solution was quenched with aqueous NaHCO3 
solution (30 mL). The reaction mixture was extracted with Et2O (30 mL ×3) and dried over 
anhydrous MgSO4. After the solvent was evaporated, the crude product 65h-i was purified 
by column chromatography (hexane/ethyl acetate 9:1) to give 65 as white solids. 
 
Synthesis of 1-(1-phenylethyl)-2,5-dihydro-1H-pyrrole (65h).253 
Yield: 75% (194.6 mg). 1H NMR (400 MHz, CDCl3): δ 7.31–7.14 (m, 5H), 
5.71 (s, 2H), 3.50–3.24 (m, 5H), 1.32 (d, J = 6.5 Hz, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 145.6, 128.4, 127.8, 127.3, 126.9, 65.2, 58.6, 23.6 ppm. 
LRMS (ESI+): m/z = 174 [M + H]+. 
 
Synthesis of methyl-2-(2,5-dihydro-1H-pyrrol-1-yl)-4-methylpentanoate (65i). 
Yield: 76% (224.6 mg). 1H NMR (400 MHz, CDCl3): δ 5.75-5.63 (m, 
2H), 3.71-3.64 (m, 2H), 3.63 (s, 3H), 3.55-3.47 (m, 2H), 3.43 (t, J = 7.0 
Hz, 1H), 1.66-1.43 (m, 3H), 0.85 (d, J = 6.0 Hz, 3H), 0.88 (d, J = 6.0 Hz, 
3H) ppm. 13C NMR (100 MHz, CDCl3): δ 174.3, 127.2, 62.3, 56.0, 51.2, 
40.4, 29.7, 25.1, 22.6, 22.6 ppm. LRMS (ESI+): m/z = 198 [M + H]+ 
 
Synthesis of 1-methyl-3-phenyl-2,5-dihydro-1H-pyrrole (65j).158 
 
Pyrroline 62 (72.5 mg, 0.5 mmol, 1 eq.) was dissolved in a round bottom flask containing 
THF (10 mL). Formaldehyde aqueous solution 37% w/v (1 mmol, 2 eq.) was added to the 
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solution followed by AcOH (0.028 mL, 0.5 mmol, 1 eq.). The reaction mixture was allowed 
to stir at room temperature for 20 minutes. Then, NaBH(AcO)3 (443.8 mg, 2 mmol, 4 eq.) 
was added and the solution was left stirring at room temperature for 18 h. After completion 
of the reaction, the solution was quenched with aqueous NaOH 1M solution (30 mL) .The 
reaction mixture was extracted with EtOAc (30 mL × 3) and dried over anhydrous MgSO4. 
After the solvent was evaporated, the crude product was purified by column chromatography 
(ethyl acetate/MeOH 4:1) to give 65j as a white solid. Yield: 99% (78.7 mg). 1H NMR (400 
MHz, CDCl3): δ 7.49–7.35 (m, 5H), 6.28 (s, 1H), 4.56 (s, 2H), 4.34 (s, 2H), 3.09 (s, 3H) 
ppm. 13C NMR (100 MHz, CDCl3): δ  137.6, 132.1, 126.2, 125.3, 123.2, 119.8, 60.3, 59.8, 
40.5 ppm. LRMS (ESI+): m/z = 160 [M + H]+.  
 
 
Synthesis of 1-isopropyl-3-phenyl-2,5-dihydro-1H-pyrrole (65k). 
 
 
 
Pyrroline 62 (72.6 mg, 0.5 mmol, 1 eq.) was dissolved in a round bottom flask containing 
acetone (10 mL) and AcOH (0.028 mL, 0.5 mmol, 1 eq.). The reaction mixture was allowed 
to stir at room temperature for 20 minutes. Then, NaBH(AcO)3 (443.8 mg, 2 mmol, 4 eq.) 
was added and the solution was left stirring at room temperature for 18 h. After completion 
of the reaction, the solution was quenched with aqueous NaOH 1M solution (30 mL) .The 
reaction mixture was extracted with EtOAc (30 mL × 3) and dried over anhydrous MgSO4. 
After the solvent was evaporated, the crude product was purified by column chromatography 
(ethyl acetate/MeOH = 4/1) to 65k as a white solid. Yield: 99% (185.1 mg). 1H NMR (400 
MHz, CDCl3): δ 7.31-7.24 (m, 4H), 7.20-7.17 (m, 1H), 6.07 (s, 1H), 3.88 (s, 2H), 3.69 (s, 
2H), 2.81-2.75 (m, 1H), 1.13 (d, J = 8.0 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ 
139.3, 134.0, 128.5, 127.7, 125.5, 121.3, 58.1, 57.6, 54.6, 21.1 ppm. LRMS (ESI+): m/z = 
188 [M + H]+. 
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General procedure for the MAO-N catalysed biotransformation of 3-pyrrolines into 
pyrroles 66 and 67. 
 
 
 
In a Falcon tube (15 mL), freeze dried whole cells of E.coli expressing recombinant 
monoamine oxidase MAO-N (variants D5, D9) (140 mg) were suspended in 800 µL of 
potassium phosphate buffer (1M pH = 7.8). Then, the appropriate pyrroline 64 or 65 (0.1 
mmol) dissolved in DMF (12.9 μL) was added leading to a solution with a final concentration 
of 0.02 g/mL. The reaction mixture was incubated at 37 ºC and shaken at 280 rpm for 24 h. 
The reaction mixture was added  EtOAc (5 mL) and then centrifuged at 4000 rpm for 10 
minutes. The organic layer was then separated and dried over anhydrous MgSO4. After the 
solvent was evaporated, the crude product was analysed through 1H-NMR spectroscopy and 
the conversion values were determined by integration. The crude product was finally purified 
by column chromatography affording the pure pyrroles 41d, 66 or 67 as yellow-brown oils. 
 
General procedure for the 6-HDNO catalysed biotransformation of 3-pyrrolines into 
pyrroles 66 and 67. 
 
 
 
In a Falcon tube (15 mL), freeze dried whole cells of E.coli expressing recombinant 
monoamine oxidase 6-HDNO (140 mg) were suspended in 1 mL of potassium phosphate 
buffer (1M pH = 7.8). Then, the appropriate pyrroline 64 or 65 (0.1 mmol) was added and 
the reaction mixture was incubated at 37 ºC and shaken at 280 rpm for 24 h. The reaction 
mixture was added EtOAc (5 mL) and then centrifuged at 4000 rpm for 10 minutes. The 
organic layer was then separated and dried over anhydrous MgSO4. After the solvent was 
evaporated, the crude product was analysed through 1H-NMR spectroscopy and the 
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conversion values were determined by integration. The crude product was finally purified 
by column chromatography affording the pure pyrrole 41d, 66 or 67 as yellow-brown oils. 
 
General procedure for the chemoenzymatic cascade biotransformation (Method A). 
 
 
 
In a Falcon tube (15 mL), freeze dried whole cells of E.coli expressing recombinant 
monoamine oxidase MAO-D5 (140 mg) were suspended in 800 µL of potassium phosphate 
buffer (1M pH = 7.8). Then, the appropriate N-N-diallylaniline/amine 63 (0.1 mmol, 1 eq.) 
dissolved in isooctane (200 μL) was added to the reaction mixture leading to a final 
concentration of 0.02 g/mL. Grubbs cat. II gen. GII (0.005 mmol, 0.05 eq.) was then added 
to the reaction mixture. The mixture was incubated at 37 ºC and shaken at 280 rpm for 24h. 
EtOAc (5 mL) was added and the mixture was centrifuged at 4000 rpm for 10 minutes. The 
organic layer was then separated and dried over anhydrous MgSO4. After the solvent was 
evaporated, the crude product was analysed through 1H-NMR spectroscopy and the 
conversion value was determined. The crude product was finally purified by column 
chromatography affording the desired pyrrole 41d, 66 or 67 as yellow-brown oils. 
 
General procedure for the chemoenzymatic cascade biotransformation (Method B). 
 
 
 
In a Falcon tube (15 mL), freeze dried whole cells of E.coli expressing recombinant 
monoamine oxidase MAO-D5 (140 mg) were suspended in 800 µL of potassium phosphate 
buffer (1M pH = 7.8). Then, the appropriate diallylaniline/amine 63 and 60 (0.1 mmol, 1 
eq.) dissolved in isooctane (200 μL) was added to the reaction mixture leading to a final 
concentration of 0.02 g/mL. Grubbs cat. II gen. GII (0.005 mmol, 0.05 eq.) was then added 
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to the reaction mixture. The mixture was incubated at 37 ºC and shaken at 280 rpm for 6h. 
Additional lyophilized cells (140 mg) were added and the suspension was incubated at 37 
ºC and shacked at 280 rpm for further 18h. EtOAc (5 mL) was added and the mixture was 
centrifuged at 4000 rpm for 10 minutes. The organic layer was then separated and dried over 
anhydrous MgSO4. After the solvent was evaporated, the crude product was analysed 
through 1H-NMR spectroscopy and the conversion value was determined. The crude product 
was finally purified by column chromatography affording the desired pyrrole 41d, 66 or 67 
as yellow-brown oils. 
 
Synthesis of 1-phenyl-1H-pyrrole (66a).254 
Yield: 78% (11.1 mg). 1H NMR (400 MHz, CDCl3): δ 7.34-7.28 (m, 4H), 7.14 (t, J 
= 7.0 Hz, 1H), 6.99 (d, J = 2.0 Hz, 2H), 6.26 (dd, J = 2.5, 2.0 Hz, 2H) ppm. 13C 
NMR (100 MHz, CDCl3): δ 140.82, 129.60, 125.66, 120.57, 119.37, 110.46. LRMS 
(ESI+): m/z = 144 [M + H]+.  
 
Synthesis of 1-(4-fluorophenyl)-1H-pyrrole (66b).249 
Yield: 59% (9.4 mg). 1H NMR (400 MHz, CDCl3): δ 7.37-7.34 (m, 2H), 7.15-7.11 
(m, 2H), 7.03 (d, J = 2.0 Hz, 2H), 6.36 (dd, J = 2.5, 2.0 Hz, 2H). 13C NMR (100 
MHz, CDCl3): δ 159.4, 137.1, 122.3, 122.2, 119.6, 116.4, 116.1, 110.4 ppm. LRMS 
(ESI+): m/z = 162 [M + H]+.  
 
 
 
Synthesis of 1-(4-bromophenyl)-1H-pyrrole (66c).255 
Yield: 23% (5.1 mg). 1H NMR (400 MHz, CDCl3): δ 7.48-7.46 (m, 2H), 7.21-7.18 
(m, 2H), 7.00 (d, J = 2.0 Hz, 2H), 6.32 (dd, J = 2.5, 2.0 Hz, 2H). 13C NMR (100 
MHz, CDCl3): δ 139.6, 132.5, 121.7, 119.1, 118.6, 110.8. LRMS (ESI+): m/z = 221-
223 [M + H]+. 
 
 
Synthesis of 1-(4-isopropylphenyl)-1H-pyrrole (66d).256 
 Yield: 70% (12.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.34-7.28 (m, 4H), 7.08 (d, 
J = 2.0 Hz, 2H), 6.35 (dd, J = 2.5, 2.0 Hz, 2H), 2.96 (m, 1H), 1.29 (d, J = 7.0 Hz, 
6H) ppm. 13C NMR (100 MHz, CDCl3): δ 146.8, 139.1, 127.8, 121.0, 119.8, 110.4, 
34.0, 24.4. LRMS (ESI+): m/z = 186 [M + H]+. 
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Synthesis of 1-(4-methoxyphenyl)-1H-pyrrole (66e).249 
Yield: 42% (7.3 mg). 1H NMR (400 MHz, CDCl3): δ 7.33 (d, J = 9.0 Hz, 2H), 7.02 
(d, J = 2.0 Hz, 2H), 6.96 (d, J = 9.0 Hz, 2H), 6.34 (dd, 2.5, J = 2.5, 2.0 Hz, 2H), 
3.85 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 157.6, 134.5, 122.2, 119.7, 114.6, 
109.8, 55.5 ppm. LRMS (ESI+): m/z = 174 [M + H]+. 
 
 
Synthesis of 1-(2,5-Dimethylphenyl)-1H-pyrrole (66f).257 
 Yield: 20% (3.4 mg). 1H NMR (400 MHz, CDCl3): δ 7.09 (d, J = 9.0 Hz, 2H), 
7.00 (s, 1H), 6.71 (d, J = 2.0 Hz, 2H), 6.22 (dd, J = 2.5, 2.0 Hz, 2H), 2.27 (s, 
3H), 2.09 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 136.3, 130.9, 130.3, 
128.2, 127.3, 122.0, 108.5, 20.8, 17.4 ppm. LRMS (ESI+): m/z = 172 [M + H]+.  
 
Synthesis of 1-(4-chlorophenyl)-1H-pyrrole (66l).232 
Yield: 56% (9.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.56 (d, J = 8.5 Hz, 2H), 7.29 
(d, J = 8.5 Hz, 2H), 7.07 (d, J = 2.0 Hz, 2H), 6.38 (dd, J = 2.5, 2.0 Hz, 2H). 13C 
NMR (100 MHz, CDCl3): δ 139.8, 132.6, 121.9, 119.2, 118.7, 110.9 ppm. LRMS 
(ESI+): m/z = 178 [M + H]+. 
 
 
 
Synthesis of 1-(p-tolyl)-1H-pyrrole (66m).258 
Yield: 50% (7.9 mg). 1H NMR (400 MHz, CDCl3): δ 7.31-7.30 (d, J = 8.0 Hz, 2H), 
7.24 (d, J = 8.0 Hz, 2H), 7.08 (d, J = 2.0 Hz, 2H), 6.35 (dd, J =  2.5, 2.0 Hz, 2H), 
2.40 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 138.6, 135.5, 130.2, 120.7, 119.5, 
110.2, 21.0 ppm. LRMS (ESI+): m/z = 158 [M + H]+. 
 
 
 
Synthesis of 1-(2-methoxyphenyl)-1H-pyrrole (66n).259 
Yield: 84% (14.5 mg). 1H NMR (400 MHz, CDCl3): δ 7.27-7.16 (m, 2H), 7.01-
6.94 (m, 2H), 6.90 (d, J = 2.0, Hz, 2H), 6.25 (dd, J= 2.5, 2.0, Hz, 2H), 3.83 (s, 
3H) ppm. 13C NMR (100 MHz, CDCl3): δ 152.7, 130.2, 127.3, 125.7, 122.0, 
120.8, 112.2, 108.7, 55.7 ppm. LRMS (ESI+): m/z = 174 [M + H]+. 
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Synthesis of 1-(benzo[d][1,3]dioxol-5-yl)-1H-pyrrole (66o). 
Yield: 57% (10.6 mg). 1H NMR (400 MHz, CDCl3): δ 6.92-6.88 (m, 2H), 6.82 
(dd, J = 2.0, 0.5 Hz, 1H), 6.77-6.74 (m, 2H), 6.26-6.22 (m, 2H), 5.94 (s, 2H) ppm. 
13C NMR (100 MHz, CDCl3): δ 148.3, 135.7, 119.9, 114.1, 110.0, 108.5, 103.1, 
101.6 ppm. LRMS (ESI+): m/z = 188 [M + H]+. HRMS (ESI) m/z calcd. For 
C11H9NO2 [M +H] 188.0712, found 188.0711. 
 
Synthesis of 1-benzyl-1H-pyrrole (67a).260 
Yield: 75% (11.8 mg). 1H NMR (400 MHz, CDCl3): δ 7.39-7.27 (m, 3H), 7.18-
7.11 (m, 2H), 6.72 (d, J = 1.5 Hz, 2H), 6.22 (dd, J = 2.0, 1.5 Hz, 2H), 5.09 (s, 
2H) ppm. 13C NMR (100 MHz, CDCl3): δ 138.3, 128.8, 127.8, 127.1, 121.3, 
108.6, 53.5 ppm. LRMS (ESI+): m/z = 158 [M + H]+. 
 
Synthesis of 1-isopentyl-1H-pyrrole (67b).261 
Yield: 52% (7.1 mg). 1H NMR (400 MHz, CDCl3): δ 6.58 (d, J = 2.0 Hz, 2H), 
6.06 (dd, J = 2.5, 2.0 Hz, 2H), 3.84-3.76 (m, 2H), 1.63-1.56 (m, 2H), 1.51 (d, J = 
6.5 Hz, 1H), 0.87 (s, 3H), 0.85 (s, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 120.4, 
107.8, 57.6, 40.4, 25.5, 22.4 ppm. LRMS (ESI+): m/z = 138 [M + H]+. 
 
Synthesis of 1-(cyclohexylmethyl)-1H-pyrrole (67c).262 
Yield: 63% (10.2 mg). 1H NMR (400 MHz, CDCl3): δ 6.59 (d, J = 2.0 Hz, 2H), 
6.18 (dd, J = 2.5, 2.0 Hz, 2H), 3.73 (d, J = 7.0 Hz, 2H), 1.80–1.63 (m, 6H), 
1.32–1.15 (m, 3H), 1.02–0.93 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ 
121.0, 107.5, 56.3, 39.9, 30.8, 26.3, 25.7 ppm. LRMS (ESI+): m/z = 164 [M + 
H]+. 
 
Synthesis of 1-(4-chlorobenzyl)-1H-pyrrole (67d).263 
Yield: 61% (11.6 mg). 1H NMR (400 MHz, CDCl3): δ 7.37 (d, J = 8.0 Hz, 
2H), 7.12 (d, J = 8.0 Hz, 2H), 6.66 (d, J = 2.0 Hz, 2H), 6.12 (dd, J = 2.5, 
2.0 Hz, 2H), 5.02 (s, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ 136.6, 
133.3, 128.7, 128.2, 120.9, 108.7, 52.4 ppm. LRMS (ESI+): m/z = 192 [M 
+ H]+. 
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Synthesis of 1-(cyclohexylmethyl)-2,5-dimethyl-1H-pyrrole (67e). 
Yield: 40% (7.6 mg). 1H NMR (400 MHz, CDCl3): δ = 5.69 (s, 2H), 3.46 
(d, J = 7.0 Hz, 2H), 2.13 (s, 6H), 1.65 (s, 2H), 1.56 (d, J= 12.5 Hz, 2H), 
1.12-1.07 (m, 2H), 0.81 (t, J=6.5 Hz, 5H) ppm. 13C NMR (100 MHz, 
CDCl3): δ = 127.9, 104.9, 50.0, 39.5, 31.6, 31.1, 26.4, 26.0, 22.7, 14.2, 12.9 
ppm. LRMS (ESI+): m/z = 192 [M + H]+ HRMS (ESI) m/z calcd. For C13H22N [M +H] 
192.1752, found 192.1753.  
 
Synthesis of 1-(4-chlorobenzyl)-2,5-dimethyl-1H-pyrrole (67f).264 
 Yield: 42% (9.2 mg). 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 8.5 
Hz, 2H), 6.85 (d, J = 8.5 Hz, 2H), 5.92 (s, 2H), 5.01 (s, 2H), 2.17 (s, 6H) 
ppm. 13C NMR (100 MHz, CDCl3): δ 137.0, 128.8, 127.8, 127.0, 125.6, 
46.1, 12.7, 11.2 ppm. LRMS (ESI+): m/z = 220 [M + H]+. 
 
Synthesis of 1-cyclohexyl-1H-pyrrole (67g).265 
Yield: 70% (10.4 mg). 1H NMR (400 MHz, CDCl3): δ 6.66 (d, J = 2.0 Hz, 2H), 
6.07 (dd, J = 2.5, 2.0 Hz, 2H), 3.74 (tt, J = 12.0, 4.0 Hz, 1H), 2.09-1.99 (m, 2H), 
1.81 (dt, J = 13.5, 3.0 Hz, 2H), 1.71-1.59 (m, 2H), 1.57 (d, J = 3.5 Hz, 1H), 1.54 (d, 
J = 3.5 Hz, 1H), 1.35-1.29 (m, 2H) ppm. 13C NMR (100 MHz, CDCl3): δ = 118.4, 
107.3, 34.7, 31.6, 25.7, 25.5, 22.7, 14.1 ppm. LRMS (ESI+): m/z = 150 [M + H]+. 
 
Synthesis of 1-(1-Phenylethyl)-1H-pyrrole (67h).266 
Yield: 41% (7.0 mg). 1H NMR (400 MHz, CDCl3): δ 7.14 (m, 3H), 7.01 (d, J 
= 7.5 Hz, 2H), 6.68 (d, J = 2.0 Hz 2H), 6.11 (dd, J = 2.5, 2.0 Hz, 2H), 5.20 (q, 
J = 7.0 Hz, 1H), 1.75 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): 
δ = 142.5, 127.5, 126.3, 124.7, 118.4, 106.9, 57.0, 21.0 ppm. LRMS (ESI+): 
m/z = 172 [M + H]+. 
 
Synthesis of methyl-4-methyl-2-(1H-pyrrol-1-yl)pentanoate (67i).263,266 
Yield: 21% (4.1 mg). 1H NMR (400 MHz, CDCl3): δ 6.75 (d, J = 2.0 Hz, 
2H), 6.17 (dd, J = 2.5, 2.0 Hz, 2H), 4.65 (t, J = 7.5 Hz, 1H), 3.70 (s, 3H), 
1.95 (m, 2H), 1.40 (m, 1H), 0.95 (d, J = 7.5 Hz, 3H), 0.83 (d, J = 7.5 Hz, 
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3H) ppm. 13C NMR (100 MHz, CDCl3): δ 171.0, 120.1, 108.5, 68.8, 51.9, 32.0, 19.4, 18.7 
ppm. LRMS (ESI+): m/z = 196 [M + H] +. 
 
 
Synthesis of 1-methyl-3-phenyl-1H-pyrrole (67j).199 
Yield 70% (11.0 mg). 1H NMR (400 MHz, CDCl3): δ 7.42 (dd, J = 8.0, 4.0 
Hz, 2H), 7.25 (t, J = 8.0 Hz, 2H), 7.08 (t, J = 8.0 Hz, 1H), 6.84 (d, J = 2.0 
Hz, 1H), 6.56 (s, 1H), 6.37 (d, J = 2.0 Hz, 1H), 3.62 (m, 3H) ppm. 13C NMR 
(100 MHz, CDCl3): δ 136.3, 131.0, 129.0, 125.7, 125.4, 123.1, 119.0, 106.7, 
36.8 ppm. LRMS (ESI+): m/z = 158 [M + H]+. HRMS (ESI) m/z calcd. For C11H12N [M 
+H] 158.0970, found 158.0966. 
 
 
Synthesis of 1-isopropyl-3-phenyl-1H-pyrrole (67k). 
Yield 30% (5.6 mg). 1H NMR (400 MHz, CDCl3): δ 7.46-7.34 (m, 2H), 
7.30-7.20 (m, 2H), 7.06 (tt, J = 7.4, 1.0 Hz, 1H), 6.96 (d, J = 1.5 Hz, 1H), 
6.67 (s, 1H), 6.38 (d, J =1.5 Hz, 1H), 4.18 (dt, J =6.5 Hz, 1H), 1.42 (d, J 
= 6.5 Hz, 6H) ppm. 13C NMR (100 MHz, CDCl3): δ 136.1, 128.5, 125.1, 
124.9, 124.3, 119.2, 115.1, 105.7, 51.0, 23.9 ppm. LRMS (ESI+): m/z = 186 [M + H]+. 
HRMS (ESI) m/z calcd. For C13H15N [M +H] 186.1283, found 186.1282. 
 
 
Synthesis of 3-phenyl-1H-pyrrole (67l). 
Yield: 34% (4.8 mg). 1H NMR (400 MHz, CDCl3): δ 7.47 (dd, J = 8.0, 4.0 
Hz, 2H), 7.27 (t, J = 8.0 Hz, 2H), 7.13-7.09 (m, 1H), 7.03 (d, J = 1.5 Hz, 
1H), 6.78 (d, J = 1.5 Hz, 1H), 6.49-6.48 (m, 1H) ppm. 13C NMR (100 MHz, 
CDCl3): δ 135.8, 128.6, 125.3, 125.2, 118.9, 114.6, 106.6 ppm. LRMS (ESI+): m/z = 144 
[M + H]+. 
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Synthesis of 4,4'-((1-(4-fluorophenyl)-1H-pyrrole-3,4-diyl)bis(methylene))bis(1-
phenylpiperazine) (68) via MAO-D5 - Mannich reaction cascade. 
In a Falcon tube (15 mL), whole cells of E.coli 
expressing recombinant MAO-D5 (140 mg), were 
suspended in potassium phosphate buffer 1M pH = 7.8 
(800 µL). Then, the pyrroline 64b (0.1 mmol, 1 eq.) 
dissolved in isooctane (200 μL) was added to the 
reaction mixture in order to have a final concentration 
of 0.02 g/mL. The reaction mixture was incubated at 37 ºC and shacken at 280 rpm for 24 h. 
The reaction mixture was then diluted with CH3CN (2 mL) and centrifuged. The supernatant 
was removed and added to a stirring solution of N-phenyl pyperazine (8.1 mg, 0.05 mmol, 
0.5 eq.), formaldehyde 37% w/v (0.05 mmol, 0.5 eq.) and glacial acetic acid (0.003 mL, 0.05 
mmol, 0.5 eq.) in CH3CN (2 mL). The mixture was stirred at room temperature for 12 h. 
Then, the reaction was quenched with saturated NaHCO3 aqueous solution (20 mL) and 
extracted twice with 20 mL of Et2O. The combined organic layers were collected, washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude product 
68 was purified by chromatography on silica gel, using hexane/EtOAc (4:1) as eluent. Yield 
25% (12.7 mg). 1H NMR (400 MHz, CDCl3): δ 7.45-7.27 (m, 2H), 7.24-7.13 (m, 5H), 7.05-
6.93 (m, 2H), 6.86-6.79 (m, 4H), 6.77 (tt, J = 7.3, 1.0 Hz, 2H), 6.06 (s, 2H), 3.19 (s, 4H), 
3.08-2.87 (m, 8H), 2.47-2.25 (m, 8H) ppm. 13C NMR (100 MHz, CDCl3): δ 160.7, 151.4, 
130.9, 130.8, 129.1, 119.6, 116.0, 114.9, 114.7, 108.8, 53.9, 52.4, 49.2 ppm. LRMS (ESI+): 
m/z = 509 [M + H]+. HRMS (ESI) m/z calcd. For C34H38FN3 [M +H] 509.2946, found 
509.2947. 
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